Neptune Bio: 2025 Semi-Annual Report

Full text of Shenzhen Neptune Bioengineering Co., Ltd.'s 2025 Semi-Annual Report Shenzhen Neptune Bioengineering Co., Ltd.'s 2025 Semi-Annual Report

August 2025

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 1 Important Tips, Table of Contents and Definitions

The company's board of directors, board of supervisors, directors, supervisors and senior managers guarantee that the contents of the semi-annual report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

Zhang Feng, the person in charge of the company, Shen Dakai, the person in charge of accounting work, and Li Shuang, the person in charge of the accounting department (accounting supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this semi-annual report. All directors have attended the board meeting to review this semi-annual report.

Forward-looking statements such as strategic planning for future development involved in this report do not constitute the company's substantive commitment to investors. Investors are advised to invest rationally and pay attention to investment risks.

The company's designated information disclosure media are Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and Juchao Information Network. All the company's information is subject to what the company publishes in the above designated media. Investors are requested to invest rationally.

The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Directory

Section 1 Important Tips, Table of Contents and Definitions................................................................................................2

Section 2 Company Profile and Main Financial Indicators................................................................................................7

Section 3 Management Discussion and Analysis................................................................................................10

Section 4 Corporate Governance, Environment and Society......................................................................................24

Section 5 Important Matters................................................................................................................................26

Section 6 Changes in Shares and Shareholders...................................................................................70

Section 7 Bond-related situations................................................................................................................75

Section 8 Financial Report......................................................................................................................76

Section 9 Other Submission Data................................................................................................................214

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Document directory for reference

The company prepares the following documents for reference at its office location for inquiries by relevant state departments and shareholders:

1. Financial statements signed and stamped by the person in charge of the company, the person in charge of accounting work, and the person in charge of the accounting department (accounting supervisor);

2. The text of the 2025 semi-annual report signed and stamped by the company’s legal representative;

3. The original copies of all company documents and announcements publicly disclosed during the reporting period;

4. Semi-annual reports published in other securities markets.

Legal representative of Shenzhen Neptune Bioengineering Co., Ltd.: Zhang Feng

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. on August 29, 2025

Definition

Interpretation item refers to the interpretation content

Neptune Biotechnology, the Company, and the Company refer to Shenzhen Neptune Bioengineering Co., Ltd.

Neptune Fuyao refers to Fuzhou Neptune Fuyao Pharmaceutical Co., Ltd.

Jinxiang Traditional Chinese Medicine refers to Fuzhou Neptune Jinxiang Traditional Chinese Medicine Pharmaceutical Co., Ltd.

Neptune Zhongxin Pharmaceutical refers to Beijing Neptune Zhongxin Pharmaceutical Co., Ltd.

Neptune Pharmaceutical Research Institute, Neptune Research Institute refers to Shenzhen Neptune Pharmaceutical Technology Research Institute Co., Ltd.

Galaxy Investment refers to Shenzhen Neptune Galaxy Pharmaceutical Investment Co., Ltd.

Shanghai Neptune Group refers to Shanghai Neptune Medical Equipment Group Co., Ltd.

Beijing Jianchang refers to Neptune Jianchang (Beijing) Medical Equipment Co., Ltd.

Shen Yip Pharmaceutical refers to Shenzhen Shen Yip Pharmaceutical Development Co., Ltd.

Ningbo Jianchang refers to Ningbo Jianchang Zhongxing International Trade Co., Ltd.

Neptune Intron refers to Shenzhen Neptune Intron Biotechnology Co., Ltd.

Neptune Group refers to Shenzhen Neptune Group Co., Ltd.

Neptune Xingchen refers to Shandong Neptune Xingchen Pharmaceutical Chain Group Co., Ltd.

Guangxin Group refers to Guangdong Guangxin Holding Group Co., Ltd.

Silk Textile Group refers to Guangdong Silk Textile Group Co., Ltd.

The "Share Transfer Agreement" signed by Silk Textile Group and Neptune Group on July 28, 2024 refers to the "Share Transfer Agreement Regarding Shenzhen Neptune Bioengineering Co., Ltd."

The "Voting Rights Waiver Agreement" signed by Silk Textile Group and Neptune Group and their concerted persons Mr. Zhang Simin, Mr. Zhang Feng and Ms. Wang Faye on July 28, 2024 refers to

"Agreement on Waiver of Voting Rights of Shenzhen Neptune Bioengineering Co., Ltd."

On July 28, 2024, the company signed a "Share Subscription Agreement with Effective Conditions for Shenzhen Neptune Bioengineering Co., Ltd. to Issue Stocks to Specific Targets" with Guangxin Group and Silk Fang Group respectively. The company signed a "Cooperation Agreement Regarding Shenzhen Neptune Bioengineering Co., Ltd.

Refers to the "<Cooperation Agreement Regarding Shenzhen Neptune Bioengineering Co., Ltd.> Termination Agreement"

Agreement > Termination of Agreement》

Silk Spinning Group and Neptune Group and its persons acting in concert, Mr. Zhang Simin, "<Regarding the Share Transfer of Shenzhen Neptune Bioengineering Co., Ltd." Mr. Zhang Feng and Ms. Faye Wong signed the " and <About Shenzhen Neptune Bioengineering Co., Ltd. Refers to the Voting Rights Waiver Agreement Regarding the Share Transfer of Shenzhen Neptune Bioengineering Co., Ltd.> Termination Agreement" Agreement> and <Agreement on Waiver of Voting Rights of Shenzhen Neptune Bioengineering Co., Ltd.> Termination of Agreement"

The company, Guangxin Group and Silk Textile Group signed the "Shenzhen Neptune Bioengineering Co., Ltd. issued an agreement to specific targets on June 6, 2025.

Refers to the "<Share Subscription Agreement with Effective Conditions for Shenzhen Neptune Bioengineering Co., Ltd. to issue shares to a specific target> Termination Agreement"

Share Subscription Agreement with Effective Conditions for the Issuance of Stocks > Termination Agreement" China Securities Regulatory Commission refers to the China Securities Regulatory Commission

Shenzhen Stock Exchange refers to Shenzhen Stock Exchange

Shenzhen Securities Regulatory Bureau refers to the Shenzhen Securities Regulatory Bureau of China Securities Regulatory Commission

Supply-Processing—Distribution, the medical SPD supply management system, is a typical lean management model produced under the guidance of the supply chain integration idea. Through this system, information docking between the hospital and suppliers is established, and intelligent equipment SPD indicators are invested in the hospital.

Prepare and complete the efficient supply and settlement of consumables according to the actual use of the hospital, thereby establishing the unification of commodity flow, information flow, logistics, capital flow, etc. of pharmaceutical and equipment consumables from production enterprises, circulation channels to hospital terminals, and realizing efficient and full traceability management through the support of modern information technology

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. The reporting period refers to January 1, 2025 to June 30, 2025

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 2 Company Profile and Main Financial Indicators

1. Company Profile

Stock abbreviation Neptune Biotechnology Stock code 000078 Stock abbreviation before change (if any) None

Stock exchange where stocks are listed Shenzhen Stock Exchange

The Chinese name of the company: Shenzhen Neptune Bioengineering Co., Ltd.

Company’s Chinese abbreviation (if any) Neptune Biotechnology

The company's foreign name (if any) ShenzhenNeptunusBioengineeringCo.,Ltd.

The abbreviation of the company’s foreign name (such as

None

Yes)

The legal representative of the company Zhang Feng

2. Contact person and contact information

Secretary to the Board of Directors Name of Securities Affairs Representative Wang Yunlei Lin Jianyi

Neptune Silver, No. 1, Keji Zhong 3rd Road, Nanshan District, Shenzhen. Neptune Silver, No. 1, Keji Zhong 3rd Road, Nanshan District, Shenzhen. Contact address

24th Floor, He Technology Building 24 Floor, He Technology Building Tel: 0755-26980336 0755-26980336 Fax: 0755-26968995 0755-26968995 E-mail: [email protected] [email protected]

3. Other situations

1. Company contact information

Whether the company's registered address, company office address and its postal code, company website, e-mail address, etc. have changed during the reporting period?

□ApplicableNot applicable

The company's registered address, company office address and its postal code, company website, e-mail address, etc. did not change during the reporting period. For details, please refer to the 2024 annual report.

2. Information disclosure and preparation location

Whether the location of information disclosure and preparation changes during the reporting period

□ApplicableNot applicable

The name and URL of the stock exchange website and media where the company discloses its semi-annual report. The company's semi-annual report preparation location did not change during the reporting period. For details, please refer to the 2024 annual report.

3. Other relevant information

Whether other relevant information has changed during the reporting period

□ApplicableNot applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

4. Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□YesNo

This reporting period Same period last year This reporting period Increase or decrease in operating income compared with the same period last year (yuan) 14,311,503,184.96 16,631,439,699.61 -13.95% Net profit attributable to shareholders of listed companies

31,681,707.71 45,409,831.68 -30.23% profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit from non-recurring gains and losses -70,526,104.47 38,901,697.58 -281.29% (yuan)

Net cash flow from operating activities

58,081,397.67 113,327,505.04 -48.75% (yuan)

Basic earnings per share (yuan/share) 0.0120 0.0173 -30.64% Diluted earnings per share (yuan/share) 0.0120 0.0173 -30.64% Weighted average return on equity 1.75% 1.50% 0.25%

End of the reporting period End of the previous year Total assets increased or decreased at the end of the reporting period compared with the end of the previous year (yuan) 27,668,940,104.27 28,798,320,164.17 -3.92% Net assets attributable to shareholders of listed companies

1,829,802,987.30 1,795,232,448.56 1.93% output (yuan)

Net profit after deducting the impact of share-based payments

this reporting period

Net profit after deducting the impact of share-based payment (yuan) 31,681,707.71

5. Differences in accounting data under domestic and foreign accounting standards

1. Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□ApplicableNot applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with international accounting standards and Chinese accounting standards.

2. Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□ApplicableNot applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with foreign accounting standards and Chinese accounting standards.

6. Non-recurring profit and loss items and amounts

Applicable□Not applicable

Unit: Yuan

Item Amount Description

Gains and losses on disposal of non-current assets (including accrued

87,519,703.48 Mainly due to the write-off of asset impairment provisions for gains and losses from disposal of subsidiaries)

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies 13,447,646.69

stipulates, enjoys according to determined standards, and treats the company

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Except for government subsidies that have a lasting impact on profits and losses)

Except for effective transactions related to the company’s normal business operations,

In addition to futures hedging business, non-financial enterprises hold financial

Changes in fair value of assets and financial liabilities 70,959.24 Gains and losses and disposal of financial assets and financial liabilities

profit and loss

Gains and losses from entrusting others to invest or manage assets 837,590.60 Impairment standards for accounts receivable that are individually tested for impairment

4,180,436.64 to be transferred back

Other non-operating income other than the above items and

5,932,126.30 expenses

Less: Impact on income tax 4,188,301.68

Amount affected by minority shareholders’ equity (after tax) 5,592,349.09 Total 102,207,812.18

Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□ApplicableNot applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□ApplicableNot applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 3 Management Discussion and Analysis

1. The main business of the company during the reporting period

1. Industry situation

In the first half of 2025, the pharmaceutical distribution industry will enter a stage of deep change and accelerated integration under the dual effects of policy and market. At the policy level, the Government Work Report of the State Council emphasized "optimizing the centralized purchasing policy for drugs and consumables, strengthening quality assessment and supervision, and making the people feel more confident when using medicines." The "low-price only" centralized purchasing policy may usher in an important turning point. The price-oriented centralized purchasing mechanism that has been implemented for many years is undergoing structural adjustments. By improving the quality evaluation system and market access rules, the industry ecology that relies solely on price competition will gradually change. On the other hand, the country continues to increase its efforts to standardize and rectify the industry. In March 2025, four departments including the National Medical Insurance Administration jointly issued the "Notice on Strengthening the Collection and Application of Drug Traceability Codes in the Fields of Medical Security and Work-related Injury Insurance", aiming to realize the traceability of the entire process of drugs from production to sales and ensure the safety of medical insurance funds and the safety of people's medication; in June, 14 agencies including the National Health Commission The department issued the "Notice on the Key Points of Correcting Improper Practices in the Field of Pharmaceutical Purchase and Sales and Medical Services in 2025", making efforts from various aspects such as strengthening the party's leadership in correcting work, deepening governance in the field of pharmaceutical purchase and sales, and rectifying chaos in medical services, to further purify the industry environment and standardize the operating behavior of pharmaceutical circulation companies. Compliance management has become a core element for companies to stay in the market.

At the market level, the pharmaceutical distribution industry is facing pressure from slowing growth and declining profits. According to data from the National Bureau of Statistics, from January to June 2025, the PPI of the pharmaceutical manufacturing industry fell by 1.5% year-on-year, the operating revenue of the pharmaceutical manufacturing industry above designated size was 1.23 trillion yuan, a year-on-year decrease of 1.2%, and the total profit was 176.69 billion yuan, a year-on-year decrease of 2.8%. In this context, pharmaceutical distribution companies need to accurately understand changes in market demand, optimize product and service supply, and strengthen their core competitiveness to cope with the challenges and opportunities brought about by industry changes.

2. Overview of the company’s operations during the reporting period

Facing the severe market situation, the company actively seeks ways to transform and upgrade, accelerates the pace of strategic adjustment, strives to optimize product structure, and strengthens cost control measures to cope with industry challenges. In 2025, the company will take "increase gross sales profits, ensure asset safety, improve financing channels, and optimize capital returns" as its operating and management guiding ideology, organize and carry out operating activities with cash flow as the core and efficiency maximization as the goal. In terms of operations, each branch and subsidiary fully considers the occupation of upstream and downstream funds, and optimizes and adjusts the sales structure by replacing high-margin varieties, improving low-margin varieties, and controlling the sales of low-negative-margin varieties.

During the reporting period, the company achieved operating income of approximately 14.312 billion yuan, a year-on-year decrease of 13.95%, of which pharmaceutical commercial income was approximately 13.881 billion yuan and pharmaceutical industry income was approximately 281 million yuan. The company's net profit attributable to shareholders of the listed company is approximately 31.6817 million yuan. The decline in the company's operating income was concentrated in the pharmaceutical distribution sector, mainly due to industry policy adjustments such as national centralized procurement and regional unified procurement, as well as the decrease in procurement by public medical institutions in some regions.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

influence. In addition, the company strategically and proactively abandoned some inefficient and low-gross profit margin businesses, and optimized individual subsidiaries with inefficient operations.

3. Overview of the company’s main business

The company has been deeply involved in the pharmaceutical industry for more than 30 years and has built a complete industrial chain of "research-production-sales" integrating pharmaceutical research and development, pharmaceutical manufacturing, and pharmaceutical commercial circulation. It is a comprehensive large-scale pharmaceutical enterprise with strong domestic strength. The company's main business is introduced as follows:

(1) Pharmaceutical business

The company's pharmaceutical business segment consists of two major businesses: the circulation of drugs and medical devices. It mainly provides distribution of drugs, medical devices and other medical supplies and related extended value-added services to downstream customers such as medical institutions, drug retail institutions and distributors.

In recent years, the company has strengthened supply chain management, expanded product categories upstream, and provided more efficient, professional, and personalized service solutions based on the needs of medical institutions by improving its own informatization and intelligent technologies, etc., and continuously enhanced the company's brand awareness and influence.

The company's pharmaceutical business segment focuses on the pharmaceutical and medical device business, among which logistics, warehousing and distribution capabilities are the company's core competitiveness in the pharmaceutical business field. The pharmaceutical business network layout of more than 20 years is an important support for the company's pharmaceutical distribution. During the reporting period, the company's pharmaceutical business segment achieved operating income of approximately 13.881 billion yuan, of which the medical device circulation business achieved operating income of approximately 4.986 billion yuan.

①Drug circulation

The company's pharmaceutical distribution business uses its wholly-owned subsidiary Galaxy Investment as the investment and management platform. It manages and controls its subordinate pharmaceutical commercial enterprises through a number of provincial-level regional groups such as Shandong, Sulu, Henan, Anhui, and Guangdong. It has established a huge pharmaceutical commercial logistics network system covering more than 20 provinces (autonomous regions and municipalities) across the country, and has formed a large-scale distribution system and organizational structure with regional advantages.

②Medical equipment

The company's medical device business mainly includes medical device agency sales and circulation business. At present, the company's medical device business is in a stage of rapid development. Through the two major medical device platforms of Shanghai Neptune Group and Beijing Jianchang, it is developing the medical device business in depth in Beijing, Shanghai, Shandong, Heilongjiang, Henan, Zhejiang, Anhui, Guangdong and other key provinces and regions. Relying on its strong pharmaceutical business network and customer resources, the company strengthens the expansion of medical device circulation business in mature pharmaceutical commercial circulation market areas. At present, the company has built a national equipment supply chain network covering 16 provinces, municipalities and autonomous regions across the country, with 36 equipment branches and subsidiaries.

The company invested in the establishment of the medical device platform company Neptune Medical Technology Co., Ltd. in September 2023, aiming to further integrate medical device resources and create a comprehensive medical device business platform with "a nationwide network and regional characteristics". The company concentrates more medical device resources to empower Neptune Medical Technology Co., Ltd., promotes the upgrading of traditional consignment business and develops peripheral new business lines, and strives to achieve the long-term goal of building a comprehensive device platform.

③Pharmaceutical circulation extends supply chain value-added services

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The company actively explores business model upgrades, enhances customer stickiness through digitalization and supply chain value-added services, and achieves a leap from traditional supply, marketing and distribution services to providing customers with customized supply chain management solutions. In terms of digital supply chain management, the company provides customized medical supplies supply chain services (SPD services) to pilot hospitals in Shandong, Henan, Anhui and other regional groups, fully meeting the service needs of pilot hospitals in the procurement and supply, in-hospital management, use and distribution of medical supplies. The hospital can connect with the hospital HIS and supplier ports through the system to ensure data connection and information sharing, thereby achieving online real-time management and control, effectively improving hospital management efficiency and transparency. The company actively establishes medical extended service cooperation with medical institutions, and enhances business added value by assisting hospitals with supply chain financing, providing SPD services, static distribution centers, equipment maintenance and other extended services, and strengthens the stickiness of customer cooperation. In terms of equipment maintenance services, the company provides hospital-wide medical equipment maintenance or single equipment maintenance services for many medical institutions in Tianjin, Shandong, Anhui, Xinjiang and other places, which effectively reduces management costs while improving the modern management level of medical institutions.

(2) Pharmaceutical industry

In the field of pharmaceutical industry, the company takes Neptune Fuyao, Jinxiang Traditional Chinese Medicine and Neptune Zhongxin Pharmaceutical as its core platforms. The company has currently built a diversified and multi-level pharmaceutical product structure. Neptune Fuyao's main business is the R&D, production and sales of large infusion products and Western medicine preparations; Jinxiang Traditional Chinese Medicine is a medium-sized traditional Chinese medicine production and sales enterprise in Fujian Province, responsible for the R&D, production and sales of proprietary Chinese medicines; Neptune Zhongxin Pharmaceutical is a comprehensive pharmaceutical company integrating R&D, production and sales of pharmaceutical products.

The company has two pharmaceutical production bases, located in Fuzhou and Beijing. The Fuzhou production base has 368 national drug approval numbers for Chinese patent medicines (including tablets, capsules, granules, oral liquids, tinctures, and more than a dozen dosage forms), chemical drugs (including tablets, capsules, granules, small-volume injections, large-volume injections, and other dosage forms), among which 236 products have been selected into the National Basic Medical Insurance Drug Catalog, and 147 products have been selected into the National Essential Drug Catalog. At the same time, the Fuzhou production base is also the only state-designated production base for compound preparations containing narcotics in Fujian Province. The Beijing production base is a designated production base for Class II psychotropic drugs in Beijing. It mainly produces chemical drugs (including tablets, hard capsules, powders, and granules). It holds 137 national drug approval numbers, 90 of which have been selected into the National Basic Medical Insurance Drug Catalog (64 varieties in Category A and 26 varieties in Category B), 60 products have been selected in the National Essential Drug Catalogue, and there are 31 OTC products in total (23 in Category A and 8 in Category B). Key products include oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, rifampicin capsules, estazolam tablets, etc.

Neptune Fuyao, Jinxiang Traditional Chinese Medicine, and Neptune Zhongxin Pharmaceutical continue to invest in the consistency evaluation of generic drugs and the research and development of new traditional Chinese medicines. Currently, the above three companies have 25 invention patents. In terms of generic drug consistency evaluation, the company has a total of 5 varieties that have passed the generic drug consistency evaluation, including sodium bicarbonate tablets, norfloxacin capsules, metformin hydrochloride tablets, propranolol hydrochloride tablets, and atropine sulfate injection. In addition, vitamin B6 tablets have received supplementary application approval. In terms of new drug research and development, the holder of pharmaceutical subsidiaries has obtained approval for the doxofylline injection, sodium potassium magnesium calcium concentrated solution for injection, sodium bicarbonate Ringer's injection and the self-developed generic version of sildenafil citrate orally disintegrating tablets. The company also has a number of exclusive products with independent intellectual property rights, such as the anti-gastric cancer drug Tegio Tablets, the anti-liver cancer drug Xiaozheng Yigan Tablets, the polysaccharide protein tablets to improve immunity, the anti-rhinitis drug Biyuan Capsules, the acute diarrhea drug Amaranth Berberine Capsules, the anti-inflammatory and hepatoprotective drug disodium glycyrrhizinate, the auxiliary diuretic spironolactone tablets, ischemia tablets

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Tetramethylpyrazine phosphate tablets, prefilled catheter irrigators (National Class III medical device products) and HTK myocardial protection cardioplegia (National Class III medical device products), etc. have strong competitive advantages in the pharmaceutical industry.

In 2025, the company will continue to make use of the existing network resources and customer resources of the Neptune system, give full play to the linkage advantages of the company's industrial system and business system, continue to deepen the market layout, and actively participate in the national centralized procurement of expired varieties in various regional alliances to promote bulk procurement, seize the market, and drive the sales of other products. At the same time, according to the characteristics of the product, three major channels are divided into three major channels: full-channel sales, controlled sales, and e-commerce sales to carry out distribution channel sales layout. During the reporting period, the company's pharmaceutical industry segment achieved operating income of approximately 281 million yuan.

(3) Pharmaceutical research and development

Affected by the current reform of the medical system, in order to ensure that the revenue and profits of the company's pharmaceutical manufacturing business do not decline significantly, the company has been committed to the research of innovative drugs and generic drugs. In the field of research and development, the company has technological innovation platforms such as a nationally recognized enterprise technology center, an enterprise postdoctoral research workstation, the Guangdong Provincial Ministry of Education's industry-university-research demonstration base, the Shenzhen Marine Drug Research and Development Engineering Center, and the Guangdong Provincial Small Molecule Innovative Anti-tumor Drug Engineering Technology Research Center. There are currently 228 people in the R&D technical team, and more than 30 have completed research projects and are postdoctoral fellows.

Neptune Research Institute has been rated as a national high-tech enterprise and a Shenzhen specialized small and medium-sized enterprise. It has more than 60 invention patents. It mainly carries out medical research and development work such as malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases and other major disease fields, as well as new drug development in the field of multiple diseases such as the respiratory system and digestive system, as well as providing technical support for the quality consistency evaluation of generic drugs. During the reporting period, the innovative drug HW130 injection completed Phase I clinical research, and started the production of clinical sample raw materials and preparations for Phase II clinical trials; NEP018 applied for and obtained domestic clinical approval, and also launched the production of clinical sample raw materials for Phase I clinical trials.

Patent applications during the reporting period:

Serial Number Number Description

1 202510061548.5 An abiraterone derivative and its preparation method and use

2. Analysis of core competitiveness

The company was founded in 1992 and listed on the Shenzhen Stock Exchange on December 18, 1998. It has been deeply involved in the pharmaceutical industry for more than 30 years. The company has formed three core business segments with pharmaceutical circulation as the core, including pharmaceutical research and development and pharmaceutical industry.

1. Advantages of business network layout

The company continues to expand its pharmaceutical distribution business through endogenous development and external mergers and acquisitions, and has established a huge pharmaceutical commercial business network system covering more than 20 provinces (autonomous regions and municipalities) across the country. In particular, the company has achieved full coverage of the business network in Shandong and Henan, forming a strong regional advantage. It is one of the national pharmaceutical commercial enterprises with a wide business network coverage, and has strong industry influence and market competitiveness.

The company's pharmaceutical business segment has 21 provincial logistics centers and 105 logistics warehouses with a total storage area of ​​more than 380,000 square meters. It is equipped with more than 510 self-owned logistics vehicles, including 101 refrigerated trucks, and the total cold storage area is nearly 10,000 square meters. In the first half of 2025, the company provided drug and device distribution services to nearly 120,000 customers, and its business expansion area reached more than 20 provinces, autonomous regions, and more than 70 cities.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

At present, the company's warehousing and logistics adopts an operation mode that combines self-use and third-party storage and distribution. Through the smart logistics system, the efficiency of drug distribution is improved. During the reporting period, the company continued to promote the construction of Shandong Galaxy Modern Smart Pharmaceutical Logistics Park. After the completion of the logistics park project, it will improve the efficiency of the company's logistics services and further promote the intelligent and efficient development of the company's logistics, which will help enhance the company's logistics capabilities and enhance market competitiveness.

2. Product and qualification advantages

The company's pharmaceutical industry segment relies on its subsidiaries Neptune Fortune Medicine, Jinxiang Traditional Chinese Medicine, and Neptune Zhongxin Pharmaceutical to build a diversified and multi-level pharmaceutical product structure. The company has a rich product line, covering multiple fields such as large infusion products, Western medicine preparations and Chinese patent medicines, and has 505 national drug approval numbers; 236 products from the Fuzhou production base and 90 varieties from the Beijing production base have been selected into the national basic medical insurance drug catalog.

The company's device segment covers high-value consumables, medical equipment, in vitro diagnostics (IVD) and other fields. The segment's core business is to provide one-stop distribution services for upstream products and nationwide hospital terminal distribution services.

The company's device segment ranks 8th among the key commercial enterprises of IoT medical devices in 2024. 36 device branches and subsidiaries are located in 16 provinces, municipalities and autonomous regions, of which 8 subsidiaries have obtained third-party logistics licenses for medical devices. Conventional and cold chain logistics cover major provincial capital cities, forming a national device supply chain network. It has established good cooperative relationships with the top 100 global device companies such as Medtronic, Johnson & Johnson, Abbott, Porco, Smith & Nephew, Mindray, and other major domestic device companies such as MicroPort, Lepu, and Weigao. The product line is rich, covering many production lines such as interventional, endoscopes, surgical robots, in vitro diagnostics, imaging equipment, and monitoring equipment. It serves more than 1,500 grade hospitals and more than 3,000 dealers across the country, providing them with a one-stop platform and distribution services.

The company's device segment will continue to focus on specialization and networking, focusing on leading enterprises, key terminals, and key projects, and make efforts on the intensive service platform (SPD business), the medical equipment maintenance and management service platform, and the acquisition of superior brand agents for medical devices to create a national digital operation exclusive platform for the equipment circulation business.

In terms of business qualifications, the company has 27 subsidiaries with drug and anesthetic management qualifications. In addition, the company currently has 17 third-party logistics qualification certificates, of which 1 subsidiary has pharmaceutical qualifications, 4 subsidiaries have equipment qualifications, and 6 subsidiaries have both medicine and equipment third-party logistics qualifications. Shandong Neptune Galaxy Pharmaceutical Co., Ltd., a subsidiary of the company, has three-party logistics qualifications for pharmaceuticals and is one of the vaccine transportation service companies of the Shandong Provincial Center for Disease Control and Prevention.

3. Dual-core innovation in R&D and business

The company has always regarded innovation as the lifeline of survival and development, adhered to market orientation and product as the core, and formed a dual-core driven development model of R&D innovation and commercial innovation.

In 1998, Neptune was approved to establish a nationally recognized enterprise technology center. After years of development, Neptune R&D has now developed a professional and efficient new product industrial development and achievement transformation system, including professional departments such as preparation research, pharmacological screening, quality research, clinical research, quality management, and pharmaceutical registration. It has also established modern research laboratories for natural drugs, drug synthesis, innovative preparations, and quality research.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The company's R&D center - Neptune Pharmaceutical Research Institute has been recognized as a new R&D institution in Guangdong Province by the Guangdong Provincial Department of Science and Technology. The company has also established a consistency evaluation research center to carry out pharmaceutical research on quality consistency evaluation of generic drugs.

In recent years, adhering to a market-oriented business philosophy and providing customized SPD solutions for medical institutions, the company has achieved a breakthrough in business transformation from providing product upgrades to providing service solutions. The SPD solution provided by the company is guided by "clinical needs", based on the "zero inventory" management concept, process optimization as the core, and quality management as the guarantee. It uses information technology such as radio frequency identification and barcode identification to apply the SPD management model to the classified management of medical drugs and consumables. It has achieved results in simplifying the procurement and distribution process, improving the quality of supply assurance, reducing the cost of in-hospital logistics services, and establishing a quality traceability management system for high-value consumables. The hospital can connect with the hospital HIS and supplier ports through the system to ensure data connection and information sharing, thereby achieving online real-time management and control, effectively improving hospital management efficiency and transparency.

In order to increase new profit growth points, the company is actively deploying and piloting innovative businesses. The company is expanding its business into innovative drugs, biopharmaceuticals, and high-margin generic drugs. In addition, the company is also developing new businesses in out-of-hospital business and terminal business, and is also increasing personnel investment in e-commerce business. In the traditional Chinese medicine business, the company has made some progress. The company's subsidiaries are cooperating with some hospitals to build regional smart traditional Chinese medicine pharmacies; they are cooperating with some hospitals to build preparation rooms and temporary prescription processing room projects, and provide extended services such as contract preparation, tea replacement, and ointment processing in core hospitals. The company is also accelerating the implementation of the special medical food business to meet the special needs for nutrients or meals for people with dietary restrictions, digestion and absorption disorders, metabolic disorders or specific disease states.

4. Professional team building

The company attaches great importance to the construction of talent teams in various fields. Currently, the research on talent training in the field of R&D has been completed. The Neptune Postdoctoral Workstation has been rated as an advanced postdoctoral management unit by the Shenzhen Municipal Government. In the field of medical devices, the company brings together management and sales elites from leading companies in the industry such as Boston Scientific and Siemens to ensure the professionalism and advanced management concepts of medical device-related industries. In addition, in the field of professional services, the high-end medical equipment maintenance team established by the company has obtained a number of software copyrights and has been recognized by customers in Shandong, Tianjin and other places in the past two years. The company is committed to building a professional and efficient team with a complete industrial system and outstanding business capabilities. It relies on channel advantages and team professional advantages to expand market share while enhancing customer stickiness to achieve a win-win model of sustainable development.

5. Flexible decision-making and quick service response

As a listed private enterprise, the company has the competitive advantage of flexible mechanisms and efficient decision-making. Especially in the face of many uncertain factors in the current market, the company's core management members and key business employees respond quickly through fast communication channels in a series of business decision-making processes such as how to achieve timely strategic adjustments, effectively implement strategic plans, and obtain accurate market feedback, which can give full play to the company's flexible and efficient decision-making mechanism. On the customer service side, each regional group and its subsidiaries are also actively responding to customers' service needs, from traditional pharmaceutical distribution to professional equipment maintenance to providing customized SPD solutions. Business expansion and upgrades rely on customers' recognition and trust of service quality.

6. Construction of financial sharing system

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The company's financial information construction work arrangements have achieved significant results. As of the end of the reporting period, the company has 102 subsidiaries that have launched a financial sharing system, covering modules such as expenses, funds, fixed assets, general ledger statements and operation management, to promote the digital transformation and improvement of finance.

Financial value creation capabilities and management decision support levels.

3. Main business analysis

Overview

Please refer to the relevant content of "1. Main businesses engaged in by the company during the reporting period".

Year-on-year changes in major financial data

Unit: Yuan

This reporting period Same period last year Year-on-year increase or decrease Reason for change Operating income 14,311,503,184.96 16,631,439,699.61 -13.95%

Operating costs 12,979,683,425.75 14,958,533,023.89 -13.23%

Selling expenses 512,965,617.44 567,284,856.71 -9.58%

Management expenses 432,070,744.08 508,135,561.90 -14.97%

Financial expenses 299,013,422.73 366,772,621.32 -18.47%

Mainly due to business scale income tax expense in the current period 67,847,587.28 99,758,584.37 -31.99%

caused by decline;

Cash generated from operating activities is mainly due to the business scale of the current period

58,081,397.67 113,327,505.04 -48.75%

Due to the decrease in net traffic;

Cash generated from investing activities

-74,387,529.15 -85,824,052.83 13.33%

Net flow

Cash generated from financing activities is mainly due to the scale of financing in the current period

-131,228,981.72 133,454,949.58 -198.33%

Due to the decrease in net traffic;

Cash and cash equivalents, net

-147,535,472.30 160,958,760.76 -191.66%

increase

There are significant changes in the company's profit composition or profit sources during the reporting period

□ApplicableNot applicable

There were no major changes in the company's profit composition or profit sources during the reporting period.

Operating income composition

Unit: Yuan This reporting period Same period last year

Year-on-year increase or decrease

Amount % of operating income Amount % of operating income

Total operating income 14,311,503,184.96 100% 16,631,439,699.61 100% -13.95% Industry

Pharmaceutical circulation 8,895,673,180.29 62.16% 10,670,614,672.61 64.16% -16.63% Pharmaceutical manufacturing 280,672,742.17 1.96% 346,407,734.79 2.08% -18.98% Food and health products 83,226,489.42 0.58% 119,357,971.87 0.72% -30.27%Medical equipment 4,985,535,790.61 34.84% 5,424,077,591.70 32.61% -8.09%Other income 66,394,982.47 0.46% 70,981,728.64 0.43% -6.46% by product

Company products 280,672,742.17 1.96% 346,407,734.79 2.08% -18.98% Purchased goods 13,964,435,460.32 97.58% 16,214,050,236.18 97.49% -13.87% Other income 66,394,982.47 0.46% 70,981,728.64 0.43% -6.46%

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

By region

Central China 3,096,869,159.99 21.64% 4,508,734,961.11 27.11% -31.31%East China 9,607,015,231.70 67.13% 9,960,636,220.03 59.89% -3.55%Southern China 1,060,918,603.58 7.41% 1,257,179,222.66 7.56% -15.61%Northern China 231,678,073.46 1.62% 333,225,294.51 2.00% -30.47%Other regions 248,627,133.76 1.74% 500,682,272.66 3.01% -50.34%Other income 66,394,982.47 0.46% 70,981,728.64 0.43% -6.46%Industries, products or regions accounting for more than 10% of the company's operating income or operating profit

Applicable□Not applicable

Unit: Yuan

Operating income compared to the previous year Operating costs compared to the previous year Gross profit margin compared to the previous year’s operating income Operating costs Gross profit margin

Increase/decrease over the same period of the year Increase/decrease over the same period of the year Increase/decrease over the same period of the year

By industry

8,895,673,180. 8,180,715,469.

Pharmaceutical circulation 8.04% -16.63% -16.12% -0.56%

29 58

Pharmaceutical manufacturing 280,672,742.17 179,238,248.70 36.14% -18.98% -13.03% -4.37% Food and health products 83,226,489.42 58,942,279.04 29.18% -30.27% -17.16% -11.21%

4,985,535,790. 4,543,294,060.

Medical devices 8.87% -8.09% -7.24% -0.83%

61 69

By product

Company products 280,672,742.17 179,238,248.70 36.14% -18.98% -13.03% -4.37%

13,964,435,460 12,782,951,809

Purchase goods 8.46% -13.87% -13.17% -0.74%

.32 .31

By region

3,096,869,159. 2,817,221,874.

Central China 9.03% -31.31% -31.30% -0.02% 99 84

9,607,015,231. 8,758,619,716.

East China 8.83% -3.55% -2.60% -0.89% 70 59

1,060,918,603.

South China 953,235,365.32 10.15% -15.61% -13.58% -2.11%

Northern region 231,678,073.46 208,023,742.16 10.21% -30.47% -27.99% -3.10% Other regions 248,627,133.76 225,089,359.10 9.47% -50.34% -49.22% -1.99% If the statistical caliber of the company's main business data is adjusted during the reporting period, the company's main business data for the most recent period will be adjusted based on the caliber at the end of the reporting period.

□ApplicableNot applicable

4. Analysis of non-main business

Applicable□Not applicable

Unit: Yuan

Amount Proportion of total profit Explanation of reasons Whether it is sustainable

Mainly in the form of disposal subsidiaries

Investment income 88,840,372.84 66.96% No

Gains and losses on disposal;

Mainly due to provision of transaction fees

Gains and losses from changes in fair value 70,959.24 0.05% Changes in fair value of financial assets No

produce dynamically;

Mainly due to bad accounts receivable

Asset impairment -2,809,693.07 -2.12% No

Account accrual occurs;

Mainly those that do not need to be paid

Non-operating income 10,115,881.62 7.62% No

payment formation;

Mainly used to pay donations and

Non-operating expenses 4,183,755.32 3.15% No

Formation of compensation and other payments;

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

5. Analysis of assets and liabilities

1. Major changes in asset composition

Unit: Yuan End of the reporting period End of the previous year

Increase or decrease in proportion Amount explained for major changes Proportion to total assets Amount Proportion to total assets

3,063,948,201. 3,456,273,633.

Monetary funds 11.07% 12.00% -0.93% No significant changes93 71

15,147,853,611 15,319,422,562

Accounts receivable 54.75% 53.20% 1.55% No significant changes.67 .26

3,358,262,412. 3,486,933,682.

Inventory 12.14% 12.11% 0.03% No significant change

11 12

Investment real estate 72,724,847.52 0.26% 75,059,053.08 0.26% 0.00% No major changes Long-term equity investment 194,233,433.36 0.70% 193,570,097.26 0.67% 0.03% No major changes Fixed assets 891,524,754.46 3.22% 951,245,081.84 3.30% -0.08% No significant changes to construction in progress 98,513,935.38 0.36% 84,842,238.45 0.29% 0.07% No significant changes to right-of-use assets 131,993,735.98 0.48% 147,984,570.84 0.51% -0.03% No significant change

9,772,100,764. 10,023,491,526

Short-term borrowings 35.32% 34.81% 0.51% No significant changes

26.10

Contract liabilities 389,145,560.64 1.41% 363,608,592.28 1.26% 0.15% No significant changes Long-term borrowings 319,881,486.84 1.16% 229,796,779.81 0.80% 0.36% No significant changes Lease liabilities 85,104,865.46 0.31% 99,886,812.32 0.35% -0.04% No significant change

2. Major overseas assets

□ApplicableNot applicable

3. Assets and liabilities measured at fair value

Applicable□Not applicable

Unit: Yuan

Included in equity

Fair in this period

Accumulated public accrual in the current period Purchases in the current period Sales in the current period

Item Opening amount Change in value Other changes Closing amount Impairment amount Amount due to change in fair value

Profit and loss

move

financial assets

1. Transactional money

Financing assets -

125,433,27 122,630,34 (excluding derivatives 70,959.24 2,873,889.1

6.07 6.17 Financing 4

production)

4. Other equity 140,337,20 140,337,20 Tool investment 5.00 5.00

-

Financial assets 265,770,48 262,967,55

70,959.24 2,873,889.1

Subtotal 1.07 1.17

265,770,48 - 262,967,55Total of the above 70,959.24

1.07 2,873,889.1 1.17

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

72,709,111. 72,709,111. Financial liabilities

74 74Other changes

Other changes are mainly due to the company's recovery of part of the equity payment to be received.

Whether there are any significant changes in the measurement attributes of the company's main assets during the reporting period

□YesNo

4. Restrictions on asset rights as of the end of the reporting period

Item Book value Restricted monetary funds 208,591,743.96 Performance bond monetary funds 1,651,926,701.15 Bill margin monetary funds 55,500,000.00 Time deposit monetary funds 14,542,625.47 Frozen amount monetary funds 327,662.14 Others

Monetary funds 5,000,000.00 Monetary funds pledged by deposit certificates 3,000,000.00 Loan deposit notes receivable 479,021,702.70 Notes pledged notes receivable 384,793,829.51 Unrecognized discount note inventory 43,811,176.08 Mortgage loan accounts receivable 4,055,822,303.97 Mortgage loans and other current assets 65,884,827.60 Fixed assets pledged by certificates of deposit 399,953,868.25 Mortgage loan intangible assets 54,328,799.81 Mortgage loan investment real estate 44,602,913.98 Mortgage loan

Total 7,467,108,154.62

6. Investment status analysis

1. Overall situation

Applicable□Not applicable

Investment amount during the reporting period (yuan) Investment amount during the same period last year (yuan) Change range

106,581,515.39 379,027,763.82 -71.88%

2. Major equity investments obtained during the reporting period

□ApplicableNot applicable

3. Major non-equity investments ongoing during the reporting period

□ApplicableNot applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

4. Financial asset investment

(1) Securities investment situation

□ApplicableNot applicable

The company had no securities investments during the reporting period.

(2) Derivatives investment situation

□ApplicableNot applicable

The company had no derivative investments during the reporting period.

5. Usage of raised funds

□ApplicableNot applicable

The company has no use of raised funds during the reporting period.

7. Sale of major assets and equity

1. Sale of major assets

□ApplicableNot applicable

The company did not sell any major assets during the reporting period.

2. Sale of major equity interests

□ApplicableNot applicable

8. Analysis of major holding and participating companies

Applicable□Not applicable

Information about major subsidiaries and joint-stock companies that affect the company's net profit by more than 10%

Unit: yuan Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit Neptune Medical

Equipment (Part 1) 1,489,681,5 170,364,04 1,709,008,8 70,183,968. 52,248,105.

Subsidiary Pharmaceutical Distribution 50 million yuan

Hai) Co., Ltd. 02.27 1.92 64.10 99 13Company

Fuzhou Neptune

435,624,47 364,799,51 159,705,13 113,299,41 113,854,55Fuyao Pharmaceutical Subsidiary Pharmaceutical Distribution 30 million yuan

0.63 5.11 0.41 7.80 9.53 Co., Ltd.

Acquisition and disposal of subsidiaries during the reporting period

Applicable□Not applicable

Company name Method of acquiring and disposing of subsidiaries during the reporting period Impact on overall production, operation and performance Hangzhou Infinite Fire Brand Management Co., Ltd. Sale Has a positive impact on the company's performance during the reporting period Shanghai Bohui Health Technology Co., Ltd. Sale Has a small impact on the company's performance during the reporting period Shanghai Neptune Enterprise Development Co., Ltd. Sale Has a positive impact on the company's performance during the reporting period Neptune (Yangjiang) Pharmaceutical Co., Ltd. Sale Has a small impact on the company's performance during the reporting period Zhongshan Changjian Pharmaceutical Co., Ltd. Sale Has a positive impact on the company's performance during the reporting period

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Henan Neptune Medical Technology Co., Ltd. For sale Has a positive impact on the company's performance for this reporting period Neptune Baicaotang Pharmaceutical Co., Ltd. For sale Has a small impact on the company's performance for this reporting period The establishment of Hangzhou Haige Yuexiang Health Technology Co., Ltd. will not have an impact on the company’s performance for this reporting period. It will not have an impact on the company’s performance for this reporting period.

The establishment of Hangzhou Haiqian Medical Technology Co., Ltd. had a minor impact on the company’s performance during the reporting period.

9. Structured entities controlled by the company

□ApplicableNot applicable

10. Risks faced by the company and countermeasures

1. Structural adjustment of the pharmaceutical distribution industry

At present, my country's pharmaceutical distribution industry has gradually shifted from the early stage of "horse racing" M&A expansion to a stage of high-quality development. Leading pharmaceutical distribution companies are more stringent and cautious in selecting M&A targets when making external mergers and acquisitions, and pay more attention to the regional and product line reinforcements that M&A targets can bring to them. As the number of high-quality M&A targets gradually decreases, the pace of M&A by leading companies has also slowed down significantly, and the growth rate of goodwill has dropped significantly compared with the past. Affected by national policies such as centralized procurement, the overall profit margin of the pharmaceutical distribution industry will be affected, and it may fall into the dilemma of "increasing revenue without increasing profits".

In order to deal with potential risks, the company will continue to pay close attention to industry and market dynamics, continue to strengthen research and analysis of industry policies, and take countermeasures in advance to adapt to market changes. The company has taken multiple measures to extend the supply chain layout and increase profits through "wholesale and retail collaboration", "industrial and commercial collaboration", "pharmaceutical device collaboration" and other aspects. At the same time, it continues to promote digital transformation with the empowerment of artificial intelligence and big data.

2. Decision-making risks

With the continuous changes in pharmaceutical distribution industry trends, policy environment, competitive situation and other factors, management decision-making has been posed with great challenges. In order to consolidate their industry position, leading companies in the industry continue to carry out strategic transformation and diversified development externally. Internally, they focus on supporting business sectors with high profit margins through resource integration, and expand their advantages through talent introduction and resource tilting.

As a private enterprise, the company's management must have a high degree of foresight and keen insight into the industry, accurately grasp the direction of industry policies, and formulate strategic plans that are consistent with the company's actual situation; at the same time, it also needs to pay close attention to market feedback and business completion, and timely adjust business strategies to ensure the stability and development of the company's business. In order to reduce decision-making risks, the company strengthens the construction of internal decision-making mechanisms, improves decision-making processes and decision-making support systems, and improves the scientificity and accuracy of decision-making.

3. Manage risks

As volume-based procurement continues to advance, the payment terms of upstream suppliers are strict, the payment period is shortened, and the prepayment ratio is increased; the current repayment period of medical institutions is extended, which increases the company's cash flow pressure; in addition, as a private enterprise, the company's financing costs are high, the company's capital turnover efficiency decreases, and capital efficiency declines, thus further compressing the company's profit margins.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Pharmaceutical distribution companies are highly sensitive to accounts receivable. The gradual deepening of national procurement policies has a certain delaying effect on the growth of accounts receivable of pharmaceutical distribution companies. However, under the background of pressure on local finance and medical insurance payments, the industry's trend of extending the account period is still difficult to reverse. Although leading companies maintain good risk resistance and credit levels, the industry as a whole still faces certain short-term debt repayment pressure. With the National Medical Insurance Administration and the Ministry of Finance proposing the establishment of a prepayment system, the capital turnover situation of pharmaceutical distribution companies may improve in the future.

(1) Funding structure

The pharmaceutical circulation industry is capital-intensive. In order to effectively deal with cash flow risks, companies need to pay close attention to market dynamics and policy changes. While stabilizing traditional business scale, they should strengthen the daily management of accounts receivable, inventory, prepaid accounts and other capital-occupied projects, compress inefficient and ineffective operating capital occupation, and improve the efficiency of overall fund utilization. At the same time, the company optimizes the capital structure through various measures such as improving the business structure, continues to strengthen capital management, improves the efficiency and effectiveness of capital use, and makes funds flow to businesses with high benefits. The company continues to prudently plan its financing structure and actively seeks low-cost, stable sources of funds to reduce financing management risks.

(2) Accounts receivable collection management

The company's downstream customers are mainly public hospitals of level two or above. These customers have good credit and guaranteed payment. Affected by factors such as the medical reform bidding policy, the efficiency of fund allocation and the speed of payment collection by downstream customers have shown a downward trend. There is a certain risk of extending the account period of downstream customers, which will affect the company's capital turnover efficiency.

The company has always attached great importance to the management of accounts receivable, and has currently established a management team with the chief financial officer as the chief responsible person to strengthen the management of accounts receivable, ensure timely reconciliation and collection of accounts receivable, and gradually reduce the balance of accounts receivable and reduce the risk of bad debt losses in accounts receivable.

In 2025, the company will focus on the management of accounts receivable. All regional groups, branches and subsidiaries should thoroughly implement overdue accounts receivable in 2025 and try to reduce accounts receivable with a maturity of more than one year. Each regional group and subsidiary will set up a special working group to collect overdue accounts receivable, determine the compression target of overdue accounts receivable, formulate reward and punishment measures, and perform regular assessments to accelerate the company's capital withdrawal, reduce financial costs, and ensure the company's operational security.

(3) Operation and management risks

Combined with the company's operating conditions and actual management requirements, the company has adopted comprehensive risk management measures to control the company from multiple levels and angles. In terms of management model, the company currently implements a flat three-level management and control model of headquarters-regional group-regional group subsidiaries to effectively manage subsidiaries; in terms of subsidiary governance, the company implements standardized legal person governance for all companies, and supervises the shareholders' meeting, board of directors, supervisory committee, etc. The rights and responsibilities of the board of directors and management are clearly defined and implemented, and their respective powers are constrained; in internal core positions, the financial directors of subordinate companies, the human resources directors, legal directors and audit directors of each regional group company are directly appointed and managed by the company. Through the above methods, the company has achieved effective management of its subsidiaries in terms of finance, operations, internal control, and human resources.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Since the pharmaceutical distribution industry involves many aspects such as drug procurement, storage, and distribution, it has high requirements for employees' professional quality, responsibility, and professional ethics. In order to ensure compliance operations and improve the overall quality of employees, the company has established a complete training, incentive, and restraint mechanism to improve employees' professional quality and loyalty, and reduce personnel management risks.

11. Formulation and implementation of market value management system and valuation improvement plan. Whether the company has formulated a market value management system.

□YesNo

Whether the company has disclosed plans to increase its valuation.

□YesNo

12. Implementation of the “Double Improvement of Quality and Return” action plan

Has the company disclosed an announcement on the “Dual Improvement of Quality and Return” action plan?

□YesNo

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 4 Corporate Governance, Environment and Society

1. Changes in directors, supervisors and senior managers of the company

Applicable□Not applicable

Name Position held Type Date Reason

Yang Shuancheng Vice President Retired on April 14, 2025

2. Profit distribution and conversion of capital reserve funds into share capital during the reporting period

□ApplicableNot applicable

The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital in the first half of the year.

3. Implementation of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

□ApplicableNot applicable

The company has no equity incentive plan, employee stock ownership plan or other employee incentive measures and their implementation during the reporting period.

4. Environmental information disclosure

Whether listed companies and their major subsidiaries are included in the list of companies that disclose environmental information in accordance with the law

Yes□No

Number of companies included in the list of companies that disclose environmental information in accordance with the law 4 Serial number Company name Query index of environmental information disclosure reports in accordance with the law Notice of the Shenzhen Municipal Ecological Environment Bureau on publishing the list of companies that disclose environmental information in accordance with the law in 2025

1 Shenzhen Neptune Bioengineering Co., Ltd.

https://meeb.sz.gov.cn/gkmlpt/content/12 /12145/mpost_12145445.html#3767

Announcement on the release of the "Fuzhou City's 2025 List of Enterprises Disclosing Environmental Information in accordance with the Law"

2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.

https://www.fuzhou.gov.cn/zgfzzt/shbj/zz bz/tzgg/202503/t20250331_4997093.htmAnnouncement on the announcement of the "Fuzhou City's 2025 List of Enterprises Disclosing Environmental Information in accordance with the Law"

3 Fuzhou Neptune Jinxiang Traditional Chinese Medicine Pharmaceutical Co., Ltd.

https://www.fuzhou.gov.cn/zgfzzt/shbj/zz bz/tzgg/202503/t20250331_4997093.htm Miyun District’s list of companies that disclose environmental information in accordance with the law in 2025

4 Beijing Neptune Zhongxin Pharmaceutical Co., Ltd.

https://www.bjmy.gov.cn/zwgk/gsgg/202 503/t20250324_485599.html

5. Social Responsibility

The company adheres to the national employment stabilization policy and actively fulfills its social responsibilities. During the reporting period, the company kept its mission in mind and shouldered the important task of ensuring supply. It also did its best to fulfill its social responsibilities as a listed company in terms of paying taxes in accordance with the law and giving back to the society.

(1) Some social donations:

Serial number Date Donation project name Donation amount (10,000 yuan) Donating company name

1 In February 2025, great love and charity, warm the community - Neptune Medical Love Donation Project 25 (100,000 yuan in cash, 150,000 yuan in kind) Neptune Medical Equipment (Shanghai) Co., Ltd.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Title (Second Issue) Product) Division

"Zao Huibao 2025" project (donating to Zaozhuang Charity Federation

2 This amount will be donated in June 2025 specifically to purchase jujube benefits for people living on minimum living allowances 5.25 Sulu Haiwang Pharmaceutical Group Co., Ltd.

insurance)

(2) Some important awards and honors:

Serial number Date Major events (honor) Unit

1 January 2025 Advanced unit of Zaozhuang CPPCC Member Consultation Chamber Sulu Neptune Pharmaceutical Group Co., Ltd. 2 January 2025 Smith & Nephew 2024 "Bright Star" best partner Neptune Medical Equipment (Shanghai) Co., Ltd. 3 February 2025 Enterprise with outstanding contributions to the city's high-quality development in 2024 Shandong Neptune Galaxy Pharmaceutical Co., Ltd. 4 February 2025 Advanced grassroots party organization in Xiaogan National High-tech Zone Hubei Neptune Pharmaceutical Group Co., Ltd. 5 February 2025 Kawa-Ormco Best Strategic Cooperation Award Neptune Medical Equipment (Shanghai) Co., Ltd. 6 February 2025 Top 100 Enterprises in Yangpu District in 2024 Neptune Medical Equipment (Shanghai) Co., Ltd. 7 February 2025 Fuzhou Federation of Trade Unions awarded the "Worker Pioneer Award" Fuzhou Neptune Fuyao Pharmaceutical Co., Ltd.

Third Prize in the 2024 Fuzhou Employees “Five Small” Innovation Competition (Compound Amino Acid Injection

8 February 2025 Technical improvement of nitrogen charging method in liquid production process of Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.)

The Neptune Modern Intelligent Pharmaceutical Logistics Park project was shortlisted for key projects in the modern service industry in Shandong Province

9 March 2025 Shandong Neptune Galaxy Pharmaceutical Co., Ltd. inventory

2024-2025 "Pharmaceutical Cold Chain Logistics Service Recommended Enterprise", "Pharmaceutical Cold Chain

10 March 2025 Shandong Neptune Galaxy Pharmaceutical Co., Ltd.

Best Logistics Center (Base)”

11 March 2025 2024 Operation and Management Benchmark Enterprise Sulu Neptune Pharmaceutical Group Co., Ltd. 12 April 2025 Ingram Best Strategic Cooperation Award Neptune Medical Devices (Shanghai) Co., Ltd.

Fuzhou Neptune Fuyao Pharmaceutical Co., Ltd., 13 April 2025, the Fujian Provincial Department of Commerce announced the seventh batch of "Fujian Time-honored Brands"

Fuzhou Neptune Jinxiang Traditional Chinese Medicine Pharmaceutical Co., Ltd. 14 May 2025 "Pharmaceutical Cold Chain Logistics Operation Specifications" National Standard Compliance Enterprise Sulu Neptune Pharmaceutical Group Co., Ltd. 15 June 2025 Medtronic FY25 Annual Innovation Pioneer Award Neptune Medical Devices (Shanghai) Co., Ltd.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 5 Important Matters

1. Commitments made by the company’s actual controller, shareholders, related parties, acquirers, the company and other relevant parties that have been fulfilled during the reporting period and have been overdue and unfulfilled as of the end of the reporting period

□ApplicableNot applicable

During the reporting period of the company, there were no commitments made by the company's actual controller, shareholders, related parties, acquirers, the company and other relevant parties that were fully fulfilled during the reporting period and that were overdue and unfulfilled as of the end of the reporting period.

2. Non-operating capital occupation of listed companies by controlling shareholders and other related parties □ Applicable  Not applicable

During the company's reporting period, there was no non-operational occupation of funds by the controlling shareholder or other related parties of the listed company.

3. Illegal external guarantees

□ApplicableNot applicable

The company had no illegal external guarantees during the reporting period.

4. Appointment and dismissal of accounting firms

Has the semi-annual financial report been audited?

□YesNo

The company's semi-annual report has not been audited.

5. Explanations of the Board of Directors and the Board of Supervisors on the “non-standard audit report” of the accounting firm for this reporting period □ Applicable  Not applicable

6. Explanation of the Board of Directors on the “Non-standard Audit Report” of the previous year □ Applicable  Not applicable

7. Matters related to bankruptcy and reorganization

□ApplicableNot applicable

The company had no bankruptcy or reorganization related matters during the reporting period.

8. Litigation matters

Major litigation and arbitration matters

Applicable□Not applicable

Litigation (Arbitration) Litigation (Arbitration) Litigation (Arbitration) Amount involved Whether a pre-litigation (arbitration) is formed

Trial results and execution of judgment Disclosure date Basic information on disclosure index (10,000 yuan) Liability calculation progress

Impact The full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Litigation (Arbitration) Litigation (Arbitration)

Litigation (Arbitration) Amount involved Whether a pre-litigation (arbitration) has been formed

Trial results and execution of judgment Disclosure date Basic information on disclosure index (10,000 yuan) Liability calculation progress

Influence situation

Some cases have been

Completed

Complete, some cases

The item is being fulfilled

Among them, some of the lawsuits are mainly against companies

Detailed content of litigation and arbitration cases. As a plaintiff,

Seeing that the company has not yet heard the case, please ask the other party to pay.

In April 2025, the company and its holdings have been tried or have not yet owed the company

On the 19th, 2025 subsidiaries continued to close cases and some receivables

Litigation, arbitration, etc. within twelve months from August 30, 2020, the company will

Published in "Certificate that some of the cases that have occurred cumulatively have not yet been implemented and legal action has been taken."

The case of Securities Times as the plaintiff is currently being tried (the ruling has been completed, and other measures have been strengthened)

April 2025 "Securities Day Litigation Summary" or execution of the company's current operating activities

37,566.95 No On the 19th, 2025, "China General Corporation" (including the purchase stage, part of the profits or related amounts after the period

On August 30, 2019, Securities News reported that the sale contract dispute case has been implemented and the recovery work will have an impact on profits.

"Shanghai Securities Disruption and Equity Repurchase Completed. There is uncertainty about maintenance companies and

newspaper" and Juchao purchase disputes and losses, the company will protect the legal rights of shareholders

Dispute over compensation for damage caused by online publication of information based on accounting standards, interests, part

The requirements and cases of the published "Regarding Etc." are being answered one after another

Add the actual amount of accumulated lawsuits at that time.

Litigation and arbitration are progressing, and some cases have been

The accounting department responsible for the announcement of the situation has completed the review.

Reason, specifically based on

Company audited

financial reports

shall prevail.

Some cases have been

Completed

Complete, some cases

The item is being fulfilled

in part

Details of litigation and arbitration cases

Seeing that the company's case has not yet been heard in court

Mainly involving merger companies and holdings in April 2025, which may not be heard yet

In the same dispute, on the 19th, 2025 subsidiaries closed the cases consecutively, and some

Work Contract Litigation and Arbitration Within 12 months from August 30, 2018

Disputes and labor are published in "Certificate of Accumulated Cases. Some of the cases are pending. The cases have not yet been executed."

The contract dispute involving Securities Times as the defendant is currently being tried (the ruling has been completed, and the other

etc., the company will resolve the "Securities Day Litigation Situation" in April 2025) or implement the current period of the company's

4,298.11 No Actively and properly deal with the 19th, 2025 "China General Corporation (including the merger stage), part of the profits or post-period profits"

Settle relevant disputes and increase the impact on profits.

Regarding the litigation matters, the maintenance of the "Shanghai Securities Industry Contract Contract" was completed. There is uncertainty

"Protect the company and stock newspapers" and huge tide disputes and labor issues, the company will

East interests. Information online publishing contract disputes based on accounting standards

Some cases have been published in the "On Etc."

The trial is completed. Add the actual cumulative lawsuit date

Litigation and arbitration situations

Announcement of the situation to the accounting office

Reason, specifically based on

Company audited

financial reports

shall prevail.

Other litigation matters

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

□ApplicableNot applicable

9. Punishment and Rectification

□ApplicableNot applicable

There were no penalties or rectifications during the company's reporting period.

10. Integrity status of the company, its controlling shareholders and actual controllers

Applicable□Not applicable

During the reporting period, the company's controlling shareholders and actual controllers were in good faith, and there were no large amounts of debt that were due and unpaid.

11. Major related transactions

1. Related transactions related to daily operations

Applicable□Not applicable

approved

Related sharing can be obtained

Is the related intersection related?

Related, related, related, related, transaction, quasi-transaction

Related party transaction amount exceeds transaction disclosure disclosed transaction transaction transaction transaction amount Yijin similar

Relationship Pricing Approval Settlement Date Indexer Type Content Price (10,000 Amount Transaction

Principle (10,000 amount method

Yuan) Ratio Market Price

Yuan)

My Lord

Si Xiang

Aquaman

Group

sales

My husband, the daily life of the great tide, both sides

Si Zi Information Correlation Author

Produce or NetNeptune Transaction Reciprocity

Same Sales 2025 (http:/Group (Sales Mutual

Actual profit of 5,294.47,50 Year 04/www and its sellers, - 0.20% No Cash -

Control of goods; 80 October 29. cninf son of goods, fairness

Person Our Company Japan o.com Company Procurement Transaction

Sicai .cn/ne business original

Shopping w/ind products) then.

Wang Ji ex) Tuan Zi

produce or

sales

of product

product

Daily Our Company Both Parties Juchao Related Company Directions Information Transactions Neptune Mutual Benefit Network Integration 2025

(Sale Stars Mutual (http:/海王actual 9,055. 50,00 years 04

Vendor Chain Profit, - 0.33% No Cash - /www Xingchen Control 98 October 29

Products, store sales fair .cninf people day

Purchasing and selling from trading o.com products or original .cn/ne products) agency rules. w/ind

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

product ex)

14,35 97,50Total -- -- -- -- -- -- -- --

0.78 0Details of return of large sales None

Daily correlations that will occur in this period by category

The total amount of transactions carried out is estimated, as reported N/A

Actual performance during the period (if any)

The difference between the transaction price and the market reference price is relatively

Not applicable

Big reason (if applicable)

2. Related transactions arising from asset or equity acquisition and sale

□ApplicableNot applicable

The company had no related transactions involving acquisition or sale of assets or equity during the reporting period.

3. Related transactions related to joint external investment

□ApplicableNot applicable

The company had no related transactions involving joint external investments during the reporting period.

4. Related credit and debt transactions

Applicable□Not applicable

Whether there are non-operating related creditor's rights and debt transactions

Yes□No

Claims receivable from related parties

Not applicable.

Debts payable to related parties

New additions in this period Return of opening balance in this period Interest in this period Closing balance Related party Related relationship Reason for formation Amount (ten thousand) Amount (ten thousand) Interest rate (ten thousand yuan) (ten thousand yuan) (ten thousand yuan)

Yuan) Yuan) Neptune Group

Same actual situation to related parties

and its subsidiaries 1,757.88 44,300.00 33,648.25 0.00% 0 12,409.63

Controller borrows funds

Division

Related debts have a negative impact on the company’s operations

None

impact on results and financial condition

5. Dealings with related financial companies

□ApplicableNot applicable

There are no deposits, loans, credit or other financial business between the company and its related financial companies and related parties.

6. The transactions between the financial company controlled by the company and related parties

□ApplicableNot applicable

There are no deposits, loans, credit or other financial business between the financial companies controlled by the company and related parties.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

7. Other major related transactions

□ApplicableNot applicable

The company had no other major related transactions during the reporting period.

12. Major contracts and their performance

1. Custody, contracting and leasing matters

(1) Custody situation

□ApplicableNot applicable

There was no custody situation during the company's reporting period.

(2) Contracting situation

□ApplicableNot applicable

There was no contracting situation during the reporting period of the company.

(3) Leasing situation

Applicable□Not applicable

Rental situation description

1. The company serves as the lessee

Lessor’s name Type of leased assets Lease payments payable in the current period Lease payments payable in the previous period Neptune Group Neptune Galaxy Technology Building Office Building 10,696,626.32 3,939,612.93

2. The company’s new right-of-use assets as a lessee in the current year:

Lessor’s name Type of leased assets Increased in the current period Increased in the previous period Neptune Group Neptune Galaxy Technology Building office building 12,397,518.75 14,425,595.65

3. The interest expense on lease liabilities borne by the company as the lessee in the current year:

Lessor’s name Type of leased assets Interest expense for the current period Interest expense for the previous period Neptune Group Neptune Galaxy Technology Building office building 185,573.60 417,687.43

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Projects that bring profits and losses to the company exceeding 10% of the company's total profit during the reporting period

□ApplicableNot applicable

During the company's reporting period, there were no leasing projects that brought profits or losses to the company that accounted for more than 10% of the company's total profits during the reporting period.

2. Major guarantee

Applicable□Not applicable

Unit: 10,000 yuan

External guarantees provided by the company and its subsidiaries (excluding guarantees to subsidiaries)

Guarantee amount Counter guarantee

Is the collateral related to the guarantee? Amount of guarantee actually issued. Actual guarantee. Guarantee type situation. Whether it has been fulfilled.

(For example, guarantee period, name of related party, announcement disclosure, date of birth, insured amount type (if completed, yes), guarantee disclosure date, yes)

debt period

2024

Joint and several liability limit expires

June 28, 2024 500 None Yes Yes No From the date of guarantee

April 8

two years

Shaanxi Hairi,

debt period

Wang Yinhe 2024 2024

Joint and several liability limit expires

Medical Department May 29 2,300 June 4 1,000 None Yes Yes No

From the date of appointment of guarantee

Technology limited Japan, Japan

two years

Company 2024

debt period

February 3, 2024

Joint and several liability limit expires

Date May 28 800 No Yes Yes No Guarantee from the date

day

two years

debt period

2024

Joint and several liability limit expires

March 19 3,880.5 No Yes Yes No From the date of Hubei Hailiang guarantee

2023 day

Wang Deming two years

April 4 7,585

Medicine has debt period

Day 2024

Limited company, joint and several liability limit expires

March 22 3,500 No Yes Yes No Guarantee from the date

day

two years

debt period

2024

The joint and several liability limit expires in 2024

October 8 270 None Yes Yes No Henanhai April 8 From the date of appointment of guarantee

day

Wang Medical Day, Two Years

Tech has 2024 debt period

2025

Co., Ltd. The joint and several liability limit expires on December 3

January 14 30 No Yes Yes No Date From the date of guarantee

day

two years

External guarantees approved during the reporting period

Total external guarantee amount 10,185 Total actual amount incurred 30 (A1) (A2)

Approved at the end of the reporting period

Total external guarantee limit 10,185 Total guarantee balance 0 (A3) (A4)

The company’s guarantees for subsidiaries

Guarantee amount Collateral Counter guarantee Whether it is a guarantee pair Guarantee amount Actual issuance Actual guarantee Guarantee type Whether performance

Degree related (such as: situation, guarantee period, name of related party, date of birth, insured amount, type, completion of

Announcement disclosed (Yes) (such as guarantee

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Revealed date (yes)

Debt period 2024 2024

Joint liability Expiration date April 8 September 18 58,764 Yes No No No

Date of appointment of guarantee

Two years in Jilinhai

Debt period Wang Yinhe 2025 2025

Joint and several liability Medical investment upon expiration of time limit January 10 105,784 January 9 47,000 None None No No

The minimum capital is limited on the date of any guarantee. Day.

two years company

Debt period 2024 2024

Joint liability Expiration date January 18 January 18 48,000 None None Yes No

Date of appointment of guarantee

Two years in Changchun City

Debt term Kun Lannong 2024 2024

Joint and several liability Expiration date Ye Technology April 8 45,311 September 18 45,291 Yes No No No

Any guarantee is limited to the date of

two years division

Debt period 2025

Joint and several liability limit expires on March 24 1,000 No Yes No No guarantee date

Two-year 2024 debt period

2024

The joint and several liability limit expires on April 13

March 22 1,000 No Yes Yes No date, starting from the date of any guarantee

day

Shenzhen City in 2024

April 8 Debt Period Sham Yip Medical 2022

Date, Joint and Several Liability Limit Expiration Drug Development 2,000 September 1 41.67 None Yes No No 2023 Liability Guarantee Limited Company Date

April 4 Two-year Division

day, debt period

2024

The joint and several liability limit expires in 2022

March 25 500 None Yes Yes No April 12 From the date of guarantee

day

Date Two-year debt period 2024

The joint and several liability limit expires on April 9 400 No Yes Yes No Guarantee Date

Two-year 2025 debt period

2025

May 21: Joint and several liability limit expires

March 7 1,000 None None No No date, starting from the date of any guarantee

day

2025 April 1, two years debt period

2024

Date, joint and several liability limit expires Zhejiang Hai March 12 1,000 None None Yes No 2024 Date of liability guarantee Date

April 8 4,000 for two years of service

Japan, debt maturity company 2024

The joint and several liability limit expires in 2024

April 7 500 None None Yes No March 6 From the date of guarantee

day

Day, two years 2023 2025 debt period

jointly and severally liable

April 4 April 29 1,000 None Expiration unlimited No No

Any guarantee

day day from day day

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years

Debt period 2024

Joint and several liability limit expires on January 31 1,000 None None Yes No guarantee date

two years

Debt period 2025 2025

Expiration of joint and several liability limit February 14 February 17 3,200 None None No Date of disclaimer of guarantee Day

two years

Debt period 2024 2024

Expiration date of joint and several liability limit: April 8 August 13 3,200 None None Yes No Date of Shandong Shipping Guarantee Day

Wang Pharmaceutical Two years 6,875

The Group has a debt maturity of 2025 2025

Co., Ltd. Joint and several liability limit expires on February 14 February 24 3,675 None None No Date of disclaimer of guarantee Day

two years

Debt period 2021 2022

Expiration date of joint and several liability limit March 6 March 28 3,675 None None Yes No guarantee date Day

two years

Debt period 2025

2024 The joint and several liability limit expires on March 18 1,000 None Yes No No Binzhouhai April 8 The date of the guarantee

Wang Huanghe, 1,000 per day and two years

Pharmaceutical has 2023 debt period 2024

Co., Ltd. April 4 Joint and several liability limit expires on February 6 1,000 None Yes Yes No Date From the date of any guarantee

two years

Debt period 2024

Joint and several liability limit expires in October 2025 1,000 Yes No No No guarantee April 1-10

Two years later,

Debt period 2025 2024

Joint and several liability limit expires January 17 November 1,000 Yes No No No Guarantee Starting date, 12th

Two years to 2024

Debt period December 3, 2024

Expiration date of joint and several liability limit, November 1,000 Yes No No No No Sulu Hai 12th 2024 from the date of liability guarantee

Wang Pharmaceutical 87,938. September 3 of two years

The group has 4 debt maturities, 2024

Co., Ltd. Joint and several liability limit expires on September 26, 2024 1,000 Yes No No No guarantee April 13

Two years later,

Debt period 2024 2024

Expiration date of joint and several liability limit: April 8 September 27 1,000 Yes No No No Guarantee Date and date

two years 2023

Debt period April 4, 2025

Expiration date of joint and several liability limit April 21 1,800 Yes No No No guarantee date

two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Debt period 2025

Joint and several liability limit expires on January 23 1,000 Yes No No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on February 13 2,500 Yes No No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on January 16 2,500 Yes No No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on January 13 2,000 Yes No No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on March 4 1,000 None None Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires in December 2,500 None None Yes 13 days from the date of guarantee

two years

Debt period 2024

Joint and several liability limit expires on August 15 2,500 None None Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on July 15 2,000 None None Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on September 2 20,000 Yes No No No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on September 4 10,000 Yes No No No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on August 7 6,000 None None No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires in December 830.08 Yes No No 13 days from the date of no guarantee

two years

Debt period 2024

Joint and several liability limit expires on June 28 608.89 None None Yes No guarantee date

Two years 2025 9,951.9 Joint and several liability None None Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Two years from the expiry date of the guarantee period on April 18

Debt period 2025

11,064. Joint and several liability limit expires on January 8 None None No No

8 From the date of any guarantee

two years

Debt period 2024

3,892.2 Joint and several liability expires on June 19 None None Yes No

1 The date of any guarantee

two years

Debt period 2024

4,990.8 Joint and several liability expires on April 15 None None Yes No

7 The date of guarantee

two years

Debt period 2024

Joint and several liability Expiration date: April 15 5,000 None None Yes No

The date of appointment of guarantee

two years

Debt period 2024

10,010. Joint and several liability limit expires on April 23 None None Yes No

65 The date of any guarantee

two years

Debt period 2024

11,101. Joint and several liability limit expires on January 8 None None Yes No

62 The date of any guarantee

two years

Debt period 2024

Joint and several liability limit expires in October 5,000 None Yes No No No Jining Hailiability guarantee date 23rd, 2024

Wang Huasen April 8, two years 5,800

Pharmaceuticals has debt maturity 2024

Limited company Joint and several liability Expiration date: November 800 None Yes No No

22 days from the date of appointment of guarantee

Two-year Suluhai debt period 2023 2023

Wang Medical The joint and several liability limit expires on April 4 1,600 April 27 1,600 None Yes No No No The device has a liability guarantee. Day

Co., Ltd. two years

Debt period 2024

2025 The joint liability limit expires on August 8 1,500 None Yes No No April 15 The date of the guarantee

Date, two years 2025 Debt period 2025

Jiangsu Hai April 1 Joint and several liability limit expires on March 28 476 No Yes No No Wang Medical 3,500 days from the date of the guarantee

Limited company 2024 Two-year company September 3 Debt period 2025

Date, joint and several liability limit expires on April 15 86.31 None Yes No No 2024 Date of liability guarantee

April 8, two years, 2025, joint and several liability debt period

267.52 None Yes No No Guarantee period expires on April 18

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date Two-year debt period from the date of 2025

The joint and several liability limit expires on April 27 44.73 None Yes No Starting date of no guarantee

Two-year debt period 2025

Joint and several liability limit expires on May 12 50 No Yes No No guarantee date

Two-year debt period 2025

The joint and several liability limit expires on May 27 50 No Yes No No guarantee date

Two-year debt period 2025

Joint and several liability limit expires on January 15 2,500 None None No No guarantee date

Two-year debt period 2025

Joint and several liability limit expires

June 11 2,000 None None No No From the date of guarantee in 2025

day

April 1, two-year date, debt period

2025

The joint and several liability limit expires in 2025

February 20 2,500 None None No No February 14 From the date of guarantee

day

Date, two-year debt period 2025

2025

The joint and several liability limit expires on January 17

January 22 900 None None No No date, starting from the date of any guarantee

day

2024 December 3, two years debt period

2024

Date, joint and several liability limit expires Henanhai February 21 2,500 None None Yes No 2024 Guarantee date

April 8 27,400 Two-year Group has

Japan, debt maturity company 2024

The joint and several liability limit expires in 2024

January 24 1,500 None None Yes No May 29 From the date of guarantee

day

Date, two-year debt period 2024

2025

March 6: Joint and several liability limit expires

March 26 1,300 Yes No No No date, starting from the date of any guarantee

day

2024 February 3, two years debt period

2025

Expiration of joint and several liability limit

March 28 1,500 Yes No No No Guarantee starting from 2023

day

April 4 Two-Year Date Debt Period 2024

Joint and several liability limit expires in October 2,800 None None Yes 14 days from the date of no guarantee

Two years to 2024 Debt period joint and several liability

August 1 4,500 No Indefinite expiry Yes No Guarantee

From the date of

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years

Debt period 2024

Joint and several liability limit expires in October 740 None None Yes 23 days from the date of guarantee

two years

Debt period 2024

Joint and several liability limit expires in October 538.2 None None Yes 23 days from the date of no guarantee

two years

Debt period 2025

Joint and several liability limit expires on January 15 5,000 None None No Date of no guarantee

two years

Debt period 2024

The joint liability limit expires in December 2025 5,000 None None No June 28 25 from the date of no guarantee

Two years later,

Debt period 2025 2025

Expiration date of joint and several liability limit April 1 January 17 4,700 None None No No guarantee date, day

Two years to 2025

Debt period February 14, 2024

Expiration date of joint and several liability limit, December 3,300 None None No No guarantee date 30th, 2025

January 17 of two years

Debt maturity date, 2025

Joint and several liability limit expires on April 14, 2024 5,000 Yes No No No guarantee June 29

Two years later,

Henan East debt period 2024 2024

Sen Medical Joint and several liability limit expires on May 29 45,100 August 1 3,000 None None Yes No Limited liability guarantee Date and date

Division Two Years 2024

Debt period April 20, 2024

Expiration date of joint and several liability limit, July 30 2,000 None None Yes No guarantee date 2024

February 3 of two years

Debt maturity, 2024

Joint and several liability limit expires on July 30, 2024 2,000 None None Yes April 8 from the date of guarantee

Two years later,

Debt period 2025 2024

The joint and several liability limit expires on April 1 and February 27 400 None None Yes No Guarantee Date and date

two years 2023

Debt period April 3, 2024

Expiration date of joint and several liability limit August 5 5,000 None None Yes No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on January 10 1,500 None None No Date of no guarantee

two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Debt period 2025

The joint and several liability limit expires on April 23 75 None None No No guarantee date

two years

Debt period 2025

The joint and several liability limit expires on January 22 1,425 None None No The date from which the guarantee is disclaimed

two years

Debt period 2025

Joint and several liability limit expires on January 20 2,500 None None No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on January 24 2,000 None None Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on January 23 4,000 None None Yes No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on March 6 3,000 None None No Date of no guarantee

two years

Debt period 2024

Joint and several liability limit expires on August 26 3,000 None None Yes No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on June 23 3,000 None None No Date of no guarantee

two years

Debt period 2024

Joint and several liability limit expires on June 13 3,000 None None Yes No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on January 17 1,950 None None No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on June 30 5,000 Yes No No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on April 30 5,000 None None Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on April 25 1,000 None None Yes No guarantee date

Two years 2025 991.93 Joint and several liability Yes No Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Two years from the expiration date of any guarantee period on January 17

Debt period 2024

Joint and several liability limit expires on May 20 854.68 None None Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on June 20 2,000 None None Yes No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on March 14 2,000 No Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on March 27 500 No Yes No No guarantee date

two years

Debt period 2024

The joint and several liability limit expires on March 12, 2025 3,000 None Yes Yes No April 1 from the date of guarantee

Two years later,

Debt period 2024 2024

Joint and several liability limit expires on September 3 January 18 1,000 None Yes Yes No Guarantee Date and date

Two years to 2024

Debt period May 29, 2024

Expiration date of joint and several liability limit, August 8 5,967 None Yes Yes No Henan Hailiability Guarantee Date 2024

Wang Yinhe April 13, two years 4,000

Pharmaceuticals has debt maturity, 2024

Co., Ltd. Joint and several liability limit expires on May 16, 2024 733.6 None Yes Yes No Guarantee date is April 8

Two years later,

Debt period 2024 2024

Joint and several liability limit expires February 3 October 208.7 No Yes Yes No Guarantee date, 15th

two years 2023

Debt period April 4, 2024

Expiration date of joint and several liability limit July 30 78.9 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

The joint and several liability limit expires on July 30 720.4 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires in October 519 No Yes Yes No 15 days from the date of guarantee

Two years Henan Zuo 2025 2025 Joint liability Debt period 8,000 500 None Yes No No Jinmingyi April 1 June 25 The guarantee period expires

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Pharmaceutical Co., Ltd. Date, date of the company 2025 January 17, two years debt period

2025

Expiration of joint and several liability limit

January 23 500 None Yes No No From the date of guarantee in 2024

day

April 8 Two-Year Date Debt Period 2025

Joint and several liability limit expires on January 21 1,500 None Yes No Starting date of no guarantee

Two-year debt period 2025

Joint and several liability limit expires on January 23 2,500 None Yes No Starting date of no guarantee

Two-year debt period 2024

Joint and several liability limit expires on July 24 1,500 No Yes Yes No Guarantee Date

Two-year debt period 2024

The joint and several liability limit expires on July 29 2,500 No Yes Yes No Guarantee Commencement date

Two-year debt period 2024

Joint and several liability limit expires on August 6 390 No Yes Yes No Guarantee Date

Two-year debt period 2024

Joint and several liability limit expires in November 2,000 None Yes No 26 days from the date of no guarantee

Two-year 2025 debt period

2025

The joint and several liability limit expires on April 15

February 26 1,990 None Yes No No date, starting from the date of any guarantee

day

2025 April 1, two years debt period

2024

Expiration of joint and several liability limit

March 8 1,990 None Yes Yes No From the date of guarantee in 2025

day

February 14, two-year date, debt period

2024

In 2025, the joint and several liability limit expires. Henan En September 30 500 None Yes No No January 17 The date of guarantee for Ji Pharmaceutical.

Japan, 13,490 Two-year limited company

2024 Debt Period Division 2024

The joint and several liability limit expires on December 3

September 30 500 None Yes No No date, starting from the date of any guarantee

day

2024 September 3, two years debt period

2024

Expiration of joint and several liability limit

September 30 500 None Yes Yes No From the date of guarantee in 2024

day

June 29, two-year date, 2024 debt period

jointly and severally liable

September 30, 2024 500 None Limited expiration Yes No

Any guarantee

From April 13th

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date, two years 2024 Debt period 2024

April 8 Joint and several liability limit expires in November 280 Yes Yes No No date, 28 days from the date of any guarantee

2024 February 3 of two years Debt period 2025

Date, joint and several liability limit expires on May 15 80 Yes No Yes No 2023 The date of the guarantee

April 4 Two-Year Date Debt Period 2025

The joint and several liability limit expires on May 15 40 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on May 15 80 Yes Yes No No Guarantee Commencement date

two years

Debt period 2025

Joint and several liability limit expires on January 16 40 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on February 19 90 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on February 19 110 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on February 19 80 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on August 19 40 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on August 19 280 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on April 20 200 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on April 20 200 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires in December 1,000 None Yes No 31 days from the date of no guarantee

two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Debt period 2024

Joint and several liability limit expires on July 12 500 No Yes No No guarantee date

Two-year debt period 2024

Joint and several liability limit expires on June 3 500 No Yes Yes No Guarantee Date

Two-year debt period 2024

Joint and several liability limit expires in December 4,000 Yes Yes No No 23 days from the date of guarantee

Two-year debt period 2024

Joint and several liability limit expires in December 2,000 Yes Yes No No 25 days from the date of guarantee

two-year debt period

2024

The joint and several liability limit expires in 2024

November 6 1,000 Yes Yes No No Anyangheng April 8 From the date of appointment of guarantee

day

Peak Medicine Day, Two Years

1,000

Limited company 2024 debt period

2024

Company’s joint and several liability limit expires on May 29

October 1,000 No Yes Yes No Day 14 days from the date of guarantee

Two-year debt period 2025

Joint and several liability limit expires on January 9 1,000 None Yes No Starting date of no guarantee

Two-year debt period 2025

Joint and several liability limit expires on January 20 1,000 None Yes No From the date of no guarantee

day

2025 April 1, two years debt period

2025

Expiration of joint and several liability limit

2月6 1,000 无 有 否 否2025年 任担保 之日起

day

February 14, two-year date, debt period Henanhai 2024

2024年 连带责 限届满王汇通 7月16 400 无 有 是 否04月 6,000 任担保 之日起医药有 日

13th, two-year limited company

2024 debt period

2025

April 8: Joint and several liability limit expires

6月10 700 无 有 否 否日、 任担保 之日起

day

2023 April 4, two years debt period

2025

Date The joint and several liability limit expires on June 5 800 No Yes No No guarantee date

Two-year debt period 2025

The joint and several liability limit expires on May 28 340 None Yes No Starting date of no guarantee

two years

2025 660 Joint and several liability None Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Two years from the expiration date of any guarantee period on May 29

Debt period 2024

Joint and several liability limit expires on March 25 500 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on May 13 1,000 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on June 12 800 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on June 27 700 No Yes Yes No Guarantee Date

two years

Debt period 2025

Joint and several liability limit expires on February 11 1,250 None Yes No Starting date of no guarantee

two years

Debt period 2024

The joint and several liability limit expires on August 5 1,450 No Yes Yes No Guarantee Date

Two years 2025 Debt period 2024

April 15 The joint and several liability limit expires on July 30 670.1 None Yes Yes No Date, the date of any guarantee

2025 Two-year Henanhai April 1 Debt period 2024

Wang Medical Day, joint and several liability limit expires 1,450 October 167.2 None Yes Yes No equipment has 2024 18 days from the date of warranty

Co., Ltd. September 3, two years, debt period 2024

In 2024, the joint and several liability limit expires on July 30 321.9 None Yes Yes No April 8 The starting date of any guarantee

day two years

Debt period 2024

Joint and several liability limit expires in October 265.7 No Yes Yes No 23 days from the date of guarantee

two years

Debt period 2024

Joint and several liability limit expires on June 11 1,000 No Yes Yes No Guarantee Commencement date

Two years to 2025 Debt period to 2025

Ningxia Hai April 15 Joint and several liability limit expires on January 9 1,400 Yes Yes No No Wang Medical 11,400 days from the date of liability guarantee

Co., Ltd. 2025 Two-year company April 1, 2025 Joint and several liability Debt period 2,000 Yes Yes No No Date, March 20 The guarantee limit expires

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The debt period is two years from January 17, 2025

2024

The joint and several liability limit expires in 2024

November 800 Yes Yes No No From the date of guarantee on December 3

26th

Date, two-year debt period 2024

2024

The joint and several liability limit expires on September 3

July 26 800 Yes Yes No No date, starting from the date of any guarantee

day

2024 April 13, two years debt period

2024

Expiration of joint and several liability limit

March 18 2,000 None Yes Yes No From the date of guarantee in 2024

day

April 8, two-year date, debt period

2024

The joint and several liability limit expires in 2023

July 26 800 None Yes Yes No April 4 From the date of guarantee

day

Date Two-year debt period 2024

Joint and several liability limit expires on December 6 550 No Yes No No guarantee date

Two-year debt period 2025

Joint and several liability limit expires on January 26 1,000 No Yes No No guarantee date

Two-year debt period 2024

Joint and several liability limit expires on February 29 500 No Yes Yes No Guarantee Starting date

two years

Debt period 2024 2024

Joint liability Expiration date: April 8 August 9 1,800 None Yes No No

Date of appointment of guarantee

Two years of Xinjiang sea

Debt period Wang Hongkang 2025 2025

Joint and several liability Expiration of time limit Medical Department April 1 4,800 April 22 3,000 Yes Yes No No

Any guarantee will start on a limited date.

two years company

Debt period 2023 2024

Joint liability Expiration date April 4 March 24 3,000 None Yes Yes No

Date of appointment of guarantee

Two-year 2025 debt period

2024

April 1 The joint and several liability limit expires

July 10 2,000 No Yes No No date, starting from the date of any guarantee

day

2024 Two-year Kashgar Sea

December 3 Debt Period Wang Yinhe 2024

Date, 11,800 Joint and several liability limit expires Pharmaceutical Yes September 29 3,000 No Yes No No 2024 Date of any guarantee Date

September 3, two-year date, 2024 debt period

jointly and severally liable

November 5, 2024 3,000 None Limited expiration No No

Any guarantee

From the date of April 8th

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date Two-year debt period 2024

Joint and several liability limit expires on July 25 100 No Yes No No guarantee date

Two-year debt period 2024

Joint and several liability limit expires on August 14 1,000 No Yes No No guarantee date

Two-year debt period 2024

Joint and several liability limit expires on September 13 1,000 No Yes No No guarantee date

Two-year debt period 2024

Joint and several liability limit expires on August 5 100 No Yes Yes No Guarantee Date

Two-year debt period 2025 2025

Expiration date of joint and several liability limit April 1 February 26 1,500 None Yes No No guarantee date Day

Two-year debt period 2024

Joint and several liability limit expires

May 21 500 No Yes Yes No From the date of Henan Guan’s guarantee

day

Baoyuntong two years

2,800

Pharmaceutical industry has debt period

2024 2024

Co., Ltd. Joint and several liability limit expires on April 8 April 26 300 No Yes Yes No Guarantee Day

Two-year debt period 2024

Joint and several liability limit expires on July 12 74.76 No Yes Yes No Guarantee Date

两年河南海 债务期

2024 2024

王康瑞 连带责 限届满

April 8 800 December 800 None None No No Pharmaceutical has any guarantee from the date of

Day 27

Ltd. Two-year debt period 2024

The joint and several liability limit expires in 2024

September 25 1,700 None None No No Hubei Hai April 8 From the date of appointment of guarantee

day

Wang Medical Day, two years

8,000

集团有 2024年 债务期

2024

Co., Ltd. May 29 Joint and several liability limit expires in October 2,000 None None No No Day 20 days from the date of any guarantee

两年2024年 债务期2024年

The joint and several liability limit expires on April 13

June 27 800 No Yes No No Hubei Hai, from the date of any guarantee

day

Wang Pengtai 2023 two years

1,880

医药有 4月4 债务期

2024

Co., Ltd. Date, Joint and several liability limit expires on February 29 882 None Yes No No 2024 Date of liability guarantee

April 8 two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date Debt period 2024

Joint and several liability limit expires on June 25 1,000 No Yes Yes No Guarantee Commencement date

two years

Debt period 2025 2025

Expiration of joint and several liability limit April 1 June 23 700 None None No Date of disclaimer of guarantee Day

Two years of Neptune

Debt period (Wu 2022 2022

Joint and several liability The drug will be limited from the date of expiration of the warranty date April 12 1,800 May 23 864 None None Yes No guarantee The medicine will be limited on Day Day

two years company

Debt period 2024 2024

Expiration date of joint and several liability limit: April 8 August 12 1,000 Yes No No No guarantee date Day

two years

Debt period 2025

The joint and several liability limit expires on April 3 1,500 None Yes No From the date of no guarantee

two years

Debt period 2022

The joint and several liability limit expires on May 12 1,650 No Yes Yes No Guarantee Commencement date

two years

Debt period 2025 2025

Joint and several liability limit expires on May 21 April 16 700 None Yes No No guarantee Date and date

Two years to 2025

Debt period April 1, 2024

The joint and several liability limit expires on July 5, 2024 in Hubei Province. 1,140 No Yes Yes No guarantee Wang Kaian July 5, 2024

Two Years Morning Medicine April 8 4,100

Debt term is limited to 2025

Joint and several liability limit expires June 30, 2023 800 Yes Yes No No guarantee April 4

Two years later,

Debt period 2022 2025

Expiration date of joint and several liability limit April 12 April 15 100 None Yes No No guarantee date Day

two years

Debt period 2024

Joint and several liability limit expires on September 27 700 No Yes No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on January 9 100 No Yes Yes No Guarantee Date

Two-year Neptune 2025 Debt period 2024

(Wu April 1 Joint and several liability limit expires on September 29 1,905.2 Yes Yes No No Han) Medical day, 3,000 From the date of the guarantee 6

Pharmaceutical Development 2024 Two-year limited company December 3, 2024 231.03 Joint and several liability Yes Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Company Date, November The guarantee period expires on April 8, 2024. Two years later, the debt period is 2024.

Joint and several liability limit expires in December 383.02 Yes Yes No No 20 days from the date of guarantee

two years

Debt period 2025

Joint and several liability limit expires on January 10 328.98 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on February 19 151.7 Yes Yes No No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires in October 1,000 Yes Yes No No 18 days from the date of guarantee

two years

Debt period 2024

Joint and several liability limit expires on August 9 100 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on September 1, 900 Yes Yes No No Guarantee Starting date

Two years to 2025

Debt period April 1, 2025

Expiration date of joint and several liability limit, January 15 500 Yes Yes No No guarantee 2025

January 17 of two years

Debt maturity date, 2025

Shao Yanghai Joint and several liability limit expires on February 8, 2024 444.51 Yes Yes No No Wang Medical will be responsible for the guarantee date from April 8 7,500

Limited company, two years,

Division debt period 2023 2025

Expiration of joint and several liability limit November 11 February 2,000 Yes Yes No No Guarantee 30 days and days from the date of expiry

two years 2023

Debt period April 4, 2025

Expiration date of joint and several liability limit February 14 1,055.4 Yes Yes No No guarantee date 9

two years

Debt period 2025

The joint and several liability limit expires on May 26 166.06 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on December 3 114.63 Yes Yes No No guarantee date

Two years 2025 Joint and several liability Debt period 90.52 Yes Yes No No February 8 Guarantee period expires

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years from date

Debt period 2025

The joint and several liability limit expires on April 1 131.66 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on April 28 107.47 Yes Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on March 13 155.48 Yes Yes No No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on January 23 200 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on February 21 300 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on June 6 200.05 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on June 13 238.44 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on April 30 282.21 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

1,011.0 The joint and several liability limit expires on May 12 No Yes Yes No 6 The date of the guarantee

two years

Debt period 2024

Joint and several liability limit expires on May 15 300.17 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires on May 20 633.74 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires on May 23 349.78 No Yes Yes No Guarantee Starting date

Two years to 2024 Debt period joint and several liability

May 29 202.31 No Limited expiry Yes No Guarantee

From the date of

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years

Debt period 2024

Joint and several liability limit expires on June 20 282.24 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires on July 8 98 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires on August 7 129.93 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on September 6 146.99 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires in October 121.82 No Yes Yes No 31 days from the date of guarantee

two years

Debt period 2024

Joint and several liability limit expires on September 29 69.61 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on December 3 121.3 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires in December 206.18 No Yes Yes No 11 days from the date of guarantee

Two-year Hunanhai debt period 2024 2025

Wang Medical's joint and several liability limit expires on April 8, 900 March 31, 900 No Yes No No No Technology has liability guarantee Day

Co., Ltd. two years

Debt period 2025 2025

Expiration date of joint and several liability limit April 1 February 27 1,000 None Yes No No guarantee date Day

Two-year Changdehai debt period 2024 2024

Wang Pharmaceutical Expiration date of joint and several liability limit April 8 1,000 June 25 600 None Yes Yes No Limited liability guarantee date Day

Division two years

Debt period 2023 2024

Expiration date of joint and several liability limit: April 4 February 27 1,000 None Yes Yes No Guarantee Day

Two-year Bozhouhai debt period 2024 2025

Wang Yinhe The joint and several liability limit expires on April 8 2,500 January 17 2,500 Yes No No No No Medical has liability guarantee Day

Co., Ltd. two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Debt period 2023 2024

Expiration date of joint and several liability limit April 4 January 28 1,100 None None Yes No guarantee date Day

two years

Debt period 2025

Joint and several liability limit expires on May 8 450 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on March 17 750 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

Joint and several liability limit expires on March 10 500 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on August 13 1,400 No Yes Yes No Guarantee From the date of 2025

April 1 of two years

Debt maturity, 2024

The joint and several liability limit expires in October 2024 450 None Yes Yes No Guarantee Date April 13-21

Two years later,

Anhui Hai Debt period 2024 2025

Guoan Guoan Joint and several liability limit expires on April 8 8,400 March 4 700 Yes Yes No No No Medical has liability guarantee Date and date

Ltd. Two years 2024

Debt period March 6, 2025

Expiration date of joint and several liability limit, April 14 300 Yes Yes No No guarantee 2023

April 4 of two years

Debt maturity 2024

The joint and several liability limit expires on March 13 990 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on July 4 1,335 Yes Yes No No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on July 11 1,300 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on June 4 430 No Yes Yes No Guarantee Date

Two years 2024 Debt period Neptune Medical 2024

April 8 Joint and several liability limit expires Yao Anqing July 5 2,800 Yes Yes No No date, 3,250 Limited public date from the date of guarantee

2025 Two-year Division

April 1, 2025 450 Joint and several liability Yes Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date, April 30, 2024. The guarantee period expires on September 3, 2024. The debt period is two years.

2024

The joint and several liability limit expires in 2024

April 18 500 None Yes Yes No May 29 From the date of guarantee

day

Date, two-year debt period 2024

2024

March 6: Joint and several liability limit expires

December 1,500 None Yes Yes No Day 12 days from the date of guarantee

Two-year debt period 2024

Joint and several liability limit expires on September 5 1,000 No Yes Yes No Guarantee Date

two years

Debt period 2024 2024

Joint and several liability Expiration date: September 3 July 8 600 Yes Yes No No

Date of appointment of guarantee

Two-year Anhui Hai debt period 2024 2024

Wang Tiancheng Joint and several liability limit expires on April 8 2,250 June 6 400 None Yes Yes Whether the medicine has liability guarantee Day

Co., Ltd. two years

Debt period 2024 2024

Joint liability Expiration date: May 29 July 8 500 None Yes Yes No

Date of appointment of guarantee

Two-year debt period 2024

Joint and several liability limit expires on December 9 419 None Yes No From the date of no guarantee

day

2025 Two-Year Heilongjiang April 1 Debt Period

2024

Provincial Sea King Day, joint and several liability limit expires

2,000 December 1,081 None Yes No No No Medical Yes From the date of guarantee in 2025

16th

Co., Ltd. January 17, two years, debt period 2025

The joint and several liability limit expires on March 28 115 No Yes No No guarantee date

Two-year 2025 debt period

2024

The joint and several liability limit expires on April 15

September 5 5,000 None Yes No No date, starting from the date of any guarantee

day

2025 April 1 of two years Debt period Neptune Medical 2025

Date, joint and several liability limit expires on March 26 6,460 None

February 14, two years ago) Yes

Japan, debt maturity company 2024

The joint and several liability limit expires in 2025

September 25 6,460 None Yes Yes No January 17 From the date of guarantee

day

Date, two years 2024 2025 joint liability debt period

5,200 None Yes No No December 3 February 26 Any guarantee period expires

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date, date is two years from September 3, 2024. Debt period

2025

Expiration of joint and several liability limit

January 20 1,000 None Yes No No From the date of guarantee in 2024

day

April 8, two-year date, debt period

2024

The joint and several liability limit expires in 2023

February 1 1,000 None Yes Yes No April 4 From the date of guarantee

day

Date Two-year debt period 2024

The joint and several liability limit expires in November 5,200 No Yes Yes No 27 days from the date of guarantee

Two-year debt period 2025

Joint and several liability limit expires on March 11 2,000 None Yes No Starting date of no guarantee

Two-year debt period 2024

Joint and several liability limit expires on August 16 2,500 No Yes Yes No Guarantee Commencement date

Two-year debt period 2024

Joint and several liability will expire on September 25 8,500 None Yes No No

The date of guarantee is 2025

April 15 of two years

Debt maturity date, 2025

Joint and several liability will expire on May 26, 2025 2,400 None Yes No No

April 1st from the date of appointment of guarantee

Two years later,

Shanghai side debt period 2025 2024

The joint and several liability limit for medical treatment expires on January 17th 13,400 November 2,400 No Yes Yes Whether the device has a liability guarantee The 29th day

Ltd. Two years 2024

Debt period December 3, 2025

Joint and several liability Expiration date, March 11 1,000 None Yes No No

The date of any guarantee is 2024

April 8 of two years

Debt maturity 2024

Joint and several liability limit expires on August 16 1,000 No Yes Yes No Guarantee Date

Two-year 2025 debt period

2025

April 1 The joint and several liability limit expires

February 27 770 None Yes No No date, starting from the date of any guarantee

day

2025 two-year Sichuan sea

February 14 Debt Period King Medical 2025

Date, 17,100 Joint and several liability limit expires on March 14 1,050 No Yes No No 2025 Date of any guarantee Date

January 17, two-year date, 2025 debt period

jointly and severally liable

June 17, 2024 1,260 None Limited expiry No No

Any guarantee

From the date of April 8th

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Date, two years 2024, debt period 2025

February 3 Joint and several liability limit expires on January 13 4,000 No Yes No No date, the date of any guarantee

2023 April 4 of two years Debt period 2025

Date The joint and several liability limit expires on March 25 550 No Yes No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on January 16 4,000 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on July 26 210 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on July 26 420 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on July 26 210 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on July 26 210 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on July 26 140 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on July 26 140 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires on August 23 700 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on August 23 980 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires in December 500 No Yes No 19 days from the date of no guarantee

two years

Debt period 2025

Joint and several liability limit expires on January 21 150.5 No Yes No No guarantee date

two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Debt period 2025

The joint and several liability limit expires on March 13 349.5 None Yes No From the date of no guarantee

two years

Debt period 2024

Joint and several liability limit expires on July 5 500 No Yes Yes No Guarantee Date

two years

Debt period 2025

Joint and several liability limit expires on March 13 560 No Yes No No guarantee date

two years

Debt period 2025

Expiration date of joint and several liability limit April 9 1,540 None Yes No Starting date of no guarantee

two years

Debt period 2024

Joint and several liability limit expires in December 500 No Yes No 11 days from the date of no guarantee

Two years to 2025 Debt period to 2025

April 1 The joint and several liability limit expires on May 9 500 No Yes No No date, the date of any guarantee

2025 Two-year Chengdu Rui February 14 Debt period 2025

hope Trading Japan, joint and several liability limit expires 1,500 February 19 500 None Yes No No Limited liability 2025 Date of liability guarantee

The company’s two-year date is January 17, and the debt period is 2024.

2024 Joint and several liability limit expires on May 7 500 None Yes Yes No April 8 Starting date of any guarantee

day two years

Debt period 2024

Joint and several liability limit expires on June 28 500 No Yes Yes No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires in December 500 None Yes No No guarantee 11th day of 2025

January 17 of two years

Debt maturity date, 2025

The joint and several liability limit expires on April 16, 2025 100 None Yes No No guarantee will be issued from the date of Sichuan Fan April 1

Two years away from business days,

1,500 Debt term limited 2024 2025

Expiration date of joint and several liability limit February 3 March 25 200 None Yes No No guarantee Date and date

Two years to 2024

Debt period April 8, 2025

Expiration date of joint and several liability limit March 1 100 No Yes No Starting date of no guarantee

Two years 2025 600 Joint and several liability None Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The two-year debt period starts from the expiry date of June 30, 2024.

Joint and several liability limit expires on May 7 500 No Yes Yes No Guarantee Date

Two-year debt period 2024

Joint and several liability limit expires on June 28 500 No Yes Yes No Guarantee Date

Two-year debt period 2025

The joint and several liability limit expires on March 28 733.33 Yes Yes No No Guarantee Starting date

Two-year debt period 2024 2024

Expiration date of joint and several liability limit April 8 April 24 386.67 None Yes Yes No Guarantee Date and date

Two years to 2024

debt period

May 29, 2025

Neptune Medical Joint and Several Liability Limit Expired

Date, May 12 600 No Yes No No treatment delivery and no guarantee starting from the date

2025 day

Service two years

April 1 2,000

(Guang debt period

Japan, 2025

East) has joint and several liability. The limit has expired.

May 12, 2024 100 None Yes No No Limited company May 29 from the date of guarantee

Two years later,

Debt period 2024 2024

Expiration date of joint and several liability limit: April 13 July 10 200 No Yes No No guarantee date Day

Two-year debt period 2024

The joint and several liability limit expires on April 15 800 No Yes Yes No Guarantee Date

Neptune doctor for two years

Medical Delivery Debt Period

2024 2024

Service joint and several liability limit expires

May 29 2,000 May 31 1,700 None Yes No No (from the date of guarantee

day day

South) has a two-year limited company

2025 Debt period 2025

April 15 The joint and several liability limit expires on March 17 1,000 No Yes No No date, the date of any guarantee

2024 two-year Jiangsu Hai December 3 debt period

2024

Wang Medical’s day and joint liability limit expires

3,000 September 12 1,000 None Yes No No No The device is guaranteed from the date of 2025

day

Co., Ltd. January 17, two years, debt period 2024

2025 Joint and several liability limit expires on September 18 500 None Yes No No April 1 Starting date of any guarantee

Day, two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

2024 debt period

2025

April 8: Joint and several liability limit expires

January 14 500 None Yes No No date, starting from the date of any guarantee

day

2024 May 29, two years debt period

2024

Date The joint and several liability limit expires on May 23 1,000 No Yes Yes No Guarantee Commencement date

Two-year debt period 2024

Joint and several liability limit expires on January 17 500 No Yes Yes No Guarantee Date

two-year debt period

2024

Neptune's joint and several liability limit expires

September 20 989.18 None Yes No No (days from the date of guarantee 2024)

Tianjin) Medical April 8, two years 1,000

Therapeutic Technologies Debt Maturity 2024

Limited company joint and several liability limit expiration

June 14 500 None Yes Yes No The date from which the company assumes the guarantee

Two-year debt period 2025

Joint and several liability limit expires on March 7 921.05 None Yes No From the date of no guarantee

day

2025 April 15, two years debt period

2025

Expiration of joint and several liability limit

March 24 560 None Yes No No From the date of guarantee in 2025

day

April 1, two-year date, debt period

2025

The joint and several liability limit expires in 2024

April 9 1,800 None Yes No No December 3 From the date of guarantee

day

Date, two-year debt period 2024

2024

The joint and several liability limit expires on September 3

April 12 1,500 No Yes Yes No date, Guangdong Hainan from the date of guarantee

2024 Two-year King Pharmaceutical

June 29 24,600 Debt period Group has 2024

Date, joint and several liability limit expires on April 15, 2020 1,400 No Yes Yes No Guarantee starting from 2024

day

April 13, two-year date, debt period

2024

The joint and several liability limit expires in 2024

April 18 2,870 None Yes Yes No April 8 From the date of guarantee

day

Date, two-year debt period 2024

2024

March 6: Joint and several liability limit expires

May 9 230 None Yes Yes No date, from the date of any guarantee

day

2023 April 4, two years debt period

2025

Date The joint and several liability limit expires on May 14 1,995 Yes Yes No No Guarantee Commencement date

two years

2025 905 Joint and several liability Yes Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Two years from the expiry date of the guarantee period on April 18

Debt period 2025

The joint and several liability limit expires on April 27 1,600 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

Joint and several liability limit expires on April 30 500 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on March 15 2,750 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

The joint and several liability limit expires on March 26 1,900 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

The joint and several liability limit expires on April 26 2,350 No Yes Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on May 15 1,000 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires on July 15 1,500 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on July 23 2,000 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

The joint and several liability limit expires on April 9 1,500 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

Joint and several liability limit expires on April 11 1,000 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires in December 2,000 Yes Yes No No 24 days from the date of guarantee

two years

Debt period 2024

The joint and several liability limit expires on April 15 2,000 No Yes Yes No Guarantee Commencement date

Two years 2024 Joint and several liability Debt period 850 None Yes Yes No May 8 Guarantee period expires

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years from date

Debt period 2024

Joint liability expires on March 15 137.37 None Yes Yes No

The date of appointment of guarantee

two years

Debt period 2024

Joint and several liability will expire on November 8 80.33 None Yes No No

The date of appointment of guarantee

two years

Debt period 2024

Joint and several liability limit expires in October 350.08 None Yes No No

12 days from the date of appointment of guarantee

two years

Debt period 2024

Joint and several liability limit expires in October 368.45 None Yes No No

31 days from the date of appointment of guarantee

two years

Debt period 2024

Joint and several liability will expire on November 8 168.9 None Yes No No

The date of appointment of guarantee

Two years 2025 Debt period 2024

April 1 Joint and several liability limit expires in November 45.92 None Yes No No date, 14 days from the date of any guarantee

2025 February 14, two years Debt period 2024

Neptune Day, joint and several liability limit expires in November 237.44 None Yes No No (Zhan 20 days from the date of guarantee in 2024

Jiang) Medical April 8 5,000 Two-year medicine limited date, debt period 2024

Company 2024 Joint and several liability limit expires in November 128.98 None Yes No No February 3 27 days from the date of any guarantee

Date, two years 2023, debt period 2024

April 4 The joint and several liability limit expires on December 6 244.71 None Yes No No Date The date of the guarantee.

two years

Debt period 2024

Joint and several liability will expire on December 9 110.36 None Yes No No

The date of appointment of guarantee

two years

Debt period 2024

Joint liability is limited to expiry in December 286.12 None Yes No No

12 days from the date of appointment of guarantee

two years

Debt period 2024

Joint and several liability shall expire in December 27.04 None Yes No No

17 days from the date of appointment of guarantee

Two-year 2024 debt period

jointly and severally liable

December 94.42 None Limited expiry No No

Any guarantee

From the 19th

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years

Debt period 2024

Joint and several liability limit expires in December 80.92 None Yes No 26 days from the date of no guarantee

two years

Debt period 2025

Joint and several liability limit expires on January 3 198.45 None Yes No Starting date of no guarantee

two years

Debt period 2025

Joint and several liability limit expires on January 7 131.39 No Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on January 9 172.56 No Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on February 11 180.58 No Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on February 17 251.23 No Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on February 21 48.52 No Yes No No guarantee date

two years

Debt period 2025

The joint and several liability limit expires on March 7 242.53 None Yes No Starting date of no guarantee

two years

Debt period 2025

Joint and several liability limit expires on March 10 207.22 None Yes No Starting date of no guarantee

two years

Debt period 2025

Joint and several liability limit expires on March 19 243.25 No Yes No No guarantee date

two years

Debt period 2025

Joint and several liability limit expires on March 26 153.64 No Yes No No guarantee date

two years

Debt period 2025

The joint and several liability limit expires on April 3 189.54 None Yes No Starting date of no guarantee

two years

Debt period 2025

The joint and several liability limit expires on April 9 89.49 None Yes No Starting date of no guarantee

two years

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Debt period 2025

The joint and several liability limit expires on April 14 165.34 No Yes No No guarantee date

two years

Debt period 2025

The joint and several liability limit expires on April 27 52.92 No Yes No No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on March 19 178.06 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on March 20 54.20 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on March 26 133.96 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

Joint and several liability limit expires on March 28 141.63 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on April 3 416.42 No Yes Yes No guarantee date

two years

Debt period 2024

The joint and several liability limit expires on April 10 414.78 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on April 16 491.54 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires on April 23 147.70 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on April 26 153 No Yes Yes No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on May 14 273.88 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

The joint and several liability limit expires on May 23 126.83 No Yes Yes No Guarantee Starting date

Two years Neptune 2025 4,000 2024 249 Joint liability Yes Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(The guarantee period expires on April 1 and January 2) Medical Pharmaceutical Co., Ltd. will start from the date of April 8, 2024. The two-year debt period of the company is April 8, 2024.

Date, joint and several liability limit expires on February 29 270 Yes No Yes No 2023 The date of the guarantee

April 4 Two-Year Date Debt Period 2024

The joint and several liability limit expires on March 27 200 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on April 3, 300 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on April 26 480 Yes Yes No No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on June 19 201 Yes Yes No No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires on November 8 490 Yes Yes No No Guarantee Date

two years

Debt period 2024

Joint and several liability limit expires in November 100 Yes Yes No No 18 days from the date of guarantee

two years

Debt period 2025

The joint and several liability limit expires on June 26 490 Yes Yes No No Guarantee Starting date

two years

Debt period 2025

Joint and several liability limit expires on March 18, 2025 600 Yes Yes No No guarantee April 1

Two years later,

Debt period 2024 2025

Joint and several liability limit expires on June 29 March 19 600 Yes Yes No No guarantee from the date of Neptune day, day

Two years (Qing 2024

Debt maturity) Medical April 13 4,950 2025

Joint and several liability Expiration Date, March 21 700 Yes Yes No No Guarantee The company will start from the date of 2024

April 8 of two years

Debt maturity date, 2025

The joint and several liability limit expires on March 24, 2023 800 Yes Yes No No guarantee April 4

Two years ago

2025 Joint and several liability Debt period 800 Yes Yes No No March 28 The guarantee limit expires

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

two years from date

Debt period 2024

The joint and several liability limit expires on March 20 600 No Yes Yes No Guarantee Starting date

two years

Debt period 2024

The joint and several liability limit expires on March 22 1,300 No Yes Yes No guarantee date

two years

Debt period 2024

Joint and several liability limit expires on March 26 1,600 No Yes Yes No Guarantee Commencement date

two years

Debt period 2024

Joint and several liability limit expires in November 700 None Yes No 20 days from the date of no guarantee

two years

Debt period 2024

Joint and several liability limit expires in November 300 No Yes No 25 days from the date of no guarantee

two years

Debt period 2024

Expiration of joint and several liability limit in November 1,000 None Yes No No guarantee date 19th, 2025

April 1 of two years

Debt maturity date, 2025

Joint and several liability limit expires on May 13, 2024 700 None Yes No No guarantee will be issued on December 3

Two years later,

Guangxi Gui debt period 2024 2024

Lin Haiwang The joint and several liability limit expires on September 3 3,750 May 11 700 None Yes Yes Whether the medicine has liability guarantee Date and date

Ltd. Two years 2024

Debt period April 8, 2024

The joint and several liability limit expires on June 19, 2024. 300 No Yes Yes No Guarantee Date 2024

March 6, two years

Debt maturity 2024

Joint and several liability limit expires on June 28 1,000 No Yes Yes No Guarantee Date

two years

Debt period 2025

The joint and several liability limit expires on March 26 694 Yes Yes No No Guarantee Date

two years

Debt period 2024

The joint and several liability limit expires in November 770.51 No Yes Yes No 12 days from the date of guarantee

Two-year Guangxi Hai 2024 2024 Joint liability for debt period

Wang Yinhe April 8 650 December 650 None Limited expiration No No guarantee

Medicine has a date starting from the 13th

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ltd. Two-year debt period 2025

The joint and several liability limit expires on March 27 930 Yes Yes No No Guarantee Starting date

Two-year debt period 2024

The joint and several liability limit expires in November 1,000 No Yes Yes No 14 days from the date of guarantee

Approval of subsidiaries during the two-year reporting period Approval of subsidiaries during the reporting period

The company's total guarantee amount is 559,078.4 and the actual guarantee amount is 229,410.01 (B1). (B2)

Approved at the end of the reporting period

Guarantee limit for subsidiaries 559,078.4 Total actual guarantee balance 470,470.54 Total (B3) (B4)

Guarantees provided by subsidiaries to subsidiaries

Guarantee amount Counter guarantee

Is the collateral related to the guarantee? Amount of guarantee actually issued. Actual guarantee. Guarantee type situation. Whether it has been fulfilled.

(For example, guarantee period, name of related party, announcement disclosure, date of birth, insured amount type (if completed, yes), guarantee disclosure date, yes)

Debt period Beijing Hai 2024

Joint and several liability Expiration date Wang Zhongxin August 23 1,400 Yes No No No

From the date of appointment of guarantee, the pharmaceutical stocks will be

Two years limited

Debt period company 2024 2024

Expiration of joint and several liability limit (guarantee April 8 3,050 August 28 1,100 None None No No

Date of appointment of guarantee: Shenzhen day day

Two years of Zhenhaiwang

Debt maturity 2024

Joint and several liability Expired medicine limited October 500 None None No No

10 days from the date of appointment of the company as a guarantee

Two years in Shandong Sea

Wang Medical

The group has

Ltd. debt period

2024 2024

(Guarantee joint and several liability limit expires

April 8 2,000 September 27 2,000 None None No No: From the date of guarantee

day day

King of the East China Sea Two Years of Galaxy Medicine

Medicine is limited

company)

Weihaihai

Wang Medical

limited company

company (guaranteed debt period)

2025 2025

Defendant: Joint and several liability limit expires

April 1 3,000 March 26 2,950 Yes No No No From the date of Weihai Hai’s guarantee

day day

Wang Yinhe has invested in two years

Limited public service

Division)

Binzhouhai 2024 500 2024 497 Joint and several liability None Yes Debt period No No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Wang Huanghe April 8 to June 28 The guarantee period expires and the company has two years from the date of date (guarantee

Square: Mountain

King of East China Sea

Galaxy Medicine

Medicine is limited

company)

shandong sea

Wang Xinchen

Medicine has

Ltd. debt period

2024 2025

(Guarantee joint and several liability limit expires

April 8 950 January 10 925 None None No No: From the date of guarantee

day day

King of the East China Sea Two Years of Galaxy Medicine

Medicine is limited

company)

Debt period 2025

Joint and several liability limit expires on March 4 1,000 None Yes No From the date of no guarantee

day

Jininghai two years

2024

Wang Huasen debt period

April 8, 2024

Medical joint and several liability limit expires

Date, February 5 490 No Yes Yes No The limited company will provide guarantee starting from the date

2023 day

(Guaranteed for two years

April 4 2,000

Party: Su Debt period

Japan, 2024

King Lu Hai is jointly and severally liable, the limit has expired

March 28, 2024 500 No Yes Yes No From the date of medical collective guarantee

May 29

The tour is limited to two years

day

Company) Debt period 2024

Joint and several liability limit expires on August 8 1,000 None Yes No Starting date of no guarantee

Two years in Hezehai

Wang Medical

limited company

company (guaranteed debt period)

2022 2023

Defendant: Joint and several liability limit expires

April 12 998 February 24 998 No Yes No No No From the date of Sulu Hai’s appointment as guarantee

day day

Wang Pharmaceutical Group has two years of

Limited public service

Division)

Henan Zuo

Modern and Ming medicine

Medicine Limited Debt Period

2024 2024

The company’s joint and several liability limit expires

April 8 2,000 August 21 1,352 Yes Yes No No (from the date of guarantee)

day day

Side: River Two Years South Sea King

Medicine set

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Limited tour

company)

Henanhai

Wang Huitong

Medicine has

Ltd. debt period

2023 2024

(Guarantee joint and several liability limit expires

April 4 450 March 19 430 None Yes No No: He From the date of appointment of guarantee

day day

King of the South China Sea two-year medical collection

Limited tour

company)

Henan crown

Bao Yuntong

Pharmaceutical industry has

Ltd. debt period

2022 2023

(Guarantee joint and several liability limit expires

April 12 490 March 31 400 None Yes No No: He From the date of appointment of guarantee

day day

King of the South China Sea two-year medical collection

Limited tour

company)

Henanhai

Wang Wenfeng

Medicine has

Ltd. debt period

2022 2023

(Guarantee joint and several liability limit expires

April 12 490 March 29 450 None Yes No No: He starts from the date of guarantee

day day

King of the South China Sea two-year medical collection

Limited tour

company)

Debt period 2025

Joint and several liability expires on February 28 180 None Yes No No

The date of appointment of guarantee starts from Pingdingshan day

Two years of Neptune Silver 2024

Debt Period River Pharmaceuticals April 8, 2025

Joint and Several Liability Limited Expiration Sales Date, February 28 20 None Yes No No

The date of appointment of the Guarantee Co., Ltd. is 2025.

Two years (guaranteed January 17 600

Debt term: Heri, 2024

Joint and several liability Expiration date Nanhaiwang January 3, 2023 300 None Yes Yes No

Any guarantee date for medical collection is April 4th

Two-year tour limited day

Debt period company) 2024

Joint and several liability limit expires in December 300 No Yes No 28 days from the date of no guarantee

Two years in Hubei sea

Debt period Juntongyi 2024 2024

Joint and several liability Expired treatment equipment April 8 1,000 April 25 900 None None No No

Any guarantee is limited to the date of

Two years of work

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Defendant:

hubei sea

Wang Medical

The group has

Limited public service

Division)

Aquaman

(Wu

Han) medicine

Medicine is limited

Debt period company 2023 2024

Expiration of joint and several liability limit (guarantee April 4 1,000 March 29 1,000 None None No No

Date of appointment of guarantee: Lake Day Day

Two years of Beihai King

Medicine set

Limited tour

company)

Bengbu Sea

Wang Yinhe

Pharmaceutical sales

Limited sales

Debt period company 2024 2024

Expiration of joint and several liability limit (guarantee April 8 790 October 790 None Yes No No

Date of appointment of guarantee: Anniversary 18th

Huihaiwang in two years

Medicine set

Limited tour

company)

Debt period 2023

Joint and several liability limit expires on February 16 2,000 None None No From the date of no guarantee

day

Bozhouhai two years

2022

Wang Yinhe debt period

April 12, 2025

Medical joint and several liability limit expires

Date, March 20 2,000 Yes No No No Limited company from the date of guarantee

2023 day

(Guaranteed for two years

April 4 4,000

Party: An Debt period

Japan, 2024

King Huihai’s joint and several liability limit expires

February 8, 2024 2,000 None None Yes No From the date of collective medical guarantee

April 8

The tour is limited to two years

day

Company) Debt period 2024

Expiration date of joint and several liability limit April 1 2,000 None None Yes No guarantee date

Anhui sea in two years

Wang Guoan

Medicine has

Debt maturity company 2024 2025

Expiration of joint and several liability limit (guarantee April 8 200 March 25 200 None Yes No No

The date of appointment of guarantee: Ann day day

Huihaiwang in two years

Medicine set

Limited tour

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

company)

Anhui Hai debt period

2024

Wang Wannan jointly and severally liable, time limit expires

December 1,000 Yes Yes No No No The medicine has any guarantee since the date

26, 2023

Co., Ltd. two years

April 4

(Guaranteed debt period

Japan, 2025

Party: An is jointly and severally liable. The limit has expired.

January 1, 2024 800 Yes Yes No No Huihaiwang will be appointed as a guarantee from the date

April 8 1,800

Medicine Collection Two Years

day,

Limited tour

2024

company, debt period

February 3, 2024

Neptune Medical Joint and Several Liability Limit Expired

Date February 5 1,000 No Yes Yes No Drug Anqing From the date of any guarantee

day

Co., Ltd. (two years)

Debt period 2024

Joint and several liability limit expires on August 12 500 No Yes No No guarantee date

Two-year debt period 2024

Joint and several liability limit expires on August 12 400 No Yes No No 2025 From the date of any guarantee

day

Anhui Hai April 1, two years, Wang Tiancheng, day, debt period

2025

Pharmaceutical’s joint and several liability limit expires in 2024

March 14 500 Yes Yes No No Limited company September 3 From the date of appointment of guarantee

day

(Guaranteed for 12 days and 2 years

1,890

Fang: An 2024 debt period

2025

Hui Hai Wang April 8 Joint and Several Liability Limit Expired

June 27 490 No Yes No No Medical collection date, date of any guarantee

day

Group Co., Ltd. 2023 (two-year company) April 4 Debt period 2024

Date The joint and several liability limit expires on March 15 1,000 No Yes Yes No Guarantee Commencement date

Two-year debt period 2024

Joint and several liability limit expires on February 6 490 No Yes Yes No Guarantee Date

Approval of subsidiaries during the two-year reporting period Approval of subsidiaries during the reporting period

The total amount of the company's guarantees is 27,208. The total actual amount of guarantees is 9,065 (C1). Total (C2)

Approved at the end of the reporting period

Guarantee limit for subsidiaries 27,208 Total actual guarantee balance 26,082 Total (C3) (C4)

The total amount of company guarantees (i.e. the total of the first three major items)

Approval of guarantees during the reporting period Actual guarantees during the reporting period

Total quota 596,471.4 Total amount incurred 238,505.01 (A1+B1+C1) (A2+B2+C2)

Actual guarantees approved at the end of the reporting period

Total guarantee limit 596,471.4 Total balance 496,552.54 (A3+B3+C3) (A4+B4+C4)

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The actual total guarantee amount (i.e. A4+B4+C4) accounts for the company’s net

271.37% asset ratio

Among them:

Provide guarantees for shareholders, actual controllers and their related parties

The balance (D)

Directly or indirectly, for those whose asset-liability ratio exceeds 70%

496,552.54 Debt guarantee balance provided by the insured party (E)

The amount of the total guarantee exceeding 50% of the net assets

405,062.39(F)

The total amount of the above three guarantees (D+E+F) 901,614.93 For unexpired guarantee contracts, guarantee liabilities occurred during the reporting period

There may be any evidence indicating the possibility of being jointly and severally liable for repayment. Not applicable

Description of the situation (if any)

Explanation of providing external guarantees in violation of prescribed procedures (such as

Not applicable

Yes)

3. Entrusted financial management

□ApplicableNot applicable

The company did not have entrusted financial management during the reporting period.

4. Other major contracts

□ApplicableNot applicable

The company had no other major contracts during the reporting period.

13. Description of other major matters

Applicable□Not applicable

The company disclosed the "Announcement on the Termination of Changes in Control and Issuance of Stocks to Specific Targets" on June 7, 2025.

The company, Neptune Group and Silk Textile Group signed the "Dissolution Agreement on the Cooperation Agreement Regarding Shenzhen Neptune Bioengineering Co., Ltd.". Silk Textile Group and Neptune Group and its concerted parties, Mr. Zhang Simin, Mr. Zhang Feng, and Ms. Wang Fei, signed the "Resultation Agreement on the Share Transfer Agreement Regarding Shenzhen Neptune Bioengineering Co., Ltd." and the "Agreement on Waiver of Voting Rights of Shenzhen Neptune Bioengineering Co., Ltd.". This change of control of the company was terminated.

In view of the termination of the change of control of the company, the company held the third special meeting of independent directors in 2025, the 24th meeting of the 9th Board of Directors, and the 20th meeting of the 9th Board of Supervisors on June 6, 2025, and reviewed and approved matters related to the termination of the issuance of A shares to specific objects, agreed to terminate the issuance of A shares to specific objects, and signed a termination agreement for the share subscription agreement.

At present, the company's various businesses are carried out in an orderly manner, and production and operations are in normal condition. After this change of control and the termination of the issuance of shares to specific objects, the company's controlling shareholder and actual controller have not changed, and will not have an adverse impact on the company's normal operations and sustained and stable development. After the termination of the above-mentioned matters, the company will still actively negotiate with interested state-owned entities on equity cooperation matters, and explore ways to expand new development space and create new opportunities for the company through the integration of superior resources and deepening business synergy in the future.

For this termination of the change of control and the issuance of shares to specific objects, the matters contained in the "Simplified Equity Change Report (Shenzhen Neptune Group Co., Ltd.)" and the "Detailed Equity Change Report (Guangdong Guangxin Holding Group Co., Ltd., Guangdong Silk Textile Group Co., Ltd.)" disclosed by the company on July 31, 2024 did not actually occur, so the above equity change report did not take effect.

The company deeply apologizes for the inconvenience this matter has caused to investors and thanks investors for their continued attention and support to the company. The company will continue to deepen its core business, focus on resource integration and market expansion of the medical device business sector, and accelerate business transformation by optimizing industrial layout and deepening strategic cooperation.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Type upgrade. In the future, the company will continue to uphold its sound business philosophy, strive to create more benefits for investors, customers and society, and perform its information disclosure obligations in a timely manner in strict accordance with relevant regulations to effectively safeguard the legitimate rights and interests of the company and all investors.

14. Major events of the company’s subsidiaries

Applicable□Not applicable

In order to comply with the guidance of national medical and health policies, further integrate regional resources and promote innovative development in the field of pharmaceutical circulation, and at the same time deepen strategic cooperation with the Weifang Municipal Government, the company reviewed and approved the "About the Whole-Place Development Plan" at the 14th meeting of the 9th Board of Directors held on April 23, 2024. "Proposal on the Relocation of the Logistics Warehouse of the Capital Subsidiary and the Plan to Invest in the Construction of a New Smart Logistics Park", which approved the company's wholly-owned subsidiary Shandong Neptune Galaxy Pharmaceutical Co., Ltd. (hereinafter referred to as "Shandong Galaxy") to build a Neptune Smart Pharmaceutical Logistics Park. The first-phase investment of the project is expected to not exceed 298 million yuan. At the same time, the management and relevant staff are authorized to handle relocation matters within the scope of authority of the board of directors stipulated in the company's articles of association, and handle related matters such as purchasing land and building smart logistics park projects within the scope of the review quota for the above matters, including but not limited to signing relevant agreements. So far, Shandong Galaxy has signed the "Neptune Smart Pharmaceutical Logistics Park Project Contract" with the Weifang High-tech Industrial Development Zone Management Committee, and has acquired a new land parcel through bidding, auction and listing for 27.3568 million yuan; Shandong Galaxy has signed the "Neptune Modern Smart Pharmaceutical Logistics Park Project Phase I Construction General Contract" with Weifang Changda Construction Group Co., Ltd. The signing and performance of this contract are key steps to promote the implementation of the smart pharmaceutical logistics park project and provide engineering implementation guarantee for the smooth construction of the project. After the completion of the logistics park project, it will improve the efficiency of the company's logistics services and further promote the intelligent and efficient development of the company's logistics, which will help enhance the company's logistics capabilities and enhance market competitiveness.

For details, please refer to the company’s relevant announcements published in Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and Juchao Information Network on April 25, 2024 and June 28, 2025.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 6 Share changes and shareholder status

1. Changes in shares

1. Changes in shares

Unit: Before the change in share capital, increase or decrease in this change (+, -) After this change, transfer of provident fund

Quantity Proportion Issuance of new shares Bonus shares Others Subtotal Quantity Proportion

shares

1. Limited

Conditional shares 4,682,119 0.18% 0 0 0 0 0 4,682,119 0.18% shares

1. Country

0 0.00% 0 0 0 0 0 0 0.00% family holdings

2. Country

There is a legal person holding 0 0.00% 0 0 0 0 0 0 0.00% shares

3. Its

Other domestic investors hold 4,682,119 0.18% 0 0 0 0 0 4,682,119 0.18% shares

its

Medium: Domestic 0 0.00% 0 0 0 0 0 0 0.00% legal person shareholding

within the territory

Natural persons hold 4,682,119 0.18% 0 0 0 0 0 4,682,119 0.18% shares

4. Outside

0 0.00% 0 0 0 0 0 0 0.00% capital holding

its

Medium: Overseas 0 0.00% 0 0 0 0 0 0 0.00% legal person shareholding

overseas

Natural persons hold 0 0.00% 0 0 0 0 0 0 0.00% shares

2. Unlimited

2,626,441 2,626,441

Conditional shares 99.82% 0 0 0 0 0 99.82%

,138 ,138

portion

1. People

2,626,441 2,626,441

RMB Ordinary 99.82% 0 0 0 0 0 99.82%

,138 ,138

shares

2. Environment

0 0.00% 0 0 0 0 0 0 0.00% foreign-invested shares listed in China

3. Environment

Externally listed 0 0.00% 0 0 0 0 0 0 0.00% foreign-invested shares

4. Its 0 0.00% 0 0 0 0 0 0 0.00%

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

him

3. Shares 2,631,123 2,631,123

100.00% 0 0 0 0 0 100.00%Total ,257 ,257

Reasons for share changes

□ApplicableNot applicable

Approval status of share changes

□ApplicableNot applicable

Transfer status of changes in shares

□ApplicableNot applicable

Implementation progress of share buybacks

□ApplicableNot applicable

Implementation progress of using centralized bidding method to reduce and repurchase shares

□ApplicableNot applicable

The impact of share changes on financial indicators such as basic earnings per share and diluted earnings per share in the most recent year and period, net assets per share attributable to the company's common shareholders □Applicable Not applicable

Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□ApplicableNot applicable

2. Changes in restricted shares

Applicable□Not applicable

Unit: Unlocked sales restrictions in the equity period. Increased sales restrictions in this period.

Name of shareholder Number of restricted shares at the beginning of the period Number of restricted shares at the end of the period Reason for selling restrictions Release date of selling restrictions

Number of shares Number of shares

Zhang Simin 2,551,299 0 0 2,551,299 Executive locked shares Unlocked in accordance with regulations Zhang Feng 998,320 0 0 998,320 Executive locked shares Unlocked in accordance with regulations Shen Dakai 1,125,000 0 0 1,125,000 Executive locked shares Unlocked in accordance with regulations Yingrui 7,500 0 0 7,500 Executive locked shares Total unlocked according to regulations 4,682,119 0 0 4,682,119 -- --

2. Securities issuance and listing

□ApplicableNot applicable

3. Number of shareholders and shareholding status of the company

Unit: Total number of ordinary shareholders at the end of the reporting period Total number of preference shareholders with restored voting rights at the end of the reporting period

125,586 0 Number Number (if any) (see Note 8)

Shareholding status of shareholders holding more than 5% of the shares or the top 10 shareholders (excluding shares lent through refinancing)

During the reporting period Limited holdings Unlimited holdings Pledge, marking or freezing status

end of reporting period

Name of shareholder Nature of shareholder Shareholding ratio Increase or decrease Conditions for sale Conditions for sale

Number of shares held Share status Quantity

Situation Number of shares Number of shares

Shenzhen Neptune

Domestic non-state 1,216,445,1 1,216,445,1 1,214,318,8 Group shares 46.23% 0 0 Pledge

There is a legal person 28 28 78 Co., Ltd.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Hong Kong Central

Settlement Limited Overseas legal person 0.65% 17,113,132 4154841 0 17,113,132 Not applicable 0 company

Nature within the territory

Xu Linfang 0.35% 9,305,100 9305100 0 9,305,100 Not applicable 0 people

Nature within the territory

Hu Gang 0.33% 8,800,000 200000 0 8,800,000 Not applicable 0 people

Nature within the territory

Zhang Hua 0.33% 8,619,840 13300 0 8,619,840 Not applicable 0 people

Nature within the territory

Liu Dapeng 0.29% 7,500,000 7500000 0 7,500,000 Not applicable 0 people

Nature within the territory

Bai Shiwei 0.26% 6,868,200 6868200 0 6,868,200 Not applicable 0 people

Nature within the territory

Sun Yinsuo 0.22% 5,800,050 0 0 5,800,050 Not applicable 0 people

Nature within the territory

Chen Jianmin 0.18% 4,731,900 -160100 0 4,731,900 Not applicable 0 people

Nature within the territory

Xu Wenkun 0.17% 4,537,300 -9210700 0 4,537,300 Not applicable 0

people

Strategic investors or general legal persons

Became top 10 due to placement of new shares

None

The situation of shareholders (if any) (see

See note 3)

The above-mentioned shareholder related relationship or a

It is unknown whether other shareholders constitute related relationships or persons acting in concert.

instructions for action

The above shareholders are involved in entrustment/trusteeship

Voting rights and waiver of voting rights Not applicable

explanation of the situation

Buybacks exist among the top 10 shareholders

Special instructions for special accounts (if any) Not applicable

(See note 11)

Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)

Share type

Name of shareholder Number of shares without selling restrictions held at the end of the reporting period

Type of shares Quantity Shenzhen Neptune Group Co., Ltd. RMB 1,216,445,1

1,216,445,128

Company Common Stock 28

RMB general

Hong Kong Securities Clearing Company Limited 17,113,132 17,113,132 General shares

RMB general

Xu Linfang 9,305,100 9,305,100 shares

RMB general

Hu Gang 8,800,000 8,800,000 common shares

RMB general

Zhang Hua 8,619,840 8,619,840 shares

RMB general

Liu Dapeng 7,500,000 7,500,000 common shares

RMB general

Bai Shiwei 6,868,200 6,868,200 shares

RMB general

Sun Yinsuo 5,800,050 5,800,050 shares

RMB general

Chen Jianmin 4,731,900 4,731,900 common shares

RMB general

Xu Wenkun 4,537,300 4,537,300

common stock

It is unknown whether the top 10 shareholders without selling restrictions are related parties or persons acting in concert.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

between, and top 10 unlimited

Selling Conditions Shareholders and Top 10 Shares

relationship or consistency between

description of action

The company's shareholder Xu Linfang holds 9,305,100 shares through the customer credit transaction guaranteed securities account of Huatai Securities Co., Ltd.;

Company shareholder Liu Dapeng holds 7,500,000 participating shares of the top 10 ordinary shareholders through the customer credit transaction guaranteed securities account of Cathay Haitong Securities Co., Ltd.;

Description of margin trading business: The company’s shareholder Bai Shiwei holds 6,868,200 shares through the customer credit transaction guaranteed securities account of CITIC Securities Co., Ltd.; (if any) (see Note 4) The company’s shareholder Chen Jianmin holds 4,731,900 shares through the customer credit transaction guaranteed securities account of Cathay Haitong Securities Co., Ltd.;

The company's shareholder Xu Wenkun holds 4,084,700 shares through the customer credit transaction guaranteed securities account of Great Wall Securities Co., Ltd. Situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares □Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□ApplicableNot applicable

Whether the company's top 10 common shareholders and the top 10 common shareholders without selling restrictions conducted agreed repurchase transactions during the reporting period Yes  No

The company's top 10 common shareholders and the top 10 common shareholders without selling restrictions did not conduct agreed repurchase transactions during the reporting period.

4. Changes in shareholdings of directors, supervisors and senior managers

□ApplicableNot applicable

The shareholdings of the company's directors, supervisors and senior managers did not change during the reporting period. For details, please refer to the 2024 annual report.

5. Changes in controlling shareholders or actual controllers

Changes in controlling shareholders during the reporting period

□ApplicableNot applicable

The company's controlling shareholder did not change during the reporting period.

Changes in actual controller during the reporting period

□ApplicableNot applicable

The actual controller of the company did not change during the reporting period.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

6. Relevant information on preference shares □Applicable Not applicable

There were no preferred shares in the company during the reporting period.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 7 Bond-Related Information □Applicable Not Applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 8 Financial Report

1. Audit report

Has the semi-annual report been audited?

□YesNo

The company's semi-annual financial report has not been audited.

2. Financial statements

The unit of statements in the financial notes is: Yuan

1. Consolidated balance sheet

Prepared by: Shenzhen Neptune Bioengineering Co., Ltd.

June 30, 2025

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 3,063,948,201.93 3,456,273,633.71 Settlement reserves

Loan funds

Trading financial assets 122,630,346.17 125,433,276.07 Derivative financial assets

Notes receivable 810,849,804.04 900,426,597.57 Accounts receivable 15,147,853,611.67 15,319,422,562.26 Receivables financing 59,132,839.22 164,791,057.77 Prepayments 350,382,156.91 317,289,075.05 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 1,775,293,809.31 1,822,982,141.21 Including: interest receivable

Dividends receivable 8,613,579.12 8,613,579.12 Financial assets purchased under resale agreements

Inventory 3,358,262,412.11 3,486,933,682.12

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year 2,156,061.33 23,691,517.50 Other current assets 245,507,854.36 217,579,675.78 Total current assets 24,936,017,097.05 25,834,823,219.04

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment 194,233,433.36 193,570,097.26 Other equity instrument investment 140,337,205.00 140,337,205.00 Other non-current financial assets

Investment real estate 72,724,847.52 75,059,053.08 Fixed assets 891,524,754.46 951,245,081.84 Construction in progress 98,513,935.38 84,842,238.45 Productive biological assets

oil and gas assets

Right-of-use assets 131,993,735.98 147,984,570.84 Intangible assets 323,306,694.32 367,599,585.50

Among them: data resources

Development expenditure 109,311,425.61 102,657,567.09

Among them: data resources

Goodwill 378,703,201.02 378,703,201.02 Long-term deferred expenses 25,007,048.26 29,527,172.10 Deferred income tax assets 332,559,242.31 357,016,449.49 Other non-current assets 34,707,484.00 134,954,723.46 Total non-current assets 2,732,923,007.22 2,963,496,945.13 Total assets 27,668,940,104.27 28,798,320,164.17 Current liabilities:

Short-term borrowings 9,772,100,764.26 10,023,491,526.10 Borrowings from the central bank

borrowing funds

Trading financial liabilities 72,709,111.74 72,709,111.74 Derivative financial liabilities

Notes payable 1,298,370,015.82 1,759,604,232.21 Accounts payable 7,133,234,307.56 7,343,295,089.09 Advance payments 1,710,178.41 1,272,452.78 Contract liabilities 389,145,560.64 363,608,592.28 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 77,758,646.13 124,119,130.97 Taxes payable 102,420,092.86 116,143,353.78 Other payables 4,965,939,557.59 5,095,830,356.06

Among them: interest payable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Dividends payable 91,550,416.99 143,514,334.91 Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 126,408,898.04 221,102,388.47 Other current liabilities 451,582,968.15 457,986,589.55 Total current liabilities 24,391,380,101.20 25,579,162,823.03 Non-current liabilities:

insurance contract reserves

Long-term borrowings 319,881,486.84 229,796,779.81 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 85,104,865.46 99,886,812.32 Long-term payables 4,927,653.45 3,514,443.05 Long-term employee benefits payable 181,968.74 181,968.74 Estimated liabilities 499,526.81 19,542,639.52 Deferred income 4,879,000.00 10,191,377.74 Deferred income tax liabilities 11,846,843.98 12,279,806.40 Other non-current liabilities

Total non-current liabilities 427,321,345.28 375,393,827.58 Total liabilities 24,818,701,446.48 25,954,556,650.61 Owners’ equity:

Share capital 2,631,123,257.00 2,631,123,257.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 2,099,191,174.72 2,096,302,343.69 Less: treasury shares

Other comprehensive income -60,303,050.40 -60,303,050.40 Special reserves

Surplus reserve 52,141,669.22 52,141,669.22 General risk reserve

Undistributed profits -2,892,350,063.24 -2,924,031,770.95 Total owners’ equity attributable to the parent company 1,829,802,987.30 1,795,232,448.56 Minority shareholders’ equity 1,020,435,670.49 1,048,531,065.00 Total owners’ equity 2,850,238,657.79 2,843,763,513.56 Total liabilities and owners’ equity 27,668,940,104.27 28,798,320,164.17 Legal representative: Zhang Feng Person in charge of accounting work: Shen Dakai Head of accounting department: Li Shuang

2. Balance sheet of the parent company

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 6,320,587.42 13,382,366.36

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Trading financial assets 93,085,021.35 91,910,021.35 Derivative financial assets

Notes receivable

Accounts receivable

Receivables Financing

advance payment

Other receivables 6,709,938,265.22 6,648,457,337.37 Including: interest receivable

Dividends receivable

Inventory

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 12,042,511.19 11,473,389.44 Total current assets 6,821,386,385.18 6,765,223,114.52 Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 659,440,073.33 659,439,600.09 Other equity instrument investments 670,000.00 670,000.00 Other non-current financial assets

Investment real estate 53,353,964.67 55,200,929.79 Fixed assets 4,352,561.05 4,517,394.75 Construction in progress

productive biological assets

oil and gas assets

Right-of-use assets 10,331,265.63 9,797,575.10 Intangible assets 9,658,506.93 12,194,403.70

Among them: data resources

Development expenditure 120,289,149.49 116,391,930.53

Among them: data resources

goodwill

Long-term deferred expenses 487,870.62 662,657.94 Deferred income tax assets 32,558,803.05 32,544,654.66 Other non-current assets 60,800.00 60,800.00 Total non-current assets 891,202,994.77 891,479,946.56 Total assets 7,712,589,379.95 7,656,703,061.08 Current liabilities:

Short-term borrowings 815,922,183.12 844,337,896.53 Trading financial liabilities

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Derivative financial liabilities

Notes payable

Accounts payable 18,025.36 Advance receipts 4,780.00 Contract liabilities

Employee benefits payable 4,072,407.13 7,741,620.45 Taxes payable 279,363.12 2,527,899.64 Other payables 2,998,554,037.95 2,993,887,433.82 Including: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year 3,902,429.56 Other current liabilities 570,915.53 Total current liabilities 3,818,827,991.32 3,852,991,000.89 Non-current liabilities:

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 3,898,067.86 6,134,591.64 Long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 3,000,000.00 6,160,000.00 Deferred income tax liabilities

Other non-current liabilities

Total non-current liabilities 6,898,067.86 12,294,591.64 Total liabilities 3,825,726,059.18 3,865,285,592.53 Owners’ equity:

Share capital 2,631,123,257.00 2,631,123,257.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 2,558,092,654.36 2,558,092,654.36 Less: treasury shares

Other comprehensive income -4,130,000.40 -4,130,000.40 Special reserves

Surplus reserve 52,141,669.22 52,141,669.22 Undistributed profits -1,350,364,259.41 -1,445,810,111.63 Total owners’ equity 3,886,863,320.77 3,791,417,468.55 Total liabilities and owners’ equity 7,712,589,379.95 7,656,703,061.08

3. Consolidated income statement

Unit: Yuan

Project Half-year 2025 Half-year 2024

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

1. Total operating income 14,311,503,184.96 16,631,439,699.61 Including: operating income 14,311,503,184.96 16,631,439,699.61 Interest income

Premiums earned

Fee and commission income

2. Total operating costs 14,284,140,795.44 16,469,747,831.28 Including: operating costs 12,979,683,425.75 14,958,533,023.89 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 38,734,701.01 47,493,178.65 Sales expenses 512,965,617.44 567,284,856.71 Management expenses 432,070,744.08 508,135,561.90 Research and development expenses 21,672,884.43 21,528,588.81Financial expenses 299,013,422.73 366,772,621.32Including: Interest expenses 297,658,906.22 375,496,773.81

Interest income 15,689,947.79 29,235,153.98 Add: other income 13,447,646.69 15,224,888.09 Investment income (losses are filled in with "-"

88,840,372.84 -9,469,425.89 columns)

Of which: for associates and joint ventures

309,768.25 124,123.41 Enterprise investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gain (losses indicated by “—”

(Fill in the number)

Gains from changes in fair value (losses represented by “—

70,959.24 254,336.16 "Fill in the number)

Credit impairment losses (losses are marked with “—”

-5,521,341.46 34,194,312.43 fill in the column)

Asset impairment losses (losses are marked with “—”

2,711,648.39 6,422,504.73 fill in the column)

Income from asset disposal (losses are marked with “—”

-173,310.51 5,463,104.04 fill in the column)

3. Operating profit (losses are listed with "-") 126,738,364.71 213,781,587.89 Plus: non-operating income 10,115,881.62 7,182,845.46 Less: non-operating expenses 4,183,755.32 5,924,366.32

4. Total profit (total loss is filled in with “—”

132,670,491.01 215,040,067.03 columns)

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Less: Income tax expense 67,847,587.28 99,758,584.37

5. Net profit (net loss is listed with “—”) 64,822,903.73 115,281,482.66

(1) Classification by business continuity

1. Net profit from continuing operations (net loss is represented by “—”

No. 64,822,903.73 115,281,482.66 (please fill in the list)

2. Net profit from discontinued operations (net loss is represented by “—”

(Fill in the number)

(2) Classification according to ownership ownership

1. Net profit attributable to shareholders of the parent company

31,681,707.71 45,409,831.68 (Net loss is listed with "—")

2. Profit and loss of minority shareholders (net loss is marked with “—”

33,141,196.02 69,871,650.98 (please fill in the column)

6. Net amount of other comprehensive income after tax -790,000.00 Other comprehensive income attributable to the owners of the parent company

-Net of tax of 790,000.00

(1) Others that cannot be reclassified into profit or loss

-790,000.00 comprehensive income

1. Remeasure changes in defined benefit plans

Um

2. Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

3. Fair value of other equity instrument investments

change

4. Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

combined income

1. Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

2. Changes in fair value of other debt investments

3. Financial assets are reclassified into other comprehensive

Amount of combined income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements

7.Others

Other comprehensive income attributable to minority shareholders

net of tax

7. Total comprehensive income 64,822,903.73 114,491,482.66 Total comprehensive income attributable to owners of the parent company

31,681,707.71 44,619,831.68

Total comprehensive income attributable to minority shareholders 33,141,196.02 69,871,650.98

8. Earnings per share:

(1) Basic earnings per share 0.0120 0.0173

(2) Diluted earnings per share 0.0120 0.0173

Legal representative: Zhang Feng Person in charge of accounting work: Shen Dakai Person in charge of accounting department: Li Shuang

4. Income statement of the parent company

Unit: Yuan

Project Half-year 2025 Half-year 2024

1. Operating income 2,783,046.09 9,387,095.89 Less: Operating costs 1,846,965.12 1,871,389.88

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Taxes and surcharges 6,540.00 sales expenses

Management expenses 44,488,974.77 47,727,235.81 Research and development expenses

Financial expenses 37,351,271.73 47,019,731.59 Including: interest expenses 102,258,358.24 119,368,980.13

Interest income 65,804,718.61 72,386,777.93 Plus: other income -1,461,444.58 331,761.95 Investment income (losses are filled in with "-"

177,426,473.24 columns)

Of which: for associates and joint ventures

473.24 Industry investment income

Money measured at amortized cost

Gains from the derecognition of financial assets (losses are marked with “—”

Fill in the column)

Net exposure hedging gain (losses indicated by “—”

(Fill in the number)

Gains from changes in fair value (losses represented by “—

"Fill in the column)

Credit impairment losses (losses are marked with “—”

68,519.07 fill in the column)

Asset impairment losses (losses are marked with “—”

Fill in the column)

Income from asset disposal (losses are marked with “—”

253,195.56 fill in the column)

2. Operating profit (losses are listed with "-") 95,376,037.76 -86,899,499.44 plus: non-operating income 56,881.05 37,050.00 minus: non-operating expenses 1,214.98 503,916.53

3. Total profit (total loss is filled in with “—”

95,431,703.83 -87,366,365.97 columns)

Less: Income tax expense -14,148.39

4. Net profit (net loss is listed with "—") 95,445,852.22 -87,366,365.97

(1) Net profit from continuing operations (net loss divided by

95,445,852.22 -87,366,365.97 (Fill in “—”)

(2) Net profit from discontinued operations (net loss equal to

Fill in the column with "—" sign)

5. Net amount of other comprehensive income after tax

(1) Others that cannot be reclassified into profit or loss

Comprehensive income

1. Remeasure changes in defined benefit plans

Um

2. Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

3. Fair value of other equity instrument investments

change

4. Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

combined income

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

1. Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

2. Changes in fair value of other debt investments

3. Financial assets are reclassified into other comprehensive

Amount of combined income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements

7.Others

6. Total comprehensive income 95,445,852.22 -87,366,365.97

7. Earnings per share:

(1) Basic earnings per share

(2) Diluted earnings per share

5. Consolidated cash flow statement

Unit: Yuan

Project Half-year 2025 Half-year 2024

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 14,100,111,719.33 16,924,929,752.33 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 3,885,538.77 333,486.17 Other cash received related to operating activities 2,126,537,819.21 1,925,612,356.02 Subtotal of cash inflows from operating activities 16,230,535,077.31 18,850,875,594.52 Cash paid for purchasing goods and receiving services 12,115,217,351.23 15,012,615,983.65 Net increase in customer loans and advances

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 493,335,319.32 508,582,027.19 Various taxes and fees paid 311,966,805.19 395,210,740.84 Other cash paid related to operating activities 3,251,934,203.90 2,821,139,337.80 Subtotal cash outflow from operating activities 16,172,453,679.64 18,737,548,089.48 Net cash flow generated from operating activities 58,081,397.67 113,327,505.04

2. Cash flow generated from investing activities:

Cash received from recovery of investment 19,582,769.92 274,966,000.00 Cash received from investment income 688,000.00 7,507,135.09 Disposal of fixed assets, intangible assets and other long-term assets

5,219,607.53 3,241,475.30 Net cash amount from asset recovery

Received from disposal of subsidiaries and other business units

6,703,608.79 7,489,100.60 Net cash

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Other cash received related to investing activities

Subtotal of cash inflows from investing activities 32,193,986.24 293,203,710.99 Purchase and construction of fixed assets, intangible assets and other long-term assets

86,544,612.39 59,342,073.11 Cash paid for assets

Cash paid for investment 20,036,903.00 284,315,000.00 Net increase in pledged loans

Obtain payment from subsidiaries and other business units

35,370,690.71 Net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 106,581,515.39 379,027,763.82 Net cash flow generated from investing activities -74,387,529.15 -85,824,052.83

3. Cash flow generated from financing activities:

Cash received from investment 2,000,000.00 6,500,000.00 Including: Income from investment by subsidiaries from minority shareholders

2,000,000.00 6,500,000.00 cash received

Cash received from borrowings 3,542,058,226.07 3,711,158,501.35 Cash received from other financing activities 4,642,733,105.34 4,117,442,909.88 Subtotal of cash inflows from financing activities 8,186,791,331.41 7,835,101,411.23 Cash paid to repay debts 3,577,221,874.50 3,628,640,714.57 Cash paid to distribute dividends, profits or pay interest

297,405,156.48 362,837,022.69 cash

Including: shares paid by subsidiaries to minority shareholders

75,886,964.35 78,635,902.89 Profit and profit

Cash payments related to other financing activities 4,443,393,282.15 3,710,168,724.39 Subtotal of cash outflows from financing activities 8,318,020,313.13 7,701,646,461.65 Net cash flow generated from financing activities -131,228,981.72 133,454,949.58

4. The impact of exchange rate changes on cash and cash equivalents

-359.10 358.97 impact

5. Net increase in cash and cash equivalents -147,535,472.30 160,958,760.76 Plus: opening balance of cash and cash equivalents 1,272,594,941.51 1,136,730,048.28

6. Balance of cash and cash equivalents at the end of the period 1,125,059,469.21 1,297,688,809.04

7. Cash flow statement of the parent company

Unit: Yuan

Project Half-year 2025 Half-year 2024

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services

tax refund received

Other cash received related to operating activities 2,533,179,493.59 2,645,726,925.90 Subtotal of cash inflows from operating activities 2,533,179,493.59 2,645,726,925.90 Cash paid for purchasing goods and receiving services

Cash paid to and for employees 45,273,528.50 40,982,581.20 Various taxes paid 38,162.26 1,457,873.43 Cash paid for other operating activities 2,520,457,601.13 2,279,130,394.79 Subtotal of cash outflows from operating activities 2,565,769,291.89 2,321,570,849.42 Net cash flow generated from operating activities -32,589,798.30 324,156,076.48

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income 177,426,000.00

Disposal of fixed assets, intangible assets and other long-term

75,000.00

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 1,200,000.00

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Subtotal of cash inflows from investing activities 177,501,000.00 1,200,000.00 Purchase and construction of fixed assets, intangible assets and other long-term assets

522,128.65 1,025,612.00 Cash paid for assets

Cash paid for investment 1,400,000.00

Obtain payment from subsidiaries and other business units

net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 522,128.65 2,425,612.00 Net cash flow generated from investing activities 176,978,871.35 -1,225,612.00

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Cash received from borrowing 817,922,183.12 563,000,000.00

Other cash received related to financing activities 107,049,301.41 22,208,000.00 Subtotal of cash inflows from financing activities 924,971,484.53 585,208,000.00 Cash paid to repay debts 845,000,000.00 617,000,000.00 distributed dividends, profits or paid interest

39,537,317.20 49,551,094.77 cash

Cash payments related to other financing activities 196,980,615.23 237,055,758.85 Subtotal cash outflows from financing activities 1,081,517,932.43 903,606,853.62 Net cash flow generated from financing activities -156,546,447.90 -318,398,853.62

4. The impact of exchange rate changes on cash and cash equivalents

influence

5. Net increase in cash and cash equivalents -12,157,374.85 4,531,610.86

Add: Balance of cash and cash equivalents at the beginning of the period 13,382,366.36 12,155,207.35

6. Balance of cash and cash equivalents at the end of the period 1,224,991.51 16,686,818.21

7. Consolidated statement of changes in owners’ equity

Amount of current period

Unit: Yuan

2025 half year

Less equity attributable to owners of the parent company

Other equity instruments Part 1 There is a decrease and there is no amount

Project capital: Other shareholders' equity, preferred shares, perpetual bonds, other capital reserves, comprehensive income, reserves, surplus reserves, risk reserves, other subtotal shareholders' equity, equity, joint venture profits

Benefit plan

2,63 2,09 52,1 1,79 1,04 2,84

60,3 2,92

1. Previous year period 1,12 6,30 41,6 5,23 8,53 3,76

03,0 4,03

Closing balance 3,25 2,34 69.2 2,44 1,06 3,51 50.4 1,77

7.00 3.69 2 8.56 5.00 3.56 0 0.95

Add: yes

Changes in accounting policies

before

period error correction

its

him

2,63 2,09 - 52,1 - 1,79 1,04 2,84

2. Current year 1,12 6,30 60,3 41,6 2,92 5,23 8,53 3,76 Beginning balance 3,25 2,34 03,0 69.2 4,03 2,44 1,06 3,51

7.00 3.69 50.4 2 1,77 8.56 5.00 3.56 Full text of Shenzhen Neptune Bioengineering Co., Ltd. 2025 Semi-annual Report

0 0.95

-

3. Increase in this period 31,6 34,5

2,88 28,0 6,47 minus changes 81,7 70,5

8,83 95,3 5,14 (reduced to “— 07.7 38.7

1.03 94.5 4.23 (please fill in the column with "") 1 4

31,6 31,6 33,1 64,8

(1) Comprehensive 81.7 81.7 41.1 22.9 Total income 07.7 07.7 96.0 03.7 1 1 2 3 33.9 36.8

(2) All 2,88 2,88

57,2 46,0 input and minus 8,83 8,83

11.2 42.2 Less capital 1.03 1.03

4 7

• • 1. owner

5,00 5,00 ordinary investment

0,00 0,00 shares

0.00 0.00 2． Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

owner's equity

Um

38,9 41,8 2,88 2,88

57,2 46,0 4. Others 8,83 8,83

11.2 42.2 1.03 1.03

4 7

• • 95,1 95,1

(3) Profit

93,8 93,8 allocation

01.7 01.7

7 7 1. Withdraw profit

surplus public space

2. Extract one

General risk preparation

3． to all

person (or share

East) distribution

• • 95,1 95,1 4. Others 93.8 93.8 01.7 01.7

7 7

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

2,63 2,09 52,1 1,82 1,02 2,85

60,3 2,89

4. This period 1,12 9,19 41,6 9,80 0,43 0,23

03,0 2,35

Closing balance 3,25 1,17 69.2 2,98 5,67 8,65 50.4 0,06

7.00 4.72 2 7.30 0.49 7.79

0 3.24

Amount of previous year

Unit: Yuan

2024 half year

Less equity attributable to owners of the parent company

Other equity instruments Part 1 There is a decrease and there is no amount

Project capital: Other shareholders' equity, preferred shares, perpetual bonds, other common reserves, treasury shares, comprehensive income, reserves, reserves, risks, reserves, profits, other subtotals, shareholders' equity, equity, joint profit reserves - -

2,75 2,24 275, 52,1 3,00 1,21 4,21

36,8 1,73

1. Previous year period 0,83 2,48 118, 41,6 2,92 4,52 7,44

03,0 0,61

Closing balance 3,25 5,82 243. 69.2 2,64 2,62 5,26 50.4 6,81

7.00 3.64 17 2 0.59 1.16 1.75 0 5.70

Add: yes

Changes in accounting policies

before

period error correction

its

him

2,75 2,24 275, 52,1 3,00 1,21 4,21

36,8 1,73

2. Current period 0,83 2,48 118, 41,6 2,92 4,52 7,44

03,0 0,61

Opening balance 3,25 5,82 243. 69.2 2,64 2,62 5,26 50.4 6,81

7.00 3.64 17 2 0.59 1.16 1.75

0 5.70

3. Increase in the current period - 45,4 44,6 - 32,2 minus change amount 790, 09,8 19,8 12,4 06,9 (decrease by "- 000. 31.6 31.6 12,8 52.8

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

” number) 00 8 8 78.8 7

• 45,4 44,6 69,8 114,

(1) Comprehensive 790, 09,8 19,8 71,6 491, total income 000. 31.6 31.6 50.9 482.

00 8 8 8 66

(2) All 6,50 6,50 investors invested and reduced capital 0,00 0,00 0.00 0.00

1． Owner 6,50 6,50 Common invested 0,00 0,00 shares 0.00 0.00

2. Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

owner's equity

Um

4． Others

88,7 88,7

(3) Profit

84,5 84,5 allocation

29.7 29.7

9 9 1. Withdraw profit

surplus public space

2. Extract one

General risk preparation

• • 3. Distribution to all shareholders (or shareholders) 29.7 29.7

9 9 4. Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

2,75 2,24 275, 52,1 3,04 1,20 4,24

37,5 1,68

4. Current period 0,83 2,48 118, 41,6 7,54 2,10 9,65

93,0 5,20

Closing balance 3.25 5.82 243.69.2 2.47 9.74 2.21

50.4 6,98

7.00 3.64 17 2 2.27 2.35 4.62

0 4.02

8. Statement of changes in owner’s equity of the parent company

Amount of current period

Unit: Yuan

2025 half year

Other equity instruments All

Less: Others not divided

Project Capital Special Surplus Owner's Equity Priority Perpetual Inventory Comprehensive Distribution Others

Other public reserves, reserves, equity joint ventures, bonds, shares, profits

plan

2,631, 2,558, 52,14 3,791,

1. Previous year period 4,130, 1,445,

123,2 092,6 1,669. Balance at the end of 417,4 000.4 810,11

57.00 54.36 22 68.55

0 1.63

Add: yes

Changes in accounting policies

before

period error correction

its

him

2,631, 2,558, 52,14 3,791,

2. Current period 4,130, 1,445,

123,2 092,6 1,669. 417,4 Beginning balance 000.4 810,11

57.00 54.36 22 68.55

0 1.63

3. Added in this issue

95,44 95,44 minus changes

5,852. 5,852. (Reduced to “—

22 22 "Fill in the column)

95,44 95,44

(1) Comprehensive

5,852. 5,852. Total income

22 22

(2) All

investor input and reduction

less capital

1． owner

ordinary investment

shares

2. Other rights

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Equity instrument holders invest capital

3． The amount of share-based payment included in owners’ equity

4． Others

(3) Profit distribution

1． Withdrawal from surplus reserve

2. Distributions to owners (or shareholders)

3． Others

(4) Internal carryover of owners’ equity

1． Conversion of capital reserves to capital (or share capital)

2. Conversion of surplus reserves to capital (or share capital)

3． Surplus reserve to cover losses

4． Changes in defined benefit plans are carried forward to retained earnings

5. Other comprehensive income carried forward to retained earnings

6． Others

(5) Special reserves

1． Extract this period

2. Used in this issue

(6) Others

2,631, 2,558, 52,14 3,886,

4. This period 4,130, 1,350,

123.2 092.6 1,669. 863.3 Ending balance 000.4 364.2 57.00 54.36 22 20.77

0 59.41

Amount of previous year

Unit: Yuan

2024 Semi-Annual Project

Equity Other Equity Instruments Capital Less: Other Special Surplus Undivided Others All

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Public reserve inventory, comprehensive reserve, public reserve dividend distribution, priority is given to sustainable

Other shares income profit joint stock bonds

plan

2,750, 2,713, 275,1 52,14 4,052,

1. Previous year period 4,100, 1,184,

833,2 708,1 18,24 1,669. Ending balance of 641,0 000.4 823,7

57.00 71.11 3.17 22 58.97 0 94.79

Add: yes

Changes in accounting policies

before

period error correction

its

him

2,750, 2,713, 275,1 52,14 4,052,

2. Current year 4,100, 1,184,

833,2 708,1 18,24 1,669. 641,Beginning balance 000.4 823,7

57.00 71.11 3.17 22 58.97

0 94.79

3. Increase in current period - - decrease in change amount 88,20 88,20 (decreases are listed with "- 0,155. 0,155. ") 37 37

(1) Comprehensive 88,20 88,20Total income 0,155. 0,155.

37 37

(2) All

investor input and reduction

less capital

1． owner

ordinary investment

shares

2. Other rights

beneficial instruments held

investors invest capital

3． Share branch

Payment is included in all

owner's equity

Um

4． Others

(3) Profit

allocate

1． Withdraw profit

surplus public space

2. to all

person (or share

East) distribution

3． Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(or equity)

2. surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

5. Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

2. This issue makes

use

(6) Others

2,750, 2,713, 275,1 52,14 3,964,

4. This period 4,100, 1,273,

833,2 708,1 18,24 1,669. Ending balance of 440,9 000.4 023,9

57.00 71.11 3.17 22 03.60

0 50.16

3. Basic situation of the company

1. Company profile

Shenzhen Neptune Bioengineering Co., Ltd. (hereinafter referred to as the company) is a joint-stock company registered in Shenzhen City, Guangdong Province, with registered capital: 2,631,123,300 yuan, unified social credit code: 91440300192444086R, legal representative: Zhang Feng. The RMB common A shares issued by the company were listed on the Shenzhen Stock Exchange in December 1998. The company's headquarters is located on the 24th floor of Neptune Galaxy Technology Building, No. 1, Keji Zhong 3rd Road, Nanshan District Science and Technology Park, Shenzhen. The company is mainly engaged in pharmaceutical production, manufacturing and distribution, health products and food sales, and medical device sales.

These financial statements and notes to the financial statements were approved by the 26th meeting of the ninth board of directors of the company on August 28, 2025.

2. Scope of consolidated financial statements

Serial number Subsidiary name Subsidiary abbreviation

1 Shenzhen Neptune Galaxy Pharmaceutical Investment Co., Ltd. Galaxy Investment 2 Shenzhen Neptune Intron Biotechnology Co., Ltd. Neptune Intron 3 Shenzhen Neptune Oriental Investment Co., Ltd. Oriental Investment 4 Xiaogan Neptune Galaxy Investment Co., Ltd. Xiaogan Investment 5 Hubei Neptune Pharmaceutical Group Co., Ltd. Hubei Neptune 6 Esther Biotechnology Co., Ltd. Esther 7 Sulu Neptune Pharmaceutical Group Co., Ltd. Sulu Neptune 8 Shandong Neptune Galaxy Pharmaceutical Co., Ltd. Shandong Galaxy 9 Zaozhuang Neptune Galaxy Investment Co., Ltd. Zaozhuang Investment 10 Weihai Neptune Galaxy Investment Co., Ltd. Weihai Investment

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Serial number Subsidiary name Subsidiary abbreviation

11 Heze Neptune Galaxy Investment Co., Ltd. Heze Investment 12 Henan Dongsen Pharmaceutical Co., Ltd. Henan Dongsen 13 Fuzhou Neptune Fortune Pharmaceutical Co., Ltd. Neptune Fortune 14 Shenzhen Neptune Changjian Pharmaceutical Co., Ltd. Neptune Changjian 15 Shenzhen Galaxy Technology Co., Ltd. Galaxy Technology 16 Henan Neptune Pharmaceutical Group Co., Ltd. Henan Neptune 17 Heze Neptune Pharmaceutical Co., Ltd. Heze Neptune 18 Weihai Neptune Pharmaceutical Co., Ltd. Weihai Neptune 19 Yantai Neptune Pharmaceutical Co., Ltd. Yantai Neptune 20 Fuzhou Fuyao Pharmaceutical Co., Ltd. Fuyao Pharmaceutical 21 Fuzhou Neptune Jinxiang Traditional Chinese Medicine Pharmaceutical Co., Ltd. Jinxiang Traditional Chinese Medicine 22 Anhui Neptune Medical Equipment Co., Ltd. Anhui Neptune 23 Jiamusi Neptune Pharmaceutical Co., Ltd. Jiamusi Neptune 24 Hubei Neptune Pengtai Pharmaceutical Co., Ltd. Hubei Pengtai 25 Binzhou Neptune Yellow River Pharmaceutical Co., Ltd. Binzhou Yellow River 26 Shandong Neptune Galaxy Medical Equipment Co., Ltd. Shandong Medical Equipment 27 Tengzhou Neptune Pharmaceutical Co., Ltd. Tengzhou Neptune 28 Dongming Jinxin Pharmaceutical Co., Ltd. Dongming Jinxin 29 Jining Neptune Huasen Pharmaceutical Co., Ltd. Jining Huasen 30 Neptune (Wuhan) Pharmaceutical Co., Ltd. Wuhan Pharmaceutical 31 Heilongjiang Neptune Pharmaceutical Co., Ltd. Heilongjiang Neptune 32 Puyang Neptune Pharmaceutical Co., Ltd. Puyang Neptune 33 Shenzhen Shenye Pharmaceutical Development Co., Ltd. Shem Yip Pharmaceutical 34 Shenzhen Neptune Pharmaceutical Technology Research Institute Co., Ltd. Research Institute 35 Shenzhen Hairong International Medical Development Co., Ltd. Hairong International 36 Bozhou Neptune Galaxy Pharmaceutical Co., Ltd. Bozhou Neptune 37 Bengbu Neptune Galaxy Pharmaceutical Sales Co., Ltd. Bengbu Neptune 38 Henan Neptune Huitong Pharmaceutical Co., Ltd. Henan Huitong 39 Pingdingshan Neptune Yinhe Pharmaceutical Sales Co., Ltd. Pingdingshan Neptune 40 Henan Neptune Medical Equipment Co., Ltd. Henan Medical Equipment 41 Hubei Neptune Enshi Pharmaceutical Co., Ltd. Hubei Enshi 42 Guangxi Neptune Yinhe Pharmaceutical Co., Ltd. Guangxi Neptune 43 Neptune Jianchang (Beijing) Medical Equipment Co., Ltd. Beijing Neptune 44 Shandong Neptune Pharmaceutical Group Co., Ltd. Shandong Group 45 Anhui Neptune Pharmaceutical Group Co., Ltd. Anhui Group 46 Guangdong Neptune Pharmaceutical Group Co., Ltd. Guangdong Group 47 Shandong Kangnuo Shengshi Pharmaceutical Co., Ltd. Shandong Kangnuo 48 Neptune Medical Distribution Service (Guangdong) Co., Ltd. Guangdong Distribution 49 Qingdao Huaren Pharmaceutical Distribution Co., Ltd. Qingdao Huaren 50 Shandong Neptune Xinchen Pharmaceutical Co., Ltd. Shandong Xinchen 51 Heilongjiang Neptune Huatong Medical Device Development Co., Ltd. Heilongjiang Huatong 52 Hubei Neptune Kai'anchen Pharmaceutical Co., Ltd. Hubei Kai'anchen 53 Zhoukou Renhe Pharmaceutical Co., Ltd. Zhoukou Renhe 54 Henan Haiwang Kangrui Pharmaceutical Co., Ltd. Henan Kangrui 55 Anyang Hengfeng Pharmaceutical Co., Ltd. Anyang Hengfeng

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Serial number Subsidiary name Subsidiary abbreviation

56 Henan Guanbao Yuntong Pharmaceutical Co., Ltd. Henan Guanbao 57 Anhui Haiguo'an Pharmaceutical Co., Ltd. Anhui Guoan 58 Guangxi Guilin Neptune Pharmaceutical Co., Ltd. Guilin Neptune 59 Hunan Neptune Pharmaceutical Co., Ltd. Hunan Neptune 60 Hunan Kangfulai Pharmaceutical Co., Ltd. Hunan Kangfulai 61 Shaoyang Neptune Pharmaceutical Co., Ltd. Shaoyang Neptune 62 Henan Dejitang Pharmaceutical Co., Ltd. Henan Dejitang 63 Neptune Pharmaceutical Anqing Co., Ltd. Anqing Neptune 64 Neptune (Wuhan) Pharmaceutical Development Co., Ltd. Wuhan Development 65 Weihai Rutai Pharmaceutical Sales Co., Ltd. Weihai Rutai 66 Shandong Mingyang Pharmaceutical Co., Ltd. Shandong Mingyang 67 Heilongjiang Neptune Conrad Biotechnology Co., Ltd. Heilongjiang Conrad 68 Henan Kanghong Pharmaceutical Co., Ltd. Henan Kanghong 69 Anhui Neptune Wannan Pharmaceutical Co., Ltd. Wannan Neptune 70 Neptune Medical Equipment (Shanghai) Co., Ltd. Shanghai Medical Equipment 71 Henan Neptune Galaxy Pharmaceutical Co., Ltd. Henan Galaxy 72 Neptune Medical Distribution Service (Fujian) Co., Ltd. Fujian Medical Distribution 73 Heilongjiang Neptune Yinhai Pharmaceutical Group Co., Ltd. Heilongjiang Yinhai 74 Yichang Neptune Galaxy Pharmaceutical Co., Ltd. Yichang Neptune 75 Ningbo Jianchang Zhongxing International Trade Co., Ltd. Ningbo Neptune 76 Shanghai Neptune Medical Equipment Group Co., Ltd. Shanghai Neptune 77 Shandong Neptune Sunshine Cigna Pharmaceutical Co., Ltd. Shandong Cigna 78 Changde Neptune Pharmaceutical Co., Ltd. Changde Neptune 79 Henan Enji Pharmaceutical Co., Ltd. Henan Enji 80 Henan Zuojinming Pharmaceutical Co., Ltd. Henan Zuojinming 81 Kashgar Neptune Galaxy Pharmaceutical Co., Ltd. Kashgar Galaxy 82 Xinjiang Neptune Hongkang Pharmaceutical Technology Co., Ltd. Kashgar Hongkang 83 Henan Tiansheng Pharmaceutical Co., Ltd. Henan Tiansheng 84 Anhui Neptune Tiancheng Pharmaceutical Co., Ltd. Anhui Tiancheng 85 Neptune (Tianjin) Medical Technology Co., Ltd. Tianjin Medical Technology 86 Sichuan Neptune Medical Technology Co., Ltd. Sichuan Medical Technology 87 Chengdu Ruixi Trading Co., Ltd. Chengdu Ruixi 88 Neptune (Zhanjiang) Pharmaceutical Co., Ltd. Zhanjiang Neptune 89 Neptune (Shaoguan) Pharmaceutical Co., Ltd. Shaoguan Neptune 90 Neptune (Qingyuan) Pharmaceutical Co., Ltd. Qingyuan Neptune 91 Neptune Pharmaceutical (Foshan) Co., Ltd. Foshan Neptune 92 Hunan Neptune Medical Technology Co., Ltd. Hunan Medical Technology 93 Weishi County Pharmaceutical Co., Ltd. Weishi County Pharmaceutical 94 Ningxia Neptune Pharmaceutical Co., Ltd. Ningxia Neptune 95 Lu'an Neptune Pharmaceutical Co., Ltd. Lu'an Neptune 96 Wuhu Neptune Sunshine Pharmaceutical Co., Ltd. Wuhu Sunshine 97 Neptune Medical Distribution Service (Hunan) Co., Ltd. Hunan Medical Distribution 98 Neptune Medical Distribution Service (Guangxi) Co., Ltd. Guangxi Medical Distribution 99 Jiangsu Neptune Medical Equipment Co., Ltd. Jiangsu Medical Equipment 100 Sichuan Fanyuan Trading Co., Ltd. Sichuan Fanyuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Serial number Subsidiary name Subsidiary abbreviation

101 Linyi Dongrui Pharmaceutical Co., Ltd. Linyi Dongrui 102 Shanghai Fangcheng Medical Equipment Co., Ltd. Shanghai Fangcheng 103 Anhui Juying Medical Technology Co., Ltd. Anhui Juying 104 Neptune Yewei Medical Technology (Shanghai) Co., Ltd. Neptune Yewei 105 Henan Neptune Wenfeng Pharmaceutical Co., Ltd. Henan Nanyang Wenfeng 106 Suzhou Neptune Pharmaceutical Co., Ltd. Suzhou Neptune 107 Hubei Neptune Medical Equipment Co., Ltd. Hubei Equipment 108 Shandong Handi Medical Equipment Technology Co., Ltd. Shandong Handi 109 Jilin Neptune Galaxy Pharmaceutical Investment Co., Ltd. Jilin Galaxy 110 Xinxiang Yinhai Medical Testing Laboratory Co., Ltd. Xinxiang Yinhai 111 Sulu Neptune Medical Equipment Co., Ltd. Sulu Equipment 112 Yantai Longshu Enterprise Management Consulting Co., Ltd. Yantai Longshu 113 Weifang Xinzheng Information Technology Co., Ltd. Weifang Xinzheng 114 Jining Anruitai Pharmaceutical Technology Co., Ltd. Jining Anruitai 115 Henan Dongsen Wandu Medical Equipment Co., Ltd. Henan Wandu 116 Guangzhou Haihong Pharmaceutical Technology Development Co., Ltd. Guangzhou Haihong 117 Nanning Haihong Pharmaceutical Technology Development Co., Ltd. Nanning Haihong 118 Hefei Jianyuan Information Consulting Co., Ltd. Hefei Jianyuan 119 Heilongjiang Hejia Mingxi Investment Co., Ltd. Heilongjiang Hejia Mingxi 120 Shenzhen Neptune Medicine and Health Co., Ltd. Shenzhen Medicine and Health 121 Shenzhen Neptune Health Industry Development Co., Ltd. Shenzhen Health Development 122 Zhejiang Neptune Data Service Co., Ltd. Zhejiang Neptune Data 123 Hainan Jiachi Technology Co., Ltd. Hainan Jiachi 124 Beijing Neptune Zhongxin Pharmaceutical Co., Ltd. Beijing Neptune Zhongxin 125 Jiangsu Neptune Pharmaceutical Co., Ltd. Jiangsu Neptune 126 Changchun Kunlan Agricultural Technology Co., Ltd. Changchun Kunlan 127 Shenzhen Neptune Cloud Service Co., Ltd. Neptune Cloud 128 Hubei Haijuntong Medical Equipment Co., Ltd. Hubei Haijuntong 129 Hainan Neptune Changjian Trading Co., Ltd. Hainan Changjian 130 Neptune Medical Technology Co., Ltd. Neptune Medical Technology 131 Hangzhou Haihe Data Service Co., Ltd. Hangzhou Haihe 132 Anhui Haihe Industrial Investment Co., Ltd. Anhui Haihe 133 Zaozhuang Neptune Medical Equipment Co., Ltd. Zaozhuang Medical Equipment 134 Zibo Neptune Medical Equipment Co., Ltd. Zibo Medical Equipment 135 Hangzhou Huawu Medical Equipment Co., Ltd. Hangzhou Huawu 136 Shandong Zhengjin Neptune Medical Investment Management Co., Ltd. Shandong Zhengjin 137 Henan Enji Logistics Co., Ltd. Enji Logistics 138 Zhejiang Haiqing Future Technology Development Co., Ltd. Haiqing Future 139 Zhejiang Haizhi Future Technology Development Co., Ltd. Haizhi Future 140 Hangzhou Haige Yuexiang Health Technology Co., Ltd. Haige Yuexiang 141 Hangzhou Haiqian Medical Technology Co., Ltd. Haiqian Medical

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

4. Basis for preparation of financial statements

1. Basics of preparation

These financial statements are prepared in accordance with the Accounting Standards for Business Enterprises and their application guidelines, interpretations and other relevant regulations issued by the Ministry of Finance (collectively: "Accounting Standards for Business Enterprises"). In addition, the company also discloses relevant financial information in accordance with the China Securities Regulatory Commission's "Information Disclosure and Preparation Rules for Companies that Offer Securities to the Public No. 15 - General Provisions on Financial Reports (2023 Revision)".

The Company's accounting is based on the accrual basis. Except for certain financial instruments, these financial statements are measured on the basis of historical cost. If an asset is impaired, corresponding impairment provisions will be made in accordance with relevant regulations.

2. Continued operations

These financial statements are presented on a going concern basis.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

Specific accounting policies and accounting estimation tips:

The Company determines its revenue recognition policy based on its own production and operation characteristics. For specific accounting policies, please refer to the relevant policy descriptions.

1. Statement on compliance with corporate accounting standards

This financial statement complies with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflects the company's consolidated and company financial status as of June 30, 2025, as well as the consolidated and operating results, consolidated and company cash flows and other relevant information from January to June 2025.

2. Accounting period

The company's accounting period adopts the Gregorian calendar year, that is, from January 1 to December 31 each year.

3. Business cycle

The company's operating cycle is 12 months.

4. Accounting standard currency

The company and its domestic subsidiaries use RMB as their functional currency for accounting. The currency used by the Company in preparing these financial statements is RMB.

5. Determination method and selection basis of importance standards

Applicable□Not applicable

Item Importance standard: Important individual receivables with provision for bad debts. Individual provision amount > 0.5% of the net assets at the end of the period. Important receivables written off in the current period. Important construction-in-progress projects with individual amounts exceeding 5% of the balance of accounts receivable. The book balance of a single-item construction-in-progress accounted for 0.5% of the total asset balance.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The total assets of non-wholly-owned subsidiaries account for more than 10% of the company's total assets at the end of the period or non-wholly-owned subsidiaries with important profits

The total amount accounts for more than 10% of the company's total profits

6. Accounting treatment methods for business combinations under the same control and those not under the same control

(1) Business merger under common control

For business mergers under common control, the assets and liabilities of the merged party acquired by the merging party during the merger shall be measured based on the book value of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date. The difference between the book value of the merger consideration and the book value of the net assets obtained in the merger is adjusted to the capital reserve. If the capital reserve is insufficient for offset, the retained earnings are adjusted.

The merger of enterprises under the same control is realized step by step through multiple transactions.

The assets and liabilities of the merged party acquired by the merging party during the merger are measured based on their book values in the consolidated financial statements of the ultimate controlling party on the merger date; the difference between the book value of the investments held before the merger plus the book value of the new consideration paid on the merger date and the book value of the net assets acquired during the merger is adjusted to the capital reserve. If the capital reserve is insufficient for offset, the retained earnings are adjusted. For long-term equity investments held by the merging party before acquiring control of the merged party, relevant profits and losses, other comprehensive income and other changes in owner's equity have been recognized between the date of acquisition of the original equity and the date when the merging party and the merged party are under the final control of the same party, whichever is later, to the date of merger, and shall be offset against the opening retained earnings or current profits and losses of the comparative statement period respectively.

(2) Business combination not under common control

For business combinations not under common control, the combination cost is the fair value of the assets paid, liabilities incurred or assumed, and equity securities issued to obtain control of the purchased party on the acquisition date. On the purchase date, the acquired assets, liabilities and contingent liabilities of the purchased party are recognized at fair value.

The difference between the merger cost and the fair value share of the acquiree's identifiable net assets obtained in the merger is recognized as goodwill, and subsequent measurement is carried out at cost less accumulated impairment reserves; the difference between the merger cost and the fair value share of the acquiree's identifiable net assets obtained in the merger is included in the current profit and loss after review.

The merger of enterprises not under common control is realized step by step through multiple transactions.

The merger cost is the sum of the consideration paid on the purchase date and the fair value of the purchased party's equity held before the purchase date on the purchase date. The equity of the purchased party that has been held before the purchase date will be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value will be included in the investment income of the current period; the equity of the purchased party that has been held before the purchase date involves other comprehensive income, other owners Changes in equity are converted into current income on the date of purchase, except for other comprehensive income arising from the investee's remeasurement of changes in net liabilities or net assets of the defined benefit plan and other comprehensive income related to investments in non-trading equity instruments originally designated as measured at fair value and whose changes are included in other comprehensive income.

(3) Treatment of transaction costs in business mergers

Intermediary fees such as auditing, legal services, evaluation and consulting, and other related management fees incurred for business mergers are included in the current profit and loss when incurred. The transaction costs of equity securities or debt securities issued as consideration for the merger shall be included in the initial recognition amount of the equity securities or debt securities.

7. Judgment standards for control and preparation methods of consolidated financial statements

(1) Judgment criteria for control

The scope of consolidation in consolidated financial statements is determined on the basis of control. Control means that the company has power over the invested unit, enjoys variable returns by participating in the relevant activities of the invested unit, and has the ability to use its power over the invested unit to affect its return amount. The Company will reassess when changes in relevant facts and circumstances result in changes in the relevant elements involved in the definition of control.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. When determining whether to include a structured entity within the scope of consolidation, the company evaluates whether to control the structured entity based on comprehensive facts and circumstances, including assessing the purpose and design of the structured entity, identifying the types of variable returns, and whether it assumes part or all of the return variability by participating in its related activities. (2) Preparation method of consolidated financial statements

The consolidated financial statements are based on the financial statements of the Company and its subsidiaries, and are prepared by the Company based on other relevant information. When preparing consolidated financial statements, the accounting policies and accounting period requirements of the Company and its subsidiaries are consistent, and significant inter-company transactions and balances are eliminated.

Subsidiaries and businesses that are added due to business combinations under the same control during the reporting period are deemed to be included in the company's consolidation scope from the date they are both controlled by the ultimate controlling party, and their operating results and cash flows from the date they are both controlled by the ultimate controlling party are included in the consolidated income statement and consolidated cash flow statement respectively. For subsidiaries and businesses added during the reporting period due to business combinations not under common control, the income, expenses and profits of the subsidiaries and businesses from the date of acquisition to the end of the reporting period are included in the consolidated income statement, and their cash flows are included in the consolidated cash flow statement.

The part of the subsidiary's shareholders' equity that is not owned by the company is listed separately as minority shareholders' equity under the shareholders' equity in the consolidated balance sheet; the share of the subsidiary's current net profit and loss that is minority shareholders' equity is listed as "minority shareholders' profits and losses" under the net profit item in the consolidated income statement. If the losses of a subsidiary shared by minority shareholders exceed the minority shareholders' share of the opening owner's equity of the subsidiary, the balance will still offset the minority shareholders' equity.

(3) Purchase minority shareholders’ equity in subsidiaries

The difference between the cost of the newly acquired long-term equity investment due to the purchase of a minority stake and the share of the subsidiary's net assets calculated continuously from the date of purchase or merger based on the new shareholding ratio, as well as the difference between the disposal price obtained from partial disposal of the equity investment in the subsidiary without losing control and the share of the subsidiary's net assets continuously calculated from the date of purchase or merger corresponding to the disposal of the long-term equity investment, will be adjusted to the capital reserve in the consolidated balance sheet. If the capital reserve is insufficient for offset, the retained earnings will be adjusted.

(4) Treatment of loss of control of subsidiaries

If control of the original subsidiary is lost due to the disposal of part of the equity investment or other reasons, the remaining equity shall be remeasured according to its fair value on the date of loss of control; the sum of the consideration obtained for the disposal of the equity and the fair value of the remaining equity, minus the sum of the share of the book value of the original subsidiary's net assets calculated continuously from the date of purchase and goodwill calculated based on the original shareholding ratio, shall be included in the investment income in the current period when control is lost.

Other comprehensive income related to the equity investment of the original subsidiary will be accounted for on the same basis as the original subsidiary's direct disposal of relevant assets or liabilities when control is lost. Other changes in owner's equity related to the original subsidiary that are accounted for under the equity method will be transferred to the current profit and loss when control is lost.

8. Classification of joint arrangements and accounting treatment methods for joint operations

A joint arrangement refers to an arrangement that is jointly controlled by two or more parties. The Company's joint venture arrangements are divided into joint operations and joint ventures.

(1) Joint operation

A joint operation refers to a joint arrangement in which the Company enjoys the relevant assets of the arrangement and assumes the relevant liabilities of the arrangement.

The company confirms the following items related to the interest share in joint operations, and performs accounting treatments in accordance with the relevant accounting standards for enterprises:

A. Recognize the assets held individually, and recognize the assets held jointly according to their shares;

B. Recognize the liabilities borne individually and recognize the liabilities borne jointly according to their shares;

C. Recognize the income generated from the sale of its share of joint operating output;

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. D. The income generated by the joint operation from the sale of output is recognized according to its share;

E. Recognize the expenses incurred individually, and recognize the expenses incurred by joint operations according to their share.

(2) Joint venture

A joint venture is a joint arrangement in which the Company only has rights to the net assets of the arrangement.

The Company accounts for investments in joint ventures in accordance with the provisions on equity method accounting for long-term equity investments.

9. Determination standards for cash and cash equivalents

Cash refers to cash on hand and deposits that can be used for payment at any time. Cash equivalents refer to investments held by the Company that are short-term, highly liquid, easily convertible into known amounts of cash, and have little risk of value changes.

10. Foreign currency business and foreign currency statement conversion

The company's foreign currency business is converted into the recording currency amount based on the spot exchange rate on the date of the transaction.

On the balance sheet date, foreign currency monetary items are converted using the spot exchange rate on the balance sheet date. The exchange difference arising from the difference between the spot exchange rate on the balance sheet date and the spot exchange rate at the time of initial recognition or the previous balance sheet date is included in the current profit and loss; foreign currency non-monetary items measured at historical cost are still converted using the spot exchange rate on the date of the transaction; For foreign currency non-monetary items measured at fair value, they are converted using the spot exchange rate on the date when the fair value is determined. The difference between the converted accounting functional currency amount and the original accounting functional currency amount is included in the current profit and loss or other comprehensive income according to the nature of the non-monetary item.

11. Financial instruments

A financial instrument is a contract that forms a financial asset of one party and a financial liability or equity instrument of another party.

(1) Recognition and derecognition of financial instruments

The Company recognizes a financial asset or financial liability when it becomes a party to a financial instrument contract.

Financial assets shall be derecognized if they meet one of the following conditions:

①The contractual right to receive cash flows from the financial asset terminates;

②The financial asset has been transferred and meets the following conditions for derecognition of financial asset transfer.

If the current obligation of a financial liability has been discharged in whole or in part, the financial liability or part of it shall be derecognised. If the company (debtor) and its creditor sign an agreement to replace existing financial liabilities by assuming new financial liabilities, and the contract terms of the new financial liabilities are substantially different from the existing financial liabilities, the existing financial liabilities will be derecognised and the new financial liabilities will be recognized at the same time.

When financial assets are bought and sold in a regular manner, accounting recognition and derecognition will be carried out based on the transaction date.

(2) Classification and measurement of financial assets

Upon initial recognition, the Company divides financial assets into the following three categories based on the business model for managing financial assets and the contractual cash flow characteristics of financial assets: financial assets measured at amortized cost, financial assets measured at fair value with changes included in other comprehensive income, and financial assets measured at fair value with changes included in current profits and losses.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Financial assets are measured at fair value upon initial recognition. For financial assets measured at fair value and whose changes are included in the current profit and loss, the relevant transaction costs are directly included in the current profit and loss; for other types of financial assets, the relevant transaction costs are included in the initial recognition amount. For receivables arising from the sale of products or provision of services that do not include or take into account significant financing components, the amount of consideration that the company is expected to be entitled to receive shall be regarded as the initial recognition amount.

Financial assets measured at amortized cost

The Company will classify financial assets that meet the following conditions and are not designated as measured at fair value through profit or loss for the current period as financial assets measured at amortized cost:

 The company’s business model for managing this financial asset is aimed at collecting contractual cash flows;

 The contractual terms of the financial asset stipulate that the cash flows generated on a specific date are only payments of principal and interest based on the outstanding principal amount.

Pay.

After initial recognition, such financial assets are measured at amortized cost using the effective interest rate method. Gains or losses arising from financial assets that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when they are derecognized, amortized according to the effective interest method, or impairment is recognized.

Financial assets measured at fair value through other comprehensive income

The Company will classify financial assets that meet the following conditions and are not designated as measured at fair value through profit or loss for the current period as financial assets measured at fair value through other comprehensive income:

 The company’s business model for managing the financial assets aims at both collecting contractual cash flows and selling the financial assets;

 The contractual terms of the financial asset stipulate that the cash flows generated on a specific date are only payments of principal and interest based on the outstanding principal amount.

Pay.

After initial recognition, such financial assets are subsequently measured at fair value. Interest, impairment losses or gains and exchange gains and losses calculated using the effective interest rate method are included in the current profit and loss, and other gains or losses are included in other comprehensive income. When derecognition is terminated, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in the current profit and loss.

Financial assets measured at fair value with changes included in current profits and losses

Except for the above-mentioned financial assets measured at amortized cost and at fair value with changes included in other comprehensive income, the Company classifies all remaining financial assets as financial assets measured at fair value with changes included in current profits and losses. At the time of initial recognition, in order to eliminate or significantly reduce accounting mismatches, the Company irrevocably designates some financial assets that should have been measured at amortized cost or at fair value through other comprehensive income as financial assets at fair value through profit or loss for the current period.

After initial recognition, such financial assets are subsequently measured at fair value, and the resulting gains or losses (including interest and dividend income) are included in the current profits and losses, unless the financial assets are part of a hedging relationship.

The business model for managing financial assets refers to how the company manages financial assets to generate cash flow. The business model determines whether the source of cash flow from the financial assets managed by the company is collection of contractual cash flow, sale of financial assets or both. The Company determines the business model for managing financial assets based on objective facts and specific business objectives for managing financial assets determined by key management personnel.

The Company evaluates the contractual cash flow characteristics of financial assets to determine whether the contractual cash flows generated by the relevant financial assets on a specific date are only payments of principal and interest based on the outstanding principal amount. Among them, principal refers to the fair value of the financial asset at the time of initial recognition; interest includes consideration for the time value of money, the credit risk associated with the outstanding principal amount in a specific period, and other basic lending risks, costs and profits. In addition, the Company evaluates contract terms that may cause changes in the time distribution or amount of contractual cash flows of financial assets to determine whether they meet the requirements of the above contractual cash flow characteristics.

Full text of the 2025 Semi-Annual Report of Shenzhen Neptune Bioengineering Co., Ltd. Only when the company changes the business model for managing financial assets, all affected related financial assets will be reclassified on the first day of the first reporting period after the change in the business model. Otherwise, the financial assets shall not be reclassified after initial recognition.

(3) Classification and measurement of financial liabilities

The Company's financial liabilities are classified upon initial recognition into: financial liabilities measured at fair value with changes included in current profits and losses, and financial liabilities measured at amortized cost. For financial liabilities that are not classified as measured at fair value and whose changes are included in current profits and losses, relevant transaction costs are included in their initial recognition amount.

Financial liabilities measured at fair value through profit or loss for the current period

Financial liabilities at fair value through profit or loss include trading financial liabilities and financial liabilities designated as fair value through profit or loss upon initial recognition. For such financial liabilities, subsequent measurement is carried out at fair value, and gains or losses arising from changes in fair value, as well as dividends and interest expenses related to such financial liabilities, are included in the current profits and losses.

Financial liabilities measured at amortized cost

Other financial liabilities adopt the actual interest rate method and are subsequently measured at amortized cost. Gains or losses arising from derecognition or amortization are included in the current profits and losses.

The difference between financial liabilities and equity instruments

Financial liabilities refer to liabilities that meet one of the following conditions:

①Contractual obligation to deliver cash or other financial assets to other parties.

② Contractual obligations to exchange financial assets or financial liabilities with other parties under potentially adverse conditions.

③ Non-derivative contracts that must or can be settled with the enterprise's own equity instruments in the future, and the enterprise will deliver a variable number of its own equity instruments according to the contract. ④ Derivative contracts that must or can be settled with the enterprise's own equity instruments in the future, except for derivative contracts that exchange a fixed number of its own equity instruments for a fixed amount of cash or other financial assets.

Equity instruments refer to contracts that prove ownership of the remaining equity in the assets of an enterprise after deducting all liabilities.

If the Company cannot unconditionally avoid delivering cash or other financial assets to fulfill a contractual obligation, the contractual obligation meets the definition of a financial liability. If a financial instrument must or can be settled with the company's own equity instruments, it is necessary to consider whether the company's own equity instruments used to settle the instrument are used as a substitute for cash or other financial assets, or to enable the holder of the instrument to enjoy the remaining interest in the issuer's assets after deducting all liabilities. If it is the former, the instrument is the company's financial liability; if it is the latter, the instrument is the company's equity instrument.

(4) Derivative financial instruments and embedded derivatives

The derivative transaction contract is initially measured at its fair value on the date when the contract is signed, and subsequently measured at its fair value. Derivative financial instruments with a positive fair value are recognized as an asset, and derivative financial instruments with a negative fair value are recognized as a liability. Any gains or losses arising from changes in fair value that do not comply with the hedging accounting regulations are directly included in the current profits and losses.

For hybrid instruments containing embedded derivatives, such as if the main contract is a financial asset, the relevant provisions on the classification of financial assets shall apply to the hybrid instrument as a whole. If the main contract is not a financial asset, and the hybrid instrument is not measured at fair value and its changes are included in the current profit and loss for accounting treatment, and the embedded derivative is not closely related to the main contract in terms of economic characteristics and risks, and the conditions are the same as the embedded derivative, and the stand-alone instrument meets the definition of a derivative, the embedded derivative is separated from the hybrid instrument and treated as a separate derivative financial instrument. If the embedded derivative cannot be measured separately at the time of acquisition or subsequent balance sheet dates, the hybrid instrument as a whole is designated as a financial asset or financial liability at fair value through profit or loss for the current period.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(5) Fair value of financial instruments

The fair value determination method of financial assets and financial liabilities is as follows:

Fair value refers to the price that can be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date.

The Company measures relevant assets or liabilities at fair value and assumes that an orderly transaction to sell assets or transfer liabilities is conducted in the main market for the relevant assets or liabilities; if there is no main market, the Company assumes that the transaction is conducted in the most favorable market for the relevant assets or liabilities. The main market (or the most advantageous market) is the trading market that the company can enter on the measurement date. The Company uses assumptions used by market participants to maximize their economic interests when pricing the asset or liability.

For financial assets or financial liabilities that have an active market, the Company determines their fair value using quotes in the active market. If there is no active market for a financial instrument, the Company uses valuation techniques to determine its fair value.

When measuring non-financial assets at fair value, the ability of market participants to use the asset for its best purpose to generate economic benefits is considered, or the ability to sell the asset to other market participants who can use it for its best purpose to generate economic benefits.

The Company adopts valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information, giving priority to the use of relevant observable input values. Only when observable input values ​​cannot be obtained or are impractical to obtain, unobservable input values ​​will be used.

For assets and liabilities measured or disclosed at fair value in financial statements, the fair value level to which they belong is determined based on the lowest level input value that is significant to the overall fair value measurement: the first level input value is the unadjusted quoted price in the active market for the same asset or liability that can be obtained on the measurement date; the second level input value is the directly or indirectly observable input value of the relevant assets or liabilities in addition to the first level input value; the third level input value is the unobservable input value of the relevant asset or liability.

At each balance sheet date, the Company reassesses the assets and liabilities recognized in the financial statements that continue to be measured at fair value to determine whether there is a transition between fair value measurement levels.

(6) Impairment of financial assets

Based on expected credit losses, the company performs impairment accounting on the following items and recognizes loss provisions:

 Financial assets measured at amortized cost;

 Receivables and investments in debt instruments measured at fair value through other comprehensive income;

 Contract assets as defined in "Accounting Standards for Business Enterprises No. 14 - Revenue";

 Lease receivables;

 Financial guarantee contract (measured at fair value through profit or loss, financial asset transfer does not meet the conditions for derecognition or continues to be involved in the transferred

(except those formed by financial assets).

Measurement of expected credit losses

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original actual interest rate, that is, the present value of all cash shortfalls.

The company considers reasonable and well-founded information about past events, current conditions and predictions of future economic conditions, weights the risk of default, calculates the probability-weighted amount of the present value of the difference between the cash flow receivable in the contract and the cash flow expected to be received, and recognizes expected credit losses.

The Company measures the expected credit losses of financial instruments at different stages respectively. If the credit risk of a financial instrument has not increased significantly since initial recognition, it is in the first stage, and the Company will measure loss provisions based on the expected credit losses within the next 12 months; if the credit risk of a financial instrument has increased significantly since initial recognition but no credit impairment has occurred, it is in the second stage, and the Company will measure loss provisions based on the expected credit losses throughout the entire duration of the instrument; if a financial instrument has experienced credit impairment since initial recognition, it is in the third stage, and the Company will measure loss provisions based on the expected credit losses throughout the entire duration of the instrument.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

For financial instruments with low credit risk on the balance sheet date, the company assumes that its credit risk has not increased significantly since initial recognition, and measures loss provisions based on expected credit losses within the next 12 months.

Lifetime expected credit losses refer to the expected credit losses caused by all possible default events that may occur during the entire expected life of a financial instrument. Expected credit losses within the next 12 months refer to the expected credit losses caused by default events on financial instruments that may occur within 12 months after the balance sheet date (if the expected duration of the financial instrument is less than 12 months, the expected duration), and are part of the expected credit losses throughout the duration.

When measuring expected credit losses, the maximum period that the company needs to consider is the longest contract period for which the enterprise faces credit risk (including consideration of renewal options).

For financial instruments in the first and second stages and with lower credit risk, the company calculates interest income based on its book balance before impairment provisions and actual interest rate. For financial instruments in the third stage, interest income is calculated based on its book balance minus the amortized cost and actual interest rate after impairment provisions have been made.

For receivables such as notes receivable, accounts receivable, receivables financing, other receivables, and contract assets, if the credit risk characteristics of a certain customer are significantly different from those of other customers in the portfolio, or the credit risk characteristics of the customer change significantly, the company will make a separate provision for bad debts for the receivables. In addition to the receivables for which bad debt provisions are made individually, the Company divides the receivables into combinations based on credit risk characteristics and calculates bad debt provisions on a combination basis.

Notes receivable, accounts receivable and contract assets

For notes receivable, accounts receivable, and contract assets, regardless of whether there is a significant financing component, the Company always measures its loss provisions at an amount equivalent to the expected credit losses during the entire duration.

When a single financial asset or contract asset cannot assess the expected credit loss information at a reasonable cost, the company divides the notes receivable, accounts receivable and contract assets into combinations based on the credit risk characteristics, and calculates the expected credit losses on the basis of the combination. The basis for determining the combination is as follows:

A. Notes receivable

 Notes Receivable Portfolio 1: Bank Acceptance Bill

 Notes Receivable Portfolio 2: Commercial Acceptance Bill

B. Accounts receivable

 Accounts receivable portfolio 1: Drug receivables from hospital customers

 Accounts receivable portfolio 2: Device receivables from hospital customers

 Accounts receivable portfolio 3: due from non-hospital customers

 Accounts receivable portfolio 4: Receivables from related parties within the scope of consolidation

For notes receivable and contract assets divided into portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and the expected credit loss rate throughout the duration.

For accounts receivable divided into portfolios, the Company refers to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepares a comparison table between the aging of accounts receivable and the expected credit loss rate for the entire duration, and calculates expected credit losses.

Other receivables

The company divides other receivables into several combinations based on credit risk characteristics, and calculates expected credit losses on the basis of the combinations. The basis for determining the combinations is as follows:

 Other receivables portfolio 1: deposits and security deposits receivable

 Other receivables portfolio 2: mortgage claims receivable

 Other receivables portfolio 3: other receivables

For other receivables classified into portfolios, the Company calculates expected credit losses through default risk exposure and expected credit loss rate within the next 12 months or throughout the duration.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

long-term receivables

The company's long-term receivables include receivables such as installment payments for goods sold.

For installment receivables from the sale of goods, the Company refers to historical credit loss experience, current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and the expected credit loss rate throughout the duration.

Debt investment, other debt investment

For debt investments and other debt investments, the Company calculates expected credit losses based on the nature of the investment, various types of counterparties and risk exposures, and through the default risk exposure and the expected credit loss rate within the next 12 months or throughout the duration.

Assessment of significant increase in credit risk

The Company compares the risk of default of a financial instrument on the balance sheet date with the risk of default on the initial recognition date to determine the relative change in the default risk of the financial instrument during its expected duration to assess whether the credit risk of the financial instrument has increased significantly since initial recognition.

When determining whether credit risk has increased significantly since initial recognition, the Company considers reasonable and supportable information, including forward-looking information, that is available without unnecessary additional cost or effort. Information considered by the Company includes:

 The debtor fails to pay the principal and interest on the due date of the contract;

 An actual or expected significant deterioration in the external or internal credit rating (if any) of the financial instrument;

 An actual or expected significant deterioration in the debtor’s operating results;

 Existing or expected changes in the technological, market, economic or legal environment that will have a material adverse impact on the debtor's ability to repay the Company. Depending on the nature of the financial instrument, the Company evaluates whether the credit risk has increased significantly on the basis of a single financial instrument or a combination of financial instruments. When evaluating based on a portfolio of financial instruments, the Company may classify financial instruments based on common credit risk characteristics, such as overdue information and credit risk ratings.

Credit-impaired financial assets

The Company assesses whether credit impairment has occurred on financial assets measured at amortized cost and debt investments measured at fair value through other comprehensive income on the balance sheet date. When one or more events that have an adverse impact on the expected future cash flows of a financial asset occur, the financial asset becomes a credit-impaired financial asset. Evidence that a financial asset has been credit-impaired includes the following observable information:

 Significant financial difficulties of the issuer or debtor;

 The debtor breaches the contract, such as default or overdue payment of interest or principal;

 The Company makes concessions to the Debtor that it would not make under any other circumstances due to economic or contractual considerations related to the Debtor’s financial difficulty;  It is probable that the Debtor will go bankrupt or undergo other financial reorganization;

 Financial difficulties of the issuer or debtor result in the disappearance of an active market for the financial asset.

Presentation of expected credit loss provisions

In order to reflect changes in the credit risk of financial instruments since initial recognition, the company remeasures expected credit losses on each balance sheet date, and the resulting increase or reversal of loss provisions shall be included in the current profit and loss as impairment losses or gains. For financial assets measured at amortized cost, the loss provision is deducted from the book value of the financial asset listed in the balance sheet; for debt investments measured at fair value with changes included in other comprehensive income, the company recognizes its loss provision in other comprehensive income and does not deduct the book value of the financial asset.

Write off

Full text of Shenzhen Neptune Bioengineering Co., Ltd.'s 2025 Semi-Annual Report If the company no longer reasonably expects that the contractual cash flows of a financial asset can be fully or partially recovered, it will directly write down the book balance of the financial asset. Such a write-down constitutes the derecognition of the relevant financial asset. This situation typically occurs when the Company determines that the debtor does not have the assets or sources of income to generate sufficient cash flow to repay the amount that will be written down. However, in accordance with the Company's procedures for recovering due amounts, financial assets that are written down may still be affected by execution activities.

If a financial asset that has been written down is later recovered, the reversal of the impairment loss will be included in the profit and loss of the current period of recovery.

(7) Transfer of financial assets

The transfer of financial assets refers to the transfer or delivery of financial assets to another party (the transfer-in party) other than the issuer of the financial assets.

If the Company has transferred substantially all risks and rewards of ownership of a financial asset to the transferee, the financial asset shall be derecognized; if the Company has retained substantially all risks and rewards of ownership of the financial asset, the financial asset shall not be derecognised.

If the company neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, the following situations will be dealt with: if it gives up control of the financial asset, it will terminate the recognition of the financial asset and recognize the resulting assets and liabilities; if it does not give up control of the financial asset, the relevant financial assets will be recognized according to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly.

(8) Offset of financial assets and financial liabilities

When the company has the legal right to offset the recognized financial assets and financial liabilities, and the legal right is currently enforceable, and the company plans to settle on a net basis or realize the financial assets and pay off the financial liabilities at the same time, the financial assets and financial liabilities will be listed in the balance sheet at the amount after offsetting each other. Otherwise, financial assets and financial liabilities are presented separately in the balance sheet and are not offset against each other.

12. Notes receivable

For relevant policies, see 11. Financial Instruments

13. Accounts receivable

For relevant policies, see 11. Financial Instruments

14. Accounts receivable financing

For relevant policies, see 11. Financial Instruments

15. Other receivables

Determination method and accounting treatment method of expected credit losses of other receivables

For relevant policies, see 11. Financial Instruments

16. Contract assets

For relevant policies, see 11. Financial Instruments

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

17. Inventory

(1) Classification of inventory

The company's inventories are divided into raw materials, work in progress, low-value consumables, goods in stock, goods shipped, etc. (2) Valuation method for issued inventory

The Company's inventories are valued at actual cost when acquired. Raw materials, inventory, etc. are priced using the weighted average method when shipped. (3) Determination basis and accrual method of inventory depreciation reserve

On the balance sheet date, inventories are measured at the lower of cost and net realizable value. When the net realizable value is lower than the cost, a provision for inventory depreciation is made. Net realizable value is the estimated selling price of the inventory minus the estimated costs to be incurred upon completion, estimated selling expenses and related taxes. When determining the net realizable value of inventories, it is based on the conclusive evidence obtained and the purpose of holding the inventories and the impact of events after the balance sheet date are also considered. The Company usually accrues inventory depreciation provisions based on individual inventory items.

On the balance sheet date, if the factors that previously caused the inventory value to be written down have disappeared, the inventory depreciation provision shall be reversed within the amount originally accrued. (4) Inventory inventory system

The company's inventory inventory system adopts the perpetual inventory system.

(5) Amortization method for low-value consumables and packaging materials

The Company adopts the one-time write-off method for amortization of low-value consumables when they are used.

Turnover packaging is included in costs in installments based on the estimated number of uses.

18. Assets held for sale

Not applicable.

19. Debt investment

Not applicable.

20. Other debt investments

Not applicable.

21. Long-term receivables

The company's long-term receivables include receivables such as installment payments for goods sold.

For installment receivables from the sale of goods, the Company refers to historical credit loss experience, current conditions and predictions of future economic conditions, and calculates expected credit losses through default risk exposure and the expected credit loss rate throughout the duration.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

For other receivables and long-term receivables that are divided into portfolios except installment receivables for goods sold, the expected credit losses are calculated based on the default risk exposure and the expected credit loss rate within the next 12 months or the entire duration.

22. Long-term equity investment

Long-term equity investments include equity investments in subsidiaries, joint ventures and associates. If the company can exert significant influence on the invested unit, it is an associate of the company.

(1) Determination of initial investment cost

For long-term equity investments formed by business combinations: For long-term equity investments obtained through business combinations under the same control, the share of the book value of the merged party’s owner’s equity in the ultimate controlling party’s consolidated financial statements on the date of merger shall be regarded as the investment cost; for long-term equity investments obtained through business combinations not under the same control, the investment cost of long-term equity investments shall be based on the merger cost.

For long-term equity investments obtained by other means: for long-term equity investments obtained by paying cash, the actual purchase price paid will be used as the initial investment cost; for long-term equity investments obtained by issuing equity securities, the fair value of the equity securities issued will be used as the initial investment cost.

(2) Subsequent measurement and profit and loss recognition methods

Investments in subsidiaries are accounted for using the cost method, unless the investment qualifies as held for sale; investments in associates and joint ventures are accounted for using the equity method.

For long-term equity investments accounted for using the cost method, in addition to the actual price paid when acquiring the investment or the cash dividends or profits that have been declared but not yet distributed included in the consideration, the cash dividends or profits declared to be distributed by the investee shall be recognized as investment income and included in the current profit and loss.

For long-term equity investments accounted for using the equity method, if the initial investment cost is greater than the fair value share of the investee's identifiable net assets at the time of investment, the investment cost of the long-term equity investment will not be adjusted; if the initial investment cost is less than the fair value share of the investee's identifiable net assets at the time of investment, the book value of the long-term equity investment will be adjusted, and the difference will be included in the current profit and loss of the investment.

When accounting using the equity method, investment income and other comprehensive income are recognized respectively according to the share of net profits and losses and other comprehensive income realized by the investee that should be enjoyed or shared, and the book value of long-term equity investments is adjusted at the same time; according to the profit or cash declared by the investee to be distributed The portion to be enjoyed in the calculation of dividends will be reduced accordingly and the book value of the long-term equity investment will be reduced accordingly; other changes in the owner's equity of the investee other than net profits and losses, other comprehensive income and profit distribution, the book value of the long-term equity investment will be adjusted and included in the capital reserve (other capital reserve). When confirming the share of the investee's net profits and losses, it is based on the fair value of the investee's identifiable assets when the investment is obtained, and in accordance with the company's accounting policies and accounting periods, the net profit of the investee is adjusted and recognized.

If the investee is able to exert significant influence or implement joint control due to additional investment or other reasons but does not constitute control, on the conversion date, the sum of the fair value of the original equity plus the new investment cost will be used as the initial investment cost to be accounted for under the equity method. If the original equity is classified as a non-trading equity instrument investment measured at fair value and its changes are included in other comprehensive income, the related cumulative fair value changes originally included in other comprehensive income will be transferred to retained earnings when it is accounted for under the equity method.

If the joint control or significant influence on the invested unit is lost due to the disposal of part of the equity investment or other reasons, the remaining equity after disposal will be accounted for in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" on the date of loss of joint control or significant influence, and the difference between the fair value and the book value shall be included in the current profit and loss. Other comprehensive income recognized due to the equity method accounting for the original equity investment will be accounted for on the same basis as the investee's direct disposal of relevant assets or liabilities when the equity method accounting is terminated; other changes in owner's equity related to the original equity investment will be transferred to the current profit and loss.

If control of the invested unit is lost due to the disposal of part of the equity investment or other reasons, and the remaining equity after disposal can jointly control or exert significant influence on the invested unit, it shall be accounted for according to the equity method, and the remaining equity shall be deemed to have been accounted for using the equity method since the time of acquisition and adjusted; after disposal If the remaining equity cannot jointly control or exert significant influence on the invested unit, accounting treatment shall be carried out in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", and the difference between its fair value and book value on the date of loss of control shall be included in the current profit and loss.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

If the company's shareholding ratio decreases due to capital increase by other investors and thus loses control but can exercise joint control or exert significant influence on the investee, the company's share of the investee's net assets increased due to the capital increase and share expansion shall be confirmed based on the new shareholding ratio, and the difference between the original book value of the long-term equity investment corresponding to the decrease in shareholding ratio that should be carried forward shall be included in the current profit and loss; then, according to the new shareholding ratio, it will be deemed to have been adjusted using the equity method since the investment was obtained.

Unrealized gains and losses from internal transactions between the Company and its associates and joint ventures are calculated based on the shareholding ratio and are attributable to the Company, and investment gains and losses are recognized on an offsetting basis. However, if the unrealized internal transaction losses between the company and the invested unit are impairment losses on the transferred assets, they will not be offset.

(3) Basis for determining joint control and significant influence on the invested unit

Joint control refers to the shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided only with the unanimous consent of the parties sharing control rights. When judging whether there is joint control, first judge whether the arrangement is collectively controlled by all participants or a combination of participants, and secondly whether decisions on activities related to the arrangement must be unanimously agreed upon by the participants who collectively control the arrangement. If all participants or a group of participants must act in concert to decide the relevant activities of an arrangement, then all participants or a group of participants are considered to collectively control the arrangement; if there are two or more parties that can collectively control an arrangement, it does not constitute joint control. When determining whether joint control exists, the protective rights enjoyed are not taken into account.

Significant influence means that the investor has the power to participate in decision-making on the financial and operating policies of the invested unit, but it is not able to control or jointly control the formulation of these policies with other parties. When determining whether it can exert significant influence on the invested unit, the investor's direct or indirect holding of voting shares of the invested unit and the impact of the current executable potential voting rights held by the investor and other parties are assumed to be converted into equity in the invested unit, including the impact of current convertible warrants, stock options and convertible corporate bonds issued by the invested unit.

When the company directly or indirectly through subsidiaries owns more than 20% (including 20%) but less than 50% of the voting shares of the invested unit, it is generally considered to have a significant influence on the invested unit, unless there is clear evidence that it cannot participate in the production and operation decisions of the invested unit. policy and does not have a significant impact; when the company owns less than 20% (exclusive) of the voting shares of the invested unit, it is generally not considered to have a significant impact on the invested unit, unless there is clear evidence that it can participate in the production and operation decisions of the invested unit and have a significant impact.

(4) Impairment testing method and impairment provision accrual method

For investments in subsidiaries, associates and joint ventures, please refer to "30. Impairment of long-term assets" in this section for the method of calculating asset impairment.

23. Investment real estate

Investment real estate measurement model

Cost method measurement

Depreciation or amortization method

Investment property is property held to earn rentals or for capital appreciation, or both. The company's investment real estate includes leased land use rights, land use rights held and prepared to be transferred after appreciation, and leased buildings.

The Company's investment real estate is initially measured based on the cost when acquired, and depreciation or amortization is provided periodically in accordance with the relevant regulations on fixed assets or intangible assets.

For investment real estate that adopts the cost model for subsequent measurement, please refer to "30. Impairment of long-term assets" in this section for the method of accruing asset impairment.

The difference between the income from the sale, transfer, scrapping or damage of investment real estate after deducting its book value and relevant taxes is included in the current profit and loss.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

24. Fixed assets

(1) Confirmation conditions

The company's fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a service life of more than one accounting year. A fixed asset can only be recognized when the economic benefits related to the fixed asset are likely to flow into the enterprise and the cost of the fixed asset can be measured reliably. The company's fixed assets are initially measured based on the actual cost when acquired.

Subsequent expenditures related to fixed assets are included in the cost of fixed assets when the economic benefits related to them are likely to flow into the company and their costs can be measured reliably. Daily repair costs of fixed assets that do not meet the conditions for subsequent expenditures for capitalization of fixed assets are included in the current profit and loss or included in the cost of related assets according to the beneficiary objects when incurred. For the replaced part, its book value is derecognized.

(2) Depreciation method

Category Depreciation method Depreciation life Salvage value rate Annual depreciation rate Houses and buildings Average life method 20-30 5%-10% 4.75%-3% Machinery and equipment Average life method 10 5% 9.50%

Transportation equipment Average age method 5-10 5% 19%-9.50% Others Average age method 5-10 5% 19%-9.50%

25. Projects under construction

The cost of the company's construction-in-progress is determined based on actual project expenditures, including various necessary project expenditures incurred during the construction period, borrowing costs that should be capitalized before the project reaches its intended usable state, and other related expenses.

Construction in progress is transferred to fixed assets when it reaches the intended usable state.

For the method of accruing asset impairment for projects under construction, please refer to “30. Impairment of long-term assets” in this section.

26. Borrowing costs

(1) Recognition principles for capitalization of borrowing costs

If the borrowing costs incurred by the company can be directly attributed to the purchase, construction or production of assets that meet the capitalization conditions, they will be capitalized and included in the cost of the relevant assets; other borrowing costs will be recognized as expenses based on the amount incurred when they are incurred and included in the current profits and losses. If borrowing costs meet the following conditions at the same time, capitalization begins: ① Asset expenditures have occurred, and asset expenditures include expenditures in the form of cash payments, transfers of non-cash assets, or interest-bearing debts for the acquisition, construction or production of assets that meet the capitalization conditions;

②The borrowing costs have been incurred;

③The necessary purchase, construction or production activities to bring the assets to the intended usable or salable state have begun.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. (2) Capitalization period of borrowing costs

When the assets purchased, constructed or produced by the company that meet the capitalization conditions reach the intended usable or salable state, the capitalization of borrowing costs will cease. Borrowing costs incurred after the assets that meet the capitalization conditions reach the intended usable or salable state are recognized as expenses based on the amount incurred when incurred and included in the current profit and loss. If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs will be suspended; the borrowing costs during the normal interruption period will continue to be capitalized.

(3) Calculation method of capitalization rate of borrowing costs and capitalization amount

The interest expenses actually incurred on special borrowings in the current period shall be capitalized after deducting the interest income from unused borrowing funds deposited in banks or investment income from temporary investments; the capitalization amount of general borrowings shall be determined based on the weighted average of asset disbursements exceeding the part of special borrowings multiplied by the capitalization rate of the occupied general borrowings. The capitalization rate is calculated and determined based on the weighted average interest rate of general borrowings.

During the capitalization period, all exchange differences on special foreign currency borrowings are capitalized; exchange differences on general foreign currency borrowings are included in the current profits and losses.

27. Biological assets

Not applicable

28. Oil and gas assets

Not applicable

29. Intangible assets

(1) Useful life and its determination basis, estimation, amortization method or review procedure

The company's intangible assets include land use rights, proprietary technology, software, etc.

Intangible assets are initially measured based on cost, and their service life is analyzed and judged when the intangible assets are acquired. If the service life is limited, from the time the intangible asset becomes available for use, an amortization method that can reflect the expected realization method of the economic benefits related to the asset will be used and amortized over the expected service life; if the expected realization method cannot be reliably determined, the straight-line method will be used for amortization; intangible assets with indefinite service life will not be amortized.

The amortization method of intangible assets with limited useful life is as follows:

service life

Category Useful life (years) Amortization method Remarks

Determination basis

Land use rights 40-70 Property rights registration period Straight-line method

Know-how 10 Expected economic benefit years Straight-line method

Software 3-10 Expected economic benefit period Straight-line method

At the end of each year, the company reviews the useful life and amortization method of intangible assets with limited service life. If it is different from the previous estimate, the original estimate is adjusted and treated as a change in accounting estimate.

If it is expected that an intangible asset will no longer bring future economic benefits to the enterprise on the balance sheet date, all the book value of the intangible asset will be transferred to the current profit and loss. For the method of accruing asset impairment for intangible assets, please refer to “30. Impairment of long-term assets” in this section.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

The company's R&D expenditures are expenditures directly related to the company's R&D activities, including R&D personnel salary, direct investment costs, depreciation expenses and long-term prepaid expenses, design expenses, amortization expenses of intangible assets, entrusted external research and development expenses, other expenses, etc.

The Company divides the expenditures on internal research and development projects into expenditures in the research phase and expenditures in the development phase.

Expenditures in the research stage are included in the current profits and losses when incurred.

Expenditures in the development stage can only be capitalized if they meet the following conditions: it is technically feasible to complete the intangible asset so that it can be used or sold; there is the intention to complete the intangible asset and use or sell it; the intangible asset generates economic benefits in a manner that can prove the use of the intangible asset to produce products There is a market or there is a market for the intangible asset itself, and if the intangible asset will be used internally, its usefulness can be proven; there is sufficient technical, financial and other resource support to complete the development of the intangible asset, and the ability to use or sell the intangible asset; the expenditures attributable to the development stage of the intangible asset can be measured reliably. Development expenditures that do not meet the above conditions are included in the current profit and loss.

The company's research and development projects will enter the development stage after meeting the above conditions and passing technical feasibility and economic feasibility studies to form a project.

Capitalized expenditures in the development phase are listed as development expenditures on the balance sheet and are converted into intangible assets from the date the project reaches its intended use.

Capitalization conditions for specific R&D projects:

The work performed by the company before obtaining the "Clinical Trial Approval" from the State Food and Drug Administration (including the time when the "Clinical Trial Approval" was obtained) is the research stage, and all expenditures incurred during this stage are expensed and included in the current profit and loss. The work performed after obtaining the "Clinical Trial Approval" from the State Food and Drug Administration is the development stage. The expenditures incurred in this stage will be capitalized when they meet the above conditions for capitalization of the development stage. Otherwise, all expenditures incurred will be included in the current profits and losses. If it is indeed impossible to distinguish the expenditures that should be attributed to the expenses incurred before or after obtaining the "Clinical Trial Approval" from the State Food and Drug Administration, all the expenses incurred will be expensed and included in the current profits and losses. The consistency evaluation expenses will be capitalized when the BE trial is filed and the BE clinical trial is started. If the BE is exempted, capitalization will begin when the consistency evaluation office approves the exemption.

30. Impairment of long-term assets

The asset impairment of long-term equity investments in subsidiaries, associates and joint ventures, investment real estate, fixed assets, construction in progress, right-of-use assets, intangible assets, goodwill, etc. that are subsequently measured using the cost model (except inventories, investment real estate measured using the fair value model, deferred income tax assets, and financial assets) is determined according to the following method:

On the balance sheet date, it is judged whether there are any signs that the asset may be impaired. If there are signs of impairment, the company will estimate its recoverable amount and conduct an impairment test. Goodwill formed due to business mergers, intangible assets with indefinite useful lives and intangible assets that have not yet reached a usable state are subject to impairment testing every year regardless of whether there are signs of impairment.

The recoverable amount is determined based on the higher of the asset's fair value less disposal costs and the present value of the asset's expected future cash flows. The Company estimates the recoverable amount on the basis of a single asset; if it is difficult to estimate the recoverable amount of an individual asset, the recoverable amount of the asset group to which the asset belongs is determined based on the asset group. The identification of an asset group is based on whether the main cash inflow generated by the asset group is independent of the cash inflows of other assets or asset groups.

When the recoverable amount of an asset or asset group is lower than its book value, the company will write down its book value to the recoverable amount, and the amount of the write-down will be included in the current profit and loss, and the corresponding asset impairment provision will be made.

As far as the impairment test of goodwill is concerned, the book value of goodwill formed due to a business combination shall be allocated to the relevant asset groups in a reasonable manner from the date of purchase; if it is difficult to allocate it to the relevant asset groups, it shall be allocated to the relevant asset group combinations. The relevant asset group or asset group combination is an asset group or asset group combination that can benefit from the synergy effects of the business combination, and is no larger than the reporting segment determined by the company.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

During impairment testing, if there are signs of impairment in an asset group or combination of asset groups related to goodwill, first conduct an impairment test on the asset group or combination of asset groups that does not contain goodwill, calculate the recoverable amount, and recognize the corresponding impairment loss. Then conduct an impairment test on the asset group or asset group combination containing goodwill, and compare its book value with the recoverable amount. If the recoverable amount is lower than the book value, the impairment loss of goodwill is recognized.

Once the asset impairment loss is recognized, it will not be reversed in subsequent accounting periods.

31. Long-term deferred expenses

The long-term deferred expenses incurred by the company are measured at actual costs and amortized evenly over the expected benefit period. For long-term deferred expense items that cannot benefit future accounting periods, their amortized value shall be fully included in the current profit and loss.

32. Contract liabilities

The Company's unconditional (subject only to the passage of time) right to receive consideration from customers is presented as receivables. The Company's obligation to transfer goods or services to customers for consideration received or receivable from customers is treated as a contract liability.

33. Employee compensation

(1) Accounting treatment method for short-term compensation

During the accounting period when employees provide services, the company recognizes the actual employee wages, bonuses, social insurance premiums such as medical insurance premiums, work-related injury insurance premiums, maternity insurance premiums, and housing provident funds paid for employees according to prescribed standards and proportions as liabilities, and includes them in the current profit and loss or related asset costs.

(2) Accounting treatment of post-employment benefits

Post-employment benefit plans include defined contribution plans and defined benefit plans. Among them, a defined contribution plan refers to a post-employment benefit plan in which the enterprise no longer bears further payment obligations after paying a fixed fee to an independent fund; a defined benefit plan refers to a post-employment benefit plan other than a defined contribution plan.

Set up a savings plan

Defined contribution plans include basic pension insurance, unemployment insurance, etc.

During the accounting period when employees provide services, the deposit amount payable calculated according to the defined contribution plan is recognized as a liability and included in the current profit and loss or related asset costs. (3) Accounting treatment method for dismissal benefits

If the company provides dismissal benefits to employees, the employee compensation liabilities arising from the dismissal benefits will be recognized and included in the current profit and loss at the earliest of the following two situations: when the company cannot unilaterally withdraw the dismissal benefits provided due to the termination of labor relations plan or layoff proposal; when the company recognizes the costs or expenses related to the restructuring involving the payment of dismissal benefits.

If an internal retirement plan is implemented for employees, the economic compensation before the official retirement date shall be regarded as dismissal benefits. From the date when the employee stops providing services to the normal retirement date, the wages and social insurance premiums to be paid to the employees who retire early shall be included in the current profit and loss in one go. Financial compensation after the official retirement date (such as normal pension and pension) will be treated as post-employment benefits.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. (4) Accounting treatment methods for other long-term employee benefits

Other long-term employee benefits provided by the company to employees that meet the conditions of a defined contribution plan shall be handled in accordance with the above-mentioned relevant regulations on defined contribution plans. If it is in compliance with a defined benefit plan, it will be handled in accordance with the above-mentioned relevant provisions on defined benefit plans, but the "changes resulting from the remeasurement of the net liabilities or net assets of the defined benefit plan" in the relevant employee compensation costs will be included in the current profit and loss or related asset costs.

34. Estimated liabilities

If the obligations related to contingencies meet the following conditions at the same time, the company will recognize them as estimated liabilities:

(1) The obligation is the current obligation of the company;

(2) The performance of this obligation is likely to result in the outflow of economic benefits from the company;

(3) The amount of the obligation can be measured reliably.

Estimated liabilities are initially measured based on the best estimate of the expenditure required to fulfill the relevant current obligations, and factors such as risks, uncertainties, and time value of money related to contingencies are comprehensively considered. If the time value of money has a significant impact, the best estimate is determined by discounting the relevant future cash outflows. The Company reviews the book value of estimated liabilities on the balance sheet date and adjusts the book value to reflect the current best estimate.

If all or part of the expenses required to settle the recognized estimated liabilities are expected to be compensated by a third party or other parties, the compensation amount can only be recognized separately as an asset when it is basically certain that it will be received. The amount of compensation recognized shall not exceed the book value of the liability recognized.

35. Share-based payment

(1) Types of share-based payment

The Company's share-based payment is divided into equity-settled share-based payment and cash-settled share-based payment.

(2) Method for determining the fair value of equity instruments

The Company determines the fair value of options and other equity instruments granted in active markets based on quoted prices in active markets. For equity instruments such as options granted for which there is no active market, the fair value is determined using an option pricing model. The selected option pricing model considers the following factors: A. The exercise price of the option; B. The validity period of the option; C. The current price of the underlying stock; D. The expected volatility of the stock price; E. The expected dividend of the stock; F. The risk-free interest rate during the validity period of the option.

(3) Basis for confirming the best estimate of exercisable equity instruments

On each balance sheet date during the waiting period, the Company makes its best estimate based on the latest changes in the number of vested employees and other subsequent information, and revise the number of equity instruments expected to be vested. On the vesting date, the number of equity instruments ultimately expected to be vested should be consistent with the actual number of vested equity instruments.

(4) Accounting treatments related to the implementation, modification, and termination of share-based payment plans

Equity-settled share-based payments are measured at the fair value of the equity instruments granted to employees. If the rights become exercisable immediately after grant, the fair value of the equity instrument on the grant date will be included in the relevant costs or expenses, and the capital reserve will be increased accordingly. If the vesting cannot be vested until the services within the waiting period are completed or the specified performance conditions are met, on each balance sheet date during the waiting period, based on the best estimate of the number of vested equity instruments and the fair value of the equity instrument on the grant date, the services obtained in the current period will be included in the relevant costs or expenses and capital reserves. No adjustments will be made to the recognized related costs or expenses and the total owner's equity after the vesting date.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Cash-settled share-based payments are measured based on the fair value of the liability calculated and determined based on shares or other equity instruments assumed by the company. If the rights become exercisable immediately after grant, the fair value of the liability assumed by the Company on the date of grant will be included in the relevant costs or expenses, and the liability will be increased accordingly. For cash-settled share-based payments that are exercisable after completing services during the waiting period or meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation and the fair value of the liability borne by the company, the services obtained in the current period will be included in costs or expenses and corresponding liabilities. On each balance sheet date and settlement date before the settlement of relevant liabilities, the fair value of the liability is remeasured, and its changes are included in the current profit and loss.

When the company modifies the share-based payment plan, if the modification increases the fair value of the equity instruments granted, the increase in services obtained shall be recognized accordingly according to the increase in the fair value of the equity instruments; if the modification increases the number of equity instruments granted, the fair value of the increased equity instruments shall be recognized accordingly as an increase in services obtained. The increase in the fair value of equity instruments refers to the difference between the fair values ​​of the equity instruments before and after the modification on the modification date. If the modification reduces the total fair value of share-based payment or the terms and conditions of the share-based payment plan are modified in other ways that are unfavorable to employees, the accounting treatment for the services obtained will continue to be performed as if the change has never occurred, unless the company cancels some or all of the equity instruments that have been granted.

During the waiting period, if the granted equity instruments are canceled (except for those canceled due to failure to meet non-market conditions for vesting), the company will treat the cancellation of the granted equity instruments as accelerated exercise, and the amount that should be recognized during the remaining waiting period will be immediately included in the current profit and loss, and the capital reserve will be recognized at the same time. If employees or other parties can choose to meet the non-vesting conditions but fail to do so within the waiting period, the company will treat it as the cancellation of the equity instruments granted.

36. Preferred shares, perpetual bonds and other financial instruments

Not applicable.

37. Income

Disclose accounting policies adopted for revenue recognition and measurement by business type

(1) General principles

The company fulfills its performance obligations in the contract, that is, when the customer obtains control of the relevant goods or services, revenue is recognized.

If the contract contains two or more performance obligations, the Company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods or services promised by each individual performance obligation on the contract commencement date, and measure revenue based on the transaction price allocated to each individual performance obligation.

When one of the following conditions is met, the performance obligation is performed within a certain period of time; otherwise, the performance obligation is performed at a certain point in time:

① When the company performs the contract, the customer obtains and consumes the economic benefits brought by the company's performance of the contract.

②Customers can control the products under construction during the company's performance of the contract.

③The goods produced by the company during the performance of the contract have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period.

For performance obligations performed within a certain period of time, the Company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred by the company are expected to be compensated, revenue will be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined.

For performance obligations fulfilled at a certain point in time, the Company recognizes revenue at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods or services, the company will consider the following signs:

Full text of Shenzhen Neptune Bioengineering Co., Ltd.'s 2025 Semi-Annual Report ① The company has the current right to receive payment for the goods or services, that is, the customer has current payment obligations for the goods.

②The company has transferred the legal ownership of the product to the customer, which means that the customer already has the legal ownership of the product.

③The company has transferred the physical goods of the goods to the customer, that is, the customer has physical possession of the goods.

④ The company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity. ⑤The customer has accepted the goods or services.

⑥Other indications that the customer has obtained control of the product.

(2) Specific methods

The company's product sales are mainly divided into four categories: pharmaceutical commercial circulation, pharmaceutical manufacturing, health products and food, and medical devices. The specific method of revenue recognition is as follows: ① Pharmaceutical commercial circulation

The company's pharmaceutical business circulation includes dealer sales model and direct sales model.

Under the dealer sales model, the company delivers the product to the customer at the time and place specified in the sales contract, and the sales revenue is confirmed after the customer's acceptance; under the direct sales model, the customers are major hospitals. This model can be further divided into a buyout sales model and a co-pharmacy sales model. Under the buyout sales model, the company The product is delivered to the customer at the time and place stipulated in the sales contract, and the sales revenue is confirmed after the customer's acceptance. Under the co-pharmacy sales model, the company delivers the product to the co-managed pharmacy of each hospital according to the time stipulated in the sales contract. After the medicine is finally sold to the patient, the sales revenue is confirmed based on the sales list issued by the hospital.

②Drug manufacturing

The company delivers the product to the customer at the time and location specified in the sales contract, and sales revenue is confirmed after inspection and acceptance by the customer.

③Health products and food

The company delivers the product to the customer at the time and location specified in the sales contract, and sales revenue is confirmed after the customer accepts the delivery.

④Medical equipment

The company delivers the product to the customer at the time and location specified in the sales contract, and sales revenue is confirmed after the customer accepts the delivery.

38. Contract costs

Contract costs include incremental costs incurred to obtain the contract and contract performance costs.

The incremental costs incurred to obtain the contract refer to costs that the company would not have incurred if it had not obtained the contract (such as sales commissions, etc.). If the cost is expected to be recovered, the company will recognize it as the contract acquisition cost and as an asset. Other expenses incurred by the Company to obtain the contract, except for the incremental costs expected to be recovered, are included in the current profits and losses when incurred.

If the costs incurred to fulfill the contract do not fall within the scope of other accounting standards for enterprises such as inventories and meet the following conditions, the company will recognize them as contract performance costs as an asset:

① The cost is directly related to a current or expected contract, including direct labor, direct materials, manufacturing overhead (or similar expenses), costs clearly borne by the customer, and other costs incurred solely because of the contract;

Full text of Shenzhen Neptune Bioengineering Co., Ltd.'s 2025 Semi-Annual Report ② This cost increases the company's resources for fulfilling its performance obligations in the future;

③The cost is expected to be recovered.

Assets recognized as contract acquisition costs and assets recognized as contract performance costs (hereinafter referred to as "assets related to contract costs") are amortized on the same basis as the revenue recognition of goods or services related to the assets and included in the current profit and loss.

When the book value of the assets related to the contract cost is higher than the difference between the following two items, the company makes an impairment provision for the excess and recognizes it as an asset impairment loss: ① The remaining consideration that the company expects to obtain from the transfer of goods or services related to the asset;

② The estimated cost that will be incurred to transfer the relevant goods or services.

39. Government subsidies

Government subsidies are recognized when the conditions attached to the government subsidies are met and can be received.

Government subsidies for monetary assets are measured based on the amount received or receivable. Government subsidies for non-monetary assets are measured at fair value; if the fair value cannot be obtained reliably, they are measured at a nominal amount of 1 yuan.

Asset-related government subsidies refer to government subsidies obtained by the company and used to purchase, construct or otherwise form long-term assets; in addition, they are government subsidies related to income.

For government documents that do not clearly stipulate the subsidy objects and can form long-term assets, the part of the government subsidy corresponding to the asset value shall be regarded as the government subsidy related to the assets, and the remaining part shall be regarded as the government subsidy related to the income; if it is difficult to distinguish, the entire government subsidy shall be regarded as the government subsidy related to the income.

Government subsidies related to assets are recognized as deferred income and are included in profits and losses in installments according to a reasonable and systematic method during the use period of the relevant assets. If government subsidies related to income are used to compensate for relevant costs or losses that have already occurred, they will be included in the current profits and losses; if they are used to compensate for relevant costs or losses in subsequent periods, they will be included in deferred income and will be included in the current profits and losses during the period when the relevant costs or losses are recognized. Government subsidies measured according to the nominal amount are directly included in the current profit and loss. The company handles the same or similar government subsidy business in a consistent manner.

Government subsidies related to daily activities shall be included in other income according to the economic business essence. Government subsidies unrelated to daily activities are included in non-operating income. When a confirmed government subsidy needs to be returned, if the book value of the relevant assets is offset at the time of initial recognition, the book value of the assets is adjusted; if there is a balance of relevant deferred income, the book balance of the relevant deferred income is offset, and the excess is included in the current profit and loss; in other cases, it is directly included in the current profit and loss.

40. Deferred income tax assets/deferred income tax liabilities

Income tax includes current income tax and deferred income tax. Except for adjustments to goodwill arising from business combinations, or deferred income taxes related to transactions or events directly included in owners' equity, which are included in owners' equity, they are all included in current profits and losses as income tax expenses.

The company uses the balance sheet debt method to recognize deferred income tax based on the temporary differences between the book values ​​of assets and liabilities on the balance sheet date and their tax basis.

Each taxable temporary difference is recognized as a related deferred income tax liability, unless the taxable temporary difference is generated in the following transactions:

(1) Initial recognition of goodwill, or the initial recognition of assets or liabilities arising from a transaction with the following characteristics: the transaction is not a business combination, and the transaction affects neither accounting profits nor taxable income when the transaction occurs (except for individual transactions where the initial recognition of assets and liabilities results in equal amounts of taxable temporary differences and deductible temporary differences);

Full text of the 2025 Semi-Annual Report of Shenzhen Neptune Bioengineering Co., Ltd. (2) For taxable temporary differences related to investments in subsidiaries, joint ventures and associates, the time for the reversal of the temporary differences can be controlled and the temporary differences are likely not to be reversed in the foreseeable future.

For deductible temporary differences, deductible losses and tax credits that can be carried forward to future years, the company recognizes the resulting deferred income tax assets to the extent that it is likely to obtain future taxable income that can be used to offset the deductible temporary differences, deductible losses and tax credits, unless the deductible temporary differences are generated in the following transactions:

(1) The transaction is not a business combination, and when the transaction occurs, it affects neither accounting profits nor taxable income (except for individual transactions in which the initial recognition of assets and liabilities results in equal amounts of taxable temporary differences and deductible temporary differences);

(2) For deductible temporary differences related to investments in subsidiaries, joint ventures and associates, corresponding deferred income tax assets are recognized if the following conditions are met: the temporary differences are likely to be reversed in the foreseeable future, and it is likely to be taxable income that can be used to offset the deductible temporary differences in the future.

On the balance sheet date, the Company's deferred income tax assets and deferred income tax liabilities are measured at the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled, and the income tax impact of the expected method of recovering the asset or settling the liability on the balance sheet date is reflected.

On the balance sheet date, the Company reviews the book value of deferred income tax assets. If it is probable that sufficient taxable income will not be available in future periods to offset the benefits of deferred tax assets, the carrying amount of the deferred tax assets will be reduced. The amount of the write-down is reversed when it is probable that sufficient taxable income will be obtained.

On the balance sheet date, deferred income tax assets and deferred income tax liabilities are presented as the net amount after offsetting when the following conditions are met at the same time:

(1) The tax payer within the company has the legal right to settle current income tax assets and current income tax liabilities on a net basis;

(2) Deferred income tax assets and deferred income tax liabilities are related to income taxes levied by the same tax collection and administration department on the same taxpayer within the company.

41. Leasing

(1) Accounting treatment method for leasing as lessee

On the start date of the lease period, the Company recognizes right-of-use assets and lease liabilities for all leases, except short-term leases and low-value asset leases that are simplified.

For accounting policies on right-of-use assets, please refer to “30. Impairment of long-term assets” in this section.

Lease liabilities are initially measured based on the present value of the unpaid lease payments at the beginning of the lease term using the interest rate implicit in the lease. If the interest rate implicit in the lease cannot be determined, the incremental borrowing rate is used as the discount rate. Lease payments include: fixed payments and substantive fixed payments, if there are lease incentives, less the amount related to the lease incentives; variable lease payments that depend on an index or ratio; the exercise price of the purchase option, provided that the lessee is reasonably certain that the option will be exercised; the amount required to exercise the option to terminate the lease, provided that the lease term reflects that the lessee will exercise the option to terminate the lease; and the amount expected to be paid based on the residual value of the guarantee provided by the lessee. Subsequently, the interest expense of the lease liability for each period during the lease term is calculated based on the fixed periodic interest rate and included in the current profit and loss. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss when actually incurred.

short term rental

A short-term lease refers to a lease with a lease term of no more than 12 months on the start date of the lease period, except for leases that include a purchase option.

The company will include the lease payments of short-term leases into the relevant asset costs or current profits and losses on a straight-line basis during each period of the lease term.

For short-term leases, the Company will select projects that meet the short-term lease conditions and adopt the above simplified treatment method.

Shenzhen Neptune Bioengineering Co., Ltd. 2025 Semi-annual Report Full Text Low-Value Asset Leasing

Low-value asset leases refer to leases where the value of a single leased asset is less than 40,000 yuan when it is a brand-new asset.

The company will include the lease payments for low-value asset leases into the relevant asset costs or current profits and losses on a straight-line basis during each period of the lease term.

For low-value asset leases, the Company chooses to adopt the above simplified treatment method based on the specific circumstances of each lease.

Lease changes

If a lease changes and the following conditions are met at the same time, the company will account for the lease change as a separate lease: ① The lease change expands the scope of the lease by adding the right to use one or more leased assets; ② The increased consideration is equivalent to the amount of the individual price of the expanded part of the lease scope adjusted according to the conditions of the contract.

If the lease change is not accounted for as a separate lease, on the effective date of the lease change, the company re-allocates the consideration of the contract after the change, re-determines the lease term, and re-measures the lease liability based on the present value of the lease payment after the change and the revised discount rate.

If a change in the lease results in a reduction in the scope of the lease or a shortening of the lease period, the company will reduce the book value of the right-of-use assets accordingly, and include the related gains or losses from the partial or complete termination of the lease into the current profits and losses.

If other lease changes result in the remeasurement of lease liabilities, the company will adjust the book value of the right-of-use assets accordingly.

(2) Accounting treatment method for leasing as lessor

When the Company acts as a lessor, leases that substantially transfer all risks and rewards related to asset ownership are recognized as finance leases, and leases other than finance leases are recognized as operating leases.

finance lease

In financial leases, on the date of the start of the lease period, the company uses the net investment in the lease as the entry value of the financial lease receivable. The net investment in the lease is the sum of the unguaranteed residual value and the present value of the lease receivables that have not been received on the date of the start of the lease period, discounted at the interest rate implicit in the lease. As the lessor, the Company calculates and recognizes interest income for each period during the lease term based on fixed periodic interest rates. Variable lease payments obtained by the Company as a lessor that are not included in the measurement of the net lease investment are included in the current profit and loss when actually incurred.

The derecognition and impairment of finance lease receivables shall be accounted for in accordance with the provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" and "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets".

operating lease

For rents in operating leases, the company recognizes current profits and losses according to the straight-line method in each period during the lease term. The initial direct expenses incurred in connection with the operating lease shall be capitalized, amortized during the lease period on the same basis as the rental income recognition, and included in the current profit and loss in installments. Variable lease payments related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur.

Lease changes

If an operating lease changes, the Company will account for it as a new lease from the effective date of the change, and the amount of lease receipts received in advance or receivable related to the lease before the change is regarded as the amount of receipts from the new lease.

Shenzhen Neptune Bioengineering Co., Ltd. 2025 Semi-annual Report Full Text If there is a change in the financial lease and the following conditions are met at the same time, the company will account for the change as a separate lease: ① The change expands the scope of the lease by increasing the use rights of one or more leased assets; ② The increased consideration is equivalent to the amount of the independent price of the expanded part of the lease scope adjusted according to the conditions of the contract.

If a financial lease is changed and is not accounted for as a separate lease, the company will treat the changed lease under the following circumstances: ① If the change takes effect on the lease commencement date, the lease will be classified as an operating lease, the company will account for it as a new lease from the effective date of the lease change, and The net lease investment before the effective date of the lease change is used as the book value of the leased asset; ② If the change takes effect on the lease start date, the lease will be classified as a finance lease, and the company will conduct accounting treatment in accordance with the provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments" regarding modification or renegotiation of contracts.

42. Other important accounting policies and accounting estimates

The Company continuously evaluates the important accounting estimates and key assumptions adopted based on historical experience and other factors, including reasonable expectations for future events. The important accounting estimates and key assumptions that are likely to cause a significant adjustment in the book value of assets and liabilities in the next fiscal year are listed below:

Classification of financial assets

The Company's significant judgments involved in determining the classification of financial assets include analysis of business models and contractual cash flow characteristics.

The Company determines the business model for managing financial assets at the level of financial asset portfolios. Factors considered include the way to evaluate and report the performance of financial assets to key management personnel, the risks that affect the performance of financial assets and their management methods, and the way in which relevant business managers are remunerated.

When the company evaluates whether the contractual cash flows of financial assets are consistent with basic lending arrangements, the company makes the following main judgments: whether the time distribution or amount of the principal may change during the duration due to early repayment and other reasons; whether interest only includes the time value of money, credit risk, other basic lending risks and consideration for costs and profits. For example, whether the amount of early repayment only reflects the unpaid principal and interest based on the unpaid principal, as well as reasonable compensation paid for early termination of the contract.

Measurement of expected credit losses on accounts receivable

The Company calculates the expected credit losses of accounts receivable through the default risk exposure of accounts receivable and the expected credit loss rate, and determines the expected credit loss rate based on the probability of default and the loss given default rate. When determining the expected credit loss rate, the company uses internal historical credit loss experience and other data, and adjusts historical data based on current conditions and forward-looking information. When considering forward-looking information, the Company uses indicators including the risk of economic downturn, external market environment, technological environment and changes in customer conditions. The Company regularly monitors and reviews assumptions related to the calculation of expected credit losses.

Goodwill impairment

The Company assesses whether goodwill is impaired at least annually. This requires an estimate of the value in use of the asset group to which goodwill is assigned. When estimating value in use, the company needs to estimate future cash flows from the asset group and select an appropriate discount rate to calculate the present value of future cash flows.

development expenditure

When determining the amount to be capitalized, management must make assumptions regarding the expected future cash generation of the asset, the discount rate that should be applied, and the expected period of benefit. Deferred tax assets

Deferred tax assets should be recognized for all unused tax losses to the extent that it is probable that sufficient taxable profits will be available against which the losses can be utilised. This requires management to use a lot of judgment to estimate the timing and amount of future taxable profits, combined with tax planning strategies, to determine the amount of deferred income tax assets that should be recognized. Determination of fair value of unlisted equity investments

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The fair value of unlisted equity investments is the estimated future cash flows discounted based on current discount rates for projects with similar terms and risk characteristics. Such valuation requires the Company to estimate expected future cash flows and discount rates and is therefore uncertain. In limited circumstances, if there is insufficient information to determine fair value, or if possible estimates of fair value are spread over a wide range, and the cost represents the best estimate of fair value within that range, the cost may represent an appropriate estimate of fair value within that range.

43. Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

□ApplicableNot applicable

(2) Changes in important accounting estimates

□ApplicableNot applicable

(3) Adjustments to relevant items in the financial statements at the beginning of the year when the new accounting standards are implemented for the first time in 2025.

□ApplicableNot applicable

44. Others

Not applicable.

6. Taxes

1. Main tax types and tax rates

Type of tax Tax calculation basis Tax rate

Taxable value-added amount (taxable amount is based on taxable sales

Value-added tax: The sales amount is multiplied by the applicable tax rate to deduct the amount allowed for the current period: 13%, 9%, 6%, 3%

Calculation of the balance after input tax)

Urban maintenance and construction tax Actual turnover tax paid 7% Corporate income tax Taxable income 25% Education fee surcharge Actual turnover tax paid 3% Local education fee surcharge Actual turnover tax paid 2% If there are taxpayers with different corporate income tax rates, a description of the disclosure

Name of taxpayer Income tax rate Shandong Xinchen 20%

Changde Sea King 20%

Weihai Rutai 20%

Shandong Handi 20%

Suzhou Neptune 20%

Hunan Medical Distribution 20%

Heilongjiang Hejia Mingxi 20%

Neptune's Blessing Medicine 15%

Golden Elephant Chinese Medicine 15%

Beijing Zhongxin 15%

Ningxia Neptune 15%

Sichuan Fanyuan 20%

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Hubei Haijuntong 20%

2. Tax incentives

(1) The company's subsidiaries Shandong Xinchen, Changde Haiwang, Weihai Rutai, Shandong Handi, Suzhou Haiwang, Hunan Medical Distribution, Heilongjiang Hejia Mingxi, Sichuan Fanyuan, and Hubei Haijuntong are small and micro enterprises stipulated in the "Announcement of the Ministry of Finance and the State Administration of Taxation on Further Implementing Preferential Income Tax Policies for Small and Micro Enterprises" (Caishui [2022] No. 13), and the corporate income tax rate is 20%.

(2) The company's subsidiary Neptune Fuyao passed the review as a high-tech enterprise in December 2023. According to the Corporate Income Tax Law and relevant regulations, the corporate income tax rate will be 15% within three years starting from 2023.

(3) The company's subsidiary Jinxiang Traditional Chinese Medicine passed the review of high-tech enterprises in December 2022. According to the Corporate Income Tax Law and relevant regulations, the corporate income tax rate will be 15% within three years starting from 2022.

(4) The company's subsidiary Ningxia Haiwang is an enterprise recognized by the "Catalogue of Encouraged Industries in the Western Region (2020 Edition)" No. 40 of the National Development and Reform Commission of the People's Republic of China (9) Ningxia Hui Autonomous Region's 21st Medical Institution Operation Regulations and meets the preferential conditions for the Western Development. The applicable corporate income tax rate is 15%.

(5) The company's subsidiary Beijing Zhongxin passed the review of high-tech enterprises in December 2022. According to the Corporate Income Tax Law and relevant regulations, the corporate income tax rate will be 15% within three years starting from 2022.

(6) The company's subsidiary Research Institute passed the review as a high-tech enterprise in December 2024. According to the Corporate Income Tax Law and relevant regulations, the corporate income tax rate will be 15% within three years starting from 2022.

3. Others

Not applicable.

7. Notes on Consolidated Financial Statement Items

1. Monetary funds

Unit: Yuan

Item Ending balance Beginning balance

Cash on hand 625,848.92 879,096.09 Bank deposits 1,124,433,620.29 1,279,413,026.50 Other monetary funds 1,938,888,732.72 2,175,981,511.12 Total 3,063,948,201.93 3,456,273,633.71Other instructions:

At the end of the period, the details of the Company’s funds that are restricted for use due to mortgage, pledge or freezing are as follows:

Item Closing balance

Bill security deposit 1,651,926,701.15 Deposit certificate pledge 60,500,000.00 Performance security deposit 208,591,743.96 Loan security deposit 3,000,000.00

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Item Closing balance

Frozen amounts 14,542,625.47 Others 327,662.14

Total 1,938,888,732.72

2. Trading financial assets

Unit: Yuan

Item Ending balance Beginning balance

Measured at fair value with changes included in current profit and loss

122,630,346.17 125,433,276.07 beneficial financial assets

Among them:

Investment in equity instruments 99,994,499.60 98,819,499.60 Financial products 16.32 2,092.32 Equity payment to be received 19,755,830.25 23,731,684.15 Others 2,880,000.00 2,880,000.00Total 122,630,346.17 125,433,276.07

3. Derivative financial assets

Not applicable.

4. Notes receivable

(1) Classified presentation of notes receivable

Unit: Yuan

Item Ending balance Beginning balance

Bank acceptance notes 111,382,741.77 199,252,288.59 Commercial acceptance notes 699,467,062.27 701,174,308.98 Total 810,849,804.04 900,426,597.57

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

its

Medium:

by combination

bad provision

814,887, 4,037,65 810,849, 905,137, 4,710,50 900,426, Account provision 100.00% 0.50% 100.00% 0.52%

459.75 5.71 804.04 103.79 6.22 597.57 receivables

bill

its

Medium:

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Bank commitments 112,019, 636,500. 111,382, 200,362, 1,110,00 199,252,

13.75% 0.57% 22.14% 0.55%

Exchange 242.15 38 741.77 297.43 8.84 288.59 Commercial commitment 702,868, 3,401,15 699,467, 704,774, 3,600,49 701,174,

86.25% 0.48% 77.86% 0.51%

Exchange 217.60 5.33 062.27 806.36 7.38 308.98

814,887, 4,037,65 810,849, 905,137, 4,710,50 900,426, total 100.00% 0.50% 100.00% 0.52%

459.75 5.71 804.04 103.79 6.22 597.57 Category name of bad debt provision by group: Acceptance bill

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Bank acceptance bill 112,019,242.15 636,500.38 0.57% Commercial acceptance bill 702,868,217.60 3,401,155.33 0.48% Total 814,887,459.75 4,037,655.71

If bad debt provisions for notes receivable are made according to the general expected credit loss model:

□ApplicableNot applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Notes receivable 4,710,506.22 672,850.51 4,037,655.71Total 4,710,506.22 672,850.51 4,037,655.71Among them, the amount of bad debt provision recovered or reversed in the current period is important:

□ApplicableNot applicable

(4) The company’s pledged notes receivable at the end of the period

Unit: Yuan

Project Amount pledged at the end of the period

Bank acceptance notes 179,148.90 Commercial acceptance notes 320,250,000.00 Total 320,429,148.90

(5) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan

Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

Bank acceptance notes 201,663,012.12

Commercial acceptance notes 129,595,857.64

Total 331,258,869.76

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(6) Notes receivable actually written off in the current period

Not applicable.

5. Accounts receivable

(1) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 12,977,769,952.13 13,167,236,807.36 1 to 2 years 2,141,330,914.75 2,160,182,556.36 2 to 3 years 476,971,283.81 487,839,697.06 More than 3 years 308,627,830.60 371,216,924.55 3 to 4 years 134,321,895.84 180,074,058.32 4 to 5 years 90,576,373.49 130,618,632.87

More than 5 years 83,729,561.27 60,524,233.36 Total 15,904,699,981.29 16,186,475,985.33

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

bad provision

72,822,7 67,056,2 5,586,54 92,422,6 86,656,0 5,766,54Account provision 0.46% 92.08% 0.57% 93.76%

75.99 32.41 3.58 04.71 61.13 3.58 receivables

Accounts

its

Medium:

by combination

Bad provision 15,831,8 15,142,2 16,094,0 15,313,6

689,790, 780,397,

Account provision 77,205.3 99.54% 4.36% 67,068.0 53,380.6 99.43% 4.85% 56,018.6

137.21 361.94

Accounts receivable 0 9 2 8

its

Medium:

Drugs receivable 10,728,3 10,380,6 10,579,5 10,176,6

347,898, 402,909,

96,438.5 67.45% 3.24% 77,572.3 48,319.0 65.36% 3.81% 39,263.1

866.16 055.84

Customer 3 7 0 6 Transceiver

3,513,76 160,217, 3,353,55 3,841,32 169,597, 3,671,72 Mechanical Hospital 22.09% 4.56% 23.73% 4.42%

8,127.65 518.27 0,609.38 5,829.32 401.61 8,427.71Customers

Receivables from non-

1,589,71 181,673, 1,408,03 1,673,17 207,890, 1,465,28 Hospital customers 10.00% 11.43% 10.34% 12.42%

2,639.12 752.78 8,886.34 9,232.30 904.49 8,327.81 households

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

15,904,6 15,147,8 16,186,4 15,319,4

756,846, 867,053,

Total 99,981.2 100.00% 4.76% 53,611.6 75,985.3 100.00% 5.36% 22,562.2 369.62 423.07

9 7 3 6

Category name of bad debt provision based on individual provision: Individual provision

Unit: Yuan

Beginning balance Closing balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Xinjiang Baohe Tang Medical

18,885,298.59 18,885,298.59

Pharmaceutical Co., Ltd.

Neixiang Jutan Hospital 12,373,021.96 12,373,021.96 12,373,021.96 12,373,021.96 100.00% It is expected that Guoke (Hubei) cannot be recovered

9,897,171.80 9,897,171.80 9,897,171.80 9,897,171.80 100.00% It is not expected to be recovered by Pharmaceutical Co., Ltd.

Jiuzhou Fangyuan Medicine

9,863,505.40 9,863,505.40 9,863,505.40 9,863,505.40 100.00% Hubei Co., Ltd. is not expected to be recovered

Baoji City Hongyuan Sheng

Biotechnology Co., Ltd. 7,241,450.00 7,241,450.00 7,241,450.00 7,241,450.00 100.00% It is expected that the company cannot be recovered

Guangdong Kanglang Pharmaceutical

5,614,189.67 5,614,189.67 5,614,189.67 5,614,189.67 100.00% Expected to be unrecoverable Co., Ltd.

Tongbai Maoji New District

4,570,654.20 4,570,654.20 4,390,654.20 4,390,654.20 100.00% It is expected that the hospital cannot be recovered

Minsheng Group Henan minority shareholders guarantee

4,442,049.08 4,442,049.08

Pharmaceutical Co., Ltd. Gold Guarantee Beijing Zhongli Purui

Investment Management Co., Ltd. 3,697,773.75 3,697,773.75 3,697,773.75 3,697,773.75 100.00% It is expected that the company cannot recover

Sun Wei 2,704,171.60 2,704,171.60 2,704,171.60 2,704,171.60 100.00% It is expected that Beijing Tong Ren Tang (亳) cannot be recovered

Not expected to be available in all states) Yin Pian Limited Liability 2,648,989.00 1,324,494.50 2,648,989.00 1,324,494.50 50.00%

take back

Ren company

Guangdong Ruifuyuan Hospital

2,007,932.89 2,007,932.89 2,007,932.89 2,007,932.89 100.00% Expected to be irrecoverable Pharmaceutical Co., Ltd.

Gansu Friends of Health

Pharmaceutical Co., Ltd. 1,902,884.48 1,902,884.48 1,902,884.48 1,902,884.48 100.00% It is expected that the company cannot be recovered

Shaanxi Friends of Health

1,495,896.56 1,495,896.56 1,495,896.56 1,495,896.56 100.00% It is not expected to be recovered by Pharmaceutical Co., Ltd.

Lichuan Hengai Medical Hospital

1,013,532.53 1,013,532.53 1,013,532.53 1,013,532.53 100.00% It is expected that the hospital cannot be recovered

Others 4,064,083.20 4,064,083.20 3,529,553.07 3,529,553.07 100.00% Total expected to be unrecoverable 92,422,604.71 86,656,061.13 72,822,775.99 67,056,232.41

Category name of provision for bad debts by combination: Drug receivables from hospital customers

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Receivables from pharmaceutical hospital customers 10,728,396,438.53 347,898,866.16 3.24% Total 10,728,396,438.53 347,898,866.16

Category name of provision for bad debts by combination: Device receivables from hospital customers

Unit: Yuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ending balance

Name

Book balance Bad debt provision Provision ratio

Receivables from device hospital customers 3,513,768,127.65 160,217,518.27 4.56% Total 3,513,768,127.65 160,217,518.27

Category name of bad debt provision accrued by portfolio: Receivable from non-hospital customers

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Receivables from non-hospital customers 1,589,712,639.12 181,673,752.78 11.43% Total 1,589,712,639.12 181,673,752.78

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□ApplicableNot applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Accounts receivable 867,053,423.07 26,264,378.09 10,614,627.00 864,379.49 124,992,425.05 756,846,369.62Total 867,053,423.07 26,264,378.09 10,614,627.00 864,379.49 124,992,425.05 756,846,369.62

(4) Accounts receivable actually written off in the current period

Item Write-off Amount

Accounts receivable actually written off 864,379.49

(5) Accounts receivable and contract assets of the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of total amount Value preparation closing balance Weifang People's Hospital 1,237,233,106.82 1,237,233,106.82 7.78% 18,219,305.13 Nanyang Central Hospital 346,457,731.80 346,457,731.80 2.18% 259,700.95 People in Tengzhou city center

331,882,038.70 331,882,038.70 2.09% 8,861,307.84 Hospital

Weifang Yidu Center

249,389,321.55 249,389,321.55 1.57% 2,979,129.96 Hospital

Binzhou Medical College Yantai

242,661,607.67 242,661,607.67 1.53% 8,702,885.82 Affiliated hospitals

Total 2,407,623,806.54 2,407,623,806.54 15.15% 39,022,329.70 Full text of the 2025 Semi-annual Report of Shenzhen Neptune Bioengineering Co., Ltd.

6. Contract assets

Not applicable.

7. Accounts receivable financing

(1) Classified presentation of financing receivables

Unit: Yuan Item Closing balance Opening balance Notes receivable 59,132,839.22 164,791,057.77 Total 59,132,839.22 164,791,057.77 (2) Disclosure by classification according to bad debt accrual method

Not applicable.

(3) Bad debt provisions accrued, recovered or reversed in the current period

Not applicable.

(4) Financing of the company’s pledged receivables at the end of the period

Not applicable.

(5) Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet expired on the balance sheet date

Unit: Yuan Item Amount derecognized at the end of the period Amount not derecognized at the end of the period Bank acceptance bill 1,391,432,042.37

Total 1,391,432,042.37

(6) Financing of receivables actually written off in the current period

Not applicable.

(7) Increases and decreases in receivables financing during the current period and changes in fair value

Not applicable.

(8) Other instructions

Not applicable.

8. Other receivables

Unit: Yuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Item Ending balance Beginning balance

Dividends receivable 8,613,579.12 8,613,579.12 Other receivables 1,766,680,230.19 1,814,368,562.09 Total 1,775,293,809.31 1,822,982,141.21 (1) Interest receivable

Not applicable.

(2) Dividends receivable

1. Classification of dividends receivable

Unit: Yuan

Project (or invested unit) Closing balance Opening balance

Shenzhen Taiheng Medical Investment Co., Ltd. 7,011,000.00 7,011,000.00 Henan Province South-to-North Water Diversion Counterpart Collaboration Industry Investment Fund

1,602,579.12 1,602,579.12 gold (limited partnership)

Total 8,613,579.12 8,613,579.12 2) Important dividends receivable aged more than 1 year

Not applicable.

3. Classified disclosure according to bad debt accrual method

□ApplicableNot applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Not applicable.

5. Dividends receivable actually written off in the current period

Not applicable.

(3) Other receivables

1. Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Reserve fund 12,578,261.29 14,776,062.01 Pledge deposit and security deposit 531,298,071.70 603,724,388.26 Supplier rebate 343,891,940.06 295,798,101.83 Current accounts 1,276,861,970.39 1,325,719,947.39 Others 72,516,782.31 56,683,256.04Total 2,237,147,025.75 2,296,701,755.53

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

2. Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 1,193,861,543.71 1,259,546,024.89 1 to 2 years 189,271,829.37 183,838,051.94 2 to 3 years 272,715,281.39 251,800,195.79 More than 3 years 581,298,371.28 601,517,482.91 3 to 4 years 103,813,344.83 130,904,907.44 4 to 5 years 178,725,311.88 201,627,835.49

More than 5 years 298,759,714.57 268,984,739.98 Total 2,237,147,025.75 2,296,701,755.53

3. Classified disclosure according to bad debt accrual method

Applicable□Not applicable

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

123,433, 123,433, 127,477, 127,203, 274,490. Bad provision 5.52% 100.00% 5.55% 99.78%

142.60 142.60 904.10 413.27 83 Account preparation

Among them:

by combination

2,113,71 347,033, 1,766,68 2,169,22 355,129, 1,814,09 Bad provision 94.48% 16.42% 94.45% 16.37%

3,883.15 652.96 0,230.19 3,851.43 780.17 4,071.26Account preparation

Among them:

pledge

Funds and insurance 505,680, 6,686,50 498,994, 583,807, 6,686,50 577,121,

22.60% 1.32% 25.42% 1.15%

Securities and Finance Group 937.69 0.00 437.69 727.80 0.00 227.80 combined

Mortgage debt 29,491,2 29,491,2 29,491,2 29,491,2

1.32% 1.28%

Rights combination 29.13 29.13 29.13 29.13 Other receivables

1,578,54 340,347, 1,238,19 1,555,92 348,443, 1,207,48 Other amounts 70.56% 21.56% 67.75% 22.39%

1,716.33 152.96 4,563.37 4,894.50 280.17 1,614.33 combination

2,237,14 470,466, 1,766,68 2,296,70 482,333, 1,814,36Total 100.00% 21.03% 100.00% 21.00%

7,025.75 795.56 0,230.19 1,755.53 193.44 8,562.09 Name of bad debt provision based on individual items: Individual provision

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Beijing Huiying Internet

1,250,000.00 1,250,000.00 1,250,000.00 1,250,000.00 100.00% Expected to be unrecoverable Technology Co., Ltd.

Guangdong Hongyu Pharmaceutical

48,758,313.86 48,483,823.03 44,793,401.26 44,793,401.26 100.00% Expected to be unrecoverable Co., Ltd.

Guangdong Hongyu Pharmaceutical 8,505,132.00 8,505,132.00 8,505,132.00 8,505,132.00 100.00% Expected to be unrecoverable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Limited company shareholders

(Zhou Peng, Zhang Xiu

Li)

Hangzhou Yingku Medical

6,600,000.00 6,600,000.00 6,600,000.00 6,600,000.00 100.00% Expected to be unrecoverable Technology Co., Ltd.

Henan Kangsheng Pharmaceutical

1,208,664.13 1,208,664.13 1,208,664.13 1,208,664.13 100.00% Expected to be unrecoverable Co., Ltd.

Henan Taisheng Dashi

1,000,000.00 1,000,000.00 1,000,000.00 1,000,000.00 100.00% Expected to be irrecoverable Industry Co., Ltd.

Hubei Hongqiao Pharmaceutical

3,237,880.56 3,237,880.56 3,237,880.56 3,237,880.56 100.00% Expected to be unrecoverable Co., Ltd.

Hubei Mulan Tong University

2,406,823.80 2,406,823.80 2,406,823.80 2,406,823.80 100.00% It is not expected to be recovered by Technology Co., Ltd.

Hunan Renxiang Medical

1,072,000.00 1,072,000.00 1,072,000.00 1,072,000.00 100.00% Expected to be unable to recover Equipment Co., Ltd.

Jinan Yaping Medical

17,536,329.89 17,536,329.89 17,766,495.86 17,766,495.86 100.00% Equipment Co., Ltd. is not expected to be recovered

Loudi Xiangzhong Coal

Tan Hospital Co., Ltd. 3,738,369.36 3,738,369.36 3,738,369.36 3,738,369.36 100.00% It is expected that the company cannot be recovered

Lu Qun 3,000,000.00 3,000,000.00 3,000,000.00 3,000,000.00 100.00% It is expected that Shanghai Xiwang Enterprise cannot be recovered

4,995,000.00 4,995,000.00 4,995,000.00 4,995,000.00 100.00% It is expected that the management center cannot be recovered

Shenzhen Ju Ming Lantern

5,598,544.79 5,598,544.79 5,311,135.79 5,311,135.79 100.00% It is not expected to be recovered by Jewelry Co., Ltd.

Shenyang Fengzhiye Doctor

Medical Equipment Co., Ltd. 1,391,262.84 1,391,262.84 1,391,262.84 1,391,262.84 100.00% It is expected that the company cannot be recovered

Tianjin Zhongcai Commercial

1,048,900.00 1,048,900.00 1,048,900.00 1,048,900.00 100.00% Expected to be unrecoverable Factoring Co., Ltd.

Tongbai Maoji New District

1,400,000.00 1,400,000.00 1,400,000.00 1,400,000.00 100.00% The hospital is not expected to be recovered

Wu Zhiyu 5,072,134.39 5,072,134.39 5,072,134.39 5,072,134.39 100.00% It is expected that Henan Zhuoer Bangyi cannot be recovered

Medical Equipment Co., Ltd. 1,272,000.00 1,272,000.00 1,272,000.00 1,272,000.00 100.00% It is expected that the company cannot be recovered

Nanyang Neptune Medicine

1,472,771.50 1,472,771.50 1,472,771.50 1,472,771.50 100.00% Expected to be unrecoverable Industrial Co., Ltd.

Others 6,913,776.98 6,913,776.98 6,891,171.11 6,891,171.11 100.00% Total expected to be unrecoverable 127,477,904.10 127,203,413.27 123,433,142.60 123,433,142.60

Category name of bad debt provisions accrued by combination: pledge deposit, margin combination

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Pledge deposit and margin combination 505,680,937.69 6,686,500.00 1.32% Total 505,680,937.69 6,686,500.00

Category name of bad debt provisions accrued by portfolio: Mortgage debt portfolio

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Mortgage debt portfolio 29,491,229.13 0.00 0.00% Total 29,491,229.13 0.00

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Category name of bad debt provisions accrued by combination: Other accounts receivable combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Portfolio of other accounts receivable 1,578,541,716.33 340,347,152.96 21.56% Total 1,578,541,716.33 340,347,152.96

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2025 355,129,780.17 127,203,413.27 482,333,193.44 Balance on January 1, 2025

In this issue

Provision in this period 9,955,749.22 230,165.97 10,185,915.19 Transfer in this period 15,641,037.67 4,000,436.64 19,641,474.31 Write-off in this period 981.75 981.75 Other changes 2,409,857.01 2,409,857.01 As of June 30, 2025

347,033,652.96 123,433,142.60 470,466,795.56

Changes in book balances with significant changes in loss provision during the current period

□ApplicableNot applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off or write-off Others

Other receivables 482,333,193.44 10,185,915.19 19,641,474.31 981.75 2,409,857.01 470,466,795.56 Total 482,333,193.44 10,185,915.19 19,641,474.31 981.75 2,409,857.01 470,466,795.56

5. Other receivables actually written off in the current period

Unit: Yuan

Item Write-off Amount

Other receivables actually written off 981.75

6. Other receivables with top five closing balances collected by debtors

Unit: Yuan accounted for other receivable period

Name of the unit with the ending balance of bad debt provision Nature of the payment Ending balance Aging Total ending balance

Um

Proportion

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Xinjiang Haiwang Xinjia Medical Center

Current account 90,025,223.10 Within 1 year 4.02% 0.00 Pharmaceutical Co., Ltd.

Binzhou Medical College Yantai

Security deposit 81,691,081.99 More than 3 years 3.65% 2,877,710.20 Affiliated Hospital

Guangdong Hongyu Pharmaceutical Co., Ltd.

Current accounts 44,793,401.26 More than 3 years 2.00% 44,793,401.26 Co., Ltd.

Henan Shipu Enterprise Management

Counseling Center (General current funds 43,000,060.39 2-3 years 1.92% 40,234,896.11 through partnership)

Nanjing Keyunxi Trading

Current accounts 38,333,600.00 2-3 years 1.71% 33,946,023.16 Co., Ltd.

Taierzhuang District, Zaozhuang City

Security deposit 34,182,500.00 1-2 years 1.53% 0.00 People’s Hospital

Total 332,025,866.74 14.83% 121,852,030.73

7. Presented in other receivables due to centralized management of funds

Not applicable.

9. Advance payment

(1) Prepayments are listed based on aging

Unit: Yuan Ending balance Beginning balance

Aging

Amount Ratio Amount Ratio

Within 1 year 287,019,465.56 81.91% 259,533,392.99 81.80% 1 to 2 years 45,314,781.36 12.93% 44,916,515.66 14.16% 2 to 3 years 11,162,781.27 3.19% 8,489,986.63 2.68% More than 3 years 6,885,128.72 1.97% 4,349,179.77 1.36% Total 350,382,156.91 317,289,075.05

(2) Prepayments of the top five closing balances by prepayment objects

Ratio to the total closing balance of prepayments Unit name Closing balance of prepayments

Example%

Shandong Zhuorun Medical Technology Co., Ltd. 19,038,291.00 5.43% Hangzhou Qiankun Zhonghe Technology Co., Ltd. 12,850,000.00 3.67%

Shanghai International Science and Technology Co., Ltd. 10,000,000.00 2.85%

Hunan Qiangsheng Medical Equipment Co., Ltd. 9,800,000.00 2.80% Hunan Kangyou Medical Technology Co., Ltd. 8,982,000.00 2.56% Total 60,670,291.00 17.31%

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

10. Inventory

Whether the company needs to comply with the real estate industry’s disclosure requirements

No

(1) Inventory classification

Unit: Yuan Ending balance Beginning balance

Provision for inventory decline Provision for inventory decline

Project

Book balance or contract performance costs Book value Book balance or contract performance costs Book value

This impairment provision This impairment provision

Raw materials 46,361,436.78 2,752,713.06 43,608,723.72 45,840,227.58 4,175,452.69 41,664,774.89 Products in progress 39,633,404.72 103,678.72 39,529,726.00 51,538,730.83 103,678.72 51,435,052.11

3,304,718,669. 3,199,026,456. 3,375,684,304. 3,264,817,965. Inventory goods 105,692,213.26 110,866,339.25

38 12 89 64 Turnover materials 7,120,997.11 7,120,997.11 7,182,431.99 7,182,431.99 Goods shipped 68,976,509.16 68,976,509.16 121,833,457.49 121,833,457.49

3,466,811,017. 3,358,262,412. 3,602,079,152. 3,486,933,682. Total 108,548,605.04 115,145,470.66

15 11 78 12

(2) Data resources confirmed as inventory

Not applicable.

(3) Provision for inventory depreciation and provision for impairment of contract performance costs

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 4,175,452.69 1,026,135.97 396,603.66 2,752,713.06 Work in progress 103,678.72 103,678.72 Inventory goods 110,866,339.25 4,097,751.22 5,783,263.64 3,488,613.57 105,692,213.26 Total 115,145,470.66 4,097,751.22 6,809,399.61 3,885,217.23 108,548,605.04 Provision for inventory decline and provision for impairment of contract performance costs (continued)

Transfer or write-off in this period

Determine the net realizable value/remaining consideration and what will be incurred

Item Specific basis for the cost of inventory devaluation provision/contract performance cost impairment provision

The reason why net realizable value is based on the estimated sales of finished goods produced

The price minus the estimated costs to be incurred upon completion,

The amount after the recovery in value of raw materials and work-in-progress or estimated sales expenses and related taxes is recognized.

determined

Net realizable value is the estimated selling price of the goods minus the estimated

Inventory items recover in value or are sold

Amount determined after sales charges and related taxes

(4) Explanation that the closing balance of inventory includes the capitalized amount of borrowing costs

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. (5) Explanation of the amortization amount of contract performance costs for the current period

Not applicable.

11. Assets held for sale

Not applicable.

12. Non-current assets due within one year

Unit: Yuan

Item Ending balance Beginning balance

Debt investments due within one year 0.00 0.00 Other debt investments due within one year 0.00 0.00 Long-term receivables due within one year 2,156,061.33 2,766,859.96 Time deposit certificates due within one year 20,924,657.54 Total 2,156,061.33 23,691,517.50 (1) Debt investments due within one year

□ApplicableNot applicable

(2) Other debt investments due within one year

□ApplicableNot applicable

13. Other current assets

Unit: Yuan

Item Ending balance Beginning balance

Input tax to be deducted 125,032,685.28 161,985,139.12 Prepaid income tax 28,189,287.65 37,288,692.21 Time deposit within one year 65,884,827.60

Others 26,401,053.83 18,305,844.45 Total 245,507,854.36 217,579,675.78

14. Debt investment

Not applicable.

15. Other debt investments

Not applicable.

16. Investment in other equity instruments

Unit: yuan Project name Opening balance Included in this period Included in this period Accumulated at the end of this period Accumulated at the end of this period Confirmed in this period Ending balance Designated as

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Other comprehensive Other comprehensive income is included in other comprehensive income. Other comprehensive income is included in other comprehensive income. Other comprehensive income is included in other comprehensive income. Other comprehensive income is included in other comprehensive income. Changes in gains and losses are included in other comprehensive income.

Because

Provision 111,250,00 111,250,00 Healthcare 0.00 0.00Southern Henan Province

water-to-north diversion

Oral Cooperation Industry 27,627,205. 27,627,205. Industry Investment Fund 00 00 (limited

partnership)

Jiangsu measuring point

Technology Co., Ltd. 670,000.00 670,000.00 Company

Shenzhen Neptune

Food Co., Ltd. 790,000.00 790,000.00 Company

140,337,20 140,337,20Total

5.00 5.00

17. Long-term receivables

Not applicable.

18. Long-term equity investment

Unit: Yuan

Increases and decreases in the current period

Beginning of period Equity declaration End of period

Impairment Impairment investment balance Other disbursement balance under the law

Preparation Other Provisions Provision Notes (Account Addition Decrease Confirmation Comprehensive Cash (Account

Equity Impairment at the Beginning of the Period Others Ending of the Period Face Price Investment Investment Income from Investment Dividends Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

Zhuhai

Aquaman

China

Equity

6,018, 6,019,investment 473.24

638.93 112.17Fund

(Yes

Limited combination

Guy)

Shandong

Kangli

127,79 127,84Medical 32,944 21,167

3,036. 7,149. Equipment .72 .68

74 14 Technology

limited

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

company

Zhongke

Milky Way

19,155 - 19,146Medical

,409.5 9,072. ,336.5 Technology

4 97 7 Limited

company

Shenzhen

Shitai

Hengyi 29,874 - 29,854 Medical investment, 537.7 20,206, 331.3 Capital owned 5.44 1 Limited public company

Division

binzhou

Guorong

medical

7,982, 277,19 8,259,investment

666.46 8.52 864.98 Management

limited

company

Weifang

Aquaman

Milky Way

Medical 1,144, 1,144, new technology 206.73 206.73technical

Limited public service

Division

Sichuan

Aquaman

Qianjiang

500,00 500,00Medical

0.00 0.00Technology

limited

company

Qingdao

Kanghai

1,084, 350,00 28,431 1,462,Pharmaceutical

001.28 0.00 .18 432.46Limited

company

Hangzhou

good

do things -

17,599

Electronics 17,599

.83

Business .83

limited

company

193,57 - 194,23

350,00 309,76 21,167

Subtotal 0,097. 17,599 3,433. 0.00 8.25 .68

26 .83 36 193,57 - 194,23

350,00 309,76 21,167

Total 0,097. 17,599 3,433. 0.00 8.25 .68

26 .83 36

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□ApplicableNot applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The recoverable amount is determined based on the present value of expected future cash flows.

□ApplicableNot applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Not applicable.

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Not applicable.

19. Other non-current financial assets

Not applicable.

20. Investment real estate

(1) Investment real estate using cost measurement model

Applicable□Not applicable

Unit: Yuan

Projects Houses and buildings Land use rights Construction in progress Total

1. Original book value

1. Balance at the beginning of the period 149,199,879.41 149,199,879.41 2. Increase in the current period

(1) Outsourcing

(2) Inventory\

Fixed assets\construction in progress transfer

enter

(3) Enterprise cooperation

and increase

3. Reduction amount in this period

(1) Disposal

(2) Other transfers

out

4. Ending balance 149,199,879.41 149,199,879.41

2. Accumulated depreciation and accumulation

Amortization

1. Balance at the beginning of the period 74,140,826.33 74,140,826.33 2. Increased amount in the current period 2,334,205.56 2,334,205.56 (1) Provision or

2,334,205.56 2,334,205.56 Amortization

3. Reduction amount in this period

(1) Disposal

(2) Other transfers

out

4. Ending balance 76,475,031.89 76,475,031.89

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

(2) Other transfers

out

4. Ending balance

4. Book value

1. Book value at the end of the period 72,724,847.52 72,724,847.52 2. Book value at the beginning of the period 75,059,053.08 75,059,053.08 The recoverable amount is determined based on the net amount of fair value minus disposal costs.

□ApplicableNot applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□ApplicableNot applicable

(2) Investment real estate using fair value measurement model

□ApplicableNot applicable

(3) Converted to investment real estate and measured at fair value

Not applicable.

(4) Investment real estate for which title certificates have not been obtained

Not applicable.

21. Fixed assets

Unit: Yuan

Item Ending balance Beginning balance

Fixed assets 891,524,754.46 951,245,081.84 Total 891,524,754.46 951,245,081.84

(1) Fixed assets

Unit: Yuan Item Houses and buildings Machinery and equipment Transportation equipment Electronic equipment Other equipment Total

1. Original books

Value:

1. Opening balance 1,052,071,965. 2,042,924,487.

516,914,013.53 145,664,518.29 170,072,355.04 158,201,634.92

Amount 76 54 2. Increase in this period 21,393,376.14 11,101,093.96 2,995,683.50 4,681,747.82 3,715,128.46 43,887,029.88

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Add amount

(1

2,778,095.37 11,101,093.96 2,995,683.50 4,681,747.82 3,715,128.46 25,271,749.11) Purchase

(2

) Projects under construction are transferred 18,615,280.77 18,615,280.77

(3

) Business merger increases

add

3. Less for this period

47,937,583.39 7,624,504.55 10,518,633.02 5,795,694.29 3,282,249.13 75,158,664.38 Small amount

(1

1,360,394.68 2,394,518.84 6,796,570.48 2,810,477.11 820,946.38 14,182,907.49) Disposal or scrapping

(2) Merger minus

46,577,188.71 5,229,985.71 3,722,062.54 2,985,217.18 2,461,302.75 60,975,756.89 less

4. Ending balance 1,025,527,758. 2,011,652,853.

520,390,602.94 138,141,568.77 168,958,408.57 158,634,514.25

Amount 51 04

2. Accumulated depreciation

1. Opening balance 1,070,062,581. 352,706,179.07 356,012,188.00 102,569,878.19 141,186,105.32 117,588,231.13

Amount 71 2. Increase in this period

14,212,222.52 20,537,217.57 5,554,492.11 4,125,887.73 4,759,425.09 49,189,245.02Add amount

(1

14,212,222.52 20,537,217.57 5,554,492.11 4,125,887.73 4,759,425.09 49,189,245.02) Provision

3. Less for this period

8,025,001.98 4,088,707.14 2,729,526.11 2,980,866.78 2,843,192.10 20,667,294.11 Small amount

(1

203,173.72 1,193,830.88 2,340,458.88 2,617,962.43 652,088.66 7,007,514.57) Disposal or scrapping

(2) Merger minus

7,821,828.26 2,894,876.26 389,067.23 362,904.35 2,191,103.44 13,659,779.54 less

4. Ending balance 1,098,584,532. 358,893,399.61 372,460,698.43 105,394,844.19 142,331,126.27 119,504,464.12

Amount 62

3. Impairment provision

1. Balance at the beginning of the period

16,065,912.81 5,258,968.20 73,258.03 77,651.02 141,033.93 21,616,823.99

2.Increase in this period

Add amount

(1

) accrual

3. Less for this period

73,258.03 73,258.03 Less amount

(1

73,258.03 73,258.03) Disposal or scrapping

4. End of period balance

16,065,912.81 5,258,968.20 77,651.02 141,033.93 21,543,565.96

4. Book value

1. Period-end accounts

650,568,446.09 142,670,936.31 32,746,724.58 26,549,631.28 38,989,016.20 891,524,754.46 Face value

2. Opening account 683,299,873.88 155,642,857.33 43,021,382.07 28,808,598.70 40,472,369.86 951,245,081.84

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

face value

(2) Temporarily idle fixed assets

Not applicable.

(3) Fixed assets leased through operating leases

Not applicable.

(4) Fixed assets for which property rights certificates have not been obtained

Unit: Yuan

Item Book value Reasons for not completing the property ownership certificate Anyang Hengfeng Office Building 12,384,131.94 Processing in progress

Zhoukou Renhe House and Warehouse 8,363,512.34 Processing in progress

Shandong Neptune Galaxy Real Estate 11,934,662.41 Unpaid amount

Anhui Haiwang Medical Equipment Warehouse 16,108,458.07 Processing in progress

Tiansheng Medical Park 11,958,002.00 In process

(5) Impairment testing of fixed assets

□ApplicableNot applicable

(6) Fixed assets liquidation

Not applicable.

22. Projects under construction

Unit: Yuan

Item Ending balance Beginning balance

Construction in progress 98,513,935.38 84,842,238.45 Total 98,513,935.38 84,842,238.45

(1) Projects under construction

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Shandong Kangnuo Modern

1,409,172.30 1,409,172.30 1,409,172.30 1,409,172.30Logistics center

Jinan Logistics Park 44,550,351.58 44,550,351.58 23,003,509.57 23,003,509.57 Smart Logistics Park 46,033,216.73 46,033,216.73 43,871,428.37 43,871,428.37 Zhoukou City Renhe Hospital

Drug flow industrial park 0.00 0.00 13,982,303.35 13,982,303.35 project

Other sporadic projects 6,521,194.77 6,521,194.77 2,575,824.86 2,575,824.86Total 98,513,935.38 98,513,935.38 84,842,238.45 84,842,238.45

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. (2) Changes in important construction projects under construction during this period

Unit: Yuanqi Engineering

Interest in the current period: Accumulated in the current period

Capital transferred in this period Project budget in this period Beginning of period Others End of period Input project interest funds

Increase Fixed Accumulated Interest Name Number Balance Decrease Balance Account for Pre-Progress Capital Source Amount Asset Calculation Capital Amount Ratio Ratio Amount Example of Funding

Jinan 500,00 23,003 21,546 44,550

20.13

Logistics 0,000. ,509.5 ,842.0 ,351.5 25% Others

%

Garden 00 7 1 8

Wisdom 50,478 43,871 46,033

2,161,91.19

Logistics,100.0,428.3,216.7 99% Others

788.36%

Garden 0 7 3

Medicine

Logistics 21,210 13,982 14,300

318,03 67.42

Industry ,000.0 ,303.3 ,333.7 100% Others

0.40%

Garden items 0 5 5

Head

571,68 80,857 24,026 14,300 90,583

Total 8,100. ,241.2 ,660.7 ,333.7 ,568.3

00 9 7 5 1

(3) Provision for impairment of projects under construction in the current period

Not applicable.

(4) Impairment testing of projects under construction

□ApplicableNot applicable

(5) Engineering materials

Not applicable.

23. Productive biological assets

(1) Productive biological assets using cost measurement model

□ApplicableNot applicable

(2) Impairment testing of productive biological assets using the cost measurement model

□ApplicableNot applicable

(3) Productive biological assets using fair value measurement model

□ApplicableNot applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

24. Oil and gas assets

□ApplicableNot applicable

25. Right-of-use assets

(1) Right-of-use assets

Unit: Yuan

Item Houses and buildings Others Total

1. Original book value

1. Opening balance 286,833,893.65 533,710.31 287,367,603.96 2. Increase in the current period 30,570,091.99 30,570,091.99 (1) Lease 30,570,091.99 30,570,091.99 (2) Other increases

2. Decrease amount in the current period 44,006,010.20 44,006,010.20 (1) Lease expiration or early termination 41,439,336.29 41,439,336.29 (2) Consolidated decrease 2,566,673.91 2,566,673.91 (3) Other decreases

3. Closing balance 273,397,975.44 533,710.31 273,931,685.75

2. Accumulated depreciation

1. Opening balance 139,241,780.46 141,252.66 139,383,033.12 2. Increase in the current period 31,212,037.68 11,676.97 31,223,714.65

(1) Provision 31,212,037.68 11,676.97 31,223,714.65 3. Decrease amount in the current period 28,668,798.00 28,668,798.00

(1) Disposal

(2) Lease expiration or early termination 27,286,528.83 27,286,528.83 (3) Consolidated decrease 1,382,269.17 1,382,269.17 (4) Other decreases

4. Ending balance 141,785,020.14 152,929.63 141,937,949.77

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 131,612,955.30 380,780.68 131,993,735.98 2. Book value at the beginning of the period 147,592,113.19 392,457.65 147,984,570.84

(2) Impairment testing of right-of-use assets

□ApplicableNot applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

26. Intangible assets

(1) Intangible assets

Unit: Yuan

Item Land use rights Patent rights Non-patented technology Total

1. Original book value

1. Opening balance 338,090,776.78 150,251,932.96 106,064,045.84 594,406,755.58 2. Increase in the current period 23,293.68 1,618,875.52 4,934,428.00 6,576,597.20 (1) Purchase 23,293.68 1,618,875.52 4,934,428.00 6,576,597.20

(2) Internal research

send

(3) Enterprise cooperation

and increase

(4) R&D carryover

3. Decrease amount in this period 23,678,515.50 1,471,200.18 32,557,254.56 57,706,970.24

(1) Disposal 34,940.52 286,101.19 24,066,688.63 24,387,730.34 (2) Consolidated decrease 23,643,574.98 1,185,098.99 8,490,565.93 33,319,239.90 4. Closing balance 314,435,554.96 150,399,608.30 78,441,219.28 543,276,382.54

2. Accumulated amortization

1. Opening balance 70,596,905.37 95,885,780.08 60,324,484.63 226,807,170.08 2. Increase in the current period 3,330,452.76 7,731,076.96 6,511,809.91 17,573,339.63

(1) Provision 3,330,452.76 7,731,076.96 6,511,809.91 17,573,339.63

3. Decrease amount in this period 6,316,278.07 321,764.83 17,772,778.59 24,410,821.49

(1) Disposal 2,557,829.06 62,367.96 10,556,009.40 13,176,206.42 (2) Consolidated decrease 3,758,449.01 259,396.87 7,216,769.19 11,234,615.07 4. Closing balance 67,611,080.06 103,295,092.21 49,063,515.95 219,969,688.22

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 246,824,474.90 47,104,516.09 29,377,703.33 323,306,694.32 2. Book value at the beginning of the period 267,493,871.41 54,366,152.88 45,739,561.21 367,599,585.50

(2) Data resources recognized as intangible assets

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(3) Land use rights for which property rights certificates have not been obtained

Unit: Yuan

Item Book value Reason for not completing the property rights certificate

Tiansheng Medical Park 5,880,000.00 Not yet processed

(4) Impairment testing of intangible assets

□ApplicableNot applicable

27. Goodwill

(1) Original book value of goodwill

Unit: Yuan

Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Opening balance Formed by business combination Disposal of closing balance

matters of

Shandong Galaxy 24,278,449.47 24,278,449.47 Sulu Sea King 760,000.00 760,000.00 Anhui Sea King 1,904,088.66 1,904,088.66 Weihai Sea King 1,925,000.00 1,925,000.00 Heze Neptune 2,153,306.89 2,153,306.89 Binzhou Yellow River 5,100,000.00 5,100,000.00 Tengzhou Neptune 2,900,000.00 2,900,000.00 Wuhan Medicine 30,624,430.00 30,624,430.00 Heilongjiang Neptune 32,500,000.00 32,500,000.00 Shum Yip Pharmaceutical 49,670,342.37 49,670,342.37 Bozhou Neptune 3,789,000.00 3,789,000.00 Bengbu Sea King 4,849,752.19 4,849,752.19 Shandong Group 54,058,757.50 54,058,757.50 Henan Baicaotang 437,500.00 437,500.00

Beijing Neptune 201,683,224.22 201,683,224.22 Anhui Group 59,641,462.46 59,641,462.46 Guangdong Group 144,000,000.00 144,000,000.00 Shandong Kangnuo 396,000,000.00 396,000,000.00 Guangdong Distribution 54,147,236.73 54,147,236.73 Qingdao Huaren 110,500,000.00 110,500,000.00 Shandong Xinchen 43,000,000.00 43,000,000.00 Heilongjiang Huatong 54,963,763.63 54,963,763.63 Hubei Kai'anchen 60,480,000.00 60,480,000.00 Zhoukou Renhe 71,500,000.00 71,500,000.00 Henan Kangrui 4,900,000.00 4,900,000.00 Anyang Hengfeng 104,300,000.00 104,300,000.00 Henan Guanbao 91,000,000.00 91,000,000.00 Anhui Guoan 202,000,000.00 202,000,000.00 Guilin Haiwang 9,800,000.00 9,800,000.00 Hunan Neptune 214,400,000.00 214,400,000.00 Hunan Kangfulai 126,000,000.00 126,000,000.00 Shaoyang Neptune 85,178,567.41 85,178,567.41 Henan Deji Hall 180,003,000.00 180,003,000.00 Anqing Haiwang 110,000,000.00 110,000,000.00 Wuhan Development 55,890,000.00 55,890,000.00

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Sichuan Medical Technology 95,959,119.06 95,959,119.06 Henan Enji 96,000,000.00 96,000,000.00 Henan Zuo Jinming 67,500,000.00 67,500,000.00 Tianjin Medical Technology 61,484,102.22 61,484,102.22 Shandong Cigna 31,000,000.00 31,000,000.00 Ningxia Haiwang 38,500,000.00 38,500,000.00 Kashgar Galaxy 48,132,000.00 48,132,000.00 Anhui Tiancheng 43,200,000.00 43,200,000.00 Shaoguan Haiwang 36,786,150.09 36,786,150.09 Zhongshan Changjian 23,045,804.37 23,045,804.37

Weishi County Medicine 13,000,000.00 13,000,000.00 Yangjiang Haiwang 10,050,000.00 10,050,000.00

Foshan Neptune 9,580,577.10 9,580,577.10 Zhanjiang Neptune 7,000,000.00 7,000,000.00 Lu'an Neptune 5,600,000.00 5,600,000.00 Henan Tiansheng 3,000,000.00 3,000,000.00 Wuhu Sunshine 800,000.00 800,000.00 Linyi Dongrui 4,877,404.13 4,877,404.13 Shanghai Fangcheng 46,464,705.60 46,464,705.60 Beijing Neptune Zhongxin 96,524,196.30 96,524,196.30

3,332,841,940. 3,299,308,636. Total 33,533,304.37

40 03

(2) Goodwill impairment provision

Unit: Yuan

Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Balance at the beginning of the period. Balance at the end of the period. Provision for disposal.

matters

Anhui Neptune 1,904,088.66 1,904,088.66 Heze Neptune 2,153,306.89 2,153,306.89 Binzhou Yellow River 5,100,000.00 5,100,000.00 Wuhan Pharmaceutical 30,624,430.00 30,624,430.00 Heilongjiang Neptune 32,500,000.00 32,500,000.00 Shum Yip Pharmaceutical 27,475,381.86 27,475,381.86 Bozhou Neptune 3,789,000.00 3,789,000.00 Shandong Group 54,058,757.50 54,058,757.50Henan Baicaotang 437,500.00 437,500.00 0.00Beijing Neptune 54,149,757.67 54,149,757.67Anhui Group 59,641,462.46 59,641,462.46 Guangdong Group 144,000,000.00 144,000,000.00 Shandong Kangnuo 396,000,000.00 396,000,000.00 Guangdong Distribution 23,552,718.10 23,552,718.10 Qingdao Huaren 103,740,064.74 103,740,064.74 Heilongjiang Huatong 54,963,763.63 54,963,763.63 Hubei Kai'anchen 60,480,000.00 60,480,000.00 Anyang Hengfeng 104,300,000.00 104,300,000.00 Henan Guanbao 91,000,000.00 91,000,000.00 Anhui Guoan 202,000,000.00 202,000,000.00 Guilin Haiwang 9,800,000.00 9,800,000.00 Hunan Haiwang 214,400,000.00 214,400,000.00 Hunan Kangfulai 126,000,000.00 126,000,000.00 Shaoyang Haiwang 81,383,098.43 81,383,098.43 Henan Dejitang 180,003,000.00 180,003,000.00 Anqing Haiwang 110,000,000.00 110,000,000.00

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Wuhan Development 55,890,000.00 55,890,000.00 Henan Enji 96,000,000.00 96,000,000.00 Ningxia Sea King 38,500,000.00 38,500,000.00 Shaoguan Sea King 36,786,150.09 36,786,150.09 Zhongshan Changjian 23,045,804.37 23,045,804.37 0.00 Weishi County Medicine 13,000,000.00 13,000,000.00 Foshan Neptune 9,580,577.10 9,580,577.10 Lu'an Neptune 5,600,000.00 5,600,000.00 Henan Tiansheng 3,000,000.00 3,000,000.00 Wuhu Sunshine 800,000.00 800,000.00 Linyi Dongrui 4,877,404.12 4,877,404.12 Bengbu Sea King 4,849,752.19 4,849,752.19 Shandong Xinchen 43,000,000.00 43,000,000.00 Zhoukou Renhe 71,500,000.00 71,500,000.00 Henan Kangrui 4,900,000.00 4,900,000.00 Henan Zuojinming 67,500,000.00 67,500,000.00 Tianjin Medical Technology 53,987,632.18 53,987,632.18 Shandong Xinnuo 31,000,000.00 31,000,000.00 Kashgar Galaxy 48,132,000.00 48,132,000.00 Anhui Tiancheng 43,200,000.00 43,200,000.00 Yangjiang Neptune 10,050,000.00 10,050,000.00 0.00 Zhanjiang Neptune 7,000,000.00 7,000,000.00 Beijing Neptune Zhongxin 33,102,024.14 33,102,024.14 Sichuan Medical Technology 75,381,065.25 75,381,065.25

2,954,138,739. 2,920,605,435. Total 33,533,304.37

38 01

(3) Relevant information about the asset group or asset group combination where the goodwill is located

The composition of the asset group or portfolio to which it belongs and

Name, operating segment and basis. Is the basis consistent with previous years?

Includes fixed assets that make up the asset group

Shandong Kangnuo Properties, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Beijing Neptune Property, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Hunan Kangfulai Property, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Henan Zuojinming Properties, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Sichuan Medical Technology Properties, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Shaoyang Neptune Property, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Zhou Kou Renhe Properties, intangible assets, long-term deferred expenses / Yes

long-term assets

Includes fixed assets that make up the asset group

Henan Enji Properties, intangible assets, long-term deferred expenses / Yes

long-term assets

Tianjin Medical Technology includes fixed assets that make up the asset group / Yes

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

assets, intangible assets, long-term deferred expenses

long-term assets

Includes fixed assets that make up the asset group

Kashgar Galaxy Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Anhui Tiancheng Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Qingdao Huaren Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Shum Yip Pharmaceutical Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Shandong Xinchen Property, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Zhanjiang Neptune Property, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Henan Kangrui Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Guangdong Distribution Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Shanghai Party Property, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Hubei Kai'an Chen Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Shandong Galaxy long-term assets such as property, intangible assets, long-term deferred expenses/use and so on

Includes fixed assets that make up the asset group

Heilongjiang Neptune Property, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Henan Dejitang Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Anyang Hengfeng Properties, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Anqing Neptune Property, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Anhui Guoan Property, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Beijing Neptune China’s new assets, intangible assets, long-term deferred expenses/use and other long-term assets

Includes fixed assets that make up the asset group

Tengzhou Neptune Property, intangible assets, long-term deferred expenses / Yes

long-term assets

Weihai Haiwang includes fixed assets that make up the asset group / Yes

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

assets, intangible assets, long-term deferred expenses

long-term assets

Includes fixed assets that make up the asset group

Sulu Haiwang Property, intangible assets, long-term deferred expenses / Yes

long-term assets

(4) Specific determination method of recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□ApplicableNot applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□ApplicableNot applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Not applicable.

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Not applicable.

(5) Completion of performance commitments and corresponding impairment of goodwill

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period

□ApplicableNot applicable

28. Long-term deferred expenses

Unit: Yuan

Item Beginning balance Increase in the current period Amortization in the current period Other decreases Closing balance Decoration and maintenance expenses 23,848,687.75 4,813,625.04 7,990,850.29 20,671,462.50 Others 5,678,484.35 1,093,672.37 2,156,129.86 280,441.10 4,335,585.76 Total 29,527,172.10 5,907,297.41 10,146,980.15 280,441.10 25,007,048.26

29. Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset

Unit: Yuan Ending balance Beginning balance

Project

Deductible temporary differences Deferred income tax assets Deductible temporary differences Deferred income tax assets Asset impairment provision 1,328,416,255.65 317,810,361.40 1,428,442,489.76 341,779,000.05 Unrealized profits from internal transactions 7,627,894.45 1,906,973.61 7,627,894.45 1,906,973.61 Deductible losses 37,937,640.65 9,484,410.16 37,937,640.65 9,484,410.16 Deferred income 6,160,000.00 1,540,000.00 6,160,000.00 1,540,000.00 Unrealized financing income 0.00 0.00 40,800.00 10,200.00 Lease liabilities 207,460,121.91 48,409,024.75 210,562,125.51 52,092,935.96 Total 1,587,601,912.66 379,150,769.92 1,690,770,950.37 406,813,519.78

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(2) Deferred income tax liabilities without offset

Unit: Yuan Ending balance Beginning balance

Project

Taxable temporary differences, deferred income tax liabilities, taxable temporary differences, deferred income tax liabilities due to business combinations involving enterprises not under common control

45,742,179.64 11,435,544.91 46,846,582.44 11,711,645.61 Asset appraisal value added

Right-of-use assets 189,832,767.31 47,002,826.68 203,414,081.93 50,365,231.08 Total 235,574,946.95 58,438,371.59 250,260,664.37 62,076,876.69

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

Unit: Yuan Deferred income tax assets and liabilities Deferred income tax assets after offset Deferred income tax assets and liabilities Deferred income tax items after offset

Offset amount at the end of the debt period Ending balance of assets or liabilities Offsetting amount at the beginning of the debt period Deferred income tax assets 46,591,527.61 332,559,242.31 49,797,070.29 357,016,449.49 Deferred income tax liabilities 46,591,527.61 11,846,843.98 49,797,070.29 12,279,806.40

(4) Details of deferred income tax assets not recognized

Unit: Yuan

Item Ending balance Beginning balance

Deductible temporary differences 125,832,180.18 125,059,440.88 Deductible losses 2,663,184,145.66 2,681,746,332.09 Total 2,789,016,325.84 2,806,805,772.97

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

Unit: Yuan

Year Ending amount Beginning amount Remarks

2025 396,499,947.27

2026 246,039,620.57 246,039,620.57

2027 537,417,794.63 537,417,794.63

2028 649,408,881.16 649,408,881.16

2029 852,380,088.46 852,380,088.46

2030 377,937,760.84

Total 2,663,184,145.66 2,681,746,332.09

30. Other non-current assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Intangible assets prepaid

11,267,077.64 11,267,077.64 10,600,795.05 10,600,795.05

Prepaid project funds 68,418.18 68,418.18 68,418.18 68,418.18 Prepaid housing and equipment

360,619.04 360,619.04 902,943.80 902,943.80 Reserve

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Regularly for more than one year

20,508,748.86 20,508,748.86 117,480,419.84 117,480,419.84Deposit

Others 2,502,620.28 2,502,620.28 5,902,146.59 5,902,146.59Total 34,707,484.00 34,707,484.00 134,954,723.46 134,954,723.46

31. Assets whose ownership or use rights are restricted

Unit: Yuan

End of period Beginning of period

Project

Book balance Book value Restriction type Restriction situation Book balance Book value Restriction type Restriction situation

208,591,74 208,591,74 Performance guarantee 160,654,00 160,654,00 Performance guarantee monetary funds Security deposit Security deposit

3.96 3.96 Gold 9.28 9.28 Gold has not been terminated. Confirmed has not been terminated.

384,793,99 384,793,82 330,646,51 328,431,27

Notes receivable Discounted bills Discount recognized Discounted bills Discount recognized 1.67 9.51 4.57 6.81

bill bill

46,363,364. 43,811,176. 49,033,403. 46,481,215.

Inventory Mortgage Mortgage Mortgage Mortgage 44 08 73 37

636,895,84 399,953,86 387,289,11 261,539,09

Fixed assets Mortgage Mortgage loan Mortgage Mortgage loan 9.02 8.25 7.18 0.07

72,807,435. 54,328,799. 60,691,565. 46,164,329.

Intangible assets Mortgage Mortgage loan Mortgage Mortgage loan 76 81 20 58

1,651,926,7 1,651,926,7 Bill guarantee 1,934,832,1 1,934,832,1 Bill guarantee monetary funds Security deposit Margin

01.15 01.15 Gold 86.37 86.37 Gold

55,500,000. 55,500,000. 67,573,867. 67,573,867.

Monetary funds time deposits time deposits time deposits time deposits

00 00 22 22

14,542,625. 14,542,625. 14,515,921. 14,515,921.

Monetary funds frozen frozen funds frozen frozen funds 47 47 06 06

Monetary funds from third parties 655,598.71 655,598.71 Supervision account

Monetary funds in supervision account 327,662.14 327,662.14 Others Others 447,109.56 447,109.56 Others Others

5,000,000.0 5,000,000.0 5,000,000.0 5,000,000.0

Monetary funds pledge Deposit certificate pledge Pledge Deposit certificate pledge 0 0 0 0

480,262,00 479,021,70 319,775,25 318,784,40

Pledge of notes receivable Pledge of notes Pledge Pledge of notes receivable 0.00 2.70 5.32 4.95

4,192,876,1 4,055,822,3 4,959,544,3 4,886,249,9

Accounts Receivable Mortgage Mortgage Mortgage Mortgage

75.89 03.97 74.69 47.13

Arrive within a year

20,924,657. 20,924,657.

Non-current pledge of the period Deposit certificate pledge

54 54

Live assets

Investment housing 94,634,799. 44,602,913. 97,642,547. 47,038,862.

Mortgage Mortgage Mortgage Mortgage Property 41 98 97 34

3,000,000.0 3,000,000.0 Loan guarantee

Monetary funds margin

0 0 gold

Other flows 65,884,827. 65,884,827.

Pledge Deposit certificate pledge

Assets 60 60

7,913,407,1 7,467,108,1 8,409,226,1 8,139,292,4

total

76.51 54.62 28.40 75.99

32. Short-term borrowing

(1) Classification of short-term loans

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Pledge loans 868,339,225.35 538,757,515.73 Mortgage loans 878,709,493.05 210,879,529.40 Guaranteed loans 4,269,368,361.48 5,743,668,544.11 Credit loans 38,879,252.47 34,258,353.08 Bill discount 3,716,804,431.91 3,495,927,583.78 Total 9,772,100,764.26 10,023,491,526.10

(2) Overdue short-term borrowings that have not been repaid

Not applicable.

33. Trading financial liabilities

Unit: Yuan

Item Ending balance Beginning balance

Trading financial liabilities 72,709,111.74 72,709,111.74

Among them:

Equity payment to be paid 72,709,111.74 72,709,111.74

Among them:

Total 72,709,111.74 72,709,111.74

34. Derivative financial liabilities

Not applicable.

35. Notes payable

Unit: Yuan

Category Ending balance Beginning balance

Commercial acceptance bill 152,245,653.50 60,000,000.00 Bank acceptance bill 1,146,124,362.32 1,699,604,232.21 Total 1,298,370,015.82 1,759,604,232.21

36. Accounts payable

(1) Presentation of accounts payable

Unit: Yuan

Item Ending balance Beginning balance

Payment for goods 7,128,139,811.76 7,333,447,910.58 Project payment 2,833,929.00 2,611,826.50 Equipment payment and others 2,260,566.80 7,235,352.01 Total 7,133,234,307.56 7,343,295,089.09

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(2) Important accounts payable that are aged more than 1 year or are overdue

Unit: Yuan

Item Closing balance Reason for outstanding or carried forward

Henan Zhenkang Medical Management Co., Ltd. 6,525,093.31 outstanding amount

Ruiyang Pharmaceutical Co., Ltd. 13,362,574.61 outstanding amount

Jiangxi Qichang Hui Medical Equipment Co., Ltd. 10,949,807.00 Outstanding amount

Jinan Dirui Medical Equipment Co., Ltd. 13,262,555.57 outstanding amount

Total 44,100,030.49

37. Other payables

Unit: Yuan

Item Ending balance Beginning balance

Dividends payable 91,550,416.99 143,514,334.91 Other payables 4,874,389,140.60 4,952,316,021.15 Total 4,965,939,557.59 5,095,830,356.06

(1) Interest payable

Not applicable.

(2) Dividends payable

Unit: Yuan

Item Ending balance Beginning balance

Legal person shareholders 84,024,518.53 110,222,191.99 Natural person shareholders 7,525,898.46 33,292,142.92 Total 91,550,416.99 143,514,334.91

(3) Other payables

1. List other payables according to the nature of the payment

Unit: Yuan

Item Ending balance Beginning balance

Current accounts 3,545,233,134.71 3,564,751,908.43 Promotion fees 476,291,213.81 481,183,754.02 Deposit 626,185,629.36 665,633,977.46 Equity acquisition payable 23,000,000.00 58,000,000.00 Others 203,679,162.72 182,746,381.24Total 4,874,389,140.60 4,952,316,021.15

2. Important other payables aged more than 1 year or overdue

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

38. Advance payments

(1) Presentation of advance receipts

Unit: Yuan

Item Ending balance Beginning balance

Rent received in advance 1,710,178.41 1,272,452.78 Total 1,710,178.41 1,272,452.78

(2) Important advances from customers aged more than 1 year or overdue

Not applicable.

39. Contract liabilities

Unit: Yuan

Item Ending balance Beginning balance

Advance payment 389,145,560.64 363,608,592.28 Total 389,145,560.64 363,608,592.28

40. Employee compensation payable

(1) Presentation of employee benefits payable

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Short-term salary 123,330,724.86 402,827,635.06 448,845,619.83 77,312,740.09

2. Post-employment benefits-settings

788,406.11 40,642,003.67 40,984,503.74 445,906.04 Withdrawal plan

Total 124,119,130.97 443,469,638.73 489,830,123.57 77,758,646.13

(2) Presentation of short-term remuneration

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Salary, bonus, allowance

120,561,056.72 349,598,116.81 396,675,994.12 73,483,179.41 and subsidies

2. Employee welfare fees 840,380.52 17,492,088.65 16,571,255.47 1,761,213.70

3. Social insurance premiums 496,802.24 23,078,079.81 23,255,383.52 319,498.53 including: medical insurance

484,326.04 21,264,319.15 21,439,203.88 309,441.31 fee

Work injury insurance

12,409.96 1,287,904.07 1,290,323.05 9,990.98 fee

maternity insurance

66.24 525,856.59 525,856.59 66.24 fee

4. Housing provident fund 89,580.32 10,155,518.50 10,180,055.50 65,043.32

5. Trade union funds and employee education 1,342,905.06 2,503,831.29 2,162,931.22 1,683,805.13

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

education funds

Total 123,330,724.86 402,827,635.06 448,845,619.83 77,312,740.09

(3) Display of defined contribution plan

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Basic pension insurance 760,243.24 39,072,014.17 39,400,894.61 431,362.80

2. Unemployment insurance premium 28,162.87 1,569,989.50 1,583,609.13 14,543.24 Total 788,406.11 40,642,003.67 40,984,503.74 445,906.04

3. Taxes payable

Unit: Yuan

Item Ending balance Beginning balance

Value-added tax 41,568,777.19 39,839,641.00Corporate income tax 41,696,637.11 54,003,499.58Personal income tax 7,467,962.73 8,180,399.49Urban maintenance and construction tax 1,901,552.05 2,544,980.14 Education surcharge 1,474,100.76 1,876,563.76 Property tax 2,233,407.34 2,503,837.12 Land use tax 2,212,943.84 2,093,903.67 Other taxes 3,864,711.84 5,100,529.02Total 102,420,092.86 116,143,353.78

42. Liabilities held for sale

Not applicable.

43. Non-current liabilities due within one year

Unit: Yuan

Item Ending balance Beginning balance

Long-term borrowings due within one year 71,976,666.66 154,062,657.26 Long-term payables due within one year 4,359,050.02 3,777,051.78 Lease liabilities due within one year 50,073,181.36 63,262,679.43 Total 126,408,898.04 221,102,388.47

44. Other current liabilities

Unit: Yuan

Item Ending balance Beginning balance

Accrued expenses 406,950,158.46 414,100,021.68 Output tax to be transferred 44,632,809.69 43,886,567.87 Total 451,582,968.15 457,986,589.55 Increase or decrease in short-term bonds payable:

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Not applicable.

45. Long-term borrowing

(1) Classification of long-term loans

Unit: Yuan

Item Ending balance Beginning balance

Pledge loan 59,300,000.00 12,214,181.08 Mortgage loan 97,628,153.50 84,331,676.93 Guaranteed loan 200,070,000.00 277,302,579.06 Credit loan 34,860,000.00 10,011,000.00 Less: Long-term borrowings due within one year -71,976,666.66 -154,062,657.26 Total 319,881,486.84 229,796,779.81

46. Bonds payable

Not applicable.

47. Lease liabilities

Unit: Yuan

Item Ending balance Beginning balance

Operating lease assets 135,178,046.82 163,149,491.75 Less: Lease liabilities due within one year -50,073,181.36 -63,262,679.43 Total 85,104,865.46 99,886,812.32

48. Long-term payables

Unit: Yuan

Item Ending balance Beginning balance

Long-term payables 4,927,653.45 3,514,443.05 Total 4,927,653.45 3,514,443.05

(1) List long-term payables according to the nature of the payment

Unit: Yuan

Item Ending balance Beginning balance

Finance lease payable 9,286,703.47 7,291,494.83 Less: long-term payables due within one year -4,359,050.02 -3,777,051.78 Total 4,927,653.45 3,514,443.05

(2) Special accounts payable

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

49. Long-term employee benefits payable

(1) Long-term employee salary payable table

Unit: Yuan Item Ending balance Beginning balance

Early retirement benefits payable 240,430.30 240,430.30 Less: Long-term employee benefits payable due within one year -58,461.56 -58,461.56 Total 181,968.74 181,968.74 (2) Changes in defined benefit plans

Not applicable.

50. Estimated liabilities

Unit: Yuan Item Ending balance Beginning balance Reason for formation

Pending litigation 19,043,112.71 Litigation disputes

Traffic accident compensation 499,526.81 499,526.81 Accident

Total 499,526.81 19,542,639.52

51. Deferred income

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Reasons for formation

Government subsidies 10,191,377.74 5,312,377.74 4,879,000.00

Total 10,191,377.74 5,312,377.74 4,879,000.00

52. Other non-current liabilities

Not applicable.

53. Share capital

Unit: Yuan Increase or decrease in this change (+, -)

Balance at the beginning of the period Balance at the end of the period Issuance of new shares Bonus shares Conversion of public reserve funds Others Subtotal

2,631,123,25 2,631,123,25 Total shares

7.00 7.00

54. Other equity instruments

(1) Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(2) Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Not applicable.

55. Capital reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Capital premium (equity premium

1,952,584,849.98 1,952,584,849.98 price)

Other capital reserves 111,234,012.26 2,888,831.03 114,122,843.29 Capital reserves transferred under the original system 32,483,481.45 32,483,481.45 Total 2,096,302,343.69 2,888,831.03 2,099,191,174.72

56. Treasury stocks

Not applicable.

57. Other comprehensive income

Unit: Yuan Amount incurred in the current period

Less: previous period Less: previous period

Income for the current period is included in other items and is included in other items. Attribution after tax

Item Opening balance Less: Income Attribution after tax Ending balance before tax Comprehensive income Comprehensive income Attributable to minority shares

Tax expenses at the parent company

Amount transferred in the current period Transferred in in the current period

Profit and loss Retained earnings

1. Can’t

Reclassified into - - Profit and loss 60,303,050. 60,303,050. Other comprehensive income 40 40

Others

• -Equity Instruments

60,303,050. 60,303,050. Fair investment

40 40 value change

• -Other comprehensive

60,303,050. 60,303,050. Total income

40 40

58. Special reserves

Not applicable.

59. Surplus reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 44,516,230.95 44,516,230.95

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Discretionary surplus reserve 7,625,438.27 7,625,438.27 Total 52,141,669.22 52,141,669.22

60. Undistributed profits

Unit: Yuan

Projects in this issue Previous issue

Undistributed profit at the end of the previous period before adjustment -2,924,031,770.95 -1,730,616,815.70 Undistributed profit at the beginning of the period after adjustment -2,924,031,770.95 -1,730,616,815.70 Plus: Net profit attributable to owners of the parent company for the current period

31,681,707.71 -1,193,414,955.25 profit

Undistributed profits at the end of the period -2,892,350,063.24 -2,924,031,770.95 Adjustment details of undistributed profits at the beginning of the period:

Not applicable.

61. Operating income and operating costs

Unit: Yuan Amount of current period Amount of previous period

Project

revenue cost revenue cost

Main business 14,245,108,202.49 12,962,190,058.01 16,560,457,970.97 14,928,338,633.94 Other businesses 66,394,982.47 17,493,367.74 70,981,728.64 30,194,389.95 Total 14,311,503,184.96 12,979,683,425.75 16,631,439,699.61 14,958,533,023.89 Decomposition information of operating income and operating costs:

Unit: Yuan

Segment 1 Total

Contract classification

Operating income Operating cost Operating income Operating cost Business type 14,311,503,184.96 12,979,683,425.75 14,311,503,184.96 12,979,683,425.75 Among them:

Pharmaceutical circulation 8,895,673,180.29 8,180,715,469.58 8,895,673,180.29 8,180,715,469.58 Pharmaceutical manufacturing 280,672,742.17 179,238,248.70 280,672,742.17 179,238,248.70 Food and health products 83,226,489.42 58,942,279.04 83,226,489.42 58,942,279.04 Medical devices 4,985,535,790.61 4,543,294,060.69 4,985,535,790.61 4,543,294,060.69 Other businesses 66,394,982.47 17,493,367.74 66,394,982.47 17,493,367.74 Classified by operating region

Among them:

Central China 3,096,869,159.99 2,817,221,874.84 3,096,869,159.99 2,817,221,874.84 East China 9,607,015,231.70 8,758,619,716.59 9,607,015,231.70 8,758,619,716.59Southern China 1,060,918,603.58 953,235,365.32 1,060,918,603.58 953,235,365.32Northern China 231,678,073.46 208,023,742.16 231,678,073.46 208,023,742.16Other regions 248,627,133.76 225,089,359.10 248,627,133.76 225,089,359.10Other businesses 66,394,982.47 17,493,367.74 66,394,982.47 17,493,367.74Contract type

Among them:

Recognized at a certain point in time 14,245,108,202.49 12,962,190,058.01 14,245,108,202.49 12,962,190,058.01 Other business income 66,394,982.47 17,493,367.74 66,394,982.47 17,493,367.74

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Total 14,311,503,184.96 12,979,683,425.75 14,311,503,184.96 12,979,683,425.75

62. Taxes and surcharges

Unit: Yuan

Item Amount for the current period Amount for the previous period

Urban maintenance and construction tax 13,094,517.87 15,681,774.33 Education fee surcharge 8,817,999.43 10,894,479.50 Resource tax 0.00 0.00 Property tax 3,987,864.60 4,825,411.18 Land use tax 4,258,082.42 4,663,924.12 Vehicle and vessel use tax 123,264.56 142,084.67 Stamp tax 7,783,451.18 9,904,730.66 Water conservancy construction fund 559,264.31 1,206,909.74 Others 110,256.64 173,864.45 Total 38,734,701.01 47,493,178.65

63. Management expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 236,826,567.66 247,663,191.89 Office expenses 50,205,129.80 60,911,156.15 Depreciation and amortization 79,534,002.02 89,892,519.32 Intermediary agency expenses 24,350,295.42 52,586,855.08 Business entertainment expenses 22,116,397.50 31,573,981.24 Transportation and miscellaneous expenses 7,389,834.63 9,215,131.10 Travel expenses 4,268,019.99 5,689,889.96 Property losses 6,399,963.85 7,063,945.42 Others 980,533.21 3,538,891.74 Total 432,070,744.08 508,135,561.90

64. Sales expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Market development expenses 231,535,188.64 271,122,983.50 Employee compensation 198,681,038.37 212,136,463.62 Office expenses 52,587,906.55 52,198,500.27 Advertising expenses 6,468,382.42 7,280,243.39 Travel expenses 13,476,120.92 13,883,455.06 Rental expenses 1,132,146.09 3,110,847.74 Conference fees 4,902,265.61 4,019,236.95 Others 4,182,568.84 3,533,126.18 Total 512,965,617.44 567,284,856.71

65. Research and development expenses

Unit: Yuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Item Amount for the current period Amount for the previous period

Labor fee 13,533,800.20 12,530,180.90 Material fee 2,764,611.28 3,166,625.71 Water, electricity and gas fee 1,742,844.87 1,853,938.53 Depreciation fee 1,901,094.66 1,867,907.17 Office expenses 67,596.06 99,922.09 Business entertainment expenses 52,260.60 33,422.41 Travel expenses 38,550.48 56,593.14 Product development expenses 1,266,123.72 1,479,763.20 Consulting fees 28,301.89 0.00 Repair fee 34,270.34 36,742.04 Others 243,430.33 403,493.62 Total 21,672,884.43 21,528,588.81

66. Financial expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Interest expense 297,658,906.22 375,496,773.81 Less: Interest income 15,689,947.79 29,235,153.98 Handling fees and others 17,044,464.30 20,511,001.49 Total 299,013,422.73 366,772,621.32

67. Other income

Unit: Yuan

Sources of other income Amount incurred in the current period Amount incurred in the previous period

Government subsidies 11,993,749.93 13,156,839.86 Refund of personal income tax withholding fees 660,137.79 756,354.98 Value-added tax exemption 793,758.97 1,311,693.25 Total 13,447,646.69 15,224,888.09

68. Net exposure hedging income

Not applicable.

69. Gains from changes in fair value

Unit: Yuan

Sources of income from changes in fair value Amount incurred in the current period Amount incurred in the previous period

Trading financial assets 70,959.24 254,336.16 Total 70,959.24 254,336.16

70. Investment income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Income from long-term equity investments accounted for by the equity method 309,768.25 124,123.41 Investment income from disposal of long-term equity investments 87,693,013.99 -10,834,881.36

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Others 837,590.60 1,241,332.06 Total 88,840,372.84 -9,469,425.89

71. Credit impairment losses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Bad debt losses on notes receivable 672,850.51 424,320.61 Bad debt losses on accounts receivable -15,649,751.09 -5,851,697.28 Bad debt losses on other receivables 9,455,559.12 39,621,689.10 Total -5,521,341.46 34,194,312.43

72. Asset impairment losses

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Inventory depreciation losses and contract performance cost deductions

2,711,648.39 4,267,475.64 value loss

4. Impairment losses on fixed assets 2,155,029.09 Total 2,711,648.39 6,422,504.73

5. Income from asset disposal

Unit: Yuan

Source of asset disposal income Amount incurred in the current period Amount incurred in the previous period

Gains from the disposal of fixed assets (losses are listed with "-") -1,365,535.67 5,331,603.56 Gains from the disposal of intangible assets (losses are listed with "-") -396,587.01 -84,330.94 Gains from the disposal of right-of-use assets (losses are listed with "-"

1,588,812.17 215,831.42 columns)

Total -173,310.51 5,463,104.04

74. Non-operating income

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Um

Donations accepted 5,114.02

Others 10,115,881.62 7,177,731.44 10,115,881.62 Total 10,115,881.62 7,182,845.46 10,115,881.62

75. Non-operating expenses

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Um

External donations 820,050.29 945,243.03 820,050.29 Others 3,363,705.03 4,979,123.29 3,363,705.03

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Total 4,183,755.32 5,924,366.32 4,183,755.32

76. Income tax expenses

(1) Income tax expense schedule

Unit: Yuan

Item Amount for the current period Amount for the previous period

Current income tax expense 65,751,369.45 89,997,720.85 Deferred income tax expense 2,096,217.83 9,760,863.52 Total 67,847,587.28 99,758,584.37

(2) Adjustment process of accounting profits and income tax expenses

Unit: Yuan

Item Amount incurred in this period

Total profit 132,670,491.01 Income tax expenses calculated according to statutory/applicable tax rates 33,167,622.75 The impact of different tax rates applicable to subsidiaries -2,552,055.45 The impact of non-deductible costs, expenses and losses 1,045,938.83 No deductible temporary differences or deductible temporary differences of deferred income tax assets have been recognized in the current period

36,186,081.15 Impact of loss

Income tax expenses 67,847,587.28

77. Other comprehensive income

For details, please refer to Note 57, Other Comprehensive Income of Consolidated Statement Items.

78. Cash flow statement items

(1) Cash related to operating activities

Other cash received related to operating activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Interest income 15,689,947.79 29,235,153.98 Subsidies received 9,020,539.14 11,051,211.17 Current payments received 2,088,299,153.22 1,866,630,099.59 Others 13,528,179.06 18,695,891.28 Total 2,126,537,819.21 1,925,612,356.02 Description of other cash received related to operating activities:

Not applicable.

Other cash paid related to operating activities

Unit: Yuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Item Amount for the current period Amount for the previous period

Current payment 2,764,593,549.66 1,850,897,382.28 Cash payment 473,627,672.98 954,976,635.85 Others 13,712,981.26 15,265,319.67 Total 3,251,934,203.90 2,821,139,337.80 Description of other cash paid related to operating activities:

Not applicable.

(2) Cash related to investing activities

Not applicable.

(3) Cash related to financing activities

Other cash received related to financing activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Bank acceptance bill deposit 249,472,590.46 268,157,296.28 Bill discount received 3,511,086,462.64 1,868,597,108.23 Fund lending 882,174,052.24 1,980,688,505.37 Total 4,642,733,105.34 4,117,442,909.88 Description of other cash received related to financing activities:

Not applicable.

Other cash payments related to financing activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Payment of deposit for bank acceptance bill 471,398,721.39 625,163,921.59 Payment of bank acceptance bill 3,159,626,637.69 1,378,961,593.28 Fund lending 812,367,923.07 1,706,043,209.52 Total 4,443,393,282.15 3,710,168,724.39 Description of other cash payments related to financing activities:

Not applicable.

Changes in various liabilities arising from financing activities

□ApplicableNot applicable

(4) Explanation on presenting cash flow in net amount

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(5) Major activities and financial impacts that do not involve current cash receipts and payments but affect the company's financial status or may affect the company's cash flow in the future

Not applicable.

79. Supplementary information for cash flow statement

(1) Supplementary information for cash flow statement

Unit: Yuan

Supplementary information Amount for the current period Amount for the previous period

1． Adjust net profit to cash flow from operating activities

Quantity:

Net profit 64,822,903.73 115,281,482.66 plus: asset impairment provision -2,809,693.07 -40,616,817.16 depreciation of fixed assets, depreciation of oil and gas assets

49,189,245.02 53,486,923.79 Depreciation of consumption and productive biological assets

Depreciation of right-of-use assets 31,223,714.65 35,175,948.27 Amortization of intangible assets 17,573,339.63 17,509,589.22 Amortization of long-term prepaid expenses 10,146,980.15 14,271,321.48 Disposal of fixed assets, intangible assets and other

Loss of other long-term assets (income is filled in with "-" in columns 173,310.51 -5,463,104.04)

Loss on scrapping of fixed assets (income based on

Fill in the column with "-" sign)

Loss from change in fair value (gain based on

-70,959.24 -254,336.16 (Fill in “-”)

Financial expenses (revenues are filled in with "-"

297,658,906.22 375,496,773.81 columns)

Investment losses (income is filled in with "-"

-88,840,372.84 9,469,425.89 columns)

Deferred tax assets decreased (increased by

24,457,207.18 11,182,926.82 (Fill in “-”)

Deferred tax liabilities increased (decreased by

-432,962.42 -276,100.62 (Fill in “-”)

Decrease in inventory (increase filled in with "-"

128,671,270.01 181,237,597.30 columns)

Decrease in operating receivables (increase in

-316,381,161.99 -439,190,839.68 (please fill in the list with "-")

Increase (decrease) in operating payables

-157,300,329.87 -213,983,286.54 (please fill in the list with "-")

Others

Net cash flow generated from operating activities 58,081,397.67 113,327,505.04 2. Major investments and financing that do not involve cash receipts or payments

Activities:

debt to capital

Convertible corporate bonds due within one year

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Financing leased fixed assets

3． Net changes in cash and cash equivalents:

Closing balance of cash 1,125,059,469.21 1,297,688,809.04 Less: Opening balance of cash 1,272,594,941.51 1,136,730,048.28 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents -147,535,472.30 160,958,760.76

(2) Net cash paid in the current period to acquire subsidiaries

Not applicable.

(3) Net cash received from disposal of subsidiaries in the current period

Unit: Yuan

Amount

Cash or cash equivalents received from disposal of subsidiaries in the current period 16,784,509.92, including:

Xinjiang Neptune Xinjia Pharmaceutical Co., Ltd. 5,005,800.00 Henan Neptune Medical Technology Co., Ltd. 4,800,000.00 Neptune (Yangjiang) Pharmaceutical Co., Ltd. 828,709.92 Zhongshan Changjian Pharmaceutical Co., Ltd. 3,150,000.00 Hangzhou Infinite Fire Brand Management Co., Ltd. 3,000,000.00 Less: Cash and cash equivalents held by the company on the date of loss of control 22,529,207.34 of which:

Hangzhou Infinite Fire Brand Management Co., Ltd. 10,758,207.93 Shanghai Bohui Health Technology Co., Ltd. 184,470.65 Shanghai Neptune Enterprise Development Co., Ltd. 119,827.93 Hangzhou Beiwudu Internet Technology Co., Ltd. 838.00 Neptune (Yangjiang) Pharmaceutical Co., Ltd. 4,619,111.69 Zhongshan Changjian Pharmaceutical Co., Ltd. 3,028,673.06 Henan Neptune Medical Technology Co., Ltd. 274,321.03 Neptune Baicaotang Pharmaceutical Co., Ltd. 2,177,226.25 Xinjiang Neptune Xinjia Pharmaceutical Co., Ltd. 1,366,530.80 Add: Cash or cash equivalents received in the current period from disposal of subsidiaries in previous periods 12,448,306.21 Among them:

Shaanxi Neptune Galaxy Medical Technology Co., Ltd. 6,000,000.00 Shanghai Neptune Yunhe 5,390,948.61 Guangdong Neptune Xinjian 1,057,357.60 Net cash received from disposal of subsidiaries 6,703,608.79 Other notes:

Not applicable.

(4) Composition of cash and cash equivalents

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

1. Cash 1,125,059,469.21 1,272,594,941.51 Including: cash on hand 625,848.92 879,096.09

Bank deposits that can be used for payment at any time 1,124,433,620.29 1,271,715,845.42

3. Balance of cash and cash equivalents at the end of the period 1,125,059,469.21 1,272,594,941.51

(5) Situations where the scope of use is limited but still represents cash and cash equivalents

Unit: Yuan Items that are still cash and cash equivalents Amount for the current period Amount for the previous period

Reason

Performance bond 208,591,743.96 160,654,009.28 Restricted external payments

Bill security deposit 1,651,926,701.15 1,934,832,186.37 Restricted external payments

Time deposit 55,500,000.00 67,573,867.22 Plan to hold until maturity

Frozen amounts 14,542,625.47 14,515,921.06 Restricted external payments

Third-party capital supervision account 655,598.71 Restricted external payments

Others 327,662.14 447,109.56 Restrictions on external payments

Pledge of deposit certificate 5,000,000.00 5,000,000.00 Pledge

Loan deposit 3,000,000.00 Restrictions on external payments

Total 1,938,888,732.72 2,183,678,692.20

(6) Monetary funds that are not cash and cash equivalents

Not applicable.

(7) Description of other major activities

Not applicable.

80. Notes on items in the statement of changes in owners’ equity

Explain the names of "other" items and the amount of adjustments that were made to the closing balance of the previous year:

Not applicable.

81. Foreign currency monetary items

(1) Foreign currency monetary items

Unit: Yuan

Item Foreign currency balance at the end of the period Conversion exchange rate Conversion of RMB balance at the end of the period Monetary Funds

Of which: USD 6,385.38 7.1884 45,900.67 EUR

HKD 11,980.92 0.92604 11,094.81

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

(2) Description of overseas operating entities, including for important overseas operating entities, their main overseas operating place, accounting standard currency and basis for selection should be disclosed. If the accounting standard currency changes, the reasons should also be disclosed.

□ApplicableNot applicable

82. Leasing

(1) The company serves as the lessee

Applicable□Not applicable

Variable lease payments not included in the measurement of lease liabilities

□ApplicableNot applicable

Simplified treatment of short-term leases or lease payments for low-value assets □ Applicable  Not applicable

Situations involving sale and leaseback transactions

Not applicable.

(2) The company as the lessor

Operating lease as lessor

□ApplicableNot applicable

Finance lease as lessor

□ApplicableNot applicable

Undiscounted lease payments for each of the next five years

□ApplicableNot applicable

The reconciliation of undiscounted lease receipts to net lease investment does not apply.

(3) Recognition of financial lease sales profits and losses as a manufacturer or distributor

□ApplicableNot applicable

83. Data resources

Not applicable.

84. Others

Not applicable.

8. R&D expenditures

Unit: Yuan

Item Amount incurred in the current period Amount incurred in the previous period R&D expenditure 28,326,742.95 30,658,888.06 Total 28,326,742.95 30,658,888.06

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Including: Expenditure R&D expenditure 21,672,884.43 21,528,588.81

Capitalized R&D expenditure 6,653,858.52 9,130,299.25

1. R&D projects that meet capitalization conditions

Unit: Yuan

Increase amount in this period Decrease amount in this period

Item Opening balance Internal development Confirmed as N/A Transferred to current period Closing balance Others

Expenditure tangible assets Profit and loss

acetaminophen

752.12 115.16 867.28Lin Pian

Bromohexyl hydrochloride

5,309.73 46,758.05 52,067.78New films

hydrochlorothiazide

1,061.95 1,061.95 pieces

Compound polyethylene

diol

377,358.49 377,358.49 (3350)

electrolyte powder

58,218,296. 58,269,947. Polydatin 51,650.99

13 12

22,897,152. 23,578,094. HW130 680,942.09

82 91

6,804,421.5 7,178,376.0 ABTL 373,954.52

6 8

5,203,492.8 5,250,302.3 Dapoxetine 46,809.50

4 4Medical Equipment

Fine tube 1,296,308.8

454,887.30 841,421.59

Management System 9 V4.0

NEP015 (naphthalene 30,428,188. 30,428,188. putinib) 90 90 NATAO3- 9,326,383.7 9,326,383.7 Ainaxiang 4 4 F01 (net solid 1,127,450.9 1,127,450.9 tablets) 5 5

9,072,192.6 4,234,848.1 13,307,040. NEP018

4 3 77

143,539,59 6,653,858.5 150,193,44Total

0.68 2 9.20

Significant Capitalized R&D Projects

Not applicable.

Impairment provision for development expenditures

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Closing balance Impairment test situation NEP015 (naprotil

30,428,188.90 30,428,188.90

Nigeria)

NATAO3-Ainaxiang 9,326,383.74 9,326,383.74

F01 (net solid film) 1,127,450.95 1,127,450.95

Total 40,882,023.59 40,882,023.59

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

2. Important outsourced research projects

Not applicable.

9. Changes in consolidation scope

1. Business merger not under common control

Not applicable.

2. Merger of enterprises under common control

Not applicable.

3. Reverse purchase

Not applicable.

4. Disposal of subsidiaries

Are there any transactions or events that result in the loss of control of subsidiaries during this period?

Yes□No

Unit: yuan disposal loss

Control with original price

Zigong and Chu Quanzhi

Loss Loss Corporate Stock Investment According to Nikkei

Control Control investment is fair and financial

power of power

due loss of value

Loss Loss Loss Loss Rihe Rihe Guan

Merge Control Resurface

Control Control Control Loss of control Consolidation of financial rights Consolidation of financial rights of other subsidiaries Measurement of balance sheet

Power time Power time Control time Financial report Comprehensive company name report Daily remaining shares

Point of Point Point of Rights Point of Surface Surface Surface Income is called Level Remaining Shares Equity Rights Public

Disposal Disposal Disposal Time Judgment Surplus Surplus Transfer in

The right to produce a fair price

The price ratio method is based on the profit of the remaining shares invested in the sub-proportion.

Profit and loss company with rights obtained or determined

Book fair or retained equity loss method

value value deposit share and owner

It’s a huge benefit. I need to leave.

Amount

The difference is set

Hangzhou

unlimited

2025

Fire Control 11,406

3,000, 67.50 Year 03

Brand rights transfer,713.1

000.00 % Month 19

Management Shift 6

day

limited

company

Shanghai

Bohui 2025

Control -

Health 100.00 Year 03

Transfer of rights 178,15

Technology % Month 26

Shift 2.02

Limited days

company

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Shanghai

Aquaman 2025

control

Enterprise 100.00 Year 03 6,430,

transfer of rights

Development % Month 26 005.00

move

Limited days

company

Aquaman

2025 -

(Yangjiang) Control

828,70 54.93 Year 03 10,513 Pharmaceutical Rights Transfer

9.92% Month 31,016.3 limited transfer

Day 4

company

Zhongshan

City Chang 2025 -

control

Health medicine 3,150, 73.79 Year 03 19,455

transfer of rights

Industry has 000.00% month 31,579.6

move

Limited public day 6

Division

Henan

Aquaman 2025

control

Medical 4,800, 65.00 Year 06 3,309,

transfer of rights

Technology 000.00 % Month 30 955.03

move

Limited days

company

Aquaman

Baicao 2025

Control 20,516 Tangyao 70.00 Year 02

0.00 rights transfer, 663.5 industry shares % Month 28

Shift 2

Limited public day

Division

Xinjiang

Aquaman 2025

23,005 Control 76,092Xinjia 70.00 Year 03

,800.0 Rights transfer ,627.5 Pharmaceutical % Month 31

0 shift 4

Limited days

company

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period?

□YesNo

5. Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related circumstances:

(1) Subsidiaries established and acquired in this period

Item Reason for change Zhejiang Haiqing Future Technology Development Co., Ltd. Establishment of Zhejiang Haizhi Future Technology Development Co., Ltd. Establishment of Hangzhou Haige Yuexiang Health Technology Co., Ltd. Establishment of Hangzhou Haiqian Medical Technology Co., Ltd. Establishment

(2) Subsidiaries canceled in this period

Item Reason for change Hangzhou Beiwudu Internet Technology Co., Ltd. Cancel

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

6. Others

Not applicable.

10. Interests in other entities

1. Interests in subsidiaries

(1) Composition of enterprise groups

Unit: Yuan

Shareholding ratio

Subsidiary name Registered capital Main place of business Place of registration Nature of business Acquisition method Direct Indirect

167,800,000. Neptune Intelron under common control Shenzhen Shenzhen Pharmaceutical Manufacturing 70.38% 3.13%

00 Business merger Oriental Investment 600,000.00 Shenzhen Shenzhen Equity investment 100.00% Establishment or investment

160,000,000.

Galaxy Investment Shenzhen Shenzhen Pharmaceutical Investment 100.00% Establishment or Investment

25,000,000.0

Xiaogan Investment Xiaogan Xiaogan Industrial Investment 100.00% Establishment or Investment

340,350,000.

Hubei Neptune Xiaogan Xiaogan Pharmaceutical Distribution 100.00% Establishment or investment Aster 1,040,000.00 Hong Kong Hong Kong Pharmaceutical Distribution 73.51% Establishment or investment

200,000,000. Not under common control Sulu Haiwang Zaozhuang Zaozhuang Pharmaceutical Distribution 100.00%

00 business mergers

700,000,000. Not under common control Shandong Yinhe Weifang Weifang Pharmaceutical Distribution 100.00%

00 business mergers

30,000,000.0

Zaozhuang Investment Zaozhuang Zaozhuang Industrial Investment 100.00% Establishment or investment

15,000,000.0

Weihai Investment Weihai Weihai Industrial Investment 100.00% Establishment or Investment

15,000,000.0

Heze Investment Heze Heze Industrial Investment 100.00% Establishment or investment

160,800,000. Not under common control Henan Dongsen Nanyang Nanyang Pharmaceutical Distribution 100.00%

00 business mergers

30,000,000.0 Neptune Fuyao under the same control Fuzhou Fuzhou Pharmaceutical Manufacturing 58.81%

0 Business mergers

30,000,000.0

Neptune Changjian Shenzhen Shenzhen Pharmaceutical Distribution 73.51% Establishment or investment

10,000,000.0

Galaxy Technology Shenzhen Shenzhen Commercial Trade 100.00% Establishment or Investment

1,663,140,00

Henan Haiwang Zhengzhou Zhengzhou Pharmaceutical Distribution 100.00% Establishment or Investment 0.00

25,500,000.0 Not under common control Heze Neptune Heze Heze Pharmaceutical Distribution 88.24%

0 business combinations

30,000,000.0 Not under common control Weihai Haiwang Weihai Weihai Pharmaceutical Distribution 86.66%

0 Business merger under Yantai Neptune 1,000,000.00 Yantai Yantai Pharmaceutical Distribution 100.00% Establishment or investment

10,000,000.0 Non-common control Fuyao Pharmaceutical Fuzhou Fuzhou Pharmaceutical Distribution 59.01%

0 business combinations

10,000,000.0 Non-identical Control Golden Elephant Traditional Chinese Medicine Fuzhou Fuzhou Pharmaceutical Manufacturing 5.00% 55.87%

0 business combinations

50,000,000.0 Not under common control Anhui Haiwang Hefei Hefei Pharmaceutical Distribution 65.00%

0 business combinations

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

30,000,000.0 Not under common control Jiamusi Haiwang Jiamusi Jiamusi Pharmaceutical Distribution 100.00%

0 Under business combination 18,000,000.0

Hubei Pengtai Hanchuan Hanchuan Pharmaceutical Distribution 70.00% Establishment or investment

20,000,000.0 Not under common control Binzhou Huanghe Binzhou Binzhou Pharmaceutical Distribution 70.00%

0 Under corporate merger Shandong Medical Equipment 10,000,000.0

Weifang Weifang Pharmaceutical Distribution 100.00% Establishment or Investment 0

10,000,000.0 Not under common control Tengzhou Haiwang Tengzhou Tengzhou Pharmaceutical Distribution 100.00%

0 business combinations

Not under common control Dongming Jinxin 7,000,000.00 Heze Heze Pharmaceutical Distribution 70.00%

20,000,000.0 Business combination under non-common control Jining Huasen Jining Jining Pharmaceutical Distribution 70.00%

0 Business merger under 100,000,000. Not under common control Wuhan Pharmaceutical Wuhan Wuhan Pharmaceutical Distribution 100.00%

00 Business merger under 30,000,000.0 Not under common control Heilongjiang Neptune Harbin Harbin Pharmaceutical Distribution 65.00%

0 Under business combination 50,000,000.0

Puyang Neptune Puyang Puyang Pharmaceutical Distribution 90.00% Establishment or Investment

10,500,000.0 Not under common control Shenyip Pharmaceutical Shenzhen Shenzhen Pharmaceutical Distribution 60.00%

0 100,000,000 under business combination.

Research Institute Shenzhen Shenzhen R&D 80.00% 20.00% Establishment or investment

169,400,000.

Hairong International Shenzhen Shenzhen Industrial Investment 60.00% Establishment or investment

30,000,000.0 Not under common control Bozhou Haiwang Bozhou Bozhou Pharmaceutical Distribution 100.00%

0 Business combination under non-common control 15,000,000.0 Bengbu Neptune Bengbu Bengbu Pharmaceutical Distribution 75.00%

0 Business merger under 54,350,000.0 Not under common control Henan Huitong Nanyang Nanyang Pharmaceutical Distribution 72.40%

0 Under business combination 20,000,000.0

Pingdingshan Neptune Pingdingshan Pingdingshan Pharmaceutical Distribution 70.00% Establishment or investment

Henan Medical Equipment 50,000,000.0

Zhengzhou Zhengzhou Pharmaceutical Distribution 65.00% Establishment or investment in machinery 0

30,000,000.0

Hubei Enshi Enshi Enshi Pharmaceutical Distribution 50.00% Establishment or investment

30,000,000.0

Guangxi Neptune Nanning Nanning Pharmaceutical Distribution 53.29% Establishment or investment

18,000,000.0 Not under common control Beijing Neptune Beijing Beijing Pharmaceutical Distribution 88.00%

0 Business merger under 550,000,000. Not under common control Shandong Group Jinan Jinan Pharmaceutical Distribution 100.00%

00 Business merger under 150,000,000. Anhui Group not under common control Hefei Hefei Pharmaceutical Distribution 100.00%

Business merger under 00 349,960,000. Guangdong Group not under common control Guangzhou Guangzhou Pharmaceutical Distribution 81.99%

00 Business merger under 15,000,000.0 Not under common control Shandong Kangnuo Yantai Yantai Pharmaceutical Distribution 80.00%

0 Business combination under 50,000,000.0 Not under common control Guangdong Distribution Guangzhou Guangzhou Pharmaceutical Distribution 52.00%

0 Business combination under 10,000,000.0 Not under common control Qingdao Huaren Qingdao Qingdao Pharmaceutical Distribution 65.00%

0 business combinations

Not under common control Shandong Xinchen 3,000,000.00 Jinan Jinan Pharmaceutical Distribution 100.00%

Heilongjiang Huatong 30,000,000.0 Harbin Harbin Medical equipment 65.00% Not under common control

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

0 Business combination under 30,000,000.0 Not under common control Hubei Kai'anchen Wuhan Wuhan Pharmaceutical Distribution 70.00%

0 Business merger under 56,900,000.0 Not under common control Zhoukou Renhe Zhoukou Zhoukou Pharmaceutical Distribution 100.00%

0 Business combination under 30,000,000.0 Not under common control Henan Kangrui Luohe Luohe Pharmaceutical Distribution 100.00%

0 Business merger under 21,000,000.0 Not under common control Anyang Hengfeng Anyang Anyang Pharmaceutical Distribution 70.00%

0 Business combination under 30,000,000.0 Not under common control Henan Guanbao Nanyang Nanyang Pharmaceutical Distribution 70.00%

0 Business merger under 120,000,000. Not under common control Anhui Guoan Hefei Hefei Pharmaceutical Distribution 80.00%

00 Business merger under non-common control 10,000,000.0 Guilin Neptune Guilin Guilin Pharmaceutical Distribution 81.99%

0 Business combination under 100,000,000. Not under common control Hunan Haiwang Changsha Changsha Pharmaceutical Distribution 70.00%

00 Business merger under 30,000,000.0 Not under common control Hunan Kangfulai Yueyang Yueyang Pharmaceutical Distribution 70.00%

0 Business combination under 50,000,000.0 Not under common control Shaoyang Haiwang Shaoyang Shaoyang Pharmaceutical Distribution 75.00%

0 Business combination under 55,380,000.0 Not under common control Henan Dejitang Yuzhou Yuzhou Pharmaceutical Distribution 65.00%

0 Business merger under 50,000,000.0 Not under common control Anqing Neptune Anqing Anqing Pharmaceutical Distribution 80.00%

0 Business merger under non-common control 30,000,000.0 Wuhan Development Wuhan Wuhan Pharmaceutical Distribution 70.00%

0 Business combination under 10,500,000.0 Not under common control Weihai Rutai Weihai Weihai Pharmaceutical Distribution 65.00%

0 Business combination under 10,200,000.0 Not under common control Shandong Mingyang Weihai Weihai Pharmaceutical Distribution 80.00%

0 Business merger with Heilongjiang Kanglai Not under common control 5,000,000.00 Harbin Harbin Pharmaceutical distribution 65.00%

Merger of enterprises under Germany 50,000,000.0 Not under common control Henan Kanghong Xuchang Xuchang Pharmaceutical Distribution 65.00%

0 Business combination under 10,000,000.0 Not under common control Wannan Haiwang Anqing Anqing Pharmaceutical Distribution 80.00%

0 Business merger with Shanghai Medical Devices 50,000,000.0 Not under common control

Shanghai Shanghai Medical Equipment 52.00%

100,000,000 for business combination under Mechanical 0.

Henan Galaxy Zhengzhou Zhengzhou Pharmaceutical Distribution 65.00% Establishment or Investment

Fujian Medical Distribution 20,000,000.0

Fuzhou Fuzhou Medical Equipment 41.60% 0 bonus for establishment or investment

10,000,000.0

Heilongjiang Yinhai Harbin Harbin Pharmaceutical Distribution 20.00% 80.00% Establishment or investment

15,000,000.0

Yichang Neptune Yichang Yichang Pharmaceutical Distribution 65.00% Establishment or Investment

10,000,000.0

Ningbo Neptune Ningbo Ningbo Others 88.00% Establishment or investment

200,000,000.

Shanghai Neptune Shanghai Shanghai Medical Equipment 80.00% Establishment or investment

30,000,000.0 Not under common control Shandong Xinnuo Jining Jining Pharmaceutical Distribution 70.00%

0 Under business combination 20,000,000.0

Changde Haiwang Changde Changde Pharmaceutical Distribution 65.00% Establishment or investment

45,765,000.0 Not under common control Henan Enji Luoyang Luoyang Pharmaceutical distribution 64.00%

0 business combinations

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

52,190,000.0 Not under common control Henan Zuojinming Xinxiang Xinxiang Pharmaceutical Distribution 72.00%

0 Business merger under 30,000,000.0 Not under common control Kashgar Galaxy Kashgar Kashgar Pharmaceutical Distribution 70.00%

0 Business combination under 10,000,000.0 Not under common control Kashgar Hongkang Kashgar Kashgar Medical equipment 70.00%

0 Business combination under 20,000,000.0 Not under common control Henan Tiansheng Shangqiu Shangqiu Pharmaceutical Distribution 52.00%

0 Business merger under 30,000,000.0 Not under common control Anhui Tiancheng Chuzhou Chuzhou Pharmaceutical Distribution 80.00%

0 Enterprise merger with Tianjin Medical Technology 10,800,000.0 Not under common control

Tianjin Tianjin Medical Equipment 80.00%

Business merger under Sichuan Medical Technology 0 50,000,000.0 Not under common control

Chengdu Chengdu Medical Equipment 52.00%

Business merger under technology 0

Non-common control Chengdu Ruixi 2,000,000.00 Chengdu Chengdu Medical Equipment 52.00%

10,000,000.0 Business combination not under common control Zhanjiang Neptune Zhanjiang Zhanjiang Pharmaceutical Distribution 57.39%

0 Business combination under non-common control 18,000,000.0 Shaoguan Neptune Shaoguan Shaoguan Pharmaceutical Distribution 57.39%

0 Under business combination 10,000,000.0

Qingyuan Neptune Qingyuan Qingyuan Pharmaceutical Distribution 81.99% Establishment or investment

10,000,000.0 Non-common control Foshan Neptune Foshan Foshan Pharmaceutical Distribution 57.39%

0 Under corporate merger Hunan Medical 10,000,000.0

Yueyang Yueyang Pharmaceutical Distribution 70.00% Establishment or Investment Technology 0

10,000,000.0 Weishi County Medicine not under common control Kaifeng Kaifeng Pharmaceutical Distribution 65.00%

0 Business combination under 10,000,000.0 Not under common control Ningxia Haiwang Yinchuan Yinchuan Pharmaceutical Distribution 70.00%

0 Business combination under non-common control 10,000,000.0 Lu'an Neptune Lu'an Lu'an Pharmaceutical Distribution 70.00%

0 Business combination under non-common control 10,000,000.0 Wuhu Sunshine Wuhu Wuhu Pharmaceutical Distribution 74.20%

0 Enterprise merger Hunan Medical Distribution 20,000,000.0

Changsha Changsha Medical Equipment 52.00% 0 bonus for establishment or investment

Guangxi Medical Distribution 20,000,000.0

Nanning Nanning Medical Devices 52.00% 0 bonus for establishment or investment

Jiangsu Medical Equipment 20,000,000.0

Nanjing Nanjing Medical Equipment 64.00% Establishment or Investment in Medical Equipment 0

Non-common control Sichuan Fanyuan 2,000,000.00 Chengdu Chengdu Pharmaceutical Distribution 52.00%

30,000,000.0 Business combination under non-common control Linyi Dongrui Linyi Linyi Pharmaceutical Distribution 95.00%

0 Business combination under 30,000,000.0 Not under common control Shanghai Fangcheng Shanghai Shanghai Medical Equipment 52.00%

0 Under business combination 10,000,000.0

Anhui Juying Hefei Hefei Medical Equipment 71.00% Establishment or investment

20,000,000.0

Neptune Yewei Shanghai Shanghai Medical Devices 52.00% Establishment or investment

Henan Nanyangwen 30,000,000.0

Nanyang Nanyang Pharmaceutical Distribution 51.00% Establishment or Investment Peak 0

Not under common control Suzhou Neptune 5,000,000.00 Suzhou Suzhou Pharmaceutical Distribution 80.00%

business combination

15,000,000.0

Hubei Equipment Wuhan Wuhan Medical Equipment 75.00% Establishment or Investment

Shandong Handi 52,000,000.0 Zaozhuang Zaozhuang Medical equipment 59.62% Establishment or investment

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

50,000,000.0

Jilin Galaxy Changchun Changchun Industrial Investment 100.00% Establishment or investment

Not under common control Xinxiang Yinhai 5,000,000.00 Xinxiang Xinxiang Medical testing 65.00%

business combination

20,000,000.0

Sulu Equipment Jinan Jinan Medical Equipment 65.00% Establishment or investment

Yantai Longshu 300,000.00 Yantai Yantai Management consulting 100.00% Establishment or investment in Weifang Xinzheng 200,000.00 Weifang Weifang Management consulting 100.00% Establishment or investment in Jining Anruitai 500,000.00 Jining Jining Management consulting 100.00% Establishment or investment

30,000,000.0

Henan Wandu Nanyang Nanyang Medical Equipment 100.00% Establishment or Investment

Guangzhou Haihong 500,000.00 Guangzhou Guangzhou Management consulting 81.99% Establish or invest in Nanning Haihong 500,000.00 Nanning Nanning Management consulting 81.99% Establish or invest in Hefei Jianyuan 500,000.00 Hefei Hefei Management consulting 100.00% Establish or invest in Heilongjiang Hejia

500,000.00 Harbin Harbin Industrial Investment 100.00% Establishment or investment in Mingxi

Shenzhen Medical Health Not under common control

3,010,000.00 Shenzhen Shenzhen Medical Equipment 100.00%

Kangxia Enterprises merged with Shenzhen Health Development

8,000,000.00 Shenzhen Shenzhen Medical Equipment 100.00% Establishment or Investment Exhibition

Zhejiang Neptune Number 100,000,000.

Hangzhou Hangzhou Pharmaceutical Distribution 100.00% Establishment or Investment Certificate 00

10,000,000.0 Not under common control Hainan Jiachi Chengmai Chengmai Pharmaceutical Distribution 100.00%

0 Business merger with Beijing Haiwang Zhong 100,000,000. Not under common control

Beijing Beijing Pharmaceutical Manufacturing 37.49%

Business mergers under the new 00

10,000,000.0

Jiangsu Neptune Xuzhou Xuzhou Pharmaceutical Distribution 80.00% Establishment or investment

50,000,000.0 Changchun Kunlan not under common control Changchun Changchun Management Consulting 100.00%

0 business combinations

10,000,000.0

Neptune Cloud Shenzhen Shenzhen Business Services 100.00% Establishment or Investment

10,000,000.0 Special equipment

Hubei Haijuntong Hubei Hubei 100.00% Establishment or investment

0 karma

Hainan Changjian 1,000,000.00 Hainan Hainan Wholesale industry 73.51% Establish or invest in Neptune Medical Department 200,000,000. Software and information

Shanghai Shanghai 100.00% Establishment or investment in technology 00 technology service industry

Internet and photo

Hangzhou Haihe 2,000,000.00 Hangzhou Hangzhou 100.00% Establishment or investment related services

20,000,000.0

Anhui Haihe Anhui Lu'an Real Estate Investment 99.00% Establishment or Investment

Zaozhuang Medical Equipment 20,000,000.0

Zaozhuang Zaozhuang Pharmaceutical manufacturing 42.25% Establishment or investment in machinery 0

Zibo Medical Equipment 10,000,000.0

Zibo Zibo Pharmaceutical Distribution 48.00% Establishment or investment in machinery 0

Hangzhou Huawu 500,000.00 Hangzhou Hangzhou Pharmaceutical Distribution 100.00% Establishment or investment

20,000,000.0

Shandong Zhengjin Zibo Zibo Market Services 51.20% Establishment or Investment

Enji Logistics 4,235,000.00 Luoyang Luoyang Transportation services 64.00% Establish or invest in Zhejiang Haiqingwei

5,000.00 Hangzhou Hangzhou Medical Services 80.00% Establishment or investment

Zhejiang Haizhiwei

5,000.00 Hangzhou Hangzhou Medical Services 100.00% Establishment or investment

Hangzhou Haigeyue

1,000.00 Hangzhou Hangzhou Medical Services 51.00% Establishment or investment benefits

Hangzhou Haiqian Medical 50.00 Hangzhou Hangzhou Medical Services 100.00% Establishment or investment

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

treatment

(2) Important non-wholly owned subsidiaries

Unit: Yuan Attributable to minority shareholders in this period Announcement to minority shareholders in this period Name of the company remaining in minority shareholders’ equity at the end of the period Shareholding ratio of minority shareholders

Profit and loss Amount of dividends distributed

Shanghai Medical Equipment 48.00% 25,079,090.47 91,043,536.65 Sichuan Medical Technology 48.00% 341,114.81 28,734,874.07 Neptune Fuyao 41.19% 7,766,486.83 19,000,000.00 124,910,532.93

(3) Main financial information of important non-wholly owned subsidiaries

Unit: Yuan

Ending balance Beginning balance

Zigong

non-flow non-flow non-flow non-flow

Company name Current assets Current liabilities Current assets Current liabilities Liquid capital Current liabilities Liquid capital Liquid liabilities

Said Assets Total Liabilities Total Assets Total Liabilities Total

property debt property debt

Shanghai 1,343, 146,56 1,489, 1,315, 1,319, 1,016, 124,37 1,141, 1,020, 12,069 1,032,

3,684,

Medical 115,71 5,786. 681,50 633,08 317,46 885,49 3,413. 258,90 533,80 ,689.8 603,49

370.69

Equipment 5.84 43 2.27 9.66 0.35 1.31 04 4.35 1.14 1 0.95Sichuan 440,24 12,193 452,44 377,03 379,03 582,21 13,145 595,35 521,67 523,03

2,002, 1,361,

Medical 9,107. ,181.4 2,289. 4,293. 6,301. 3,999. ,760.2 9,759. 3,137. 4,920.

007.80 782.15

Technology 89 9 38 94 74 56 8 84 98 13

271,82 163,80 435,62 70,280 70,824 281,76 181,34 463,10 115,91 117,32Neptune 544,70 1,409,

2,995. 1,474. 4,470. ,246.7 ,955.5 3,750. 3,576. 7,327. 8,925. 8,316. Blessing medicine 8.79 390.87

64 99 63 3 2 86 50 36 63 50 Unit: Yuan

Amount for the current period Amount for the previous period

Subsidiary name

Comprehensive Income Operating Activities Comprehensive Income Operating Activities Operating Income Net Profit Operating Income Net Profit

Total cash flow Total cash flow Shanghai Medical 1,709,008,8 52,248,105. 52,248,105. 53,900,640. 1,644,254,4 85,948,546. 85,948,546. 66,158,311. Equipment 64.10 13 13 98 41.88 80 80 49

-

Sichuan Medical 177,906,13 259,413,63 22,002,700. 22,002,700. 85,673,348.

710,655.85 710,655.85 25,418,722.

Technology 8.26 1.46 93 93 46 -

159,705,13 113,854,55 113,854,55 207,614,55 33,903,269. 33,903,269. 32,310,403. Neptune's Blessing Medicine 7,699,438.1

0.41 9.53 9.53 8.22 62 62 89

(4) Significant restrictions on the use of enterprise group assets and repayment of enterprise group debts

Not applicable.

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

2. Transactions in which the ownership share of the subsidiary changes and the subsidiary is still controlled

(1) Description of changes in owner’s equity shares of subsidiaries

1. In June 2024, the company's subsidiary Shanghai Neptune Pharmaceutical Group Co., Ltd. transferred 5% of its equity in Sulu Neptune Medical Devices Co., Ltd. to Neptune Medical Technology Co., Ltd., and the company's equity ratio changed from 64% to 65%;

2. In March 2025, the company's subsidiary Sulu Neptune Medical Instruments Co., Ltd. increased its capital by 2 million yuan to its subsidiary Zaozhuang Neptune Medical Instruments Co., Ltd., and the company's equity ratio changed from 41.60% to 42.25%;

3. In March 2025, the small shareholders of Linyi Dongrui Pharmaceutical Co., Ltd. failed to achieve the agreed performance targets in the historical year. After negotiation, the small shareholders transferred 10% of their equity to Sulu Neptune Pharmaceutical Group Co., Ltd. for free, and Sulu Neptune gave up its demand for performance compensation to the small shareholders. The Company's shareholding ratio in Linyi Dongrui Pharmaceutical Co., Ltd. increased from 85% to 95%.

(2) The impact of the transaction on minority shareholders’ equity and owner’s equity attributable to the parent company

Not applicable.

3. Interests in joint ventures or associated enterprises

(1) Important joint ventures or associates

Shareholding ratio Investment in joint ventures or joint ventures or associates Main place of business Registration place Nature of business

Name of operating enterprise Direct indirect accounting treatment method

Shandong Kangli Medical

Equipment Technology Co., Ltd. Zaozhuang Zaozhuang Medical Equipment 40.00% Equity method

company

(2) Main financial information of important joint ventures

Not applicable.

(3) Main financial information of important associates

Unit: Yuan Closing balance/amount of the current period Opening balance/amount of the previous period

Shandong Kangli Medical

Current assets 208,046,262.71 199,489,284.39 Non-current assets 123,212,525.02 128,390,126.69 Total assets 331,258,787.73 327,879,411.08 Current liabilities 34,814,763.36 31,084,297.03 Non-current liabilities 11,277,871.79 11,764,242.47 Total liabilities 46,092,635.15 42,848,539.50 Minority shareholders’ equity

Equity attributable to shareholders of the parent company 285,166,152.58 285,030,871.58 Share of net assets calculated based on shareholding ratio 114,066,461.03 114,012,348.63 Adjustment matters 13,780,688.11 13,780,688.11

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

--Goodwill 13,406,707.58 13,406,707.58 --Unrealized profits from internal transactions

--Others 373,980.53 373,980.53 Book value of equity investments in associates 127,847,149.14 127,793,036.74 Equity investments in associates with publicly quoted prices

fair value

Operating income 43,140,158.83 43,391,140.10 Net profit 82,361.79 310,308.56 Net profit from discontinued operations

other comprehensive income

Total comprehensive income 82,361.79 310,308.56 Dividends received from associates this year

(4) Summary financial information of unimportant joint ventures and associates

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

Joint Venture:

The total of the following items calculated based on shareholding ratio

Associates:

Total investment book value 66,386,284.22 65,777,060.52 Total of the following items calculated based on shareholding ratio

--Net profit 276,823.53 0.00 --Other comprehensive income 0.00 --Total comprehensive income 276,823.53 0.00

(5) Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company

Not applicable.

(6) Excess losses incurred by joint ventures or associates

Not applicable.

(7) Unconfirmed commitments related to investment in joint ventures

Not applicable.

(8) Contingent liabilities related to investments in joint ventures or associates

Not applicable.

4. Important joint operations

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

5. Equity in structured entities not included in the scope of consolidated financial statements

Not applicable.

6. Others

Not applicable.

11. Government subsidies

1. Government subsidies recognized according to the amount receivable at the end of the reporting period

□ApplicableNot applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

□ApplicableNot applicable

2. Liability items involving government subsidies

Applicable□Not applicable

Unit: Yuan Included in the current period

New additions in the current period are transferred to other changes in the current period and assets/income accounting accounts. Opening balance. Non-professional income. Ending balance.

Subsidy amount Other income amount Moving related amount

"Puyang City"

Efficient distribution in rural areas

Pilot construction project Related to assets 1,880,877.74 1,880,877.74

"Government Subsidy Measures for Project and Fund Management" proposes

Project subsidies

Consistency evaluation Related to income 250,000.00 250,000.00

R&D Grants Government Grants Application 2016

type technology research and development

Asset-related and major technology 3,000,000.00 3,000,000.00

Government subsidy achievement transformation specialist

funds

Founding Committee

Related to assets BRgN3vB country 3,160,000.00 3,160,000.00

government subsidy matching funds

Henan Haiwanghui

Tong Pharmaceutical Co., Ltd.

Asset-related corporate infrastructure 1,900,500.00 271,500.00 1,629,000.00

Government subsidies for the construction of facilities

funds

10,191,377.7

Total 271,500.00 5,040,877.74 4,879,000.00

3. Government subsidies included in current profits and losses

Applicable□Not applicable

Unit: Yuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Accounting accounts Amount for the current period Amount for the previous period

Government support fund 6,810,000.00 1,065,547.87 Tax refund 2,600,958.14 391,998.34 NEP018 Municipal Science and Technology Innovation Commission Special Subsidy 202322285

1,500,000.00 1,500,000.00 sticker

Job stabilization subsidy 765,380.89 1,021,093.99 Tax incentives 494,900.00 686,464.00 Others 295,997.15 285,658.94Henan Haiwang Huitong Pharmaceutical Co., Ltd. Infrastructure

271,500.00 271,500.00 Construction support funds

National High-tech Enterprise Subsidy 200,000.00 200,000.00 Social Security Subsidy for Graduates 156,813.75 19,873.38 Enterprise Incentive Funds and Subsidies 134,400.00 50,800.00 Industrial Support Fund 42,000.00 4,460,000.00 R&D Funding Subsidy -1,278,200.00 1,218,070.00 Dongsen Pharmaceutical Logistics Industrial Park settlement subsidy 1,307,600.00 Xianning High-tech Zone allocated industrial project infrastructure

267,499.98 gold

Financial allocation for emergency medical supplies reserve 222,900.00 One-time employment subsidy 89,994.88 Bureau of Commerce new warehousing reward 50,000.00 Land support funds 47,838.48 Total 11,993,749.93 13,156,839.86

12. Risks related to financial instruments

1. Various risks arising from financial instruments

The company's main financial instruments include monetary funds, notes receivable, accounts receivable, receivable financing, other receivables, non-current assets due within one year, other current assets, trading financial assets, other equity instrument investments, long-term receivables, notes payable, accounts payable, other payables, short-term borrowings, trading financial liabilities, non-current liabilities due within one year, long-term borrowings, bonds payable, lease liabilities and long-term payables. Details of each financial instrument have been disclosed in the relevant notes. The risks associated with these financial instruments, and the risk management policies adopted by the Company to mitigate these risks, are described below. The company's management manages and monitors these risk exposures to ensure that the above risks are controlled within limited limits.

(1) Risk management objectives and policies

The main risks caused by the company's financial instruments are credit risk, liquidity risk, and market risk (including exchange rate risk, interest rate risk, and commodity price risk).

The Company's goal in risk management is to achieve an appropriate balance between risks and returns, and strive to reduce the adverse impact of financial risks on the Company's financial performance. Based on this risk management objective, the Company has formulated risk management policies to identify and analyze the risks faced by the Company, set appropriate risk acceptance levels and design corresponding internal control procedures to monitor the Company's risk levels. The Company will regularly review these risk management policies and related internal control systems to adapt to changes in market conditions or the Company's operating activities. The Company's internal audit department also regularly or randomly checks whether the implementation of the internal control system complies with the risk management policy.

The Board of Directors is responsible for planning and establishing the company's risk management structure, formulating the company's risk management policies and relevant guidelines, and supervising the implementation of risk management measures. The Company has formulated risk management policies to identify and analyze the risks faced by the Company. These risk management policies clearly define specific risks and cover many aspects such as market risk, credit risk and liquidity risk management. The Company regularly evaluates changes in the market environment and the Company's operating activities to determine whether to update risk management policies and systems. The Company's risk management is carried out by the Risk Management Committee in accordance with policies approved by the Board of Directors. The Risk Management Committee identifies, evaluates and avoids relevant risks through close cooperation with other business departments of the Company. The Company's internal audit department conducts regular audits on risk management controls and procedures and reports the audit results to the Company's Audit Committee.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

The Company diversifies financial instrument risks through appropriate diversification of investments and business portfolios, and reduces risks concentrated in a single industry, specific region or specific counterparty by formulating corresponding risk management policies.

credit risk

Credit risk refers to the risk that the counterparty fails to perform its contractual obligations, resulting in financial losses for the company.

The Company manages credit risks by portfolio classification. Credit risk mainly arises from bank deposits, accounts receivable, etc.

The company's bank deposits are mainly deposited in state-owned banks and other large and medium-sized listed banks. The company does not expect that there will be significant credit risk in bank deposits.

For accounts receivable, the Company sets relevant policies to control credit risk exposure. The company evaluates the customer's credit qualifications and sets corresponding credit periods based on the customer's financial status, credit history and other factors such as current market conditions. The company will regularly monitor customer credit records. For customers with poor credit records, the company will use written reminders, shorten the credit period or cancel the credit period to ensure that the company's overall credit risk is within a controllable range.

The debtors of the Company's accounts receivable are customers located in different industries and regions. The Company continues to conduct credit assessments on the financial status of accounts receivable and purchases credit guarantee insurance when appropriate.

The Company's maximum exposure to credit risk is the carrying amount of each financial asset on the balance sheet. The Company has not provided any other guarantees that may expose the Company to credit risk.

Among the company's accounts receivable, the accounts receivable of the top five customers accounted for 15.15% of the company's total accounts receivable (2024: 15.96%); among the company's other receivables, the other receivables of the top five companies in arrears accounted for 14.83% of the company's total other receivables (2024: 11.37%).

Liquidity risk

Liquidity risk refers to the risk that the company encounters a shortage of funds when fulfilling its obligations to settle by delivering cash or other financial assets.

When managing liquidity risk, the Company maintains and monitors cash and cash equivalents that management considers sufficient to meet the Company's operating needs and reduce the impact of cash flow fluctuations. The Company's management monitors the use of bank borrowings and ensures compliance with borrowing agreements.

The Company raises working capital through funds generated from operating businesses and bank and other borrowings.

At the end of the period, the financial liability items held by the company are analyzed based on the maturity period of the undiscounted remaining contract cash flows as follows (unit: 10,000 yuan):

Ending balance

Project

Within one year Within one to five years More than five years Total

Financial liabilities:

Short-term borrowings 977,210.08 977,210.08 Trading financial liabilities 7,270.91 7,270.91 Notes payable 129,837.00 129,837.00 Accounts payable 713,323.43 713,323.43 Other payables 496,593.96 496,593.96 Non-current liabilities due within one year 12,640.89 12,640.89 Other current liabilities (excluding deferred revenue

45,158.30 45,158.30 profit)

Long-term borrowings 31,988.15 31,988.15 Lease liabilities 8,510.49 8,510.49 Long-term payables 492.77 492.77 Total financial liabilities and contingent liabilities 2,382,034.57 40,991.41 2,423,025.98

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

At the end of the previous year, the financial liabilities and off-balance sheet guarantee items held by the Company were analyzed based on the maturity period of the undiscounted remaining contractual cash flows as follows (unit: 10,000 yuan):

Ending balance

Project

Within one year Within one to five years More than five years Total

Financial liabilities:

Short-term borrowings 1,002,349.15 1,002,349.15 Trading financial liabilities 7,270.91 7,270.91 Notes payable 175,960.42 175,960.42 Accounts payable 734,329.51 734,329.51 Other payables 509,583.04 509,583.04 Non-current liabilities due within one year 22,110.24 22,110.24 Other current liabilities (excluding deferred income) 45,798.66 45,798.66 Long-term borrowings 22,979.68 22,979.68 Lease liabilities 9,988.68 9,988.68 Long-term payables 351.44 351.44 Total financial liabilities and contingent liabilities 2,497,401.93 33,319.80 2,530,721.73

The amounts of financial liabilities disclosed in the table above represent undiscounted contractual cash flows and therefore may differ from the carrying amounts in the balance sheet.

market risk

Market risk of financial instruments refers to the risk that the fair value or future cash flow of financial instruments fluctuates due to changes in market prices, including interest rate risk, exchange rate risk, etc.

rate risk and other price risks.

interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Interest rate risk can arise from recognized interest accruals

Financial instruments and unconfirmed financial instruments (such as certain loan commitments).

The Company's interest rate risk mainly arises from long-term interest-bearing debt such as long-term bank borrowings and bonds payable. Financial liabilities with floating interest rates expose the company to cash flow

Interest rate risk, fixed interest rate financial liabilities expose the company to fair value interest rate risk. The company determines fixed interest rates and floating interest rates based on the prevailing market environment.

relative proportions of contracts and maintain an appropriate mix of fixed and floating rate instruments through regular review and monitoring.

The Company pays close attention to the impact of interest rate changes on the Company's interest rate risk. The Company currently does not adopt an interest rate hedging policy. However, management is responsible for monitoring interest rate risk,

We will consider hedging significant interest rate risks when necessary.

The interest-bearing financial instruments held by the Company are as follows (unit: 10,000 yuan):

Item Amount for the current period Amount for the previous period Financial assets

Including: monetary funds

306,394.82 345,539.45 Financial liabilities

Including: short-term borrowings 977,210.08 1,002,349.15 Non-current liabilities due within one year 12,640.89 22,110.24 Long-term borrowings 31,988.15 22,979.68 Long-term payables 492.77 351.44

Total 1,328,726.71 1,393,329.96

The full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. is on June 30, 2025. If the borrowing rate calculated on a floating rate basis increases or decreases by 50 basis points, and other factors remain unchanged, the company's net profit and shareholders' equity will decrease or increase by approximately 26.8476 million yuan (December 31, 2024: 26.3344 million yuan).

For financial instruments held on the balance sheet date that expose the Company to fair value interest rate risk, the impact on net profit and shareholders' equity in the above sensitivity analysis is the impact after assuming that interest rates change on the balance sheet date and the above financial instruments are remeasured according to the new interest rate. For floating rate non-derivatives held on the balance sheet date that expose the Company to cash flow interest rate risk, the impact on net profit and shareholders' equity in the above sensitivity analysis is the impact of the above interest rate changes on annual estimated interest expenses or income. The previous year's analysis was based on the same assumptions and methodology.

Exchange rate risk

Exchange rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. Exchange rate risk can arise from financial instruments denominated in foreign currencies other than the functional currency of accounting.

The company's main operations are located in China, and its main business is settled in RMB. Therefore, the market risk of foreign exchange changes borne by the Company is not significant.

(2) Capital management

The goal of the company's capital management policy is to ensure that the company can continue to operate, thereby providing returns to shareholders and benefiting other stakeholders, while maintaining an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the Company may adjust financing methods, adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares and other equity instruments, or sell assets to reduce debt.

The Company monitors capital structure based on the asset-liability ratio (i.e., total liabilities divided by total assets). As of June 30, 2025, the company's asset-liability ratio was 89.70% (December 31, 2024: 90.13%).

2. Hedging

(1) The company carries out hedging business for risk management

□ApplicableNot applicable

(2) The company carries out qualified hedging business and applies hedging accounting

Not applicable.

(3) The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting

□ApplicableNot applicable

3. Financial assets

(1) Classification of transfer methods

□ApplicableNot applicable

(2) Financial assets derecognized due to transfer

□ApplicableNot applicable

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd. (3) Continued asset transfer financial assets

□ApplicableNot applicable

13. Disclosure of fair value

1. Closing fair value of assets and liabilities measured at fair value

Unit: Yuan Ending Fair Value

Item Level 1 fair value measurement Second level fair value measurement Third level fair value measurement

total amount amount amount

1. Sustained fair value

---

Measurement

(1) Trading finance

122,630,346.17 122,630,346.17 produced

(2) Accounts receivable financing 59,132,839.22 59,132,839.22

(3) Other equity instruments

140,337,205.00 140,337,205.00 Investment

Measured at fair value on an ongoing basis

Total assets of 322,100,390.39 322,100,390.39

(6) Transactional financial liabilities

72,709,111.74 72,709,111.74 debt

Others 72,709,111.74 72,709,111.74 Continue to be measured at fair value

Total liabilities of 72,709,111.74 72,709,111.74

2. Non-sustainable fair price

---

value measurement

2. Basis for determining the market price of continuous and non-continuous first-level fair value measurement items

Not applicable.

3. Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters

Not applicable.

4. Continuous and non-continuous third-level fair value measurement projects, valuation techniques used and qualitative and quantitative information on important parameters

Not applicable.

5. For ongoing third-level fair value measurement items, the reconciliation information between the opening and closing book values ​​and the sensitivity analysis of unobservable parameters are not applicable.

6. For ongoing fair value measurement items that are converted between levels during the current period, the reasons for the conversion and the policy for determining the time of conversion do not apply.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

7. Valuation technology changes that occurred during the current period and reasons for the changes

Not applicable.

8. Fair value of financial assets and financial liabilities not measured at fair value

Not applicable.

9. Others

Not applicable.

14. Related parties and related transactions

1. Information about the parent company of this enterprise

Parent company to this enterprise Parent company to this enterprise Parent company name Place of registration Nature of business Registered capital

Proportion of shareholding Proportion of voting rights Production and sales recovery

Instruments, medical devices

machinery, welding equipment,

Shenzhen Neptune Group shares

Shenzhen Electronic Products (involving national 12,051.62 46.23% 46.23% Co., Ltd.

Except for special provisions of the family

(External), health products and essence

Fine chemical products

Description of the parent company of this enterprise

Shenzhen Neptune Group Co., Ltd. (hereinafter referred to as "Neptune Group") held 1,216,445,128.00 shares of the company at the end of the period (all tradable shares without selling restrictions), holding 46.23% of the shares, and was the largest shareholder of the company. Shenzhen Neptune Holding Group Co., Ltd. holds 59.68% of Neptune Group's equity and is the largest shareholder of Neptune Group; (Hong Kong) Hengjian Enterprise Co., Ltd. holds 20.32% of Neptune Group's equity and is the second largest shareholder of Neptune Group; Shenzhen Haihe Investment Development Co., Ltd. holds 20.00% of Neptune Group's equity and is the third largest shareholder of Neptune Group. Mr. Zhang Simin holds 70% of the equity of Shenzhen Neptune Holding Group Co., Ltd., 15% of the equity of (Hong Kong) Hengjian Enterprise Co., Ltd., and 100% of the equity of Shenzhen Haihe Investment Development Co., Ltd. Mr. Zhang Simin actually controls Neptune Group through Neptune Holdings, Haihe Investment, and Hong Kong Hengjian, and indirectly controls the company through Neptune Group, and is the actual controller of the company.

During the reporting period, the parent company’s registered capital (paid-in capital) changed as follows:

Balance at the beginning of the period Increase during the period Decrease during the period Ending balance 12,051.62 -- -- 12,051.62 The ultimate controller of the enterprise is Mr. Zhang Simin.

2. Information about the company’s subsidiaries

For details of the company's subsidiaries, please refer to "1. Equity in subsidiaries" in Section 10 of the Notes.

3. Information on joint ventures and associated enterprises of the enterprise

For details of the company's important joint ventures or associates, please refer to "3. Equity in joint ventures and associates" in Section 10 of the Notes.

The situation of other joint ventures or associates that have related party transactions with the company in the current period, or related party transactions with the company in previous periods that resulted in balances is as follows:

Name of joint venture or associated enterprise Relationship with this enterprise

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Shandong Kangli Medical Device Technology Co., Ltd. Associate Enterprise

Binzhou Guorong Medical Investment Management Co., Ltd. Associate Company

Zhongke Galaxy Medical Technology Co., Ltd. Associate Company

Shenzhen Taiheng Medical Investment Co., Ltd. Associate

Qingdao Kanghai Pharmaceutical Co., Ltd. Associates

Qingdao Kanghui Pharmacy Co., Ltd. Associate Company

4. Other related parties

Names of other related parties Relationship between other related parties and the company Shenzhen Neptune Pharmaceutical Co., Ltd. Same controller

Shandong Neptune Youpin Health Technology Co., Ltd. Same controller

Shenzhen Neptune Jinzun Technology Development Co., Ltd. Same controller

Shenzhen Haiwang Yidianyao Pharmaceutical Co., Ltd. and its subsidiaries are the same controller

Shenzhen Quanyaowang Pharmaceutical Co., Ltd. Key management personnel of the parent company serve as a subsidiary of the company Jilin Neptune Health Technology Development Co., Ltd. Key management personnel serve as a company Jiangsu Neptune Health Biotechnology Co., Ltd. Common controller

Shenzhen Quanyao.com Technology Co., Ltd. The company where key management personnel of the parent company serve Shenzhen Neptune Property Management Co., Ltd. The same controller

Zaozhuang Neptune Health Industry Co., Ltd. Same controller

Shenzhen Neptune Youpin Health Technology Co., Ltd. Same controller

Shenzhen Neptune Health Industrial Co., Ltd. Same controller

Shenzhen Hongyang Property Management Co., Ltd. Same controller

Huzhou Haiwang Benyuan Food and Beverage Co., Ltd. Same controller

Shenzhen Haiyi Investment Co., Ltd. Same controller

Jiangsu Liangdian Technology Co., Ltd. Joint stock company

Shenzhen Neptune Food Co., Ltd. Joint stock company

Nanjing Keyunxi Trading Co., Ltd. Joint stock company

Jiangsu Deweilan Medical Equipment Co., Ltd. Joint stock company

Ningbo Xianzhi Nutritional Products Co., Ltd. Subsidiary of a joint-stock company

Henan Guolian Medical Technology Co., Ltd. Henan Xuzheng Enterprise Management Consulting Center (General Partnership), a company controlled by the directors of the subsidiary company Henan Shipu Enterprise Management Consulting Center (general partnership) controlled by the directors of the subsidiary company Shareholders of the subsidiary company

Shenzhen Ronghui Medical Development Co., Ltd. Subsidiary shareholder

Shandong Lijian Pharmacy Chain Co., Ltd. and its subsidiaries Shenzhen Chengjing Investment Development Co., Ltd., the holding company of key management personnel of subsidiaries Weifang Haiwang Traditional Chinese Medicine Pieces Co., Ltd., the holding company of key management personnel of subsidiaries Others

Nanning Neptune Health Biotechnology Co., Ltd. The company where key management personnel work Jilin Neptune Health Biotechnology Co., Ltd. The company where key management personnel work Huzhou Neptune Health Industry Development Co., Ltd. The company where key management personnel work Shenzhen Shenshang Liquor Holdings Group Co., Ltd. The company where key management personnel work Shenzhen Mingpai Industrial Co., Ltd. Parent company Key management personnel Directors, managers, financial directors and board secretaries of the holding company Key management personnel

5. Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

Unit: Yuan

Whether the transaction amount is exceeded Related party Content of related transactions Amount incurred in the current period Approved transaction limit Amount incurred in the previous period

Shenzhen Neptune Golden Zun Purchase of goods 53,125,446.45 No 10,054,531.91

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Technology Development Co., Ltd.

Division

Shenzhen Neptune Pharmaceutical Co., Ltd.

Purchase of goods 28,483,237.05 No 52,123,244.39 Co., Ltd.

Weifang Haiwang Chinese Medicine Drink

Purchase of goods 16,476,717.95 No

film co., ltd.

Hunan Neptune Xingchen Hospital

Purchase of goods 878,304.43 No 8,140,527.77 Pharmaceutical Co., Ltd.

Shandong Neptune Youpinjian

Purchase of goods 604,327.16 No 8,140,527.77 Kang Technology Co., Ltd.

Huzhou Neptune Original Food

Purchase of goods 383,684.95 No 328,244.93 Pin Beverage Co., Ltd.

Shandong Kangli Medical Equipment

Purchase of goods 378,984.05 No 328,244.93 Machinery Technology Co., Ltd.

Nanning Neptune Health Student

Purchase of goods 296,470.79 No 18,257,662.40 Wu Technology Co., Ltd.

Shenzhen Neptune Easy Point

Purchase of goods 194,283.31 No 191,150.44 Yao Pharmaceutical Co., Ltd.

Shenzhen Shenshang Liquor Industry

Holding Group Co., Ltd. Purchase of goods 101,946.94 No 191,150.44 Company

Huzhou Neptune Health Products

Expenses/purchased goods 74,495.11 No 577,407.92 Industrial Development Co., Ltd.

Shenzhen Neptune Property

Fee 50,400.00 No

Management Co., Ltd.

Jilin Neptune Health Care

Expenses 15,840.00 No 10,551,716.80 Wu Technology Co., Ltd.

Jilin Haiwang Health Department

Purchase of goods 5,734.52 No 746,857.53 Technology Development Co., Ltd.

Shenzhen Quanyao Online Drug

Purchase goods No 18,559.44 Industry Co., Ltd.

Shenzhen Whole Medicine Network Section

Purchase goods No 1,858.41 Technology Co., Ltd.

Jiangsu Liangdian Technology Co., Ltd.

Purchase goods No -61,858.41 Co., Ltd.

List of goods sold/services provided

Unit: Yuan

Related parties Related party transaction content Amount incurred in the current period Amount incurred in the previous period

Shandong Lijian Pharmacy Chain Co., Ltd.

Sales of goods 44,720,003.24 25,423,216.22 and its subsidiaries

Shenzhen Haiwang Yidianyao Pharmaceutical Co., Ltd.

Sales of goods 39,857,357.15 6,939,921.59 Company

Shenzhen Neptune Pharmaceutical Co., Ltd. Sales of goods 23,215,436.37 5,895,042.03 Shandong Neptune Xingchen Pharmaceutical Co., Ltd. Sales of goods 14,765,464.39 13,760,994.91 Jiangsu Neptune Xingchen Pharmaceutical Co., Ltd. Sales of goods 12,875,551.85 1,761,913.52 Binzhou Guorong Medical Investment Management Co., Ltd.

Sales of goods 5,640,413.42

company

Shandong Weifang Neptune Star Minkang Chain Store

Sales of goods 4,087,952.54 9,471,506.21 Pharmacy Co., Ltd.

Shanghai Neptune Xingchen Pharmacy Co., Ltd. Sales of goods 3,969,378.44

Qingdao Neptune Star Health Pharmacy

Sales of goods 3,595,423.58 416,720.19 Lock Co., Ltd.

Zhejiang Neptune Xingchen Pharmaceutical Co., Ltd. Sales of goods 3,566,044.89

Liaoning Province Neptune Xingchen Pharmaceutical Trading Co., Ltd.

Sales of goods 3,068,583.83 720,186.20 Co., Ltd.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ningbo Neptune Xingchen Health Pharmacy Co., Ltd.

Sales of goods 2,581,246.03

company

Fuzhou Neptune Star Health Pharmacy Chain

Sales of goods 833,174.47

Ltd.

Shandong Kangli Medical Device Technology Co., Ltd.

Sales of goods 295,575.22

company

Shandong Neptune Premium Health Technology Co., Ltd.

Sales of goods 261,313.27

company

Wuhan Neptune Xingchen Pharmaceutical Chain Co., Ltd.

Sales of goods 245,097.43 136,017.70 Company

Qingdao Kanghui Pharmacy Co., Ltd. Sales of goods 179,480.92

Guangzhou Neptune Xingchen Pharmaceutical Chain Co., Ltd.

Sales of goods 41,955.38 125,116.46 Co., Ltd.

Ningbo Xianzhi Nutritional Products Co., Ltd. Sales of goods 11,044.25

Jilin Neptune Health Technology Development Co., Ltd.

Sales of goods -1,670,583.37 2,489,162.76Company

Zaozhuang Neptune Health Industry Co., Ltd. Sales of goods 8,304,140.45 Shenzhen Neptune Health Industry Co., Ltd.

Sales of goods 403,827.94 divisions

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

Not applicable.

(3) Related leasing situation

As a lessor, our company:

Unit: Yuan

Name of the lessee Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period Shandong Kangli Medical Device Technology Co., Ltd.

Shandong Handi Office Building 295,575.22 286,725.66 Company

As a lessee, our company:

Unit: Yuan

Simplified short-term treatment not included in lease liabilities

Variable leases measured by leases and low-value assets Lease liabilities assumed Increased right-of-use assets

rent paid

Lessor Rental payment for the lease of the leased asset (if applicable) Interest expense Name of the asset Type of the asset (if applicable)

Posted in this issue Posted in the previous issue Posted in this issue Posted in the previous issue Posted in this issue Posted in the previous issue Posted in this issue Posted in the previous issue Posted in this issue Posted in the previous issue

Student quota Student quota Student quota Student quota Student quota Student quota Student quota Student quota Shenzhen City

Neptune Engineering

Neptune Medicine 193,092 148,139 15,772. 15,004. 839,649

Yeyuancang 0.00

Industry Limited .18 .22 59 07 .94

Library

company

Neptune Silver

Haiwang Jihe Technology 10,696, 3,939,6 185,573 417,687 12,397, 14,425, Tuan Building Office 626.32 12.93 .60 .43 518.75 595.65

public building

(4) Related guarantees

The company acts as a guarantor

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Unit: Yuan

Whether the guarantee has been fulfilled by the guaranteed party, the guarantee amount, the guarantee starting date, the guarantee expiry date

Bi Jilin Neptune Galaxy Pharmaceutical Investment

587,640,000.00 September 18, 2024 September 17, 2025 Non-owned limited company

Jilin Neptune Galaxy Pharmaceutical Investment

470,000,000.00 January 9, 2025 January 8, 2026 Non-owned limited company

Changchun Kunlan Agricultural Science and Technology

452,910,000.00 September 18, 2024 September 17, 2025 No limited company

Shenzhen Shenye Pharmaceutical Development

10,000,000.00 March 24, 2025 March 24, 2026 No limited company

Shenzhen Shenye Pharmaceutical Development

416,666.66 September 1, 2022 September 1, 2025 No limited company

Zhejiang Neptune Data Service Co., Ltd.

10,000,000.00 March 07, 2025 March 06, 2026 No Limited Company

Zhejiang Neptune Data Service Co., Ltd.

10,000,000.00 April 29, 2025 April 26, 2026 No Limited Company

Shandong Neptune Pharmaceutical Group has

32,000,000.00 February 17, 2025 July 6, 2025 No Limited Company

Shandong Neptune Pharmaceutical Group has

36,750,000.00 February 24, 2025 February 17, 2028 No Limited Company

Binzhou Neptune Huanghe Pharmaceutical Co., Ltd.

10,000,000.00 March 18, 2025 March 18, 2026 No Limited Company

Sulu Neptune Pharmaceutical Group has

10,000,000.00 October 10, 2024 October 9, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

10,000,000.00 November 12, 2024 July 11, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

10,000,000.00 November 12, 2024 July 11, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

10,000,000.00 September 26, 2024 September 24, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

10,000,000.00 September 27, 2024 September 25, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

18,000,000.00 April 21, 2025 October 21, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

10,000,000.00 January 23, 2025 July 23, 2025 No Limited company

Sulu Neptune Pharmaceutical Group has

25,000,000.00 February 13, 2025 August 13, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

25,000,000.00 January 16, 2025 July 16, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

20,000,000.00 January 13, 2025 July 13, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

200,000,000.00 September 2, 2024 September 1, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

100,000,000.00 September 4, 2024 September 3, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

60,000,000.00 August 7, 2024 August 4, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

8,300,758.47 December 13, 2024 September 13, 2025 No Limited Company

Sulu Neptune Pharmaceutical Group has

99,518,555.82 April 18, 2025 April 20, 2026 No Limited Company

Sulu Neptune Pharmaceutical Group has

110,647,631.10 January 8, 2025 January 8, 2026 No Limited Company

Jining Neptune Watson Pharmaceuticals 50,000,000.00 October 23, 2024 October 22, 2025 No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ltd.

Jining Neptune Watson Pharmaceutical Co., Ltd.

8,000,000.00 November 22, 2024 November 21, 2025 No Limited company

Sulu Haiwang Medical Equipment Co., Ltd.

16,000,000.00 April 27, 2023 April 25, 2026 No Limited Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

15,000,000.00 August 8, 2024 August 7, 2025 No Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

4,760,000.00 March 28, 2025 February 12, 2026 No Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

863,114.50 April 15, 2025 October 14, 2025 No Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

2,675,239.00 April 18, 2025 October 17, 2025 No Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

447,300.00 April 27, 2025 October 26, 2025 No Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

500,000.00 May 12, 2025 November 11, 2025 No Company

Jiangsu Neptune Pharmaceutical Co., Ltd.

500,000.00 May 27, 2025 November 26, 2025 No Company

Henan Neptune Pharmaceutical Group has

25,000,000.00 January 15, 2025 January 15, 2026 No Limited Company

Henan Neptune Pharmaceutical Group has

20,000,000.00 June 11, 2025 June 11, 2026 No Limited Company

Henan Neptune Pharmaceutical Group has

25,000,000.00 February 20, 2025 February 19, 2026 No Limited Company

Henan Neptune Pharmaceutical Group has

9,000,000.00 January 22, 2025 January 21, 2026 No Limited Company

Henan Neptune Pharmaceutical Group has

13,000,000.00 March 26, 2025 September 19, 2025 No Limited Company

Henan Neptune Pharmaceutical Group has

15,000,000.00 March 28, 2025 September 23, 2025 No Limited Company

Henan Dongsen Pharmaceutical Co., Ltd.

50,000,000.00 January 15, 2025 January 15, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

50,000,000.00 December 25, 2024 December 25, 2025 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

47,000,000.00 January 17, 2025 January 17, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

33,000,000.00 December 30, 2024 December 30, 2025 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

50,000,000.00 April 14, 2025 April 14, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

15,000,000.00 January 10, 2025 January 9, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

750,000.00 April 23, 2025 January 21, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

14,250,000.00 January 22, 2025 January 21, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

25,000,000.00 January 20, 2025 January 19, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

30,000,000.00 March 6, 2025 September 5, 2025 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

30,000,000.00 June 23, 2025 June 23, 2026 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

19,500,000.00 January 17, 2025 January 9, 2028 No Company

Henan Dongsen Pharmaceutical Co., Ltd.

50,000,000.00 June 30, 2025 June 30, 2026 No Company

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Henan Dongsen Pharmaceutical Co., Ltd.

9,919,300.00 January 17, 2025 January 17, 2026 No Company

Henan Neptune Galaxy Pharmaceutical Co., Ltd.

20,000,000.00 March 14, 2025 March 14, 2026 No Limited Company

Henan Neptune Galaxy Pharmaceutical Co., Ltd.

5,000,000.00 March 27, 2025 September 26, 2025 No Limited Company

Henan Zuojinming Pharmaceutical Co., Ltd.

5,000,000.00 June 25, 2025 December 25, 2025 No company

Henan Zuojinming Pharmaceutical Co., Ltd.

5,000,000.00 January 23, 2025 July 23, 2025 No company

Henan Zuojinming Pharmaceutical Co., Ltd.

15,000,000.00 January 21, 2025 January 21, 2026 No company

Henan Zuojinming Pharmaceutical Co., Ltd.

25,000,000.00 January 23, 2025 January 23, 2026 No company

Henan Zuojinming Pharmaceutical Co., Ltd.

20,000,000.00 November 26, 2024 November 25, 2025 No company

Henan Enji Pharmaceutical Co., Ltd.

19,900,000.00 February 26, 2025 February 26, 2026 No Company

Henan Enji Pharmaceutical Co., Ltd.

5,000,000.00 September 30, 2024 September 29, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

5,000,000.00 September 30, 2024 September 29, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

2,800,000.00 November 28, 2024 August 4, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

800,000.00 May 15, 2025 February 9, 2026 No Company

Henan Enji Pharmaceutical Co., Ltd.

400,000.00 May 15, 2025 March 9, 2026 No Company

Henan Enji Pharmaceutical Co., Ltd.

800,000.00 May 15, 2025 April 10, 2026 No Company

Henan Enji Pharmaceutical Co., Ltd.

400,000.00 January 16, 2025 September 6, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

900,000.00 February 19, 2025 October 10, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

1,100,000.00 February 19, 2025 November 20, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

800,000.00 February 19, 2025 December 6, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

10,000,000.00 December 31, 2024 December 31, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

5,000,000.00 July 12, 2024 July 11, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

40,000,000.00 December 23, 2024 December 23, 2025 No Company

Henan Enji Pharmaceutical Co., Ltd.

20,000,000.00 December 25, 2024 December 25, 2025 No Company

Anyang Hengfeng Pharmaceutical Co., Ltd.

10,000,000.00 November 6, 2024 November 6, 2025 No Company

Henan Neptune Huitong Pharmaceutical Co., Ltd.

10,000,000.00 January 9, 2025 July 9, 2025 No Limited Company

Henan Neptune Huitong Pharmaceutical Co., Ltd.

10,000,000.00 January 20, 2025 July 20, 2025 No Limited company

Henan Neptune Huitong Pharmaceutical Co., Ltd.

10,000,000.00 February 6, 2025 August 6, 2025 No Limited Company

Henan Neptune Huitong Pharmaceutical Co., Ltd.

7,000,000.00 June 10, 2025 June 9, 2026 No Limited Company

Henan Neptune Huitong Pharmaceutical 8,000,000.00 June 5, 2025 June 4, 2026 No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ltd.

Henan Neptune Huitong Pharmaceutical Co., Ltd.

3,400,000.00 May 28, 2025 May 27, 2026 No Limited Company

Henan Neptune Huitong Pharmaceutical Co., Ltd.

6,600,000.00 May 29, 2025 May 28, 2026 No Limited company

Henan Haiwang Medical Equipment Co., Ltd.

12,500,000.00 February 11, 2025 February 11, 2026 No Limited Company

Ningxia Neptune Pharmaceutical Co., Ltd.

14,000,000.00 January 9, 2025 January 2, 2026 No Company

Ningxia Neptune Pharmaceutical Co., Ltd.

20,000,000.00 March 20, 2025 March 14, 2026 No Company

Ningxia Neptune Pharmaceutical Co., Ltd.

8,000,000.00 November 26, 2024 October 24, 2025 No Company

Ningxia Neptune Pharmaceutical Co., Ltd.

8,000,000.00 July 26, 2024 July 22, 2025 No Company

Ningxia Neptune Pharmaceutical Co., Ltd.

5,500,000.00 December 6, 2024 November 27, 2025 No Company

Ningxia Neptune Pharmaceutical Co., Ltd.

10,000,000.00 January 26, 2025 January 24, 2026 No Company

Xinjiang Haiwang Hongkang Pharmaceutical Co., Ltd.

18,000,000.00 August 9, 2024 August 9, 2025 Fu Technology Co., Ltd.

Xinjiang Haiwang Hongkang Pharmaceutical Co., Ltd.

30,000,000.00 April 22, 2025 April 22, 2026 Fu Technology Co., Ltd.

Kashgar Neptune Galaxy Medicine has

20,000,000.00 July 10, 2024 July 9, 2025 No Limited company

Kashgar Neptune Galaxy Medicine has

30,000,000.00 September 29, 2024 September 28, 2025 No Limited company

Kashgar Neptune Galaxy Medicine has

30,000,000.00 November 5, 2024 November 3, 2025 No Limited company

Kashgar Neptune Galaxy Medicine has

1,000,000.00 July 25, 2024 July 24, 2025 No Limited company

Kashgar Neptune Galaxy Medicine has

10,000,000.00 August 14, 2024 August 13, 2025 No Limited company

Kashgar Neptune Galaxy Medicine has

10,000,000.00 September 13, 2024 September 12, 2025 No Limited company

Henan Guanbao Yuntong Pharmaceutical Co., Ltd.

15,000,000.00 February 26, 2025 February 25, 2026 No Limited Company

Henan Neptune Kangrui Pharmaceutical Co., Ltd.

8,000,000.00 December 27, 2024 February 27, 2026 No Limited Company

Hubei Neptune Pharmaceutical Group has

17,000,000.00 September 25, 2024 September 24, 2025 No Limited company

Hubei Neptune Pharmaceutical Group has

20,000,000.00 October 20, 2024 October 20, 2025 No Limited company

Hubei Haiwang Pengtai Pharmaceutical Co., Ltd.

8,000,000.00 June 27, 2024 June 27, 2027 No Limited company

Hubei Haiwang Pengtai Pharmaceutical Co., Ltd.

8,820,000.00 February 29, 2024 February 25, 2027 No Limited company

Neptune (Wuhan) Pharmaceutical Co., Ltd.

7,000,000.00 June 23, 2025 May 23, 2026 No Limited Company

Neptune (Wuhan) Pharmaceutical Co., Ltd.

10,000,000.00 August 12, 2024 August 12, 2025 No Limited company

Hubei Neptune Kai'anchen Pharmaceutical

15,000,000.00 April 3, 2025 April 3, 2028 No limited company

Hubei Neptune Kai'anchen Pharmaceutical

7,000,000.00 April 16, 2025 October 16, 2025 No limited company

Hubei Neptune Kai'anchen Pharmaceutical

8,000,000.00 June 30, 2025 May 31, 2026 No limited company

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Hubei Neptune Kai'anchen Pharmaceutical

1,000,000.00 April 15, 2025 April 14, 2026 No limited company

Hubei Neptune Kai'anchen Pharmaceutical

7,000,000.00 September 27, 2024 September 26, 2025 No limited company

Neptune (Wuhan) Pharmaceutical Development

19,052,620.51 September 29, 2024 September 12, 2025 Fuzhan Co., Ltd.

Neptune (Wuhan) Pharmaceutical Development

2,310,300.00 November 13, 2024 September 12, 2025 Fuzhan Co., Ltd.

Neptune (Wuhan) Pharmaceutical Development

3,830,212.40 December 20, 2024 September 12, 2025 Fuzhan Co., Ltd.

Neptune (Wuhan) Pharmaceutical Development

3,289,780.00 January 10, 2025 September 12, 2025 Fuzhan Co., Ltd.

Neptune (Wuhan) Pharmaceutical Development

1,517,000.00 February 19, 2025 September 12, 2025 Fuzhan Co., Ltd.

Shaoyang Neptune Pharmaceutical Co., Ltd.

10,000,000.00 October 18, 2024 October 17, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

1,000,000.00 August 9, 2024 August 9, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

9,000,000.00 September 1, 2024 August 31, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

5,000,000.00 January 15, 2025 January 15, 2026 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

4,445,100.00 February 8, 2025 February 8, 2026 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

20,000,000.00 February 11, 2025 February 11, 2026 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

10,554,900.00 February 14, 2025 February 14, 2026 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

1,660,550.00 May 26, 2025 November 26, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

1,146,250.00 December 3, 2024 June 3, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

905,165.00 February 8, 2025 August 8, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

1,316,600.00 April 1, 2025 October 1, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

1,074,650.00 April 28, 2025 October 28, 2025 No Company

Shaoyang Neptune Pharmaceutical Co., Ltd.

1,554,800.00 March 13, 2025 September 13, 2025 No Company

Hunan Neptune Medical Technology Co., Ltd.

9,000,000.00 March 31, 2025 March 31, 2026 No Limited Company

Changde Haiwang Pharmaceutical Co., Ltd.

10,000,000.00 February 27, 2025 February 26, 2026 No Company

Bozhou Neptune Galaxy Pharmaceutical Co., Ltd.

25,000,000.00 January 17, 2025 January 16, 2026 No Limited Company

Anhui Haiguo An Medical Co., Ltd.

4,500,000.00 May 8, 2025 December 8, 2025 No Limited company

Anhui Haiguo An Medical Co., Ltd.

7,500,000.00 March 17, 2025 October 17, 2025 No Limited company

Anhui Haiguo An Medical Co., Ltd.

5,000,000.00 March 10, 2025 September 10, 2025 No Limited Company

Anhui Haiguo An Medical Co., Ltd.

7,000,000.00 March 4, 2025 March 4, 2026 No Limited Company

Anhui Haiguo An Medical Co., Ltd.

3,000,000.00 April 14, 2025 April 14, 2026 No Limited Company

Anhui Haiguo'an Medical Co., Ltd. 13,350,000.00 July 4, 2024 July 4, 2025 No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ltd.

Anhui Haiguo An Medical Co., Ltd.

13,000,000.00 July 11, 2024 July 11, 2025 No Limited company

Neptune Pharmaceutical Anqing Co., Ltd.

28,000,000.00 July 5, 2024 July 5, 2025 No Company

Neptune Pharmaceutical Anqing Co., Ltd.

4,500,000.00 April 30, 2025 April 29, 2026 No Company

Anhui Neptune Tiancheng Pharmaceutical Co., Ltd.

6,000,000.00 July 8, 2024 July 8, 2025 No Limited Company

Heilongjiang Province Neptune Pharmaceutical Co., Ltd.

4,190,000.00 December 9, 2024 December 08, 2025 No Limited Company

Heilongjiang Province Neptune Pharmaceutical Co., Ltd.

10,810,000.00 December 16, 2024 December 15, 2025 No Limited company

Heilongjiang Province Neptune Pharmaceutical Co., Ltd.

1,150,000.00 March 28, 2025 December 5, 2025 No Limited Company

Neptune Medical Devices (Part 1)

50,000,000.00 September 5, 2024 August 29, 2025 Fuhai) Co., Ltd.

Neptune Medical Devices (Part 1)

64,600,000.00 March 26, 2025 November 17, 2025 Fuhai) Co., Ltd.

Neptune Medical Devices (Part 1)

52,000,000.00 February 26, 2025 February 25, 2026 Fuhai) Co., Ltd.

Neptune Medical Devices (Part 1)

10,000,000.00 January 20, 2025 January 19, 2026 Fuhai) Co., Ltd.

Neptune Medical Devices (Part 1)

20,000,000.00 March 11, 2025 March 10, 2026 Fuhai) Co., Ltd.

Shanghai Fangcheng Medical Equipment Co., Ltd.

85,000,000.00 September 25, 2024 September 25, 2025 No Limited company

Shanghai Fangcheng Medical Equipment Co., Ltd.

24,000,000.00 May 26, 2025 August 25, 2025 No Limited company

Shanghai Fangcheng Medical Equipment Co., Ltd.

10,000,000.00 March 11, 2025 March 10, 2026 No Limited Company

Sichuan Neptune Medical Technology Co., Ltd.

7,700,000.00 February 27, 2025 August 27, 2025 No Limited Company

Sichuan Neptune Medical Technology Co., Ltd.

10,500,000.00 March 14, 2025 September 14, 2025 No Limited company

Sichuan Neptune Medical Technology Co., Ltd.

12,600,000.00 June 17, 2025 December 17, 2025 No Limited company

Sichuan Neptune Medical Technology Co., Ltd.

40,000,000.00 January 13, 2025 January 13, 2026 No Limited Company

Sichuan Neptune Medical Technology Co., Ltd.

5,500,000.00 March 25, 2025 March 25, 2026 No Limited company

Sichuan Neptune Medical Technology Co., Ltd.

5,000,000.00 December 19, 2024 December 18, 2025 No Limited company

Sichuan Neptune Medical Technology Co., Ltd.

1,505,000.00 January 21, 2025 July 21, 2025 No Limited company

Sichuan Neptune Medical Technology Co., Ltd.

3,495,000.00 March 13, 2025 September 13, 2025 No Limited Company

Sichuan Neptune Medical Technology Co., Ltd.

5,600,000.00 March 13, 2025 September 13, 2025 No Limited Company

Sichuan Neptune Medical Technology Co., Ltd.

15,400,000.00 April 9, 2025 October 9, 2025 No Limited company

Chengdu Ruixi Trading Co., Ltd.

5,000,000.00 December 11, 2024 December 10, 2025 No appointment as company

Chengdu Ruixi Trading Co., Ltd.

5,000,000.00 May 9, 2025 May 9, 2026 No appointment as company

Chengdu Ruixi Trading Co., Ltd.

5,000,000.00 February 19, 2025 February 19, 2026 No appointment as company

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Sichuan Fanyuan Trading Co., Ltd.

5,000,000.00 December 11, 2024 December 10, 2025 No Company

Sichuan Fanyuan Trading Co., Ltd.

1,000,000.00 April 16, 2025 April 16, 2026 No Company

Sichuan Fanyuan Trading Co., Ltd.

2,000,000.00 March 25, 2025 March 25, 2026 No Company

Sichuan Fanyuan Trading Co., Ltd.

1,000,000.00 March 1, 2025 March 1, 2026 No Company

Sichuan Fanyuan Trading Co., Ltd.

6,000,000.00 June 30, 2025 June 30, 2026 No Company

Neptune Medical Delivery Service

7,333,300.00 March 28, 2025 February 28, 2026 No (Guangdong) Co., Ltd.

Neptune Medical Delivery Service

6,000,000.00 May 12, 2025 May 12, 2026 No (Guangdong) Co., Ltd.

Neptune Medical Delivery Service

1,000,000.00 May 12, 2025 May 12, 2026 No (Guangdong) Co., Ltd.

Neptune Medical Delivery Service

2,000,000.00 July 10, 2024 July 10, 2025 No (Guangdong) Co., Ltd.

Neptune Medical Delivery Service

17,000,000.00 May 31, 2024 May 6, 2026 No (Hunan) Co., Ltd.

Jiangsu Neptune Medical Equipment Co., Ltd.

10,000,000.00 March 17, 2025 March 16, 2026 No Limited Company

Jiangsu Neptune Medical Equipment Co., Ltd.

10,000,000.00 September 12, 2024 September 10, 2025 No Limited company

Jiangsu Neptune Medical Equipment Co., Ltd.

5,000,000.00 September 18, 2024 September 13, 2025 No Limited company

Jiangsu Neptune Medical Equipment Co., Ltd.

5,000,000.00 January 14, 2025 January 12, 2026 No Limited Company

Neptune (Tianjin) Medical Technology

9,891,800.00 September 20, 2024 September 19, 2025 Fushu Co., Ltd.

Guangdong Neptune Pharmaceutical Group has

9,210,500.00 March 07, 2025 March 07, 2026 No Limited company

Guangdong Neptune Pharmaceutical Group has

5,600,000.00 March 24, 2025 March 24, 2026 No Limited company

Guangdong Neptune Pharmaceutical Group has

18,000,000.00 April 9, 2025 April 9, 2026 No Limited Company

Guangdong Neptune Pharmaceutical Group has

19,950,000.00 May 14, 2025 May 14, 2026 No Limited Company

Guangdong Neptune Pharmaceutical Group has

9,050,000.00 April 18, 2025 April 18, 2026 No Limited company

Guangdong Neptune Pharmaceutical Group has

16,000,000.00 April 27, 2025 April 27, 2026 No Limited Company

Guangdong Neptune Pharmaceutical Group has

5,000,000.00 April 30, 2025 April 30, 2026 No Limited company

Guangdong Neptune Pharmaceutical Group has

15,000,000.00 July 15, 2024 July 15, 2025 No Limited company

Guangdong Neptune Pharmaceutical Group has

20,000,000.00 July 23, 2024 July 23, 2025 No Limited company

Guangdong Neptune Pharmaceutical Group has

15,000,000.00 April 9, 2025 November 9, 2025 No Limited Company

Guangdong Neptune Pharmaceutical Group has

10,000,000.00 April 11, 2025 November 11, 2025 No Limited company

Guangdong Neptune Pharmaceutical Group has

20,000,000.00 December 24, 2024 December 23, 2025 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

803,300.00 November 8, 2024 November 7, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceuticals 3,500,800.00 October 12, 2024 October 11, 2025 No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ltd.

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

3,684,500.00 October 31, 2024 October 30, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,689,000.00 November 8, 2024 November 7, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

459,200.00 November 14, 2024 November 13, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,374,400.00 November 20, 2024 November 19, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,289,800.00 November 27, 2024 November 26, 2025 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,447,100.00 December 06, 2024 December 05, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,103,600.00 December 09, 2024 December 08, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,861,200.00 December 12, 2024 December 11, 2025 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

270,400.00 December 17, 2024 December 16, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

944,200.00 December 19, 2024 December 18, 2025 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

809,200.00 December 26, 2024 December 25, 2025 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,984,500.00 January 3, 2025 January 2, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,313,900.00 January 7, 2025 January 7, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,725,600.00 January 9, 2025 January 9, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,805,800.00 February 11, 2025 February 10, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,512,300.00 February 17, 2025 February 16, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

485,200.00 February 21, 2025 February 20, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,425,300.00 March 07, 2025 March 06, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,072,200.00 March 10, 2025 March 9, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

2,432,500.00 March 19, 2025 March 18, 2026 No Limited company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,536,400.00 March 26, 2025 March 25, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,895,400.00 April 3, 2025 April 2, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

894,900.00 April 9, 2025 April 8, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

1,653,400.00 April 14, 2025 April 13, 2026 No Limited Company

Neptune (Zhanjiang) Pharmaceutical Co., Ltd.

529,200.00 April 27, 2025 April 26, 2026 No Limited company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

2,490,000.00 January 2, 2024 January 1, 2026 No Limited Company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

2,700,000.00 February 29, 2024 February 28, 2026 No Limited Company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

2,000,000.00 March 27, 2024 March 26, 2026 No Limited Company

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

3,000,000.00 April 3, 2024 April 2, 2026 No Limited Company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

4,800,000.00 April 26, 2024 April 25, 2026 No Limited Company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

2,010,000.00 June 19, 2024 June 18, 2026 No Limited Company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

4,900,000.00 November 8, 2024 November 7, 2026 No Limited company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

1,000,000.00 November 18, 2024 November 17, 2026 No Limited company

Neptune (Shaoguan) Pharmaceutical Co., Ltd.

4,900,000.00 June 26, 2025 June 25, 2027 No Limited company

Neptune (Qingyuan) Pharmaceutical Co., Ltd.

6,000,000.00 March 18, 2025 March 17, 2026 No Limited Company

Neptune (Qingyuan) Pharmaceutical Co., Ltd.

6,000,000.00 March 19, 2025 March 18, 2026 No Limited Company

Neptune (Qingyuan) Pharmaceutical Co., Ltd.

7,000,000.00 March 21, 2025 March 20, 2026 No Limited company

Neptune (Qingyuan) Pharmaceutical Co., Ltd.

8,000,000.00 March 24, 2025 March 23, 2026 No Limited Company

Neptune (Qingyuan) Pharmaceutical Co., Ltd.

8,000,000.00 March 28, 2025 March 27, 2026 No Limited Company

Guangxi Guilin Neptune Pharmaceutical Co., Ltd.

7,000,000.00 November 20, 2024 November 19, 2025 No Limited company

Guangxi Guilin Neptune Pharmaceutical Co., Ltd.

3,000,000.00 November 25, 2024 November 24, 2025 No Limited company

Guangxi Guilin Neptune Pharmaceutical Co., Ltd.

10,000,000.00 November 19, 2024 November 18, 2025 No Limited Company

Guangxi Guilin Neptune Pharmaceutical Co., Ltd.

7,000,000.00 May 13, 2025 April 27, 2026 No Limited Company

Guangxi Guilin Neptune Pharmaceutical Co., Ltd.

6,940,000.00 March 26, 2025 July 23, 2025 No Limited Company

Guangxi Neptune Galaxy Pharmaceutical Co., Ltd.

6,500,000.00 December 13, 2024 December 12, 2025 No Limited Company

Guangxi Neptune Galaxy Pharmaceutical Co., Ltd.

9,300,000.00 March 27, 2025 August 4, 2025 No Limited Company

The company as the guaranteed party

Unit: Yuan

Whether the guarantee has been fulfilled by the guarantor, the guarantee amount, the guarantee starting date, the guarantee expiry date

Bi Haiwang Group 300,000,000.00 May 23, 2025 May 22, 2026 No Haiwang Group 150,000,000.00 June 27, 2025 June 27, 2026 No Haiwang Group 112,000,000.00 March 21, 2025 March 21, 2026 No Neptune Group 138,000,000.00 March 24, 2025 March 24, 2026 No Neptune Group 2,000,000.00 February 19, 2025 August 21, 2025 No Neptune Group 2,000,000.00 February 19, 2025 November 21, 2025 No Neptune Group 79,000,000.00 February 19, 2025 February 17, 2026 No Neptune Group 50,000,000.00 August 8, 2024 August 7, 2025 No Neptune Group 70,000,000.00 August 15, 2024 August 12, 2025 No Neptune Group 50,000,000.00 August 27, 2024 July 14, 2025 No Neptune Group 90,000,000.00 November 07, 2024 November 6, 2025 No Neptune Group 67,000,000.00 November 13, 2024 November 12, 2025 No Neptune Group 11,800,000.00 August 28, 2024 August 25, 2025 No Neptune Group 24,000,000.00 August 28, 2024 August 25, 2025 No Neptune Group 45,000,000.00 October 9, 2024 October 7, 2025 No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Neptune Group 10,000,000.00 October 22, 2024 October 20, 2025 No Neptune Group 19,200,000.00 November 05, 2024 November 3, 2025 No Neptune Group 20,000,000.00 June 3, 2025 December 2, 2025 No Neptune Group 20,000,000.00 January 14, 2025 January 12, 2026 No Neptune Group 35,000,000.00 February 06, 2025 August 5, 2025 No Neptune Group 40,000,000.00 February 7, 2025 August 1, 2025 No Neptune Group 30,000,000.00 February 25, 2025 August 18, 2025 No Neptune Group 10,000,000.00 February 26, 2025 August 18, 2025 No Neptune Group 32,000,000.00 February 28, 2025 August 21, 2025 No Neptune Group 50,000,000.00 March 20, 2025 March 19, 2026 No Neptune Group 31,000,000.00 March 28, 2025 September 27, 2025 No Neptune Group 15,000,000.00 March 28, 2025 September 27, 2025 No Neptune Group 10,000,000.00 April 24, 2025 October 22, 2025 No Neptune Group 37,000,000.00 April 29, 2025 October 25, 2025 No Neptune Group 40,000,000.00 March 07, 2025 September 1, 2025 No Neptune Group 10,000,000.00 June 17, 2025 December 16, 2025 No Neptune Group 50,000,000.00 May 30, 2025 November 18, 2025 No Neptune Group 60,000,000.00 January 15, 2025 July 12, 2025 No Neptune Group 45,700,000.00 October 18, 2024 October 16, 2025 No Neptune Group 9,500,000.00 June 17, 2025 December 17, 2025 No Neptune Group 38,320,000.00 February 24, 2025 August 24, 2025 No Neptune Group 50,000,000.00 March 17, 2025 March 15, 2026 No Neptune Group 41,500,000.00 April 23, 2025 October 22, 2025 No Neptune Group 19,999,000.00 April 24, 2025 January 12, 2026 No Neptune Group 20,000,000.00 November 8, 2024 November 6, 2025 No Neptune Group 30,000,000.00 June 17, 2025 December 16, 2025 No Neptune Group 30,000,000.00 January 24, 2025 July 23, 2025 No Neptune Group 40,000,000.00 March 11, 2025 September 10, 2025 No Neptune Group 20,000,000.00 May 14, 2025 November 3, 2025 No Neptune Group 30,000,000.00 June 25, 2025 December 14, 2025 No Neptune Group 22,000,000.00 June 25, 2025 December 14, 2025 No Neptune Group 50,000,000.00 November 15, 2024 November 12, 2025 No Neptune Group 10,000,000.00 June 6, 2025 December 5, 2025 No Neptune Group 50,000,000.00 February 12, 2025 February 10, 2026 No Neptune Group 80,000,000.00 February 17, 2025 February 12, 2026 No Neptune Group 37,900,000.00 March 29, 2024 March 28, 2027 No Neptune Group 24,999,999.98 December 20, 2024 October 31, 2025 No Neptune Group 15,216,666.67 May 26, 2025 May 26, 2026 No Neptune Group 78,315,652.10 May 27, 2025 May 21, 2026 No Neptune Group 26,585,600.00 November 05, 2024 November 04, 2025 No Neptune Group 17,500,000.00 May 28, 2025 November 28, 2025 No Neptune Group 40,000,000.00 March 26, 2025 September 25, 2025 No Neptune Group 40,000,000.00 April 3, 2025 October 2, 2025 No Neptune Group 20,000,000.00 April 17, 2025 October 16, 2025 No Neptune Group 20,000,000.00 May 27, 2025 November 27, 2025 No Neptune Group 30,000,000.00 20

January 1, 2025 December 29, 2025 No Neptune Group 29,900,000.00 August 21, 2024 August 20, 2025 No Neptune Group 4,994,026.00 March 27, 2025 September 27, 2025 No Neptune Group 4,316,577.14 March 19, 2025 March 16, 2026 No Neptune Group 18,178,422.86 March 20, 2025 March 19, 2026 No Neptune Group 3,981,735.00 May 9, 2025 November 9, 2025 No Neptune Group 2,474,540.80 May 29, 2025 November 29, 2025 No Neptune Group 3,761,716.88 June 12, 2025 December 12, 2025 No Neptune Group 3,785,000.00 June 18, 2025 December 18, 2025 No Neptune Group 5,000,000.00 June 23, 2025 December 23, 2025 No Neptune Group 10,000,000.00 June 26, 2025 December 26, 2025 No

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Neptune Group 7,500,000.00 January 16, 2025 July 16, 2025 No Neptune Group 4,250,000.00 February 14, 2025 August 14, 2025 No Neptune Group 3,247,922.70 February 28, 2025 August 28, 2025 No Neptune Group 5,000,000.00 June 4, 2025 November 13, 2025 No Neptune Group 5,000,000.00 June 25, 2025 November 13, 2025 No

(5) Fund lending by related parties

Unit: Yuan

Related parties Borrowing amount Start date Maturity date Description

dismantle

Neptune Group 8,758,300.00 December 1, 2024 Neptune Group 3,000,000.00 January 13, 2025 December 02, 2024 January 13, 2025 Neptune Group 2,000,000.00 December 10, 2024 Neptune Group on January 13, 2025 841,700.00 December 19, 2024 Neptune Group on January 13, 2025 658,300.00 December 19, 2024 Neptune Group on January 13, 2025 2,000,000.00 December 31, 2024 January 13, 2025 Neptune Group 2,741,700.00 January 3, 2025 January 13, 2025 Neptune Group 7,258,300.00 January 3, 2025 February 20, 2025 Neptune Group 8,000,000.00 January 24, 2025 February 20, 2025 Neptune Group 9,741,700.00 January 27, 2025 February 20, 2025 Neptune Group 5,000,000.00 January 27, 2025 February 21, 2025 Neptune Group 500,000.00 January 27, 2025 March 4, 2025 Neptune Group 4,758,300.00 January 27, 2025 March 12, 2025 Neptune Group 5,241,700.00 February 17, 2025 March 12, 2025 Neptune Group 10,000,000.00 February 17, 2025 March 18, 2025 Neptune Group 1,200,000.00 February 17, 2025 March 21, 2025 Neptune Group 3,000,000.00 February 24, 2025 March 24, 2025 Neptune Group 3,041,700.00 March 7, 2025 March 24, 2025 Neptune Group 8,558,300.00 February 17, 2025 March 24, 2025 Neptune Group 1,958,300.00 March 7, 2025 March 31, 2025 Neptune Group 10,000,000.00 March 20, 2025 March 31, 2025 Neptune Group 20,000,000.00 March 21, 2025 March 31, 2025 Neptune Group 3,041,700.00 March 24, 2025 March 31, 2025 Neptune Group 15,000,000.00 March 24, 2025 April 3, 2025 Neptune Group 700,000.00 March 24, 2025 May 30, 2025 Neptune Group 11,258,300.00 March 24, 2025 June 18, 2025 Neptune Group 2,000,000.00 March 26, 2025 June 18, 2025 Neptune Group 2,000,000.00 March 31, 2025 June 18, 2025 Neptune Group 2,000,000.00 April 3, 2025 June 18, 2025 Neptune Group 2,000,000.00 April 3, 2025 June 18, 2025 Neptune Group 741,700.00 April 18, 2025 June 18, 2025 Neptune Group 400,000.00 April 18, 2025 June 27, 2025 Neptune Group 47,000,000.00 April 18, 2025 June 30, 2025 Neptune Group 1,858,300.00 April 18, 2025 No agreed repayment date Neptune Group 10,000,000.00 April 18, 2025 No agreed repayment date Neptune Group 5,000,000.00 April 23, 2025 No agreed repayment date Neptune Group 3,000,000.00 May 13, 2025 No repayment date agreed Neptune Group 2,000,000.00 May 30, 2025 No repayment date Neptune Group 2,000,000.00 June 25, 2025 No repayment date agreed Shenzhen Neptune Pharmaceutical Co., Ltd.

10,000,000.00 January 2, 2025 January 23, 2025 Division

Shenzhen Neptune Pharmaceutical Co., Ltd.

10,000,000.00 January 2, 2025 May 26, 2025 Division

Shenzhen Neptune Pharmaceutical Co., Ltd. 10,000,000.00 January 3, 2025 January 3, 2025

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Division

Shenzhen Neptune Pharmaceutical Co., Ltd.

8,000,000.00 January 24, 2025 January 24, 2025 Division

Shenzhen Neptune Pharmaceutical Co., Ltd.

47,000,000.00 June 30, 2025 June 30, 2025 Division

Shenzhen Neptune Pharmaceutical Co., Ltd.

47,000,000.00 June 30, 2025 June 30, 2025 Division

Shenzhen Haiyi Investment Co., Ltd.

100,000,000.00 June 26, 2025 July 1, 2025 Company

take out

(6) Asset transfer and debt restructuring of related parties

Not applicable.

(7) Remuneration of key management personnel

Unit: Yuan

Item Amount for the current period Amount for the previous period Salaries of key management personnel 8,315,976.95 8,659,999.94

(8) Other related transactions

Not applicable.

6. Accounts receivable and payable from related parties

(1) Items receivable

Unit: Yuan

Closing balance Beginning balance item name Related parties

Book balance Provision for bad debts Book balance Provision for bad debts

Shandong Lijian Drug Store

Accounts receivable Lock Co., Ltd. and its subsidiaries 44,403,635.84 18,969.57 40,566,234.47 42,177.69

Shenzhen Neptune Easy Point

Accounts receivable 40,533,775.17 267,995.51 4,134,823.75 18,970.91 Yao Pharmaceutical Co., Ltd.

Shenzhen Neptune Pharmaceutical Co., Ltd.

Accounts receivable 13,167,325.99 19,024.34 15,407,155.79 245,754.70 Co., Ltd.

Jiangsu Neptune Xingchen Hospital

Accounts receivable 11,122,798.33 100,166.46 2,044,215.73 5,832.90 Pharmaceutical Co., Ltd.

Shandong Neptune Xingchen Medical

Accounts receivable 9,146,494.02 319,770.92 8,434,665.98 123,198.09 Pharmaceutical Co., Ltd.

Liaoning Province Neptune Star

Accounts receivable Pharmaceutical Trading Co., Ltd. 4,043,771.40 726,179.60 2,072.06

Zhejiang Neptune Xingchen Hospital

Accounts receivable 4,029,630.70 70,518.54

Pharmaceutical Co., Ltd.

Shanghai Neptune Medicine

Accounts receivable 3,854,682.42 67,456.94

Housing Co., Ltd.

Qingdao Neptune Star

Accounts receivable 2,718,323.50 47,570.66 21,488.25 302.98

Health pharmacy chain has

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ltd.

Shandong Weifang Neptune

Accounts receivable Chenminkang Pharmacy Chain 2,396,585.73 41,940.25 2,221,154.45 31,318.28 Co., Ltd.

Ningbo Neptune Xingchenjian

Accounts receivable 1,987,581.01 34,782.67

Kang Pharmacy Co., Ltd.

Shenzhen Quanyao Online Drug

Accounts receivable 856,078.40 856,078.40 462,500.23 Industrial Co., Ltd.

Huzhou Neptune Health Products

Accounts receivable 700,000.00 700,000.00 11,165.48 Industrial Development Co., Ltd.

Fuzhou Neptune Xingchenjian

Accounts receivable Kang Pharmacy Chain Co., Ltd. 649,300.25 11,362.75 43,200.00 689.07 Company

Shandong Neptune Youpinjian

Accounts receivable 295,284.00

Kang Technology Co., Ltd.

Wuhan Neptune Xingchen Medical

Accounts receivable 209,534.90 1,139.11 114,864.40 1,086.92 Pharmaceutical Chain Co., Ltd.

Binzhou Guorong Medical Investment

Accounts receivable 117,000.00

Asset Management Co., Ltd.

Qingdao Kanghui Pharmacy

Accounts receivable 39,631.34 910.45 61,998.90 934.22 Co., Ltd.

Guangzhou Neptune Star

Accounts receivable Pharmaceutical Chain Co., Ltd. 34,897.25 310.18

Division

Hunan Neptune Xingchenjian

Accounts receivable Kang Pharmacy Chain Co., Ltd. 6,244.84 6,244.84 6,244.84 6,244.84Company

Jilin Haiwang Health Department

Accounts receivable 4,678,548.39 110,205.74 Technology Development Co., Ltd.

Total accounts receivable 140,312,575.09 1,008,163.19 80,016,852.95 1,062,454.11

Henan Shipu Enterprise Management

Other receivables Management Consulting Center (General 43,000,060.39 40,234,896.11 40,234,896.11 40,234,896.11 Partnership)

Nanjing Keyunxi Trading

Other receivables 38,333,600.00 33,946,023.16 38,333,600.00 33,946,023.16 Co., Ltd.

Henan Guolian Medical Department

Other receivables 9,197,861.67 178,070.60 9,369,786.86 178,070.60 Technology Co., Ltd.

Jiangsu Liangdian Technology Co., Ltd.

Other receivables 6,371,585.98 6,347,924.05 6,421,585.98 6,347,924.05 Co., Ltd.

Zhongke Galaxy Medical Department

Other receivables 4,570,000.00 4,570,000.00 4,570,000.00 4,570,000.00 Technology Co., Ltd.

Jiangsu Deweilan Medical

Other receivables Equipment Co., Ltd. 3,125,000.00 2,525,745.77 3,125,000.00 2,525,745.77 Company

Weifang Haiwang Chinese Medicine Drink

Other receivables 1,758,481.60 19,343.30 2,336,410.10 25,700.51 Piece Co., Ltd.

Shenzhen Taiheng Medical

Other receivables 1,699,751.10 1,246,397.25 1,699,751.10 1,246,397.25 Investment Co., Ltd.

Shandong Kangli Medical Equipment

Other receivables 1,626,398.09 469,010.97 1,819,782.54 469,010.97

Machinery Technology Co., Ltd.

Other receivables Neptune Group 1,002,810.00 1,002,810.00

Shenzhen Neptune Pharmaceutical Co., Ltd.

Other receivables 414,582.25 4.21 557,428.37 1,569.65 Co., Ltd.

Shenzhen Neptune Golden Bottle

Other receivables Science and Technology Development Co., Ltd. 262,725.94 262,725.94 262,725.94 262,725.94

Division

Other receivables Nanning Neptune Health Care 216,225.00 216,225.00

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Material Technology Co., Ltd.

Qingdao Kanghai Pharmaceutical Co., Ltd.

Other receivables 175,754.74 1,235.53 29,257.23 497.37 Co., Ltd.

Shenzhen Neptune Property

Other receivables 134,527.08 722.16 134,527.08 722.16 Management Co., Ltd.

Shenzhen Hongyang Property

Other receivables 79,198.59 79,198.59 Management Co., Ltd.

Jilin Haiwang Health Department

Other receivables 20,000.00 20,000.00 20,000.00 220.00 Technology Development Co., Ltd.

Shandong Neptune Youpinjian

Other receivables 443.20 358.21 443.20 358.21 Kang Technology Co., Ltd.

Shenzhen Quanyao Online Drug

Other receivables 322.77 322.77 322.77 322.77 Industry Co., Ltd.

Huzhou Neptune Health Products

Other receivables 90,600.00 996.60 Industry Development Co., Ltd.

Huzhou Neptune Original Food

Other receivables 13,274.33 146.02 Pin Beverage Co., Ltd.

Total other receivables 111,989,328.40 89,822,780.03 110,317,625.20 89,811,327.14

Nanning Neptune Health Student

Prepayment 4,000,000.00 4,000,000.00 Wu Technology Co., Ltd.

Jilin Neptune Health Care

Prepayment 4,000,000.00 2,149,096.74 Wu Technology Co., Ltd.

Shenzhen Neptune Pharmaceutical Co., Ltd.

Prepayments 287,027.25 288,313.22 Co., Ltd.

Shenzhen Quanyao Online Drug

Prepayments 78,675.25 83,206.15 Industry Co., Ltd.

Hunan Neptune Xingchen Hospital

Prepayment 71,221.59 211.50 Pharmaceutical Co., Ltd.

Shandong Kangli Medical Equipment

Prepayment 66,920.00 83,815.30 Machinery Technology Co., Ltd.

Huzhou Neptune Health Products

Prepayment 2,375.00

Industrial Development Co., Ltd.

Shenzhen Shenshang Liquor Industry

Prepayments Holding Group Co., Ltd. 552.21

Division

Huzhou Neptune Original Food

Prepayment 420.00 95,000.00 Pin Beverage Co., Ltd.

Jilin Haiwang Health Department

Advance payment 99,557.52 Technology Development Co., Ltd.

Shandong Neptune Youpinjian

Prepayment 2,679.49 Kang Technology Co., Ltd.

Total prepaid accounts 8,507,191.30 6,801,879.92

Shenzhen Neptune Property

Other current assets 4,522.59 1,800.00

Management Co., Ltd.

(2) Payable items

Unit: Yuan

Project name Related party Book balance at the end of the period Book balance at the beginning of the period

Shenzhen Neptune Jinzun Technology Development Co., Ltd.

Accounts payable 10,426,715.74 2,818,477.90

Ltd.

Accounts payable Weifang Haiwang Chinese Medicine Pieces Co., Ltd. 6,072,644.98 27,668,525.71 Accounts payable Shenzhen Haiwang Pharmaceutical Co., Ltd. 2,565,245.26 1,637,682.54

Shandong Neptune Premium Health Technology Co., Ltd.

Accounts payable 1,596,415.27 1,056,374.77

company

Accounts payable Shandong Kangli Medical Device Technology Co., Ltd. 196,944.07 261,085.75

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

company

Huzhou Neptune Health Industry Development Co., Ltd.

Accounts payable 184,867.25 185,610.61 Co., Ltd.

Jiangsu Neptune Health Biotechnology Co., Ltd.

Accounts payable 129,978.00 129,978.00Company

Jilin Neptune Health Biotechnology Co., Ltd.

Accounts payable 75,759.71 561,742.51Company

Nanning Neptune Health Biotechnology Co., Ltd.

Accounts payable 61,423.04 2,831.86

company

Accounts payable Shenzhen Quanyaowang Pharmaceutical Co., Ltd. 2,594.97 114,497.89

Total accounts payable 21,312,588.29 34,436,807.54 Other payables Shenzhen Haiyi Investment Co., Ltd. 100,000,000.00

Other payables Neptune Group 24,091,890.85 17,574,381.11

Shenzhen Ronghui Medical Development Co., Ltd.

Other payables 10,168,000.00 10,168,000.00

Division

Other payables Hubei Neptune Star Trading Co., Ltd. 6,700,600.00 6,700,600.00

Jilin Neptune Health Biotechnology Co., Ltd.

Other payables 4,000,000.00 4,000,000.00

company

Other payables Shandong Neptune Xingchen Pharmaceutical Co., Ltd. 920,046.82 60,524.97

Shandong Weifang Neptune Star Minkang Chain Store

Other payables 206,144.56 124,183.50

Pharmacy Co., Ltd.

Other payables Shandong Kangjian Pharmaceutical Co., Ltd. 82,540.37 778.31

Linyi Lijian Medical City Chain Co., Ltd.

Other payables 37,181.82 37,181.82

Division

Other payables Weifang Haiwang Chinese Medicine Pieces Co., Ltd. 25,000.00 51,738.00 Other payables Nanjing Keyunxi Trading Co., Ltd. 5,000.00 5,000.00 Other payables Shenzhen Haiwang Pharmaceutical Co., Ltd. 4,454.50 4,454.50

Qingdao Neptune Star Health Pharmacy

Other payables 4,292.45 20,821.86

lock co., ltd.

Other payables Jinan Lijian Pharmacy Co., Ltd. 2,366.37 2,366.37 Other payables Shandong Lijian Pharmacy Chain Co., Ltd. 917.81 777.90

Jilin Neptune Health Technology Development Co., Ltd.

Other payables 163.72

company

Shandong Kangli Medical Device Technology Co., Ltd.

Other payables 25.00 25.00Company

Huzhou Neptune Health Industry Development Co., Ltd.

Other payables 1.59 1.59

company

Other payables Shenzhen Neptune Food Co., Ltd. 1.00 1.00

Shenzhen Chengjing Investment Development Co., Ltd.

Other payables 175,000,000.00 Division

Total other payables 146,248,626.86 213,750,835.93

Shandong Weifang Neptune Star Minkang Chain Store

Contract liabilities 20,530.97 20,530.97

Pharmacy Co., Ltd.

Contract liabilities Shandong Lijian Pharmacy Chain Co., Ltd. 1,075.77 4,118.23 Contract liabilities Jinan Lijian Pharmacy Co., Ltd. 336.54

Contract liabilities Shandong Kangjian Pharmaceutical Co., Ltd. 275.93 275.93

Binzhou Guorong Medical Investment Management Co., Ltd.

Contract liabilities 5,013,274.34Company

Shenzhen Haiwang Yidianyao Pharmaceutical Co., Ltd.

Contract liabilities 34,918.48

company

Contract liabilities Heze Lijian Pharmacy Chain Co., Ltd. 951.76 Contract liabilities Hunan Neptune Xingchen Pharmaceutical Co., Ltd. 187.17

Total contract liabilities 22,219.21 5,074,256.88

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

7. Related party commitments

Not applicable.

8. Others

Not applicable.

15. Share-based payment

1. Overall situation of share-based payment

□ApplicableNot applicable

2. Equity-settled share-based payment □ Applicable  Not applicable

3. Cash-settled share-based payment □ Applicable  Not applicable

4. Share-based payment expenses for this period

□ApplicableNot applicable

5. The modification and termination of share-based payment does not apply.

6. Others

Not applicable.

16. Commitments and contingencies

17. Important commitments

Not applicable.

2. Contingent matters

(1) Important contingencies existing on the balance sheet date are not applicable.

(2) The company has no important contingencies that need to be disclosed, and it should also be stated that the company has no important contingencies that need to be disclosed.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

3. Others

Not applicable.

17. Events after the balance sheet date

18. Important non-adjustment matters are not applicable.

19. Profit distribution does not apply.

20. Sales return

Not applicable.

4. Other descriptions of events after the balance sheet date are not applicable.

5. Other important matters

6. Correction of accounting errors in the previous period is not applicable.

7. Debt restructuring

Not applicable.

3. Asset replacement

Not applicable.

4. Annuity plan

Not applicable.

5. Termination of operations

Not applicable.

6. Branch information

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

7. Other important transactions and matters that have an impact on investors’ decision-making

Not applicable.

8. Others

Not applicable.

19. Notes on main items of the parent company’s financial statements

1. Accounts receivable

Not applicable.

2. Other receivables

Unit: Yuan

Item Ending balance Beginning balance

Other receivables 6,709,938,265.22 6,648,457,337.37 Total 6,709,938,265.22 6,648,457,337.37 (1) Interest receivable

Not applicable.

(2) Dividends receivable

Not applicable.

(3) Other receivables

1. Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Reserve fund 3,543,790.24 2,943,206.81 Pledge deposit and security deposit 796,902.55 802,875.31 Internal current funds 6,657,407,946.71 6,626,552,869.21 Current funds 133,496,519.76 103,511,514.61 Others 466,118.76 488,403.30 Total 6,795,711,278.02 6,734,298,869.24 2) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 6,707,829,087.59 6,632,270,534.10 1 to 2 years 6,511,845.01 9,419,284.24

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

2 to 3 years 15,574,975.72 72,567,595.94 More than 3 years 65,795,369.70 20,041,454.96 3 to 4 years 48,471,116.48 6,351,701.84 4 to 5 years 3,798,125.41 579,310.43

More than 5 years 13,526,127.81 13,110,442.69 Total 6,795,711,278.02 6,734,298,869.24

3. Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

15,925,5 15,925,5 15,994,1 15,994,1

Bad provision 0.23% 100.00% 0.24% 100.00%

98.65 98.65 17.72 17.72

Account preparation

its

Medium:

by combination

6,779,78 69,847,4 6,709,93 6,718,30 69,847,4 6,648,45 Bad provision 99.77% 1.03% 99.76% 1.04%

5,679.37 14.15 8,265.22 4,751.52 14.15 7,337.37Account preparation

its

Medium:

pledge

Gold and insurance 796,902. 796,902. 802,875. 802,875.

0.01% 0.01%

Securities and Finance Group 55 55 31 31 combined

Receivable from it

6,778,98 69,847,4 6,709,14 6,717,50 69,847,4 6,647,65 Other amounts 99.76% 1.03% 99.75% 1.04%

8,776.82 14.15 1,362.67 1,876.21 14.15 4,462.06 combination

6,795,71 85,773,0 6,709,93 6,734,29 85,841,5 6,648,45Total 100.00% 1.26% 100.00% 1.27%

1,278.02 12.80 8,265.22 8,869.24 31.87 7,337.37 Name of bad debt provision category based on individual provision: Individual provision

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Guangdong Hongyu Pharmaceutical

9,723,750.00 9,723,750.00 9,655,230.93 9,655,230.93 100.00%

Ltd.

Wu Zhiyu 5,072,134.39 5,072,134.39 5,072,134.39 5,072,134.39 100.00%

Tianjin Zhongcai Commercial

1,048,900.00 1,048,900.00 1,048,900.00 1,048,900.00 100.00%

Factoring Co., Ltd.

Zhao Zhixuan 149,333.33 149,333.33 149,333.33 149,333.33 100.00%

Total 15,994,117.72 15,994,117.72 15,925,598.65 15,925,598.65

Category name of bad debt provisions accrued by combination: Other accounts receivable combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Pledge deposit and margin combination 796,902.55

Portfolio of other accounts receivable 6,778,988,776.82 69,847,414.15 1.03%

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Total 6,779,785,679.37 69,847,414.15

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Bad debt provision Total expected credit losses in the next 12 months (no credit deductions have occurred Losses (credit deductions have occurred)

loss

value) value)

Balance on January 1, 2025 69,847,414.15 15,994,117.72 85,841,531.87 Balance on January 1, 2025

In this issue

Transferred back in the current period 68,519.07 68,519.07 Remainder on June 30, 2025

69,847,414.15 15,925,598.65 85,773,012.80

Changes in book balances with significant changes in loss provision during the current period

□ApplicableNot applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off or write-off Other other receivables 85,841,531.87 68,519.07 85,773,012.80 Total 85,841,531.87 68,519.07 85,773,012.80

5. Other receivables actually written off in the current period

Not applicable.

6. Other receivables with top five closing balances collected by debtors

Unit: Yuan accounted for other receivable period

The name of the unit with the ending balance of bad debt provision. The nature of the payment. The ending balance. The aging of the account. The total amount of the ending balance.

Proportion

Shenzhen Neptune Galaxy Pharmaceutical

Current accounts 4,704,204,647.83 Within 1 year 69.22% Investment Co., Ltd.

Anhui Neptune Pharmaceutical Group has

Current accounts 713,403,537.56 Within 1 year 10.50% Co., Ltd.

Shandong Neptune Pharmaceutical Group has

Current accounts 198,207,190.92 Within 1 year 2.92% Co., Ltd.

Shenzhen Galaxy Technology Co., Ltd.

Current accounts 138,442,301.38 Within 1 year 2.04% Company

Hubei Neptune Pharmaceutical Group has

Current accounts 121,019,368.59 Within 1 year 1.78% Co., Ltd.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Total 5,875,277,046.28 86.46%

7. Presented in other receivables due to centralized management of funds

Not applicable.

3. Long-term equity investment

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value

Investment in subsidiaries 650,177,882.90 650,177,882.90 650,177,882.90 650,177,882.90 Associates and joint ventures

9,262,190.43 9,262,190.43 9,261,717.19 9,261,717.19Enterprise investment

Total 659,440,073.33 659,440,073.33 659,439,600.09 659,439,600.09

(1) Investment in subsidiaries

Unit: Yuan

Balance at the beginning of the period Changes in increases and decreases during the period Ending balance of invested orders Impairment provision Impairment provision (book price Impairment provision (book price) Opening balance Additional investment Decrease in investment Others Closing balance

Value) Preparation Value) Shenzhen Hai

Wang Yinhe Medical 333,022,54 333,022,54 Pharmaceutical Investment Co., Ltd. 9.60 9.60

Shenzhen Neptune

Oriental Investment 600,000.00 600,000.00 Co., Ltd.

Shenzhen sea

Wang Yingtelong

109,112,32 109,112,32Biotechnology

9.39 9.39 Co., Ltd.

company

Fuzhou Neptune

Golden Elephant Chinese Medicine

845,003.91 845,003.91 Pharmaceutical Co., Ltd.

company

Shenzhen Neptune

Medical Technology 80,000,000. 80,000,000. The Research Institute has 00 00 Co., Ltd.

Zhejiang Neptune

20,650,000. 20,650,000.Data services

00 00 Co., Ltd.

Shenzhen sea

Rong International Medical 101,640,00 101,640,00 Medical Development Co., Ltd. 0.00 0.00

Shenzhen sea

3,300,000.0 3,300,000.0 Wang Medical Health

0 0 Kang Limited Liability

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Ren company

Hainan Jiachi

Technology Co., Ltd. 8,000.00 8,000.00 Responsible company

Neptune Medical

1,000,000.0 1,000,000.0 Technology Co., Ltd.

0 0Company

650,177,88 650,177,88 total

2.90 2.90

(2) Investment in associates and joint ventures

Unit: Yuan

Increases and decreases in the current period

Beginning of period Equity declaration End of period

Impairment Impairment Balance Other Disbursement Balance Investment Provision Other Disbursement Provision (Account Addition Decrease Confirmation Comprehensive Cash (Billing Unit Beginning Equity Impairment Others Ending Face Price Investment Income from Investment Dividend Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

Zhuhai

Aquaman

China

Equity

9,261, 9,262,investment 473.24

717.19 190.43Fund

(Yes

Limited combination

Guy)

9,261, 9,262, subtotal 473.24

717.19 190.43 9,261, 9,262, total 473.24

717.19 190.43 The recoverable amount is determined based on the net amount of fair value minus disposal costs.

□ApplicableNot applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□ApplicableNot applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Not applicable.

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Not applicable.

(3) Other instructions

Not applicable.

4. Operating income and operating costs

Unit: Yuan

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Items of current period's previous period's amount

Revenue Cost Revenue Cost Other businesses 2,783,046.09 1,846,965.12 9,387,095.89 1,871,389.88 Total 2,783,046.09 1,846,965.12 9,387,095.89 1,871,389.88

5. Investment income

Unit: Yuan

Item Amount incurred in the current period Amount incurred in the previous period Long-term equity investment income calculated using the cost method 177,426,000.00

Long-term equity investment income calculated using the equity method 473.24

Total 177,426,473.24

6. Others

Not applicable.

20. Supplementary information

1. Detailed statement of non-recurring profits and losses for the current period

Applicable□Not applicable

Unit: Yuan

Item Amount Explanation Gains and losses from disposal of non-current assets 87,519,703.48 Mainly due to the government subsidies that the disposal gains and losses caused by the disposal of subsidiaries are included in the current profit and loss (the same as the company's regular profits and losses)

Closely related to regular business operations and in compliance with national policies

13,447,646.69

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Except for effective transactions related to the company’s normal business operations,

In addition to futures hedging business, non-financial enterprises hold financial

Changes in fair value of assets and financial liabilities 70,959.24

Profit and loss and disposal of financial assets and financial liabilities

profit and loss

Gains and losses from entrusting others to invest or manage assets 837,590.60

Impairment standards for accounts receivable that are individually tested for impairment

4,180,436.64

Ready to transfer back

Other non-operating income other than the above items and

5,932,126.30

expenditure

Less: Impact on income tax 4,188,301.68

Amount of impact on minority shareholders’ equity (after tax) 5,592,349.09

Total 102,207,812.18 --Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□ApplicableNot applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-Recurring Profit and Loss" as recurring profit and loss

Shenzhen Neptune Bioengineering Co., Ltd. 2025 Semi-annual Report Full Text Project Description

□ApplicableNot applicable

2. Return on net assets and earnings per share

earnings per share

Profit for the reporting period Weighted average return on equity

Basic earnings per share (yuan/share) Diluted earnings per share (yuan/share) Net attributable to the company’s ordinary shareholders

1.75% 0.0120 0.0120Profit

After deducting non-recurring gains and losses, attributable to

-3.89% -0.0268 -0.0268 Net profit of the company’s common shareholders

3. Differences in accounting data under domestic and foreign accounting standards

(1) Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards □ Applicable  Not applicable

(2) Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards □ Applicable  Not applicable

(3) Explanation of reasons for differences in accounting data under domestic and foreign accounting standards. If differences are adjusted for data that have been audited by an overseas audit institution, the name of the overseas institution should be indicated.

Not applicable.

4. Others

Not applicable.

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Section 9 Other reporting data

1. Other major social security issues

Whether the listed company and its subsidiaries have other major social security issues

□Yes□NoNot applicable

Whether there was any administrative penalty during the reporting period

□Yes□NoNot applicable

2. Registration form for reception of research, communication, interviews and other activities during the reporting period

Applicable□Not applicable

The main topic of discussion

Basic information of the survey: reception time, reception location, reception method, type of reception objects, reception objects, content and information provided.

condition index information

Oriental Wealth Certificate

Bonds, Deyuan Investment

Zi, Hengtai Yongcheng

Investment, cloud mass innovation

Finance Investment, Guangying "January 2025 January 2025 Neptune Galaxy Technology Capital, Solid Stone Investment Company Operations Related Investor Relations on the 8th

Field research agency

08th Building Investment, Boyue Investment Situation Department Activity Record Investment, Junlingtianxia Investment, Zhuode Investment

Capital, China Cooperation Group

and some individuals

investor

Shen Wanhongyuan, Ning

Bo Bank, Zhongtian

Guofu Securities, Mu "February 2025 February 2025 Neptune Galaxy Technology De Assets, North Company Operations Related Investor Relations on the 11th

Field research agency

On the 11th, the assets of the Asia-Pacific Building were evaluated, activity records were evaluated, China Science and Technology Co-creation Table "investments and some

individual investor

Shenzhen Hengyi Capital

Property Management Co., Ltd.

Company, Shenzhen Gold

Tian Private Securities Fund

Financial Management Co., Ltd.

Division, Shenzhen Tongyu

Quan Private Equity Fund

《June 2025

Financial Management Co., Ltd.

June 2025 Neptune Galaxy Technology Company Management Related Investor Relations on the 27th

Field research agency, Shenzhen University

The situation of the building on the 27th is related to activity records. Qin Fund Management has

Watch Co., Ltd., Guantong

Futures Co., Ltd.

Company Shenzhen Branch

Division, Shenzhen City Excellent

Meili Investment Management

Co., Ltd., Shenzhen

Shenzhen Ruizhao Assets

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Management Co., Ltd.

Division, Shenzhen Hengyi

Tianze Capital Management

Co., Ltd., Shenzhen

Shenzhen Qianhai Huicheng Consulting

Consulting Services Ltd.

companies and some individuals

human investor

January 2025 Company operations related

Neptune Galaxy Technology

Telephone communication from 01 to 2025 Individual investor status (not provided None

building

Written information on June 30, 2025) Company operations related in January 2025

Neptune Galaxy Technology Shenzhen Stock Exchange Interactive Exchange from 01 to 2025 Written Inquiry Individual Investor Information (not provided

Building platform June 30, written information)

3. Capital transactions between listed companies and controlling shareholders and other related parties

Applicable□Not applicable

Unit: 10,000 yuan

Occurrence during the reporting period Repayment during the reporting period

Name of the counterparty Nature of the transaction Opening balance Ending balance Interest income Interest expense

Uh Uh

Guangzhou Neptune

Xingchen Pharmaceutical Company Business transactions 4.70 1.21 3.49 Lock Co., Ltd.

Hunan Neptune

Chen Health Pharmacy

Operating transactions 0.62 0.62 Chain Co., Ltd.

Division

Jiangsu Neptune

Chen Pharmaceutical Co., Ltd. Operating transactions 204.42 1,454.94 547.08 1,112.28 Company

Haiwang, Liaoning Province

Xingchen Pharmaceutical Trading Business transactions 72.62 346.75 14.99 404.38 Yi Co., Ltd.

Qingdao Neptune

Star health medicine

Business transactions 2.15 404.00 134.32 271.83 Room Chain Co., Ltd.

company

Shandong Neptune

Chen Pharmaceutical Co., Ltd. Operating transactions 843.47 1,666.76 1,595.58 914.65 Company

Shandong Weifang sea

Wang Xingchen Minkang

Business transactions 222.12 461.94 444.40 239.66 Chain drug stores have

Ltd.

Shenzhen Neptune Medicine

Operating transactions 1,625.29 3,228.11 3,466.51 1,386.89 Industrial Co., Ltd.

Shandong Haiwangyou

Pin Health Technology Operating transactions 0.31 29.53 0.27 29.57 Co., Ltd.

Shenzhen Neptune

Yidianyao Pharmaceutical Operating transactions 413.48 4,484.68 844.78 4,053.38 Co., Ltd.

Fuzhou Neptune

Operating transactions 4.32 94.15 33.54 64.93 Chen Health Pharmacy

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

chain co., ltd.

Division

Wuhan Neptune

Chen Pharmaceutical Chain Operating transactions 11.49 27.53 18.07 20.95 Co., Ltd.

Zhejiang Neptune

Chen Pharmaceutical Co., Ltd. Operating transactions 402.96 402.96 Company

Ningbo Neptune

Chen Health Pharmacy Operating transactions 291.68 92.92 198.76 Co., Ltd.

Shanghai Neptune

Chen Pharmacy Co., Ltd. Operating transactions 448.54 63.07 385.47 Company

Hunan Neptune

Chen Pharmaceutical Co., Ltd. Operating transactions 0.02 148.30 141.20 7.12 Company

Huzhou Haiwangjian

Kang Industry Development Business transactions 79.06 9.92 18.74 70.24 Co., Ltd.

Huzhou Haiwang Edition

Source Food and Beverage Business transactions 10.83 71.29 82.08 0.04 Co., Ltd.

Shenzhen Shenzhen Business

Liquor Industry Holding Group Operating transactions 21.45 21.39 0.06 Group Co., Ltd.

Shenzhen Neptune Collection

Tuan Co., Ltd. Operating transactions 100.28 100.28 Company

Shenzhen Neptune

Property management has business dealings 13.45 13.45 Co., Ltd.

Shenzhen Hongyang

Property management has business dealings 7.92 7.92 Co., Ltd.

Shenzhen Neptune

Jinzun Science and Technology Development Business transactions 26.27 26.27 Exhibition Co., Ltd.

Jiangsu Haiwangjian

Kang Biotechnology Operating transactions 42.00 42.00

Ltd.

Shenzhen Neptune

Youpin Health Division Operating transactions 1.36 1.36

Technology Co., Ltd.

Shandong Lijian Medicine

store chain limited

Operating transactions 4,056.62 4,807.70 4,423.96 4,440.36The company and its subsidiaries

company

Ningbo Xianzhi

Nutritional products limited business transactions 1.25 1.25

company

Binzhou Guorong Medical

Medical investment management Operating transactions 632.98 621.28 11.70 Co., Ltd.

Qingdao Kanghuida

Pharmacy Co., Ltd. Operating transactions 6.20 20.18 22.42 3.96

Full text of the 2025 semi-annual report of Shenzhen Neptune Bioengineering Co., Ltd.

Shenzhen Whole Medicine

Net Pharmaceutical Co., Ltd. Operating transactions 93.96 0.45 93.51 Company

Jilin Haiwangjian

Kang Technology Development Operating transactions 479.81 -197.51 280.30 2.00 Co., Ltd.

Shandong Kangli Medical

Medical Device Technology Business transactions 190.36 71.23 92.26 169.33 Co., Ltd.

Jilin Haiwangjian

Kang Biotechnology Operating transactions 214.91 185.09 400.00 Co., Ltd.

Nanning Haiwangjian

Kang Biotechnology Business transactions 421.62 421.62 Co., Ltd.

Henan Shipu Enterprise

Business management consulting Non-commercial business

4,023.49 276.52 4,300.01 Center (ordinary combined)

Guy)

Jiangsu Liangdianke non-commercial business

642.16 5.00 637.16 Technology Co., Ltd. Come

Shenzhen Taiheng

Medical investment has operating transactions 169.98 169.98 Co., Ltd.

Zhongke Yinhe Medical

Non-commercial transactions

Medical Technology Co., Ltd. 457.00 457.00

Come

company

Qingdao Kanghai Medical

Business transactions 2.93 35.38 20.73 17.58 Pharmaceutical Co., Ltd.

Jiangsu Deweilan

Non-commercial transactions

Medical device stocks 312.50 312.50

Come

Co., Ltd.

Nanjing Keyunxi

Non-commercial transactions

Trading Co., Ltd. 3,833.36 3,833.36

Come

Division

Weifang Haiwang Middle School

Non-commercial transactions

Medicinal tablets limited 233.64 85,049.40 85,107.19 175.85

Come

company

Henan Guolian Medical

Non-commercial transactions

Medical Technology Co., Ltd. 936.98 32.81 50.00 919.79 32.81

Come

company

Total -- 19,713.64 104,555.62 98,188.35 26,080.91 32.81

Shenzhen Neptune Bioengineering Co., Ltd.

August 29, 2025